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Abstract 
 
OPA1 and MFN2 are two critical mitochondrial membrane proteins required for 
mitochondrial fusion. OPA1 mutations account for approximately 60% of cases of 
autosomal-dominant optic atrophy (DOA) and up to 20% of mutational carriers 
develop a more severe multi-systemic neurological phenotype (DOA+) in addition to 
visual failure. MFN2 mutations result in Charcot-Marie-Tooth disease type 2A 
(CMT-2A) and in a subgroup of patients, the peripheral neuropathy is complicated 
by optic atrophy, highlighting a degree of phenotypic overlap with DOA+. POLG1 
encodes the catalytic subunit of DNA polymerase gamma (POLG) and POLG1-
related diseases are clinically highly heterogeneous, ranging from early-onset Alpers-
Huttenlocher syndrome to late-onset isolated chronic progressive external 
ophthalmoplegia. OPA1, MFN2 and POLG1 mutations all result in disturbed 
mitochondrial DNA (mtDNA) maintenance, with both quantitative (depletion) and 
qualitative (point mutations and deletions) mtDNA abnormalities having been 
identified in patient tissue samples. In this PhD project, the disease mechanisms 
underpinning these nuclear mitochondrial disorders have been studied further. 
OPA1 and MFN2 mutations were found to result in significant mtDNA proliferation 
as a likely compensatory mechanism to impaired mitochondrial oxidative 
phosphorylation. Using a previously-validated repopulation assay, mtDNA 
replication in cultured POLG1-mutant fibroblasts was severely depressed following a 
period of ethidium bromide-induced mtDNA depletion. A similar observation was 
made with OPA1-mutant fibroblasts, but this effect was not as marked as for 
POLG1-mutant fibroblasts. Significant reorganisation of the mitochondrial network 
was also apparent for both groups of mutant fibroblasts. 
Although neuromyelitis optica (NMO) shares some clinical features with DOA, 
genetic variations within OPA1 are not associated with the risk of developing NMO.  
Finally, research into DOA and other mitochondrial optic neuropathies have been 
severely restricted by the lack of the access to retinal ganglion cells (RGCs), 
precluding direct studies to be performed on the cell type which is preferentially 
affected in this group of disorders. To circumvent this limitation, human induced 
pluripotent stem cell (hiPSC) lines have been generated from patient-derived 
 ii 
 
fibroblasts harbouring confirmed OPA1 mutations. The future differentiation of these 
induced pluripotent stem cell lines into RGCs will hopefully provide a powerful and 
versatile tool for disease modelling and the development of targeted therapeutic 
strategies.  
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1.1 The Mitochondrion 
Mitochondria are essential intracellular organelles which form a dynamic network 
throughout the cell, continuously fusing and breaking apart (Detmer and Chan, 
2007). The major function of mitochondria is to supply eukaryotic cells with 
adequate levels of adenosine triphosphate (ATP) through aerobic respiration, a 
process referred to as oxidative phosphorylation (OXPHOS). In addition to this 
fundamental role in energy conversion, mitochondria are involved in numerous other 
metabolic processes such as β-oxidation of fatty acids, the citric acid cycle, and the 
biosynthesis of heme, pyrimidines, phospholipids, amino acids and nucleotides 
(Duchen, 2004; Maechler et al., 2006; McBride et al., 2006; Rossier, 2006). 
Mitochondria play a distinctive role in the initiation and regulation of apoptosis 
(Green, 1998), intracellular calcium handling (Gunter et al., 1994; Herrington et al., 
1996; Gincel et al., 2001), and the generation of reactive nitrogen species (RNS) and 
reactive oxygen species (ROS) (Droge, 2002; Balaban et al., 2005). Mitochondria are 
found within the cytoplasm of most eukaryotic cells and their numbers can vary from 
a few hundred to several thousand depending on the cell’s metabolic requirements 
(Moyes et al., 1998; Roger and Silberman, 2002).   
1.1.1 Origin 
According to the endosymbiotic theory, mitochondria evolved from aerobic 
Alphaproteobacteria that were assimilated by primitive glycolytic eubacteria 
(Margulis, 1971; Lang et al., 1997). The sequencing of human mitochondrial DNA 
(mtDNA) (Anderson et al., 1981) and the genome of Alphaproteobacteria - 
Rickettsia prowazekii (Andersson et al., 1998) have provided solid phylogenomic 
evidence of a common genetic origin for the  mitochondrial and alphaproteobacterial 
lineages (Gray et al., 1999).   
1.1.2 Structure  
Each mitochondrion consists of four distinct compartments: an outer mitochondrial 
membrane (OMM), an inner mitochondrial membrane (IMM), an intermembrane 
space (IMS), and a matrix contained within the inner mitochondrial membrane 
(Figure 1-1). The outer mitochondrial membrane is a phospholipid bilayer composed 
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of a number of channel-forming proteins (called porins) or voltage dependent anion 
channels (VDAC) which form conduits allowing non-specific free diffusion of 
molecules smaller than 10 kDa. Compared with the outer membrane which has a 
protein-to-lipid ratio of about 1:1, the inner membrane is more enriched with proteins 
with a protein-to-lipid ratio of approximately 4:1. This is related to its increased 
enzymatic and transport functions. The inner membrane lacks porins but it is rich in 
cardiolipins. These phospholipids are found in mammalian cells almost exclusively 
within the IMM and they play an essential role in scaffolding enzymatic complexes 
(Mannella, 2006). Cardiolipins make the inner membrane highly impermeable to 
most solutes and ions, and therefore molecules from the intermembrane space need 
to be actively transported into the matrix compartment via specific active transport 
systems. This transport can be electroneutral, electrogenic, driven by the membrane 
electrical potential (ΔΨm) or a chemical pH difference (Krauss, 2001). In order to 
increase the effective surface area for ATP production, the inner membrane is 
compartmentalized into folded structures called cristae (Perkins et al., 1997). The 
mitochondrial matrix contains soluble enzymes involved in fatty acid -oxidation 
and the citric acid cycle. It also encloses mtDNA molecules packed into nucleoids, 
and the intricate machinery required for mtDNA replication and transcription 
(Alberts, 1994).  
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Figure 1-1 General structure of a mitochondrion. (Reproduced from Tobin, 
2004).  
 
1.2 Respiratory Chain 
Mitochondria are energy-converting organelles that use a transmembrane 
electrochemical gradient to synthesize ATP molecules from adenosine diphosphate 
(ADP) and inorganic phosphate (Pi) (Mitchell, 1976). This process is known as 
oxidative phosphorylation (OXPHOS) and it takes place in the mitochondrial 
respiratory chain located within the inner mitochondrial membrane. The 
mitochondrial respiratory chain consists of four transmembrane enzyme complexes (I 
– IV) and FOF1-ATP synthase, usually referred to as complex V (Figure 1-2). Each 
OXPHOS complex is made of multiple subunits which are encoded by both the 
mitochondrial and nuclear genomes, except for complex II, where all four 
polypeptide components are nuclear-encoded. Apart from enzymatic complexes, 
coenzyme Q10 and cytochrome c also play distinctive roles in OXPHOS, acting as 
electron carriers between the respiratory chain complexes.  
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In the initial steps of OXPHOS, NADH (reduced nicotinamide adenine dinucleotide) 
and FADH2 (reduced flavin adenine dinucleotide) donate electrons to complexes I 
and II respectively. As these electrons are shuttled along the respiratory chain 
complexes, energy is released and it is used to pump protons (H
+
) from the 
mitochondrial matrix to the intermembrane space. This electrochemical proton 
gradient is then used by complex V (ATP synthase) to generate ATP from ADP and 
Pi. 
 
 
Figure 1-2 Mitochondrial respiratory chain. (Reproduced from Bellance et al., 
2009). 
 
1.2.1 Complex I  
Complex I (NADH-ubiquinone oxidoreductase) is the largest respiratory chain 
complex and it consists of 47 subunits, seven of which are mitochondrially-encoded 
(ND1, ND2, ND3, ND4, ND4L, ND5 and ND6). Complex I contains a co-enzyme, 
flavin mononucleotide (FMN), and up to nine iron-sulphur clusters involved in the 
electron transfer (Hinchliffe and Sazanov, 2005). Structurally, complex I has an L-
shaped formation with the hydrophobic membrane arm embedded in the IMM and 
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the hydrophilic peripheral arm protruding into the mitochondrial matrix (Grigorieff, 
1999). Complex I is a proton pump and it translocates four protons (H
+
) per one 
molecule of oxidized NADH across the inner membrane, thereby building an 
electrochemical gradient. Oxidation of NADH to NAD
+
 results in the elimination of 
two electrons which are subsequently transferred to coenzyme Q10, also known as 
ubiquinone. The electron-rich reduced form of ubiquinone called ubiquinol (QH2) 
diffuses within the IMM.   
1.2.2 Complex II 
Unlike the other OXPHOS complexes, complex II (succinate-ubiquinone 
oxidoreductase; succinate dehydrogenase; SDH) consists of four subunits (A-D) 
which are entirely nuclear-encoded (Hatefi and Galante, 1980). Hydrophilic subunits 
A and B contain a covalently-attached flavin adenine dinucleotide (FAD) coenzyme 
(subunit A) and three iron-sulfur clusters (subunit B). The remaining two subunits: C 
and D contain heme groups. Functionally, complex II is responsible for oxidation of 
succinate to fumarate. Electrons derived from succinate by FAD coenzyme are 
transferred via three iron-sulfur clusters to finally reduce ubiquinone to ubiquinol. 
Compared with the process in complex I, this reaction is not accompanied by proton 
transfer. 
1.2.3 Complex III   
Complex III (ubiquinol-cytochrome c oxidoreductase) consists of eleven subunits; 
ten of which are nuclear-encoded and only one (cytochrome b) is mitochondrially-
encoded. Three subunits: cytochrome b carrying two haem groups, cytochrome c1 
with a covalently bound haem c, and an iron-sulfur protein called a Rieske protein, 
together form a catalytic core known as the cytochrome bc1 complex. Complex III is 
responsible for the mechanism known as the Q cycle, leading to electron transfer 
from ubiquinol (QH2) to cytochrome c, accompanied by the proton pumping. Finally, 
two ubiquinols are oxidized to ubiquinones, one ubiquinone is reduced to ubiquinol 
and two electrons are passed to the two cytochrome c molecules. Simultaneously, a 
proton gradient is built across the inner mitochondrial membrane by the release of 
four protons from the intermembrane space and the uptake of two protons from the 
matrix. 
General Introduction 
  
 
10 
 
1.2.4 Complex IV 
Complex IV (cytochrome c oxidase; COX) has 13 subunits, three of which are 
mitochondrial in origin (COX I, COX II and COX III) (Kadenbach et al., 1983). 
COX is a terminal enzyme of the respiratory chain and acts as a dimer. It is located 
in the inner membrane, facing both the IMS and the matrix, and consists of two 
copper centres (CuA and CuB) and two heme groups (cytochromes a and a3). 
Complex IV is responsible for molecular oxygen reduction to water and in order for 
this to occur, four electrons are transferred from cytochrome c to the cytochrome a3- 
CuB binuclear centre, where a rapid oxygen reduction takes place. Subsequently, four 
protons bind to the reduced oxygen moiety creating two molecules of water. These 
reactions are accompanied by the translocation of an additional four protons across 
the inner membrane which builds a proton concentration gradient.          
1.2.5 Complex V    
Complex V (FOF1-ATP synthase) is composed of seventeen subunits, two of which 
(ATP6 and ATP8) are synthesized in mitochondria. ATP synthase is a large protein 
complex comprised of two connected rotary motors: FO which forms a proton 
channel embedded in the inner mitochondrial membrane, and F1 which is located in 
the matrix and catalyses ATP synthesis/hydrolysis. The catalytic F1 motor is 
composed of five different protein subunits with the stoichiometry α3β3γδε 
(Abrahams et al., 1994). Three α-subunits and three β-subunits are arranged 
alternately, creating an (αβ)3 cylinder around the coiled-coil organization of γ-
subunit (Yoshida et al., 2001). The FO motor is composed of subunits a, b and c, 
which together form a rotor-stator mechanism (Boyer, 1997). The proton-driven 
motor is comprised of cylindrically arranged c-subunits while the stator is created by 
an ab2 complex. The two motors are connected both through the stator, extending 
between FOab2 and F1α3β3δ complexes, and through the rotor, where FO c ring is 
linked to the F1γε subunits (Yoshida et al., 2001). ATP synthesis from ADP and Pi 
occurs along the “binding change mechanism” (Kayalar et al., 1977; Gresser et al., 
1982). According to this working model, downhill proton (H
+
) translocation through 
FO along the previously generated electrochemical potential gradient causes rotation 
of the FO rotor and subsequently rotation of the F1γε subunits. The rotary movement 
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of the γ-subunit is coupled with a conformational change of the β-subunits which 
constantly cycle between three states: the first “loose” site responsible for binding 
ADP and Pi, the second “tight” site being in charge of spontaneous ATP formation, 
and the third “open” state when ATP is released (Gibbons et al., 2000).  
 
1.3 Mitochondrial Genetics 
1.3.1 Mitochondrial Genome 
Mitochondria are unique in possessing their own genome – a 16,569 base pair (bp)-
long, circular, double stranded molecule (Figure 1-3) (Anderson et al., 1981). 
Mitochondrial DNA (mtDNA) molecules are located within the matrix compartment 
and there are 2-10 copies per mitochondrion. Since eukaryotic cells contain a large 
number of mitochondria, this results in a high-copy number genome.  
The mitochondrial genome is composed of a purine-rich heavy (H) strand and a 
pyrimidine-rich light (L) strand (Anderson et al., 1981). MtDNA has no introns but it 
contains a 1.1 kb long non-coding triple-stranded DNA region called the D-loop or 
control region (Kasamatsu et al., 1971). It encompasses the origin of H-strand 
replication (OH), promoter regions for transcription of both the light-strand (LSP) 
and the heavy-strand (HSP1 and HSP2), as well as the regulatory motifs for mtDNA 
expression: multiple binding sites for mitochondrial transcription factor A (TFAM), 
three conserved sequence blocks (CSB1, CSB2, CSB3), and a conserved 
termination-associated sequence (TAS) (Sbisa et al., 1997; Suissa et al., 2009). 
The mitochondrial genome codes for 13 respiratory chain polypeptide subunits, two 
ribosomal RNAs (12S and 16S rRNAs) and 22 transfer RNAs (tRNAs) (Anderson et 
al., 1981). The majority of mtDNA-encoded genes are located on the H-strand, with 
only a single respiratory chain subunit (ND6) and eight tRNA genes placed on the L-
strand. All the remaining structural and accessory proteins required for normal 
mitochondrial function are nuclear-encoded, highlighting the mitochondrion’s 
limited autonomy. 
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Unlike nuclear DNA (nDNA), mtDNA is strictly maternally inherited (Birky, 1978; 
Giles et al., 1980) with only one single case report of paternal transmission reported 
(Schwartz and Vissing, 2002). Sperm mitochondria are labelled with the ubiquitin 
tags recognized by the oocyte’s cytoplasmic destruction machinery which eliminates 
paternal mitochondria before or during the third embryonic cleavage (Sutovsky et al., 
1999).  
Mitochondrial and nuclear genomes are also different in terms of their genetic codes 
(Barrell et al., 1979). Nuclear DNA comprises three stop codons (UAA, UGA, UAG) 
while mtDNA has only two (AGA and AGG) (Barrell et al., 1979). Furthermore, the 
nDNA stop codon UGA codes for tryptophan in mtDNA, while AUA, coding for 
nDNA isoleucine, stands for methionine in the mitochondrial genome (Barrell et al., 
1979). 
 
 
Figure 1-3 The human mitochondrial genome. Heavy strand (H; outer) codes for 
12 respiratory chain subunits, 14 tRNAs and two rRNAs. Light strand (L; inner) 
codes for one respiratory chain subunit (ND6) and eight tRNA genes. (Reproduced 
from Kyriakouli et al., 2008). 
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1.3.2 Mitochondrial Haplogroups 
As a result of its close proximity to the respiratory chain, mtDNA molecules are 
permanently exposed to high ROS levels (Raha and Robinson, 2000). Together with 
the lack of protective histones and the mechanisms allowing for effective repair, as 
well as a high replication rate favouring the occurrence of replication errors, the 
mitochondrial genome accumulates mutations drastically faster than the nuclear 
genome (Howell et al., 1996; Jazin et al., 1998). Through evolution, a large number 
of benign mtDNA base substitutions, known as single-nucleotide polymorphisms 
(SNPs), have arisen and these have been inherited successively along maternal 
lineages (Cann, 2001). Phylogenetic analyses have grouped specific mtDNA 
sequence polymorphisms with particular haplotypes and groups of these haplotypes 
can be classified further into major haplogroups (Torroni and Wallace, 1994; 
Wallace et al., 1999). Human mtDNA haplogroups demonstrate a geographical and a 
continental localization, and overall 18 major haplogroups have been distinguished 
(Torroni and Wallace, 1994; Herrnstadt and Howell, 2004). Nine of these 
haplogroups (H, U, J, T, K, W, I, V, X) are characteristic for individuals of European 
ancestry, with haplogroup H being the most common (Torroni and Wallace, 1994; 
Herrnstadt et al., 2002). 
1.3.3 Mitochondrial Heteroplasmy 
MtDNA is present in cells at a high copy number and these mitochondrial genomes 
are not always identical. MtDNA can be either homoplasmic, when every 
mitochondrial genome molecule harbours the same allele, or heteroplasmic, in which 
case only a sub-population of mtDNA molecules carries a specific allele (Smith et 
al., 1993; Harding et al., 1995). The majority of pathogenic mtDNA mutations are 
heteroplasmic and OXPHOS only becomes impaired when the percentage of the 
mutant mtDNA species exceeds a mutational threshold of 60-80% (Shoubridge et al., 
1990; Sciacco et al., 1994; Bua et al., 2006; Durham et al., 2007). Interestingly, the 
level of heteroplasmy can vary between different tissues of a single individual and 
this could in part account for the variable tissue-specific phenotypes observed in 
mitochondrial disease (Chinnery et al., 1999; McFarland et al., 2002b).    
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1.3.4 Mitochondrial Genetic Bottleneck 
The mitochondrial genetic bottleneck has been proposed to explain the rapid 
segregation of heteroplasmic mtDNA genotypes between generations (Jenuth et al., 
1996; Cree et al., 2008). To date three bottleneck mechanisms have been 
hypothesised. According to the study by Cao and colleagues, the level of 
heteroplasmy transmitted from the mother to an offspring varies significantly as a 
result of a preferential replication of clusters containing identical mtDNA molecules, 
so-called homoplasmic segregating units or nucleoids (Cao et al., 2007; Cao et al., 
2009). The second model, by Cree and colleagues, postulates the rapid genetic drift 
arises due to a marked reduction in mtDNA copy number during early germ line 
development, without a need for mtDNA aggregates (Cree et al., 2008). More 
recently, a third mechanism has been proposed where the genetic bottleneck has been 
ascribed to the replication of only a subpopulation of mitochondrial genomes, the 
latter taking place during postnatal folliculogenesis and not during embryonic 
oogenesis (Wai et al., 2008). Regardless of the actual mechanism, it is likely that the 
mitochondrial bottleneck has a protective role, reducing deleterious mtDNA 
mutational load during transmission (Cree et al., 2009).   
 
1.4 Mitochondrial DNA Maintenance 
1.4.1 Mitochondrial Nucleoids 
The mitochondrial genome was originally considered to be a bare and unprotected 
structure, unlike nuclear DNA, which is wrapped with protective histones. However, 
recent studies have revealed that mtDNA is actually protein-coated and packaged 
into aggregates called nucleoids (Chen and Butow, 2005). The number of nucleoids 
per mitochondrion is tissue-dependent (Clay Montier et al., 2009) and high-
resolution stimulated emission depletion (STED) microscopy has shown that 
mammalian nucleoids are fairly uniform in size, reaching approximately 100 nm and 
they usually contain only a single mtDNA molecule (Kukat et al., 2011). Although 
up-regulation of mtDNA copy number can lead to formation of structurally larger 
nucleoids (Ylikallio et al., 2010), mtDNA exchange between these individual 
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nucleoids is limited (Gilkerson et al., 2008). A layered structure of human 
mitochondrial nucleoids has also been suggested, where both mtDNA replication and 
transcription occur in the central core of the nucleoid, while translation and complex 
assembly take place in the peripheral region (Bogenhagen et al., 2008).  
Numerous protein components are involved in the structural organisation of 
nucleoids. Mitochondrial transcription factor A (TFAM) is the main element of 
mammalian nucleoids (Garrido et al., 2003; Bogenhagen et al., 2008) playing a key 
role in packaging mtDNA (Alam et al., 2003) and regulating mtDNA copy number 
(Ekstrand et al., 2004). Several different mtDNA-related components are associated 
with nucleoids and these include: mitochondrial DNA polymerase  (polγ), Twinkle 
helicase, and the mitochondrial single-stranded binding (mtSSB) protein (Garrido et 
al., 2003; Tyynismaa et al., 2004). In addition to components that participate directly 
in mtDNA maintenance, other nucleoid-related proteins include human prohibitins 1 
and 2. These proteins participate in many essential cellular functions, including 
apoptosis, cell cycle regulation and signal transduction (Czarnecka et al., 2006). 
Prohibitins also mediate the structure of mitochondrial cristae and help to organize 
the inner membrane (Merkwirth and Langer, 2009). Other proteins associated with 
nucleoids are mitochondrial inner membrane ATAD3 (ATPase family AAA domain-
containing 3) protein, which is able to bind to the D-loop region of mtDNA (He et 
al., 2007), and tumour suppressor protein p53 that interacts with TFAM (Yoshida et 
al., 2003).   
1.4.2 Mitochondrial Genome Replication 
Mitochondrial DNA replication is exclusively controlled by nuclear genes. It occurs 
independently of the cell cycle (Bogenhagen and Clayton, 1977) and its activity may 
differ between various tissues of the same individual (Wang et al., 1997). The 
mitochondrial replisome is an assembly of four proteins: polγ, mitochondrial 
Twinkle helicase, mtSSB and TFAM. Three models of mammalian mtDNA 
replication have been reported so far (Figure 1-4): (i) an asymmetric, strand-
displacement mode (Clayton, 1982); (ii) a strand-coupled, bidirectional mode (Holt 
et al., 2000); and (iii) a ribonucleotide incorporation throughout the lagging strand 
(RITOLS) mode (Yasukawa et al., 2006).   
General Introduction 
  
 
16 
 
 
Figure 1-4 Models of mammalian mtDNA replication. (i) Strand-displacement 
(asymmetric) model (left panel): replication is initiated at the H-strand origin of 
replication (OH). Displacement of the H-strand leads to an expansion of the D-loop 
until the L-strand origin of replication (OL) is revealed. Synthesis of the L-stand is 
then initiated in the opposite direction. (ii) Strand-coupled (bidirectional) model 
(middle panel): replication is initiated from a single zone of replication initiation 
(OriZ) and followed by progression of two replication forks around the mtDNA 
molecule. (iii) RITOLS model (right panel): replication of the leading H-strand is 
similar to the strand-displacement model but the lagging L-strand is initially 
transcribed as RNA (dashed line) before being replaced by DNA. (Reproduced from 
Kasiviswanathan et al., 2011). 
 
1.4.2.1 Strand-Displacement Mode      
In Clayton’s original strand-displacement model (Figure 1-4; left panel), replication 
is initiated at the H-strand (heavy-strand) origin of replication (OH) within the D-loop 
region (Clayton, 1982). Displacement of the H-strand continues clockwise leading to 
the expansion of the D-loop until the L-strand (light-strand) origin of replication (OL) 
is revealed. Replication of the lagging L-strand begins in the opposite direction when 
the synthesis of the leading H-strand is almost two-thirds complete. As a result of 
this asymmetry, one of the daughter mtDNA molecules is entirely synthesized, while 
the other one still contains an incompletely replicated L-strand and hence is termed a 
gapped circle (GpC) (Brown et al., 2005).   
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1.4.2.2 Strand-Coupled Mode 
The alternative, bidirectional strand-coupled model of mtDNA replication (Figure 
1-4; middle panel) was presented by Holt and colleagues (Holt et al., 2000; 
Bowmaker et al., 2003). Using two-dimensional agarose gel electrophoresis (2D-
AGE), Holt and colleagues proposed the occurrence of a simultaneous synthesis of 
both the heavy and light strands. In this model, bidirectional replication begins 
within a single zone of replication initiation (OriZ) and it is followed by the 
expansion of the two replication forks around the mtDNA molecule. As a result, two 
daughter mtDNA molecules are synthesized concurrently. As suggested by Holt and 
colleagues, a strand-coupled model of mtDNA replication can occur independently 
or coexist with the original strand-displacement model (Holt et al., 2000).      
1.4.2.3 RITOLS Mode 
The most recent RITOLS mode (Figure 1-4; right panel) (Yasukawa et al., 2006) is 
frequently considered as a modified version of the original strand-displacement 
model. In principle, both the RITOLS and strand-displacement models expect a 
major delay between the syntheses of light- and heavy-strands. Compared with the 
original Clayton’s mode, in RITOLS, the lagging strand is initially transcribed as 
RNA before being replaced by DNA in the maturation stage (Yasukawa et al., 2006).    
1.4.3 Mitochondrial DNA Copy Number Regulation   
A proper balance between the rates of mitochondrial DNA degradation and synthesis 
is crucial to maintain a steady-state mtDNA copy number that is adapted to a certain 
tissue type and its developmental stage (Berk and Clayton, 1974; Clay Montier et al., 
2009). Although both mtDNA depletion and proliferation are commonly associated 
with mitochondrial disease, with mtDNA proliferation often considered a 
compensatory mechanism, little is known about the exact mechanisms of mtDNA 
copy number regulation (Clay Montier et al., 2009; Spinazzola and Zeviani, 2009). 
Several different models trying to clarify the mechanism of mitochondrial DNA copy 
number regulation have recently been proposed. As suggested by Clay Montier and 
colleagues, mtDNA copy number can be regulated in accordance with the threshold 
hypothesis (Figure 1-5) (Clay Montier et al., 2009). In this model, when mtDNA 
copy number reaches the lower threshold, unknown factors trigger the up-regulation 
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of mtDNA replication thereby pushing the copy number back up to its steady-state 
level. Conversely, when mtDNA copy number gets to the higher threshold, as yet 
unidentified factors trigger the mechanisms controlling mtDNA degradation, which 
results in a decrease in the number of mtDNA copies (Clay Montier et al., 2009). 
Other hypotheses have been proposed where mtDNA copy number is regulated by 
various mechanisms dependent upon the availability of nucleotides (Tang et al., 
2000a), the multiple replication origins (Tang et al., 2000b), or by TFAM modifying 
the mechanism of mtDNA replication (Pohjoismaki et al., 2006). So far, 
experimental evidence in support of these models of mtDNA copy number regulation 
is lacking and further work is needed to elucidate this complex process.    
         
 
Figure 1-5 Threshold hypothesis of mtDNA copy number control. When mtDNA 
copy number drops to the lower threshold, unknown factors trigger the up-regulation 
of mtDNA replication increasing the copy number back to a steady-state level. 
Respectively, when the higher threshold of mtDNA copy number is reached, yet 
unidentified factors trigger the mechanisms responsible for mtDNA degradation, to 
decrease the number of mtDNA copies. (Reproduced from Clay Montier et al., 
2009). 
 
1.5 Mitochondrial Transcription 
Transcription from the mitochondrial H-strand results in the production of two 
rRNAs, 12 mRNAs and 14 tRNAs, whereas transcription from the L-strand enables 
creation of one mRNA and eight tRNAs. The initiation of mtDNA L-strand 
transcription occurs from a single promoter (LSP). Compared with this, transcription 
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of the H-strand can arise from two specific and differentially regulated sites - HSP1 
and HSP2 (Montoya et al., 1982). The two transcripts available from the H-strand 
differ from each other both in terms of their initiation and termination sites, as well 
as frequency of occurrence (Lodeiro et al., 2012). The more common HSP1-initiated 
transcript consists of two tRNAs (tRNA
Phe
 and tRNA
Val
) and two mitochondrial 
rRNAs. The HSP2-initiated transcript occurs less frequently and it produces a large, 
almost genome-length, polycistronic mRNA molecule (Montoya et al., 1983; 
Lodeiro et al., 2012).  
Mitochondrial transcription is controlled by a highly-specialized machinery 
consisting of a monomeric RNA polymerase (POLRMT) supported by two 
transcription initiation factors – transcription factor A (TFAM) and transcription 
factor B2 (TFB2M) (Fisher and Clayton, 1985; Tiranti et al., 1997; Falkenberg et al., 
2002; Litonin et al., 2010). Human mitochondria also contain transcription factor B1 
(TFB1M), a homologue of the mammalian TFB2M (Falkenberg et al., 2002). 
However, recent in vivo studies have revealed that despite being a crucial 
methyltransferase responsible for methylation of 12S rRNA, TFB1M is not directly 
involved in transcription (Metodiev et al., 2009; Litonin et al., 2010).  
It was assumed for a long time that the initiation of transcription occurred when 
TFAM became bound to mtDNA upstream of the promoter sites, which  then 
attracted the POLRMT-TFB2M complex (Bonawitz et al., 2006). According to this 
model, initiation of transcription required TFAM, POLRMT and TFB2M irrespective 
of the promoter site (Bonawitz et al., 2006). However, recent studies have shown that 
mitochondrial transcription can be initiated in a TFAM-independent manner and the 
absence of TFAM significantly increases transcription observed from HSP1 site, 
when compared with transcription from LSP promoter site (Shutt et al., 2010). 
Furthermore, it was shown that transcription from HSP2 requires only POLRMT and 
TFB2M, whereas TFAM represses transcription by binding to TFAM-responsive 
elements (TREs) and preventing an efficient connection of POLRMT and TFB2M 
(Lodeiro et al., 2012). 
The mechanisms regulating termination of mtDNA transcription are still under 
investigation. So far, only mitochondrial transcription terminator factor 1 – MTERF1 
(also known as mTERF) has been directly associated with termination of the HSP1 
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transcript (Kruse et al., 1989; Asin-Cayuela and Gustafsson, 2007). MTERF1 and its 
three paralogues (MTERF2, MTERF3 and MTERF4) belong to a superfamily of 
mitochondrial proteins believed to play a crucial role as controllers of mtDNA 
transcription (Linder et al., 2005; Spahr et al., 2010). As demonstrated recently, 
MTERF3 can directly interact with the promoter region and it represses the initiation 
of transcription in mammalian mitochondria (Park et al., 2007).  
 
1.6 Mitochondrial Translation 
Mitochondrial translation is still far from being completely understood, mainly due 
to the absence of an in vitro translation system. All mitochondrial ribosomal proteins 
(MRPs) are nuclear-encoded and they need to be transferred to mitochondria where 
they form ribosomal complexes together with mitochondrially encoded rRNAs – 12S 
and 16S (Pietromonaco et al., 1991; O'Brien, 2003). Interestingly, mitochondrial 
ribosomes (mitoribosomes) contain relatively low amounts of RNA but a reasonably 
high proportion of protein components, compared with their prokaryotic counterparts 
(Pietromonaco et al., 1991; O'Brien, 2003; Sharma et al., 2003).  
A total of 13 polypeptide respiratory chain subunits are synthesized in mammalian 
mitochondria (Anderson et al., 1981). Translation is initiated by two initiation factors 
– mitochondrial initiation factor 2 (IF2mt) promoting connection of fMet-tRNA to the 
small ribosomal subunit (28S) and mitochondrial initiation factor 3 (IF3mt) which 
actively dissociates the 55S ribosome, leading to the release of the 39S subunit and 
creation of a 28S:IF3mt complex (Liao and Spremulli, 1991; Koc and Spremulli, 
2002; Christian et al., 2009; Christian and Spremulli, 2011). The elongation phase is 
a cyclical process requiring three mitochondrial elongation factors: EF-Tumt,, EF-Tsmt 
and EF-G1mt (Schwartzbach and Spremulli, 1989; Chung and Spremulli, 1990; 
Christian and Spremulli, 2011). Termination of translation occurs when one of the 
four mitochondrial mRNA stop codons (UAA, UAG, AGA or AGG) is encountered. 
This is facilitated by the release factor RF1amt which induces the hydrolysis of a 
freshly generated protein (Soleimanpour-Lichaei et al., 2007). Following successful 
translation termination, the ribosome is then recycled. So far, two ribosome recycling 
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factors have been proposed to participate in the recycling process – RRFmt (Rorbach 
et al., 2008) and RRF2mt, known also as EF-G2mt (Tsuboi et al., 2009) (Figure 1-6).  
 
 
Figure 1-6 Diagram of mitochondrial translation. (I) Protein synthesis initiated by 
IF2mt and IF3mt; (II) Elongation stage requiring EF-Tumt, EF-Tsmt, and EF-G1mt; (III) 
Termination carried out by RF1amt; (IV) Ribosome recycling facilitated by RRFmt 
and RRF2mt (known also as EF-G2mt). (Reproduced from Christian et al., 2009). 
 
1.7 Nuclear-Mitochondrial Interactions 
As a consequence of their limited genetic autonomy, mitochondria are heavily 
dependent on the nuclear genome. Only 13 respiratory chain polypeptides are 
mtDNA-encoded and the vast majority of mitochondrial proteins (approximately 
1500), including those involved in the formation and maintenance of the electron 
transport chain, mtDNA replication, transcription and translation, are encoded by 
nuclear genes. These nuclear-encoded proteins are first translated in the cytosol and 
they are then subsequently targeted to mitochondria (Anderson et al., 1981; Lin et al., 
2003; Calvo et al., 2006).  
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1.7.1 Transcriptional Regulation 
Nuclear-encoded DNA-binding transcription factors and their associated coregulators 
maintain a composite network which controls the activity of mitochondrial gene 
expression (Figure 1-7) (Hock and Kralli, 2009). DNA-binding transcription factors 
target overlapping but distinct classes of mitochondrial genes, allowing for tissue-
specific modulation of dedicated mitochondrial functions (Hock and Kralli, 2009). 
Two DNA-binding transcription factors, the nuclear respiratory factor-1 (NRF-1) and 
GA-binding protein (GABP; NRF-2), are involved in the regulation of the OXPHOS 
system, mtDNA replication and transcription (Virbasius et al., 1993; Scarpulla, 
2008). Other DNA-binding factors, such as the peroxisome proliferator-activated 
receptors (PPARs; PPARα, PPARγ and PPARδ) are involved in the control of lipid 
metabolism (Evans et al., 2004), whereas estrogen-related receptors (ERRs; ERRα, 
ERRβ and ERRγ) participate in the regulation of the mitochondrial genes linked to 
the oxidation of lipids, the OXPHOS system, the tricarboxylic acid (TCA) cycle, 
mitochondrial import, mitochondrial dynamics and the cell’s defence against 
oxidative stress (Giguere, 2008; Villena and Kralli, 2008; Hock and Kralli, 2009). 
The remaining DNA-binding factors are: cAMP response element-binding (CREB) 
protein, which regulates the CYCS gene coding for cytochrome c; c-Myc, which 
binds to over a hundred mitochondrial genes including mitochondrial DNA 
polymerase γ; and finally YY1, which controls various COX genes (Kim et al., 2008; 
Scarpulla, 2008; Hock and Kralli, 2009).  
Nuclear transcriptional coregulators cooperate with multiple DNA-binding factors 
inducing either their activation (PPARγ coactivator-1 family; PGC-1α, PGC-1β and 
PRC) or repression (receptor-interacting protein 140; RIP140) (Hock and Kralli, 
2009). DNA-binding factors have a dual capacity. They can simultaneously regulate 
their own expression, e.g. ERRα controls PPARα, NRF-1, GABP, and its own 
promoter, as well as expression of their coregulators, e.g. PPARγ, PPARδ, ERRγ, 
and CREB regulate PGC-1α, whereas ERRα controls RIP140 (Huss et al., 2004; 
Mootha et al., 2004; Villena and Kralli, 2008; Hock and Kralli, 2009).    
General Introduction 
  
 
23 
 
 
Figure 1-7 The transcriptional network controlling mitochondrial gene 
expression. DNA-binding factors target overlapping but distinct classes of 
mitochondrial genes, allowing a tissue-specific modulation of dedicated 
mitochondrial functions. Coregulators interact with multiple DNA-binding factors 
inducing either their activation (PGC-1α, PGC-1β and PRC) or repression (RIP140). 
(Reproduced from Hock and Kralli, 2009). 
 
1.7.2 Post-Transcriptional Regulation  
Several post-transcriptional and post-translational mechanisms are linked to the 
regulation of mitochondrial biogenesis and function (Cannino et al., 2007). RNA-
binding proteins such as RBP38, which stabilizes mitochondrial RNA (Sbicego et al., 
2003), or LRP130, which binds polyadenylated mRNAs in mitochondria (Mili and 
Pinol-Roma, 2003), are believed to participate in these intricate nuclear-
mitochondrial interactions (Cannino et al., 2007). The reversible process of protein 
acetylation is another important post-translational modification, which in humans 
requires a nuclear-encoded SirT3 deacetylase. The latter allows deacetylation of 
several mitochondrial proteins to proceed efficiently (Schwer et al., 2002). 
Mitochondrial activity can also be coordinated via the complexes responsible for 
protein import and assembly (Koehler, 2004; Cannino et al., 2007). TIM23 and the 
presequence translocase-associated motor (PAM) complexes are involved in the 
multistep import of pre-proteins into the mitochondrial matrix or IMM (van der Laan 
et al., 2006). Another important element is the SAM (sorting and assembly 
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machinery) complex that is crucial for the integration and assembly of the outer 
membrane proteins (Pfanner et al., 2004).   
1.7.3 Mitochondrial-Nuclear Communication 
Cross-talk between the mitochondria and the nucleus can be maintained at two levels 
(Ryan and Hoogenraad, 2007). Firstly, a set of DNA-binding transcription factors 
and coactivators directly regulate nuclear and mitochondrial gene expression in 
response to changes in environmental and bioenergetic conditions, such as 
temperature, caloric intake or exercise (Puigserver et al., 1998; Lin et al., 2003; 
Norrbom et al., 2004; Ryan and Hoogenraad, 2007) (please refer to Section 1.7.1). 
Secondly, a mechanism known as mitochondrial retrograde signalling utilises 
multiple factors capable of receiving and transmitting mitochondrial signals to 
initiate changes in nuclear gene expression, thereby leading to the alteration of the 
cell’s metabolism in response to mitochondrial defects (Butow and Avadhani, 2004; 
Liu and Butow, 2006). The mitochondrial retrograde signalling has been shown to 
occur via numerous stimuli e.g. cytosolic changes in Ca
2+
 concentrations in 
mammalian skeletal myoblasts (Biswas et al., 1999; Amuthan et al., 2002) or 
translocation of cytochrome c oxidase subunit III from mitochondria to the cytosol in 
the developing rat brain (Cannino et al., 2004; Cannino et al., 2007).  
 
1.8 Mitochondrial Dynamics 
Mitochondria are dynamic organelles constantly fusing and breaking apart. It is now 
clear that the balance between fusion and fission is crucial to maintain a highly-
interconnected and stable mitochondrial network (Chen and Chan, 2005). When this 
delicate balance is perturbed, dramatic changes in mitochondrial network 
morphology can be observed with detrimental consequences for cell function. Cells 
with a high fusion-to-fission ratio comprise only few, highly-elongated mitochondria, 
whereas a low ratio is associated with numerous fragmented mitochondria, these 
appearing as small, isolated spheres or short rods (Bleazard et al., 1999; Chen et al., 
2003). Mitochondria are shuttled within the cell along cytoskeletal tracks, allowing 
their translocation to locations where they are actively needed (Frederick and Shaw, 
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2007). This is especially relevant for highly-polarized cells such as neurones and 
retinal ganglion cells (RGCs) which consist of long axonal segments covering 
relatively large anatomical distances and hence strongly relying on an effective 
bidirectional mitochondrial distribution (Figure 1-8; Figure 1-9) (Hollenbeck and 
Saxton, 2005; Frederick and Shaw, 2007; Chen and Chan, 2009). The increased 
interest in mitochondrial dynamics contributed to the discovery of numerous 
mitochondrial shaping proteins: mitofusin-1 (MFN1), mitofusin-2 (MFN2) and optic 
atrophy 1 (OPA1), which are key pro-fusion proteins, as well as dynamin-related 
protein 1 (DRP1) and mitochondrial fission 1 (hFis1), which are key pro-fission 
proteins (Suen et al., 2008; Liesa et al., 2009).  
 
 
Figure 1-8 Comparison of mitochondrial motility. (A) Wild-type neurones: 
mitochondria are able to travel from the cell body to the dendritic and axonal 
terminals; (B) Impaired motility prevents distribution of mitochondria to the 
periphery. (Reproduced from Chen and Chan, 2009). 
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Figure 1-9 Bi-directional movement of mitochondria in neurones. The 
anterograde transport is responsible for translocating mitochondria from the cell 
body toward the synapse, whereas retrograde movement returns mitochondria from 
the peripheral sites. (Reproduced from Frederick and Shaw, 2007).     
 
1.8.1 Functions of Mitochondrial Dynamics 
Fusion and fission allow cells to actively and dynamically respond to changes in their 
surrounding physiological conditions. Fusion enables mitochondrial compartments to 
mix and functionally complement each other, whereas fission forms organelles that 
are distinct both in terms of morphology and function (as reviewed in Westermann, 
2010). Together, these two processes are essential to maintain normal mitochondrial 
functions and they are critical for cell survival (Figure 1-10).  
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Figure 1-10 Functions of mitochondrial dynamics. Mitochondrial fission is 
essential for (i) the segregation of mitochondria during cell division, (ii) intracellular 
cytoskeleton-mediated transport, (iii) turnover of the damaged mitochondria by 
mitophagy, and (iv) cytochrome c release to initiate apoptosis. Mitochondrial fusion 
is crucial for the dissipation of metabolic energy and complementation of mtDNA in 
heteroplasmic cells. (Adapted from Westermann, 2010).     
 
1.8.1.1 Mitochondrial Inheritance 
The cell’s mitochondrial network morphology is dependent upon the cell cycle and 
fission is responsible for the stochastic partitioning of mitochondria to daughter cells 
during cell division (Taguchi et al., 2007; Ishihara et al., 2009; Westermann, 2010). 
Since mitochondrial fission generates highly-fragmented organelles, some of them 
may lack mtDNA molecules or other essential components. Mitochondrial fusion is 
therefore critical for the exchange and complementation of impaired or missing 
mitochondrial components, ensuring their replenishment before the organelle’s 
functionality is lost and allowing OXPHOS to be maintained at an adequate level 
(Nakada, 2009; Westermann, 2010). Recent studies have suggested the presence of 
two types of mitochondrial fusion: prolonged complete fusion allowing redistribution 
of all necessary mitochondrial components, and short-term kiss-and-run transient 
fusion (Figure 1-11) (Liu et al., 2009). The latter effectively facilitates the 
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redistribution of small solutes, mRNA or proteins, whereas complementation of 
integral membrane proteins or mtDNA remains restricted (Liu et al., 2009). Although 
both types of mitochondrial fusion are mediated by the same set of fusion proteins, 
transient and complete fusions vary in terms of their OPA1 requirements (Liu et al., 
2009). If OPA1 levels are inadequate to maintain complete fusion, transient fusion 
can still be effectively supported (Liu et al., 2009). 
 
 
Figure 1-11 Types of mitochondrial fusion. Short-term transient fusion allows 
quick replenishment of only soluble factors by IMS and matrix exchange whereas 
prolonged complete fusion allows redistribution of all necessary mitochondrial 
components. (Reproduced from Liu et al., 2009).  
  
1.8.1.2 Mitochondrial Distribution and Morphology 
The fusion and fission machineries allow the mitochondrial network to be shaped 
according to the specific functional requirements of a particular cell type (Figure 
1-12) (as reviewed in Westermann, 2010). In neuronal populations, which are good 
examples of large and extended cell types, fission controls the distribution of 
mitochondria by splitting the network into transportable units. These can then be 
further transported along cytoskeletal tracks to sites of higher energy demands (Li et 
al., 2004; Westermann, 2010). In comparison, in muscle fibres, which are also 
exceptionally large cells requiring significant amounts of energy, fusion generates 
enlarged mitochondrial networks, forming electrically coupled systems functioning 
as intracellular power-transmitting cables (Amchenkova et al., 1988; De Giorgi et al., 
2000; Skulachev, 2001). Such a configuration enables transmission of the membrane 
potential generated in the oxygen-rich areas in the periphery of the muscle fibre to 
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the oxygen-poor muscle fibre core, thereby allowing ATP synthesis to proceed there 
(Skulachev, 2001; Westermann, 2012). As shown recently, by forming a hyperfused 
network, mitochondrial fusion can also act as a protective mechanism that allows a 
degree of protection against the stress-induced high energy demand or starvation 
(Tondera et al., 2009; Westermann, 2012). Conversely, in resting cells, which only 
require a low activity of the mitochondrial respiratory chain, fragmented 
mitochondria are frequently found (as reviewed in Westermann, 2010).   
 
 
Figure 1-12 Adaptation of mitochondrial morphology to variable respiratory 
chain activity. Under normal respiratory conditions, mitochondria cyclically 
undergo fusion and fission. When the cell’s energy demand is low, mitochondria 
prefer a fragmented morphological state whereas exposure to stress or starvation 
triggers creation of hyperfused mitochondria to optimize mitochondrial function. 
(Reproduced from Westermann, 2012).        
 
1.8.1.3 Mitochondrial Quality Control and Turnover  
Mitochondrial dynamics is believed to play a central role as a quality control 
mechanism, managing mitochondrial turnover (Figure 1-13) (Twig et al., 2008). 
According to this theory, each mitochondrion cyclically oscillates between two 
morphological states – an interconnected post-fusion state and a fragmented post-
fission state (Twig et al., 2008). Fusion is a brief event and it triggers fission 
generating daughter mitochondria which either preserve intact membrane potential or 
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depolarize (Twig et al., 2008). Mitochondria that are unable to restore the membrane 
potential are unlikely to proceed to a subsequent fusion (Twig et al., 2008). After a 
few hours in a depolarized and solitary state, these mitochondria are eliminated from 
the cell by mitochondrial autophagy (mitophagy) (Twig et al., 2008).  
 
 
Figure 1-13 Model of mitochondrial life cycle. Mitochondria cyclically oscillate 
between post-fusion and post-fission states. A brief selective fusion triggers fission 
that generates daughter mitochondria. These either preserve intact membrane 
potential (red line) or depolarize (green line). Unless membrane potential is restored, 
the mitochondrion is removed by mitochondrial autophagy (mitophagy). 
(Reproduced from Twig et al., 2008).    
 
1.8.1.4 Apoptosis 
During programmed cell death, mitochondrial fission is a key feature, occurring 
concomitantly with OMM permeabilization, cristae disorganisation and the 
successive release of pro-apoptotic factors such as cytochrome c, smac/DIABLO, 
HtrA2/omi, which ultimately leads to procaspase-9 activation (Youle and Karbowski, 
2005; Suen et al., 2008; Otera and Mihara, 2012). Both the proapoptotic (Bax/Bak) 
and antiapoptotic (Bcl-2/Bcl-xL) proteins of the Bcl-2 family play significant roles in 
the regulation of mitochondrial morphology as part of the intrinsic (mitochondrial) 
apoptotic pathway (Martinou and Youle, 2011). Once apoptosis is triggered, 
mitochondrial fission is induced by Bax/Bak activation, which causes a reduction in 
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mitochondrial fusion followed by an increase in fragmentation, likely through the 
inhibition of MFN2 (Karbowski et al., 2002; Karbowski et al., 2004; Brooks et al., 
2007; Otera and Mihara, 2012). Activation of Bax/Bak also leads to a stable 
association of DRP1 with the outer mitochondrial membrane, as a consequence of 
Bax/Bak-dependent SUMO modification of DRP1 (Wasiak et al., 2007; Otera and 
Mihara, 2012). Although mitochondrial fission is directly correlated with cytochrome 
c release and activation of the apoptotic pathway, the pro-fusion OPA1 protein is 
capable of regulating the size of mitochondrial cristae junctions, thereby preventing 
cytochrome c molecules from being released and blocking intrinsic apoptotic 
activation (Frezza et al., 2006; Liesa et al., 2009) (Figure 1-14).   
 
 
Figure 1-14 Model of apoptosis progression. From left to right, Bax is translocated 
to mitochondria where it coalesces with DRP1, MFN2 and Bak. These series of 
events result in mitochondrial fission and release of cytochrome c from 
mitochondrial cristae. (Reproduced from Suen et al., 2008).  
 
1.8.2 Mitochondrial Fusion 
Mitochondrial fusion is a highly coordinated process involving firstly outer 
membrane and followed by inner membrane fusion (Chen et al., 2003; Cipolat et al., 
2004). Three large members of a dynamin-related GTPase superfamily are essential 
to the fusional process: MFN1, MFN2 and OPA1 (Figure 1-15). Mitofusins are 
responsible for the fusion of the OMM whereas OPA1 facilitates fusion of the IMM 
(Santel and Fuller, 2001; Chen et al., 2003; Cipolat et al., 2004; Song et al., 2009).   
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Figure 1-15 Diagram illustrating main proteins involved in fusion of 
mammalian mitochondria. Mitofusins (MFN1 and MFN2) facilitate OMM fusion 
while OPA1 controls IMM fusion; mitoPLD (mitochondrial phospholipase D) 
recruits fusion proteins; mitochondrial proteases: PARL (presenilin-associated 
rhomboid-like) protease, m-AAA and i-AAA are involved in OPA1 cleavage. 
(Reproduced from Suen et al., 2008).  
 
1.8.2.1 MFN1 and MFN2  
MFN1 and MFN2 are two large GTPases involved in the fusion of the OMM (Chen 
et al., 2003). Human MFN1 and MFN2 show about 60% homology and a high 
degree of evolutionary conservation to their yeast homologue Fzo1 (Hermann et al., 
1998; Santel and Fuller, 2001; Zorzano, 2010). Both mitofusins are transmembrane 
proteins integrated in the OMM, with a conserved N-terminal region containing a 
GTPase-binding domain and a coiled-coil 1 domain (CC1 or heptad-repeat 1; HR1), 
as well as a C-terminal region consisting of a bipartite transmembrane domain and 
another coiled-coil domain CC2, also known as the HR2 domain (Figure 1-16) 
(Zorzano, 2010). Both GTPase and HR2 domains face the cytosolic side of the OMM 
(Rojo et al., 2002; Zorzano, 2010). Mitofusins are capable of forming homo- or 
heterotypic complexes which mediate tethering between neighbouring mitochondria 
(Chen et al., 2003; Koshiba et al., 2004; Meeusen et al., 2004).  
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The central GTPase domain of MFN1 and MFN2 consists of five G motifs (G1 to 
G5) and these are responsible for binding the phosphate moiety of the GTP molecule 
(G1), coordinating Mg
2+
 content (G3), activating catalytic activities (G1, G2, G3), 
and providing a conformation site for GTP binding (G4, G5) (Bourne and 
McCormick, 1990; Zorzano, 2010). Apart from the GTPase domain, mitofusins 
contain two coiled-coil domains (CC1 and CC2) tethering adjacent mitochondria and 
a transmembrane domain (TM). Interestingly, the proline-rich domain (PR) involved 
in protein-protein interactions is only found in MFN2, being absent in MFN1 (Chen 
et al., 2003; Zorzano, 2010). MFN2 has been described in more detail in Section 
1.11.3 below.   
 
 
Figure 1-16 MFN1 and MFN2 protein structures - (A) and (B) respectively. 
GTPase domain motifs (G1 to G5), coiled-coil domains (CC1 and CC2), a 
transmembrane domain (TM) and a proline-rich domain (PR). (Reproduced from 
Zorzano, 2010).   
 
1.8.2.2 OPA1 
OPA1 is the major protein regulating inner mitochondrial membrane fusion 
(Meeusen et al., 2004; Meeusen et al., 2006). OPA1 is a dynamin-related GTPase 
localized within the IMM and it is orthologous to the fungal Msp1 and yeast Mgm1p 
proteins (Olichon et al., 2002; Landes et al., 2010). In humans, the OPA1 gene 
(3q28–q29) is composed of 30 exons; three exons (4, 4b and 5b) are alternatively 
spliced, resulting in eight specific mRNA isoforms (Delettre et al., 2001; Olichon et 
al., 2002). As a consequence, the OPA1 protein can range in size from 924 to 1014 
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amino acids depending on the particular splice variant that is transcribed (Delettre et 
al., 2001). OPA1 transcripts are widely expressed in human tissues but they 
predominate in the brain, retina, heart, and muscle (Alexander et al., 2000; Delettre 
et al., 2001).  
OPA1 consists of: (i) an N-terminal mitochondrial import sequence (MIS) conferring 
mitochondrial localisation; (ii) a predicted transmembrane region (TM1) associating 
OPA1 to the inner mitochondrial membrane; (iii) a coiled-coil 1 region (CC1) most 
likely involved in protein-protein interactions; (iv) a GTPase domain composed of 
three G motifs (G1, G3 and G4) associated with functions as described for adequate 
G motifs of mitofusins (please refer to Section 1.8.2.1 for details); (v) a middle 
domain, and (vi) a carboxy-terminal coiled-coil domain (CC2), also known as the 
GTPase effector domain (GED), which is predicted to facilitate interactions between 
OPA1 and mitofusins (Landes et al., 2010; Zorzano, 2010). Two transmembrane 
domains (TM2a and TM2b) and an additional coiled-coil region (CC0) are only 
available in splice variants 4b and 5b (Olichon et al., 2007) (Figure 1-17).  
 
 
Figure 1-17 OPA1 gene and protein structure. OPA1 consists of 30 exons 
(including exons 4b and 5b). The protein domains encoded by particular exons are 
highlighted below the numbering. MPP, S1 and S2 – proteolytic cleavage sites for 
Mitochondrial Processing Peptidase (MPP), Paraplegin (S1) and YME1L (S2). 
(Reproduced from Landes et al., 2010).  
 
OPA1 can exist as long (l-OPA1) and short (s-OPA1) isoforms, depending on the 
number of proteolytic cleavage sites that get activated (Landes et al., 2010). L-OPA1 
isoforms are attached to the IMM while s-OPA1 forms, missing TM1, are believed to 
be either peripherally anchored to the IMM, diffused within the IMS, or associated 
with the OMM (Olichon et al., 2002; Satoh et al., 2003; Cipolat et al., 2006; Landes 
et al., 2010). Formation of the long OPA1 isoforms (l-OPA1) involves cleavage of 
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the mitochondrial import sequence (MIS) by the mitochondrial processing peptidase 
(MPP) (Olichon et al., 2002; Satoh et al., 2003; Landes et al., 2010). Short forms are 
generated by protelolytic cleavage occurring additionally at the S1 and S2 sites, 
located within exons 5 and 5b, respectively (Ishihara et al., 2006; Song et al., 2007). 
Three mitochondrial proteases are known to recognize S1 and S2 cleavage sites: (i) 
presenilin-associated rhomboid-like (PARL) protease, which generates the s-OPA1 
isoform, soluble in the IMS (Cipolat et al., 2006), (ii) matrix AAA protease (m-
AAA), which forms homo- or heteromeric complexes (containing paraplegin, 
Afg3L1 and Afg3L2 subunits) capable of cleaving OPA1 at S1 (Ishihara et al., 
2006); and finally intermembrane AAA protease (i-AAA) YME1L, which is 
responsible for cleaving OPA1 at S2 and possibly other sites as well (Griparic et al., 
2007; Song et al., 2009). The current view is that the correct balance between long 
and short isoforms of OPA1 plays an important role in regulating the efficiency of 
mitochondrial fusion (Song et al., 2007).  
Other functions of OPA1 are described in more detail in Section 1.10.3 below. 
1.8.2.3 MitoPLD 
Mitochondrial phospholipase D (mitoPLD) is a dimeric enzyme that has recently 
been proposed to take part in mitochondrial fusion (Choi et al., 2006). MitoPLD 
binds to the OMM through an amino-terminal transmembrane segment, whereas its 
catalytic domain faces the cytosol (Jensen and Sesaki, 2006). Following mitofusin-
mediated tethering of two mitochondria, mitoPLD places its catalytic domain in the 
membrane of an adjacent mitochondrion and then it hydrolyses cardiolipin. The 
cardiolipin then produces phosphatidic acid, which is thought to activate or recruit 
other fusion proteins or to be a fusogenic lipid itself (Choi et al., 2006; Jensen and 
Sesaki, 2006; Suen et al., 2008).  
1.8.3 Mitochondrial Fission 
Mitochondrial fission in mammals requires DRP1. This key protein is recruited from 
the cytosol to interact with the outer membrane hFis1 protein (Smirnova, 2001; Yoon 
et al., 2003; Wasiak et al., 2007). DRP1 and hFis1 are the mammalian homologues of 
the yeast Dnm1 and fis1p, respectively (Bleazard et al., 1999; Fannjiang et al., 2004).  
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1.8.3.1 DRP1 and hFis1 
DRP1 consists of an amino-terminal GTPase domain, a middle domain and a 
carboxy-terminal GTPase effector domain involved in self-assembly (Westermann, 
2010). As a result of alternative splicing in humans, there is a brain-specific DRP1 
isoform that contains an additional insertion between the middle region and the 
GTPase effector domain (Smirnova et al., 1998). Mitochondrial hFis1 is a small 
outer mitochondrial membrane protein and it consists of a transmembrane domain 
and a tetratricopeptide (TPR) region (Westermann, 2010). The widely accepted 
mechanism of mammalian mitochondrial fission assumes hFis1-mediated 
recruitment of DRP1 from the cytosol and formation of DRP1-hFis1 complexes on 
the OMM, thereby initiating fission of both the outer and inner mitochondrial 
membranes (Figure 1-18) (Suen et al., 2008; Westermann, 2010). DRP1-hFis1 
complexes form spirals at division sites tightly enclosing the mitochondrial tubule, 
eventually leading to fission (Suen et al., 2008). However, the exact mechanism of 
mammalian fission is likely to be more complex. For example, recent studies have 
revealed that DRP1 is capable of assembling on mitochondria without hFis1 (Lee et 
al., 2004).      
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Figure 1-18 Mitochondrial fission machinery. DRP1 is located in the cytosol and it 
is recruited to the OMM by hFis1 protein. DRP1-hFis1 complexes form spirals at 
division sites tightly enclosing the mitochondrial tubule and leading to fission of both 
the outer and inner mitochondrial membranes. (Reproduced from Suen et al., 2008).  
 
1.9 Mitochondrial Genetic Disorders  
Mitochondrial cytopathies form a heterogeneous group of human disorders caused by 
the disturbance of mitochondrial function. Mitochondrial disorders can be classified 
into two main groups: (i) primary mitochondrial DNA disorders, associated with 
primary mtDNA point mutations or rearrangements (deletions and duplications), and 
(ii) nuclear mitochondrial disorders, related to mutations affecting a large number of 
nuclear genes required for the complex assembly and stability of the mitochondrial 
machinery. These nuclear mitochondrial disorders are frequently linked to mtDNA 
instability manifesting as either secondary mtDNA deletions or depletion (Kirkman 
et al., 2008). Mitochondria are obligate intracellular organelles and they mediate a 
host of critical cell functions, including energy production through OXPHOS. 
Unsurprisingly, mitochondrial cytopathies are clinically highly heterogeneous, with 
patients frequently manifesting a diverse combination of tissue and organ 
involvement (McFarland et al., 2002b; Sitarz et al., 2012b). 
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1.9.1 Primary Mitochondrial DNA Disorders  
Primary mtDNA disorders can be broadly classified into those secondary to mtDNA 
point mutations or mtDNA rearrangements (Tuppen et al., 2010). Pathogenic 
mtDNA point mutations are usually heteroplasmic, but several pathogenic 
homoplasmic mtDNA variants, often affecting only selected tissues and 
demonstrating incomplete penetrance, have now been identified (McFarland et al., 
2002a; Taylor et al., 2003; Tuppen et al., 2010). The clinical manifestations 
associated with primary mtDNA mutations are highly variable (Figure 1-19), and for 
some mutations, the age of onset and phenotypic severity usually reflects the 
mutational load in affected tissues (Tuppen et al., 2010). MtDNA deletions are the 
most common large-scale genomic rearrangements identified in patients with 
primary mtDNA disorders. These deletions extend across several critical tRNA and 
polypeptide-encoding genes, resulting in a significant impairment in OXPHOS and 
energy production (Schon et al., 1989; Chen et al., 1995; Tuppen et al., 2010).  
 
 
Figure 1-19 Primary mtDNA mutations and their phenotypic manifestations. 
CPEO - chronic progressive external ophthalmoplegia; LHON - Leber hereditary 
optic neuropathy; LS - Leigh syndrome; MELAS - mitochondrial myopathy, 
encephalopathy, lactic acidosis, and stroke-like episodes; MERRF - myoclonic 
epilepsy and ragged red fibres; MILS - maternally inherited Leigh syndrome; NARP 
- neurogenic weakness, ataxia, and retinitis pigmentosa; PS - Pearson syndrome. 
(Reproduced from Tuppen et al., 2010).   
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1.9.1.1  Leber Hereditary Optic Neuropathy     
Leber hereditary optic neuropathy (LHON, OMIM 535000) is the most common 
primary mitochondrial DNA disorder in the general population, with a minimum 
prevalence of approximately 1 in 31,000 in the North of England (Yu-Wai-Man et 
al., 2003). The majority (90-95%) of individuals suffering from LHON harbour one 
of the three mtDNA point mutations: (i) m.3460G>A (Howell et al., 1991; Huoponen 
et al., 1991), (ii) m.11778G>A (Wallace et al., 1988) and (iii) m.14484T>C (Johns et 
al., 1992; Mackey and Howell, 1992). The peak age of onset of visual loss is usually 
in the second and third decades of life and it is characterized by severe, painless loss 
of central vision (Johns et al., 1993). Visual loss is bilateral in about 25% of cases, 
when unilateral, the second eye is usually affected within three months (Yu-Wai-
Man et al., 2009; Yu-Wai-Man et al., 2011b). Optic disc pallor becomes evident 
about six weeks following the onset of visual loss (Yu-Wai-Man et al., 2011b). 
Pathological cupping of the optic disc is a characteristic feature of established LHON 
cases, reflecting the irreversible loss of retinal ganglion cell (RGC) axons in the 
chronic phase of the disease (Yu-Wai-Man et al., 2011b). 
LHON is characterized by incomplete penetrance and a marked sex bias, with only 
about 50% of male carriers and about 10% of female carriers losing vision during 
their lifetime (Yu-Wai-Man et al., 2011b). The overall prognosis in LHON is poor, 
even among patients harbouring the m.14484T>C mutation, which carries the best 
chance for the partial visual recovery (Yu-Wai-Man et al., 2009). LHON is typically 
a monosymptomatic disease but additional features such as cardiac conduction 
defects, peripheral neuropathy, dystonia, and myopathy have been reported as 
occurring more frequently among LHON carriers. In particular, there is a well-
reported association between the three primary mtDNA LHON mutations and a 
multiple sclerosis-like illness, especially among female carriers. Rarer pathogenic 
mtDNA variants have been linked with more atypical “LHON +” syndromes, where 
the optic neuropathy segregated with prominent neurological features including 
spastic dystonia, ataxia, juvenile-onset encephalopathy, and psychiatric disturbances 
(Yu-Wai-Man et al., 2011b; Sitarz et al., 2012b).    
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1.9.2 Nuclear Mitochondrial Disorders 
Mutations involving nuclear-encoded mitochondrial proteins participating in mtDNA 
maintenance can result in a decrease in mtDNA copy number, the accumulation of 
high-levels of somatic mtDNA mutations (point mutations and deletions), or both 
(Table 1-1) (Alberio et al., 2007; Spinazzola and Zeviani, 2009; Yu-Wai-Man et al., 
2011b). The recognition of these mtDNA abnormalities in diagnostic samples point 
towards an underlying nuclear defect and the need for additional targeted molecular 
investigations (Yu-Wai-Man et al., 2011b). MtDNA depletion is the pathological 
hallmark found in a number of early-onset nuclear mitochondrial disorders (Yu-Wai-
Man et al., 2011b). There is a significant reduction in mtDNA copy number, which 
can be highly tissue-specific, partly explaining the phenotypic variability of these 
diseases (Spinazzola et al., 2009). The histochemical investigations of muscle 
biopsies of individuals with nuclear-mitochondrial disorders frequently reveal the 
presence of COX-deficient muscle fibres (Section 1.9.4.1) (Yu-Wai-Man et al., 
2011b). The biochemical COX-defect associated with nuclear genetic mutations 
involving OPA1, POLG1 or POLG2 has been linked to the accumulation of multiple 
mtDNA deletions, which have clonally expanded above the threshold levels of 
approximately 70% (Horvath et al., 2006; Amati-Bonneau et al., 2008; Hudson et al., 
2008a; Spinazzola and Zeviani, 2009). Multiple mtDNA deletions can accumulate 
exponentially in post-mitotic tissues of both healthy elderly individuals and in those 
suffering from neurodegenerative diseases, such as Parkinson disease and 
Alzheimer’s dementia (Cortopassi et al., 1992; Bender et al., 2006; Kraytsberg et al., 
2006). Crucially, mtDNA deletions frequently span over critical regions of the 
mitochondrial genome, resulting in OXPHOS impairment and ultimately leading to 
cell death and tissue dysfunction (Yu-Wai-Man et al., 2011b).  
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Table 1-1 Nuclear mitochondrial disorders. (Adapted from Yu-Wai-Man et al., 
2011b).  
Mutations involving structural subunits of the mitochondrial respiratory chain: 
Leigh syndrome: with complex I deficiency – mutations in NDUFS1, NDUFS2, 
NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, 
NDUFA1, NDUFA8, NDUFA11, ACAD9; with complex II deficiency – mutations 
in SDHA 
Cardiomyopathy and encephalopathy with complex I deficiency – mutations in 
NDFUS2 
Optic atrophy and ataxia with complex II deficiency – mutations in SDHA 
Hypokalaemia and lactic acidosis with complex III deficiency – mutations in 
UQCRB 
Mutations involving assembly factors of the mitochondrial respiratory chain: 
Leigh syndrome: with COX defect – mutations in SURF1 and LRPPRC; with 
complex I defect – mutations in NDUFAF2, C20orf7, C8orf38 
Hepatopathy and ketoacidosis – mutations in SCO1 
Cardiomyopathy and encephalopathy – mutations in SCO2 
Leukodystrophy and renal tubulopathy – mutations in COX10 
Hypertrophic cardiomyopathy – mutations in COX15 
Encephalopathy, liver failure, and renal tubulopathy with complex III deficiency – 
mutations in BCS1L 
Encephalopathy with complex V deficiency – mutations in ATP12 and TMEM70 
Nuclear genetic disorders of intra-mitochondrial protein synthesis: 
Leigh syndrome – mutations in MTFMT and C12orf65 
Leigh syndrome, liver failure, and lactic acidosis – mutations in EFG1 
Lactic acidosis and developmental failure – mutations in MRPS16 
Infantile reversible liver failure – mutations in TRMU 
Leukodystrophy and polymicrogyria – mutations in EFTu 
Myopathy and sideroblastic anaemia – mutations in PUS1 and YARS2 
Encephalomyopathy and hypertrophic cardiomyopathy – mutations in EFTs 
Edema, hypotonia, cardiomyopathy, and tubulopathy – mutations in MRPS22 
Pontocerebellar hypolasia – mutations in RARS2 
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Nuclear genetic disorders of mitochondrial protein import 
Mohr-Tranebjaerg syndrome or deafness-dystonia-optic neuronopathy (DDON) 
syndrome – mutations in TIMM8A (DDP) 
Early-onset dilated cardiomyopathy with ataxia (DCMA) or 3-methylglutaconic 
aciduria, type V – mutations in DNAJC19 
Nuclear genetic disorders of mitochondrial DNA maintenance 
Chronic progressive external ophthalmoplegia – mutations in POLG1, POLG2, 
PEO1, SLC25A4, RRM2B, TK2 and OPA1 
Mitochondrial neurogastrointestinal encephalomyopathy – mutations in TYMP 
Alpers-Huttenlocher syndrome (AHS) – mutations in POLG1 and MPV17 
Infantile myopathy and spinal muscular atrophy – mutations in TK2 
Encephalomyopathy and liver failure – mutations in DGUOK and MPV17 
Hypotonia, renal tubulopathy, and lactic acidosis – mutations in RRM2B 
Hypotonia, movement disorder and/or Leigh syndrome with methylmalonic 
aciduria – mutations in SUCLA2 and SUCLG1 
Optic atrophy, deafness, chronic progressive external ophthalmoplegia, myopathy, 
ataxia, and peripheral neuropathy – mutations in OPA1 
Miscellaneous 
Co-enzyme Q10 deficiency – mutations in primary biosynthesis genes PDSS1, 
PDSS2, COQ2, COQ6, COQ9 and ADCK3; secondary Co-enzyme Q10 deficiency 
– mutations in ETFDH and APTX 
Barth syndrome – mutations in TAZ 
Sengers syndrome – mutations in AGK 
Cardiomyopathy and lactic acidosis associated with mitochondrial phosphate 
carrier deficiency – mutations in SLC25A3 
Alpers-Huttenlocher syndrome (AHS): epilepsy, cortical blindness, micronodular 
hepatic cirrhosis, episodic psychomotor regression; Barth syndrome: 
cardiomyopathy, hypotonia, weakness, and neutropenia; Sengers syndrome – 
congenital cataract, hypertrophic cardiomyopathy, myopathy and lactic acidosis. 
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1.9.3 Mitochondrial DNA Deletions 
1.9.3.1 Formation  
The great majority of mtDNA deletions take place within the major arc of the 
mitochondrial genome between the two origins of replication (OH and OL; please 
refer to Section 1.4.2 for details) (Samuels et al., 2004; Bua et al., 2006; Krishnan et 
al., 2008). Most mtDNA deletions (~ 60%; class I deletions) are flanked by two 13-
bp homologous direct repeat sequences, one of which is removed by the deletion 
process (Samuels et al., 2004). Class II deletions (~ 30% cases) are flanked by 
imperfect repeats, whereas class III deletions (~ 10% cases) have no direct repeat 
sequences participating in a deletion process (Samuels et al., 2004).  
Several different hypotheses have been suggested to explain the mechanism 
underlying mtDNA deletion formation (Krishnan et al., 2008). Originally mtDNA 
deletions were thought to occur through a slipped-strand replication mechanism 
based on the Clayton’s asymmetric strand-displacement replication mode (Section 
1.4.2.1) (Figure 1-20) (Clayton, 1982; Shoffner et al., 1989). However, if replication 
is the main mechanism behind the formation of mtDNA deletions, then mitotic cells, 
where mtDNA replication is a more frequent event, should have greater mtDNA 
deletion loads when compared with post-mitotic tissues (Krishnan et al., 2008). As 
recently confirmed in human colonic tissue, this is not always the case, hence a 
different model has been proposed, which explains the generation of mtDNA 
deletions during the repair of double-stranded breaks (DSBs) within mtDNA 
molecules (Figure 1-21) (Krishnan et al., 2008). According to this theory, single-
stranded fragments of mtDNA are generated through 3′→5′ exonuclease activity at 
double-strand breaks (Krishnan et al., 2008). The 5'- and 3'-repeat fragments can 
misanneal resulting in degradation of the unbound single strands, ligation of the 
double strands and ultimately the formation of deleted mtDNA molecules (Krishnan 
et al., 2008).  
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Figure 1-20 Formation of a mtDNA deletion through a slipped-strand model of 
replication. (a) The mtDNA molecule contains two direct repeats labelled 5′ and 3′; 
(b) Replication of mtDNA commences at OH of D-loop, displacing the light strand 
from the heavy strand; (c) The single-stranded 3′ repeat of the light strand misanneals 
with the newly exposed single-stranded 5′ repeat of the heavy strand, which 
generates a downstream, single-stranded and susceptible to strand breaks light-strand 
loop; (d) The damaged loop is degraded until it reaches the double-stranded regions, 
and ligation of the free ends of the heavy strand happens; (e) Replication is continued 
leading to production of a wild-type and a deleted mtDNA molecules (f). 
(Reproduced from Krishnan et al., 2008).   
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Figure 1-21 Formation of mtDNA deletions during repair of double-stranded 
breaks. (a) The mtDNA molecule contains two direct repeats labelled 5′ and 3′; (b) 
A double-stranded break occurs; (c-d) The double-stranded break is susceptible to 
3′→5′ exonuclease activity, resulting in production of single strands; (e) The 5′- and 
3′-repeat sequences can misanneal, leading to degradation of the unbound single 
strands, and ligation of the double strands; (f) A deleted mtDNA molecule containing 
copies of both the 5′ and 3′ repeats, is generated. (Reproduced from Krishnan et al., 
2008). 
 
1.9.3.2 Clonal Expansion  
Following the formation of a mtDNA deletion, a biochemical defect is only 
expressed once a mutated mtDNA molecule clonally expands to a level exceeding 
the critical threshold (Chinnery and Samuels, 1999). Two main mechanisms 
explaining clonal expansion of mutated mtDNA molecules have been proposed so 
far: (i) the random genetic drift (Chinnery and Samuels, 1999; Elson et al., 2001) and 
(ii) an advantageous replication of deleted mtDNA molecules (Fukui and Moraes, 
2009; Nicholas et al., 2009).  
The random genetic drift theory suggests that relaxed replication of mtDNA, 
followed by random genetic drift, leads to the clonal expansion of single mutant 
events during human life (Chinnery and Samuels, 1999; Elson et al., 2001). The 
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accumulation of mutated mtDNA molecules is balanced by the increase in 
mitochondrial proliferation acting as a compensatory mechanism to preserve 
sufficient levels of wild-type mtDNA genomes, allowing normal respiratory chain 
function (Chinnery and Samuels, 1999; Elson et al., 2001). However, once the 
mutational level exceeds a defined threshold level, further mitochondrial 
proliferation results in the replication of the mutated mtDNA molecules at the cost of 
wild-type genomes, leading to COX-deficiency (Chinnery and Samuels, 1999; Elson 
et al., 2001). Noteworthy, the ratio between wild-type and mutated mtDNA genomes 
can be tissue-specific (Durham et al., 2007). 
The second model suggests the occurrence of a positive selection for deleted mtDNA 
species during replication (Fukui and Moraes, 2009; Nicholas et al., 2009). 
According to this theory, smaller sized, deleted mtDNA molecules are thought to 
replicate at a higher rate than larger, wild-type mtDNA genomes (Fukui and Moraes, 
2009; Nicholas et al., 2009). The level of accumulation of mutated mtDNA species is 
believed to be inversely proportional to mtDNA deletion size (Diaz and Moraes, 
2008; Fukui and Moraes, 2009; Nicholas et al., 2009). 
1.9.4 Diagnostic Investigations  
Mitochondrial disorders are clinically and genetically heterogeneous and reaching an 
accurate diagnosis can be a challenging task. If an underlying mitochondrial genetic 
disorder is suspected, it is advisable to perform molecular investigations directly on 
the affected tissue, if available. Tissue specificity is an important consideration, e.g. 
in patients with mtDNA maintenance disorders secondary to nuclear mutations in 
POLG1, mtDNA deletions are usually not detectable in blood, an easily accessible 
tissue, but they can be identified in post-mitotic tissues such as skeletal muscle 
(McFarland et al., 2002b). The comprehensive analysis of skeletal muscle specimens 
using a range of validated histochemical, biochemical and genetic diagnostic tools, is 
crucial to reach a diagnosis for a large number of patients with suspected 
mitochondrial disease (Figure 1-22) (McFarland et al., 2002b). 
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Figure 1-22 Muscle biopsy examinations on patients with suspected mtDNA 
disorders. (Reproduced from McFarland et al., 2002b).   
 
1.9.4.1 Histochemical Assessment          
Mitochondrial histochemical staining performed on skeletal muscle sections is a 
powerful method of detecting an underlying OXPHOS defect. Numerous well-
established staining protocols are commonly used (Figure 1-23), involving: (i) 
haematoxylin and eosin (H&E), (ii) modified Gomori trichrome, (iii) COX and (iv) 
SDH, as well as (v) myofibrillar ATPase. 
H&E stain allows the demonstration of the basic muscle fibre morphology, whereas 
modified Gomori trichrome stain is performed to reveal abnormal subsarcolemmal 
accumulation of mitochondria in muscle fibres (so called ragged-red fibres; RRFs). 
RRFs can also be detected through SDH histochemistry.     
Succinate dehydrogenase (SDH; complex II) is encoded entirely by nuclear DNA 
whereas cytochrome c oxidase (COX; complex IV) consists of both mitochondrial- 
and nuclear-encoded subunits. If mtDNA integrity is compromised e.g. by point 
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mutations or deletions, this will have a deleterious effect on overall COX activity, 
whereas SDH activity remains unchanged unless a nuclear defect affects one of its 
four subunits. Muscle fibres with normal COX activity stain brown (COX-positive) 
whereas COX-deficient (COX-negative) fibres remain unstained. SDH activity is 
indicated by the intensity of the blue staining. Following dual COX/SDH staining, 
COX-negative fibres are highlighted blue whereas COX-positive fibres remain 
brown in colour. A mosaic pattern of COX-negative muscle fibres is often found in 
patients suffering from heteroplasmic mtDNA mutations and nuclear mitochondrial 
disorders characterised by the accumulation of secondary mtDNA deletions (Yu-
Wai-Man et al., 2011b). However, some caution is required as COX-negative muscle 
fibres are not always pathological. It is well established that low levels of COX-
negative fibres (1 - 2%) can be detected in skeletal muscle from normal elderly 
individuals as a result of the age-related clonal expansion of somatic mtDNA 
deletions (Brierley et al., 1998; Bodyak et al., 2001). 
The myofibrillar ATPase staining can be performed to illustrate the distribution of 
different muscle fibre types, broadly classified as type I (slow contracting, oxidative) 
or type II (fast contracting, glycolytic/oxidative). ATPase histochemistry allows 
identification of pathological features such as fibre atrophy or fibre-type grouping, 
indicative of peripheral neuropathy, a common feature of mitochondrial diseases. In 
the first step of the ATPase staining protocol, fibres are preincubated with an acid 
solution (pH ~ 4), which inhibits ATPase activity in fast (type II) fibres. As a result, 
type I muscle fibres are stained dark brown, whereas type II muscle fibres remain 
light brown in colour. 
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Figure 1-23 Histochemical features of mitochondrial dysfunction. (A) Typical 
ragged-red muscle fibre revealed by Gomori trichrome staining; (B) Serial section of 
the muscle fibre shown in (A) following SDH histochemistry; (C) Normal COX 
staining revealing presence of a mixed population of muscle fibre types (type I – 
dark, type II - light in colour); (D) Abnormal COX histochemistry from a patient 
with CPEO, showing a number of COX-deficient fibres; (E) Sequential COX/SDH 
staining on a serial section of (D), revealing abnormal COX-negative (blue) muscle 
fibres and normal COX-positive (brown) muscle fibres; (F) Dual COX/SDH 
histochemistry revealing a single COX-deficient muscle fibre in a section of the 
ageing muscle. (Reproduced from Taylor et al., 2004).  
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1.9.4.2 Biochemical Assessment  
Measurements of individual respiratory chain complex activities are routinely 
performed in patients with suspected mitochondrial disease (McFarland et al., 
2002b). Ideally, biochemical studies should be carried out on fresh muscle samples, 
however this is not always possible and frozen muscle sections can be used instead 
(Taylor et al., 2004). Mitochondrial DNA disorders can be associated either with an 
isolated defect limited to a single respiratory chain complex or present with a 
combined deficiency pattern involving several OXPHOS complexes (McFarland et 
al., 2002b). The majority of combined respiratory chain deficiencies involve 
complexes: I and IV, I and III, or I, III and IV (Loeffen et al., 2000). Interestingly, 
combined respiratory chain defects involving complex II (SDH) are relatively rare 
and if present, affect mostly the muscle tissue (Desnuelle et al., 1989; Vladutiu and 
Heffner, 2000).   
1.9.4.3 Genetic Assessment 
Molecular genetic investigation should routinely be carried out for all patients found 
to have abnormal mitochondrial histochemical and biochemical findings. Even if 
these tests are negative, consideration should still be given to genetic testing for 
those patients presenting with clear-cut mitochondrial phenotypes  (McFarland et al., 
2002b). Patients with clinical manifestations which fit a typical presentation should 
be referred for screening for the implicated mutations e.g. the m.3243A>G mutation 
in MELAS or the m.8344A>G mutation in MERRF (McFarland et al., 2002b). 
Genetic screening is routinely carried out using either restriction fragment length 
polymorphism (RFLP) assays or with direct polymerase chain reaction (PCR)-based 
sequencing (McFarland et al., 2002b). Alternatively, DNA samples from patients 
negative for the most common mtDNA mutations can be subjected to whole 
mitochondrial genome sequencing (Taylor et al., 2001; McFarland et al., 2002b). 
However, mtDNA is highly polymorphic and proving pathogenicity for novel 
variants can be challenging without functional confirmation (McFarland et al., 
2002b). If possible, genetic tests should be performed on DNA extracted from an 
affected tissue, for example, using muscle homogenate DNA in a patient with a 
myopathy.  Unfortunately, despite being highly accessible, blood is not an ideal 
sample for investigating several mitochondrial disorders as it can contain decreased 
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levels of some mtDNA mutations, a good illustration being the m.3243A>G (Pyle et 
al., 2007; Rajasimha et al., 2008). 
Mitochondrial disorders associated with mtDNA rearrangements: single deletion, 
multiple mtDNA deletions, and mtDNA duplications, can be detected using a range 
of techniques, which include Southern blot, long-range PCR and quantitative real-
time PCR assays (Taylor et al., 2004). Southern blotting has long been considered 
the ‘gold standard’ technique allowing precise detection and quantification of single 
mtDNA deletions. However, a limitation is that it may fail to detect low levels of 
multiple mtDNA deletions (Deschauer et al., 2003; Taylor et al., 2004). Long-range 
PCR analysis is more sensitive than Southern blotting, however, because it 
preferentially amplifies smaller mtDNA species, an accurate quantification of the 
deletion load is not possible (Taylor et al., 2004). Recently, fluorescent-probed real-
time PCR assays are more commonly used. This technique is very sensitive and 
moreover, it requires only small amounts of DNA, allowing quantitative genetic 
analysis to be performed at a single-cell level (He et al., 2002). Real-time PCR can 
be used to quantify mtDNA deletion levels as well as mtDNA copy number in 
individual COX-positive and COX-negative muscle fibres, providing a reliable tool 
for investigating the mutation threshold required to trigger a biochemical defect 
(Durham et al., 2005; Durham et al., 2007). 
Screening of well-characterised nuclear-encoded genes like POLG1 or PEO1, often 
allows the identification of the contributory genetic alteration in patients with 
confirmed multiple mtDNA deletions (Hudson and Chinnery, 2006; Chinnery and 
Zeviani, 2008). Nevertheless, the underlying genetic basis for a large proportion of 
suspected nuclear-encoded mitochondrial disorders have yet to be clarified and the 
development of new high-throughput sequencing techniques, such as exome 
sequencing, will prove crucial in dissecting the causative genetic defect.           
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1.10 OPA1-Related Disorders 
1.10.1 OPA1 gene 
OPA1 mutations are the most common causes of autosomal-dominant optic atrophy 
(DOA) and they are found in about 60% of patients with a clinical diagnosis of DOA 
(ADOA; OMIM 165500) (Alexander et al., 2000; Delettre et al., 2000). OPA1 is a 
highly polymorphic gene and so far over 200 pathogenic variants have been 
identified, clustering in the GTPase region and the dynamic central domain (eOPA1 
database; http://lbbma.univ-angers.fr/lbbma.php?id=9). For a structural description 
of the OPA1 gene and the encoded OPA1 protein, please refer to Section 1.8.2.2.  
1.10.2 Autosomal-Dominant Optic Atrophy 
DOA was first described as a distinct clinical entity by Poul Kjer, a Danish 
ophthalmologist, in the late 1950’s (Kjer, 1959). It has a minimum disease 
prevalence of 1 in 35,000 in the North of England (Yu-Wai-Man et al., 2010a) and 
the majority (approximately 60%) of DOA cases are linked to pathogenic mutations 
within the OPA1 gene (Cohn et al., 2007). To reduce cost, OPA1 is routinely 
sequenced using PCR-based methods, but these techniques are unfortunately unable 
to detect exonic deletions or duplications. These large-scale rearrangements have 
been identified in 10-20% of OPA1-negative families and additional molecular 
studies, although not yet widely available, are strongly recommended for probands 
with a clear-cut DOA phenotype and a strong family history (Fuhrmann et al., 2009; 
Yu-Wai-Man et al., 2011b; Sitarz et al., 2012b).  
DOA is an inherited optic neuropathy characterized by a progressive visual loss 
starting in early childhood, colour vision abnormalities, visual field defects, and a 
development of the optic nerve pallor (Votruba, 1998). Similarly to LHON, the 
primary site of pathology in DOA is the papillomacular bundle and central, 
centrocecal, and paracentral scotomas are the most common visual field defects 
(Sitarz et al., 2012b). Histopathological studies of a postmortem eye retrieved from 
one of the patients showed relative preservation of melanopsin-containing RGCs, the 
latter accounting for the lack of an afferent pupillary defect in DOA - another clinical 
peculiarity shared with LHON (La Morgia et al., 2010; Sitarz et al., 2012b). The 
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optic disc in DOA can look diffusely pale or it can have a characteristic temporal 
wedge, especially in patients at an early stage of disease when RGC loss remains 
mostly localized to the papillomacular bundle (Figure 1-24) (Fraser et al., 2010; Yu-
Wai-Man et al., 2011b; Sitarz et al., 2012b).   
 
 
Figure 1-24 Ocular fundus appearance and visual fields in an OPA1-mutated 
patient with dominant optic atrophy (DOA). Temporal wedge of the optic disc 
pallor can be noticed. OD - oculus deuter – right eye; OS – oculus sinister – left eye. 
(Adapted from Fraser et al., 2010).  
 
Although optic nerve dysfunction is the main feature of DOA, it is now well 
established that up to 20% of OPA1 carriers will develop additional neuromuscular 
complications in addition to optic atrophy, so-called DOA+ phenotypes (Yu-Wai-
Man et al., 2010b). These more severe syndromal forms of OPA1 disease are 
characterised by the development of deafness, ataxia, myopathy, neuropathy and 
CPEO (Yu-Wai-Man et al., 2010b). Patients with DOA+ phenotypes have higher 
levels of COX-deficient muscle fibres and mtDNA deletions compared to patients 
with pure DOA, implicating a direct role for these secondary mtDNA abnormalities 
in the development of more severe neuromuscular features (Amati-Bonneau et al., 
2008). Interestingly, the probability of developing DOA+ phenotype is three times 
higher with missense OPA1 mutations targeting the functional GTPase domain of the 
protein (Yu-Wai-Man et al., 2010b).  
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1.10.3 Disease Mechanisms  
1.10.3.1 Mitochondrial Fusion 
As described previously (Section 1.8.2.2), OPA1 is responsible for fusion of the 
IMM (Meeusen et al., 2004; Meeusen et al., 2006). A functional decrease in OPA1 
protein level, secondary to pathogenic OPA1 mutations or the silencing of OPA1 
variants (especially those including exon 4) by small interfering RNAs (siRNAs), 
induces significant fragmentation of the mitochondrial network (Olichon et al., 2007; 
Lenaers et al., 2009). The pathological downregulation of OPA1 expression can 
dissipate mitochondrial membrane potential, triggering a pro-fission signal, or it can 
directly affect OPA1 interactions with MFN1 and MFN2, which are essential for the 
maintenance of an interconnected mitochondrial network (Legros et al., 2002; 
Cipolat et al., 2004; Guillery et al., 2008). OPA1 pro-fusional activity is essential to 
maintain both types of mitochondrial fusion, prolonged complete fusion and short-
term kiss-and-run transient fusion, thereby allowing exchange and complementation 
of impaired or missing mitochondrial components (please refer to Section 1.8.1.1) 
(Liu et al., 2009). Overexpression of OPA1 results in excessive mitochondrial 
elongation (Olichon et al., 2002). This can act as a protective mechanism (Tondera et 
al., 2009), however, if prolonged, OPA1 overexpression can trigger cellular 
senescence as a consequence of ROS over-production and mtDNA damage (Lee et 
al., 2007; Lenaers et al., 2009).   
1.10.3.2 Respiratory Chain Activity 
OPA1 plays a key role in mitochondrial OXPHOS as it interacts directly with 
mitochondrial respiratory chain complexes I, II and III, helping to stabilise these 
structures (Zanna et al., 2008). It has also been shown that downregulation of OPA1 
or overexpression of OPA1-mutant alleles can disturb the IMM structure causing 
uncontrolled proton leakage and dissipation of the membrane potential required for 
normal mitochondrial respiratory chain function (Olichon et al., 2003).  
1.10.3.3 Control of Apoptosis 
OPA1 is closely involved in sequestering pro-apoptotic factors such as cytochrome c 
within the cristae, thereby protecting the cell from undergoing apoptosis (Lee et al., 
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2004; Olichon et al., 2007). There is experimental data to suggest that different 
OPA1 isoforms mediate distinct cellular functions. Crucially, OPA1 isoforms 
containing exon 5b are thought to directly control cytochrome c release by regulating 
the tightness of the cristae junctions (Olichon et al., 2007; Lenaers et al., 2009).  
1.10.3.4 MtDNA Maintenance   
OPA1 mutations have been associated with the accumulation of multiple mtDNA 
deletions in skeletal muscle (Hudson et al., 2008a). The origin of these deletions and 
the mechanisms driving their clonal expansion to levels high enough to trigger a 
biochemical defect, have not yet been elucidated. Based on precipitation studies, 
some investigators have suggested that OPA1 makes direct physical contact with 
mtDNA molecules as part of mitochondrial nucleoids (Wang and Bogenhagen, 2006; 
Elachouri et al., 2011). It has also been shown that cells harbouring OPA1 mutations 
show mitochondrial network fragmentation associated with dispersion of nucleoids, 
resulting in the loss of mtDNA molecules i.e. depletion (Amati-Bonneau et al., 
2008). 
 
1.11 MFN2-Related Disorders 
1.11.1 MFN2 gene 
MFN2 (1p36.22) consists of 19 exons and it codes for a 757 amino acid-long, 
transmembrane GTPase protein localized to the outer mitochondrial membrane (Rojo 
et al., 2002; Zorzano, 2010). Missense MFN2 mutations cause a specific subtype of 
Charcot-Marie-Tooth (CMT) disease, CMT-2A (OMIM 118210) (Züchner et al., 
2004). For a structural description of the MFN2 gene and MFN2 protein, please refer 
to Section 1.8.2.1.  
1.11.2 Charcot-Marie-Tooth 2A 
CMT is a heterogeneous group of disorders and it is classified into two main types: 
type 1 demyelinating form (CMT-1) and type 2 axonal form (CMT-2) (Shy, 2004; 
Chung et al., 2006). Axonal CMT consists of 9 distinct subtypes (2A, 2B, 2D, 2E, 
2F, 2G, 2I, 2K, 2L) and MFN2 mutations result in the CMT-2A phenotype (Figure 
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1-25) (Chung et al., 2006). CMT-2A is a dominant-inherited neurodegenerative 
disorder mainly affecting the long peripheral nerves (Züchner et al., 2004). It is 
characterized by distal muscle weakness and atrophy, mild sensory loss, and normal 
or near-normal nerve conduction velocities indicative of an axonal peripheral 
neuropathy (Pareyson, 2004; Chung et al., 2006). Interestingly, optic atrophy is a 
prominent clinical feature of CMT-2A, clearly implying that MFN2 plays an 
important role in the maintenance of RGC axonal function and survival (Züchner et 
al., 2006).    
 
 
Figure 1-25 MFN2 mutations confirmed to cause CMT-2A. Genetic disorders are 
grouped by affected MFN2 domains. (Reproduced from Liesa et al., 2009). 
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1.11.3 Disease Mechanisms  
MFN2 and its homologue MFN1 share a high degree of structural and functional 
complementarity with OPA1, all being dynamin GTPase proteins (Chen et al., 2003; 
Detmer and Chan, 2007). Both MFN1 and MFN2 control fusion of the OMM and 
they also form homo- or heterotypic complexes which mediate tethering between 
neighbouring mitochondria (Chen et al., 2003; Koshiba et al., 2004; Meeusen et al., 
2004). GTP hydrolysis activity is essential for MFN2-driven mitochondrial fusion 
(Eura et al., 2003) and mutations within the GTPase domain can either activate this 
process or inactivate the GTPase domain, thereby blocking fusion (Santel and Fuller, 
2001; Chen et al., 2003; Neuspiel et al., 2005; Liesa et al., 2009). Mitofusins form 
multimeric protein complexes with OPA1 and some MFN2 mutations can prevent 
formation of these complexes, thereby inhibiting mitochondrial fusion (Guillery et 
al., 2008; Liesa et al., 2009).  
In addition to OMM fusion, MFN2 regulates mitochondrial membrane potential 
independently of its role as a pro-fusion protein (Pich et al., 2005). MFN2 also plays 
a distinct role in mitochondrial oxidative output by regulating the expression of 
nuclear-encoded mitochondrial respiratory chain subunits and their stable assembly 
(Pich et al., 2005). MFN2 could also be relevant to mitochondrial axonal transport 
and the preferential involvement of the long peripheral nerves in CMT (Zorzano, 
2010). Recent studies have also confirmed that MFN2 (and not MFN1) is present in 
the endoplasmic reticulum (ER) where it controls ER morphology and tethering to 
mitochondria (de Brito and Scorrano, 2008). As a result of its dual function in both 
mitochondria and the ER, MFN2 regulates calcium homeostasis and it is crucial for 
the modulation of insulin signalling, as well as maintenance of normal glucose 
homeostasis (Sebastian et al., 2012). Unsurprisingly, downregulation of MFN2 has 
also been linked to ER stress and cellular dysfunction (Ngoh et al., 2012).   
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1.12 POLG1-Related Disorders 
1.12.1 DNA Polymerase γ  
Polymerase gamma (polγ) is the only mtDNA polymerase and it is a heterotrimeric 
holoenzyme that consists of a single 140-kDa catalytic subunit (POLG) and a 
homodimeric 55-kDa accessory subunit (POLG2), encoded by POLG1 (15q25, 
OMIM 174763) and POLG2 (17q, OMIM 604983) genes, respectively (Ito and 
Braithwaite, 1990; Gray and Wong, 1992; Yakubovskaya et al., 2006). The POLG1-
encoded catalytic subunit is composed of two distinct functional domains (Figure 
1-26 B): a C-terminal exonuclease domain (3′→5′ exonuclease activity) and an N-
terminal polymerase domain (DNA polymerase activity), separated by the linker 
region (Kaguni, 2004). Apart from its exonuclease and polymerase activities, the 
catalytic subunit has also been associated with the 5′- deoxyribose phosphate (dRP) 
lyase activity involved in the base excision repair (BER) mechanism (Pinz and 
Bogenhagen, 2000; Kaguni, 2004). Phylogenetic studies confirm a high level of 
conservation within the catalytic subunit’s sequence across species, with conserved 
active site motifs both in the 3′→5′ exonuclease domain (I, II and III) and in the 
DNA polymerase domain (A, B and C) (Kaguni, 2004; Chan and Copeland, 2009). 
The POLG2 accessory subunit is capable of binding DNA with great efficiency 
during mtDNA replication (Lim et al., 1999) and it plays a role as a maintenance 
factor regulating the mtDNA content of nucleoids (Di Re et al., 2009).   
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Figure 1-26 POLG1 gene and the catalytic subunit of polγ (POLG). (A) POLG1 
contains 22 exons encoding the catalytic subunit of polγ. (B) Catalytic subunit of 
polγ (POLG) consists of two functional domains: C-terminal exonuclease domain 
and N-terminal polymerase domain, separated by the linker region. Conserved motifs 
of exonuclease domain (I, II and III) and polymerase domain (A, B and C) are 
labelled. (Adapted from Horvath et al., 2006). 
 
1.12.2 POLG1 Mutations and Mitochondrial Disease 
Over 150 pathogenic POLG1 mutations leading to secondary defects of mtDNA 
maintenance and mitochondrial respiratory chain dysfunction have been identified 
(Figure 1-27) (Chan and Copeland, 2009; Stewart et al., 2009). POLG1 mutations 
can lead to both quantitative (depletion) and qualitative (point mutations and 
deletions) secondary mtDNA abnormalities, and these trigger COX-deficiency at the 
single cell level in affected tissues (Chan and Copeland, 2009).       
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Figure 1-27 Overview of POLG1 mutations. Reproduced from the Human DNA 
Polymerase Gamma Mutation Database available at: http://tools.niehs.nih.gov/polg/.     
 
POLG1-related disease is clinically heterogeneous. Pathogenic POLG1 mutations 
were first identified in patients with autosomal dominant CPEO (adPEO; OMIM 
157640) (Van Goethem et al., 2001), a classical mitochondrial phenotype 
characterised by bilateral, usually symmetrical, limitation of eye movements 
(ophthalmoplegia) and droopy upper eyelids (ptosis) (Suomalainen et al., 1997; Van 
Goethem et al., 2001). Compound heterozygous POLG1 mutations were 
subsequently found to cause autosomal recessive CPEO (arPEO; OMIM 258450), 
this subtype being clinically more heterogeneous and severe compared with adPEO 
(Bohlega et al., 1996; Van Goethem et al., 2001; Van Goethem et al., 2003). 
Recessive POLG1 mutations have also been identified in patients suffering from 
Alpers-Huttenlocher syndrome (AHS; OMIM 203700) (Davidzon et al., 2005; 
Nguyen et al., 2005), a disease characterised by severe developmental delay, 
intractable seizures, liver failure, death in childhood, as well as mtDNA depletion 
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and decreased POLG activity (Naviaux et al., 1999; Davidzon et al., 2005). POLG1 
mutations are also responsible for a number of other distinct clinical phenotypes, 
including mitochondrial recessive ataxia syndrome (MIRAS; OMIM 607459) 
(Hakonen et al., 2005; Tzoulis et al., 2006), sensory ataxic neuropathy dysarthria and 
opthalmoparesis (SANDO, OMIM 607459), idiopathic parkinsonism and premature 
ovarian failure (Luoma et al., 2004), and nucleoside reverse-transcriptase inhibitor 
(NRTI) toxicity (Graziewicz et al., 2006; Hudson and Chinnery, 2006; Copeland, 
2008). 
1.12.3 Disease Mechanisms 
The exact molecular mechanisms by which POLG1 mutations contribute to the 
formation and accumulation of mtDNA deletions still remains unclear. Various 
hypotheses have been put forward including the possibility that POLG1 mutations 
affect mtDNA replication by causing structural tertiary changes within POLG, 
leading to replication errors secondary to slipped H-strand mispairing (Van Goethem 
et al., 2003). As shown by Del Bo and colleagues, mutations involving the POLG1 
exonuclease domain can lead to a reduction in the proof-reading exonuclease activity 
of POLG, with a deleterious consequence on mtDNA integrity and the subsequent 
accumulation of pathogenic levels of somatic mtDNA mutations (Del Bo et al., 
2003). The significant increase in mtDNA point mutation yield in POLG1 carriers 
has recently been confirmed by the ultra-deep re-sequencing-by-synthesis (UDS) 
assay (Payne et al., 2011).     
 
1.13 Optic Nerve Disorders  
Mitochondrial dysfunction has a marked predilection for the optic nerve, a structure 
composed of the axons of approximately 1.2 million retinal ganglion cells (RGCs). 
About half of all the patients with confirmed mitochondrial disease will develop 
some degree of visual loss secondary to optic nerve degeneration. Irrespective of the 
molecular pathways involved, all mitochondrial optic neuropathies share the same 
striking set of pathological features – selective degeneration of the RGC layer, 
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leading to a progressive axonal loss and the onset of visual failure (Table 1-2) (Yu-
Wai-Man et al., 2011b; Sitarz et al., 2012b).  
 
Table 1-2 Primary inherited optic nerve disorders. (Adapted from Yu-Wai-Man 
et al., 2011b).  
Inheritance Gene Phenotype References 
Autosomal 
dominant 
OPA1 
Isolated optic atrophy and 
DOA+ phenotypes 
(Alexander et al., 2000; 
Delettre et al., 2000; 
Yu-Wai-Man et al., 
2010b) 
OPA3 
Autosomal dominant optic 
atrophy and cataracts 
(ADOAC) 
(Garcin et al., 1961; 
Reynier et al., 2004) 
OPA4 Optic atrophy (Kerrison et al., 1999) 
OPA5 Optic atrophy (Barbet et al., 2005) 
OPA8 
Optic atrophy and 
sensorineural deafness 
(Carelli et al., 2011) 
Autosomal 
recessive 
OPA3 
3-methylglutaconic aciduria 
type III (Costeff syndrome) 
(Anikster et al., 2001) 
OPA6 Optic atrophy (Barbet et al., 2003) 
OPA7 Optic atrophy (Hanein et al., 2009) 
X-linked OPA2 Optic atrophy 
(Assink et al., 1997; 
Katz et al., 2006) 
Mitochondrial - 
LHON and overlapping 
mitochondrial syndromes 
Table 1-1 
 
1.13.1 Optic Nerve Anatomy 
RGCs are specialised neurones located within the ganglion cell layer of the inner 
retina (Figure 1-28) (Levin, 2006). RGCs receive visual signals from the rod and 
cone photoreceptors via two different types of intermediate neurons: bipolar and 
amacrine cells (Levin, 2006). The human retina contains approximately 1.2 million 
RGCs and each individual cell receives signals from about 100 photoreceptors. The 
merged information is then relayed along a single axon to the following brain 
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regions: the lateral geniculate nucleus, the pretectal nucleus, the superior colliculus, 
or the suprachiasmatic nucleus (Levin, 2006). RGC axons project toward the optic 
nerve head, where the axons leave the globe to form the optic nerve (Figure 1-29 B) 
(Levin, 2006). The retinal nerve fibre layer is especially dense within the 
papillomacular region (Levin, 2006). This specific bundle of RGC axons subserves 
the central 10 degrees of the visual field and it is responsible for high-level 
discriminatory vision, accounting for the severe visual loss experienced by patients 
with mitochondrial optic neuropathies (Figure 1-29 A) (Levin, 2006).  
The efficiency and speed of axonal conduction along the optic nerve is dependent on 
the presence of an insulating myelin sheath produced by glial oligodendrocytes 
(Levin, 2006). The intraretinal ganglion cell axons are usually unmyelinated and they 
acquire a myelin covering behind the lamina cribrosa. This anatomical landmark, 
marking the transition between myelinated and unmeylinated RGC axon regions, is a 
multilayered collagen matrix peripherally continuous with the sclera (Figure 1-29 C) 
(Bisaria, 1973; Levin, 2006). Besides oligodendrocytes, the optic nerve is also reliant 
on another group of glial cells, astrocytes, which are involved in several functions, 
including ionic homeostasis, potassium transport, glycogen storage and the 
regulation of neurotransmitters (Levin, 2006).   
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Figure 1-28 Schematic representation of the main anatomical structures of the 
eye. The insert shows a cross-sectional view of the retina. RPE – retinal pigment 
epithelium. (Reproduced from Caspi, 2010). 
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Figure 1-29 Anatomy of the optic nerve. (A) Tracks of retinal ganglion cell (RGC) 
axons within the retinal nerve fibre layer. Significant accumulation of axons in the 
area of central vision – papillomacular bundle (F- fovea; P- papillomacular bundle; 
T-temporal raphe). (B) RGC axons arisen from different locations within the retina 
are travelling towards the optic disc. (C) Cross-sectional view of the optic nerve head 
(C- central retinal artery; N- nerve fibre layer; A- bundle of axons within the optic 
nerve; G- glia; L- lamina cribrosa; S- sclera). (Adapted from Levin, 2006). 
 
1.13.2 Mechanisms Contributing to RGC Loss 
The apoptotic loss of RGCs is the final pathological outcome of mitochondrial optic 
neuropathies. Several disease pathways are likely to contribute to this irreversible 
process and these have been further detailed below.   
1.13.2.1 Mitochondrial Network Dynamics 
OPA1 and MFN2 are essential for mitochondrial fusion (Section 1.8.2; Section 
1.10.3.1; Section 1.11.3). In addition, OPA1 ensures the integrity of the 
mitochondrial cristae’s tight junctions, thereby preventing pro-apoptotic cytochrome 
c molecules from being released into the cytosolic space (Section 1.10.3.3) (Lee et 
al., 2004). Unsurprisingly, the pathological hallmark of OPA1- and MFN2-mutant 
fibroblasts is mitochondrial network fragmentation, which not only impairs 
mitochondrial OXPHOS, but also leads to the uncontrolled release of calcium and 
cytochrome c into an already compromised cellular environment (Amati-Bonneau et 
al., 2008; Chevrollier et al., 2008; Zanna et al., 2008). Possibly, a similar mechanism 
may lead to RGCs loss in mitochondrial-related neuropathies.  
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1.13.2.2 Bioenergetic Failure 
Mitochondria regulate OXPHOS and as a result of this tight control, they provide 
most of the cell’s ATP requirements. As described previously (Section 1.10.3.2), 
OPA1 mutations have a detrimental impact on mitochondrial oxidative output by 
impairing the assembly and stability of the respiratory chain complexes (Zanna et al., 
2008). Although most studies, based on in vitro or in vivo assays, indicate a 
significant impairment of complex I activity leading to a reduction in mitochondrial 
membrane potential and overall ATP synthesis (Yu-Wai-Man et al., 2009), 
significant decrease in COX activity has also been reported (Chevrollier et al., 2008; 
Yu-Wai-Man et al., 2010c). This bioenergetic deficit is bound to impact negatively 
on RGCs, however this by itself cannot solely account for their selective 
vulnerability in mitochondrial optic neuropathies.  
1.13.2.3 Reactive Oxygen Species  
The increased susceptibility of RGCs in DOA could be due to an elevation of ROS 
levels, secondary to the downstream deleterious consequences triggered by OPA1 
mutations. A drosophila Opa1 (dOpa1) model has recently been established where 
homozygous mutant flies developed a rough and glossy eye phenotype due to the 
loss of hexagonal lattice cells, with decreased lens and pigment deposition. This 
genetically engineered dOpa1 mutation led to a significant increase in ROS levels, 
providing clear evidence of cellular oxidative stress (Shahrestani et al., 2009; Tang et 
al., 2009). 
1.13.2.4 Disturbed Calcium Handling   
MFN2, as described in Section 1.11.3, tethers the ER to the mitochondrial network. 
This ER-mitochondrial interaction is closely involved in the regulation of calcium 
flux within cells (de Brito and Scorrano, 2008; Sebastian et al., 2012). In CMT-2A 
neuropathy, this tethering effect is lost with dramatic deleterious consequences on 
cellular calcium homeostasis (de Brito and Scorrano, 2008; Sebastian et al., 2012). 
The ER and mitochondrial network are important calcium stores and the dynamic 
flux between these two compartments buffers against cytosolic calcium spikes that 
can sensitize the cell to various proapoptotic signals (de Brito and Scorrano, 2008; de 
Brito and Scorrano, 2009). Similar to the pathomechanism of MFN2 mutations, 
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mtDNA point mutations involving complex I and complex IV subunits have also 
been directly linked with disturbed calcium handling in neuronal populations 
(Trevelyan et al., 2010). Although speculative, it is tempting to suggest that a similar 
process is contributing to RGC dysfunction in LHON and DOA (Dayanithi et al., 
2010).   
1.13.2.5 Somatic mtDNA Defects 
Individuals with DOA+ phenotypes have pathological levels of COX-deficient 
muscle fibres, secondary to the accumulation of high levels of clonally-expanded 
somatic mtDNA deletions (Section 1.10.2) (Amati-Bonneau et al., 2008; Yu-Wai-
Man et al., 2010c). OPA1 is likely to be involved in maintaining the integrity of the 
mitochondrial genome by anchoring the mtDNA replicative machinery (nucleoids) to 
the IMM (Elachouri et al., 2011). Dominant-negative OPA1 mutations could 
therefore lead to the formation of mtDNA deletions by disturbing these delicate 
physical interactions along the IMM (Elachouri et al., 2011). Patients with DOA+ 
have more pronounced visual acuities and a significantly thinner retinal nerve fibre 
layer (RNFL) thickness compared with those who develop only isolated optic 
atrophy (Yu-Wai-Man et al., 2011a). These clinical observations suggest that the 
accumulation of somatic mtDNA deletions probably have an incremental detrimental 
effect on RGC survival.    
1.13.3 Selective Vulnerability of RGCs 
The preferential involvement of RGC loss in mitochondrial cytopathies could derive 
from the characteristic anatomy of the optic nerve, the latter acquiring a myelin 
sheath only behind the lamina cribrosa (Levin, 2006). This transition is marked by a 
sharp differential gradient with a much higher density of mitochondria and voltage-
gated sodium channels in the pre-laminar unmyelinated segment compared with the 
post-laminar myelinated segment of the optic nerve (Figure 1-30 and Figure 1-31) 
(Andrews et al., 1999; Bristow et al., 2002). These physiological adaptations 
facilitate the efficient propagation of the nerve action potentials in the absence of an 
insulating myelin cover. The pre-laminar region therefore represents a weak link, 
which is significantly more exposed to the disadvantageous consequences of 
mitochondrial biochemical defects (Yu-Wai-Man et al., 2011b). The maintenance of 
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a higher mitochondrial concentration in the pre-laminar region also highlights the 
central role played by the cytoskeleton, especially the microtubule network, in 
shuttling and localising mitochondria to appropriate cellular locations (Figure 1-31) 
(Section 1.8.1.2). Both mitochondrial respiratory chain defects or a primary 
disturbance in the cytoskeletal network can therefore lead to impaired axonal 
transport and ultimately apoptotic RGCs loss (Yu-Wai-Man et al., 2011b).  
 
 
Figure 1-30 Histological, histochemical and immunohistochemistrical 
investigations performed on serial longitudinal optic nerve sections: (A) 
haematoxylin and eosin, (B) Van Gieson’s preparation for collagen fibres (red; the 
arrow points towards the lamina cribrosa), (C) Weigert’s iron haematoxylin staining 
for myelin (dark blue), (D) staining for COX activity; darker brown stain confirms 
higher COX activity in the unmyelinated pre-laminar segment of the optic nerve, (E) 
immunohistochemistry for COX subunit IV demonstrating a pattern consistent with 
the level of mitochondrial enzyme activity, (F) immunohistochemistry for Nav 1.1 
sodium channels revealing their greater concentration in the pre-laminar region. 
(Adapted from Barron et al., 2004).   
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Figure 1-31 Function of the cytoskeletal tracks in maintaining differential 
densities of mitochondria in pre- and post-laminar cribrosa regions of the optic 
nerve. The left panel illustrates dual COX/SDH histochemistry on a longitudinal 
section of the optic nerve. The significantly darker COX staining within the 
unmyelinated, pre-laminar segment is consistent with a higher mitochondrial density. 
The right panel is a schematic representation of the dynamic cytoskeletal-
mitochondrial interactions within the optic nerve (cytoskeleton in brown; 
mitochondria in green). (Reproduced from Yu-Wai-Man et al., 2011b).      
 
1.14 Human Induced Pluripotent Stem Cells 
1.14.1 Pluripotent Stem Cells     
Pluripotent stem cells possess the unique ability to propagate indefinitely, 
maintaining the capability to spontaneously differentiate into any cell type from all 
three embryonic germ layers – ectoderm, mesoderm and endoderm (Pera et al., 2000; 
Hyslop et al., 2005). Several types of pluripotent stem cells have been distinguished 
depending on their derivation: (i) embryonic stem cells (ESCs), which are derived 
from the inner cell mass (ICM) of the blastocyst stage of pre-implantation 
mammalian embryo (Evans and Kaufman, 1981; Thomson et al., 1998); (ii) 
embryonal carcinoma cells (ECCs) isolated from teratocarcinoma (Stevens, 1967; 
Kahan and Ephrussi, 1970); (iii) embryonic germ cells (EGCs) derived from the 
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primordial germ cells (PGCs) of the post-implantation embryo (Resnick et al., 1992); 
and (iv) induced pluripotent stem cells (iPSCs), which are generated from non-
pluripotent adult somatic cells following reprogramming with a set of specific 
transcription factors (Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et 
al., 2007). The unique features of pluripotent stem cells allow their use as the cell 
sources for versatile applications, including basic biological research, disease 
modelling, drug discovery and screening, as well as regenerative medicine (Hyslop et 
al., 2005).  
Since Thomason and colleagues first derived human ESCs (hESCs) from the ICM of 
an early embryo blastocyst stage, the application of hESCs has been a major focus of 
biomedical research (Thomson et al., 1998). Initially, five hESC lines were 
established; three with a normal XY karyotype (H1, H13 and H14), and two with a 
normal XX karyotype (H7 and H9) (Thomson et al., 1998). Human ESCs are usually 
obtained either from spare donated embryos that remain after in vitro fertilisation 
(IVF) or from genetically-impaired embryos diagnosed by preimplantation 
(Thomson et al., 1998; Reubinoff et al., 2000; Pickering et al., 2003). Human ESCs 
have a distinct morphology typical of primate ESCs, being small and round, with a 
high nucleus to cytoplasm ratio and prominent nucleoli (Thomson et al., 1998). In 
addition to these morphological features, hESCs, like all pluripotent stem cells, are 
capable of unlimited proliferation coupled with the ability to differentiate into 
virtually all cell types derived from the three primary germ layers (Figure 1-32).  
Although embryonic stem cell applications carry great potential for modelling and 
treating human disease, they face a whole host of ethical, biological, and safety 
concerns. The development of human iPSCs (hiPSCs) is an attractive alternative 
strategy to overcome the limitations inherent to hESCs (Takahashi et al., 2007). 
Although various research groups have tried to establish techniques allowing hESCs 
to be obtained without destroying human embryos or by deriving them from 
developmentally-arrested embryos at very early stages of development (Zhang et al., 
2006), the requirement for human embryonic material is still the leading ethical 
controversy preventing the widespread clinical and research applications of hESCs. 
Unlike embryo-derived hESCs, hiPSCs can be artificially created from adult human 
somatic cells e.g. fibroblasts, by viral-mediated induction of reprogramming factors: 
General Introduction 
  
 
71 
 
OCT4, SOX2, KLF4 and c-MYC (Takahashi et al., 2007) (Figure 1-32) or OCT4, 
SOX2, NANOG and LIN28 (Yu et al., 2007). Since hiPSCs contain the original 
donor’s genome, they can be used for personalized in vitro disease modeling, drug 
screening and regenerative cell-replacement medicine, without concerns about 
immunological rejection, the latter remaining a great concern in relation to hESC-
mediated therapies (Madonna, 2012).   
 
 
Figure 1-32 Generation of induced pluripotent stem cells. Adult somatic cells 
(e.g. fibroblasts) are reprogrammed into induced pluripotent stem cells (iPSCs) by 
over-expression of reprogramming factors (OCT4, SOX2, KLF4 and c-MYC). The 
iPSCs can further differentiate into all somatic cell types. (Reproduced from Nsair 
and MacLellan, 2011). 
 
1.14.2 Comparison of hiPSCs and hESCs 
The lack of ethical constraints coupled with the ability to generate patient-tailored 
cells, is an obvious advantage of hiPSC applications. However, it is essential to 
assess the degree of similarity between hiPSCs and the current “gold standard” i.e. 
hESCs. Induced pluripotent and embryonic stem cells are known to share several key 
properties, including structural morphology, the ability to differentiate into all three 
germ layers, proliferation rate, pluripotency gene expression profiles, and the ability 
to form teratomas (Bilic and Izpisua Belmonte, 2012; Puri and Nagy, 2012). Human 
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ESCs and hiPSCs have also been shown to acquire similar levels of karyotypic 
abnormalities during expansion and over prolonged tissue culture times (Taapken et 
al., 2011). Both cell types also manifest almost indistinguishable histone methylation 
patterns when compared to non-pluripotent cells (Guenther et al., 2010). Recent 
seminal work has shown that tetraploid complementation with mouse iPSCs have 
resulted in viable adult mice, providing clear proof of principle that iPSCs have 
similar powerful developmental potentials to ESCs (Boland et al., 2009; Zhao et al., 
2009).    
Despite the numerous similarities between hiPSCs and hESCs, there are many 
differences, such as epigenetic and genetic inconsistencies that have an impact on the 
pluripotency, differentiation ability, stability and carcinogenicity of hiPSCs 
compared with hESCs (Bilic and Izpisua Belmonte, 2012). The incomplete silencing 
of somatic cell-of-origin genes, as well as a decrease in the overall expression of 
pluripotency genes characteristic of hESCs were observed in some hiPSC lines, 
supporting  the concept of epigenetic memory following reprogramming (Chin et al., 
2009; Marchetto et al., 2009). In addition to these epigenetic abnormalities, hiPSCs 
also accumulate various genomic mutations, including reprogramming-induced 
deletions of tumour-suppressor genes (Laurent et al., 2011). The dissimilarities 
between hiPSCs and hESCs are likely to originate from imperfections in the actual 
reprogramming mechanisms used and it is hoped that the development of new 
pluripotency inducing techniques may help to unify hiPSC and hESC-based 
applications (Maekawa et al., 2011; Bilic and Izpisua Belmonte, 2012). 
1.14.3 Methods of hiPSC Derivation   
Human iPSC lines were first successfully generated by two independent research 
teams using viral-mediated induction of four transcription factors: OCT4, SOX2, 
KLF4 and c-MYC with a retroviral system (Takahashi et al., 2007); and OCT4, 
SOX2, NANOG and LIN28 with a lentiviral system (Yu et al., 2007). Since hiPSCs 
were first created, a number of different reprogramming vectors have been trialled to 
increase the efficiency and completeness of reprogramming, as well as to reduce 
genomic insertions of transcription factors and the unpredictable consequences of 
these random genomic integrations (Drews et al., 2012; Madonna, 2012). The 
adaptation of small molecular compounds, such as vitamin C or valproic acid (VPA), 
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have been found to significantly enhance the efficiency of pluripotency induction by 
mimicking the signalling of transcription factors, thereby decreasing the amount of 
integrating vectors essential for successful reprogramming (Huangfu et al., 2008; 
Esteban et al., 2010). Alternatively, single polycistronic vectors, encoding all 
reprogramming factors, have been used to significantly reduce the number of 
genomic insertions and to increase reprogramming efficiency (Carey et al., 2009). 
The polycistronic lentiviral system contains loxP sequences flanking the viral 
cassette and these can be excised with Cre recombinase (Sommer et al., 2009). In 
order to produce genetically-unchanged hiPSCs, several alternative transduction 
vectors have been introduced, including non-integrating adenoviruses (Zhou and 
Freed, 2009), RNA-based Sendai viruses (Fusaki et al., 2009) and nonviral minicircle 
DNAs (Jia et al., 2010). More recently, successful reprogramming was achieved 
using synthetically modified mRNAs (Warren et al., 2010) and mature human ESC-
specific microRNAs. This novel approach allows the regulation of gene expression 
either through the induction of mRNA degradation or by blocking translation of 
specific mRNA species (Bartel, 2004; Miyoshi et al., 2011). The efficiency of 
pluripotency induction depends also on the type of somatic cells selected for the 
reprogramming (Chun et al., 2011). Currently, the majority of hiPSCs have been 
derived either from the mesodermal (fibroblasts, blood cells) or ectodermal 
(keratinocytes, melanocytes and neural stem cells) germ layers (Chun et al., 2011).   
 
  
 
 
 
7
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Figure 1-33 Schematic representation of methods used to derive (a) embryonic stem cells (ESCs) and (b) induced pluripotent stem cells 
(iPSCs). (Adapted from Narsinh et al., 2011).  
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1.14.4 Applications of hiPSCs 
The advent of efficient hiPSC technology should allow the creation of patient- and 
disease-specific human cells, and these could then be further applied to disease 
modeling, drug toxicity screening, and personalized cell replacement therapy. 
1.14.4.1 Disease Modelling 
A number of studies have recently demonstrated the successful generation of in vitro 
disease models using hiPSC-based methodologies. A good example where this 
strategy has been applied is spinal muscular atrophy (SMA), a neurodegenerative 
disease leading to the loss of lower motor neurones, which was investigated using 
hiPSC-derived motor neurones from affected patient fibroblasts (Ebert et al., 2009).  
Another example is Rett syndrome (RTT), a neurodevelopmental disease 
characterised by a large spectrum of autistic features, which was studied using 
neurones derived from affected patients’ fibroblasts (Marchetto et al., 2010). 
Applying hiPSC technology to successfully generate RGCs of patients with various 
mitochondrial optic neuropathies, harbouring a range of pathogenic mutations is an 
attractive strategy that would bypass the current lack of access to disease human 
tissues. These versatile disease models would allow more fundamental research into 
the underlying mechanisms accounting for the selective degeneration of RGCs in this 
group of disorders and how this ultimately leads to the onset of visual failure and the 
development of optic atrophy. 
1.14.4.2 Drug Discovery and Screening 
Access to high-throughput hiPSC technology offers a great opportunity for reliable 
and highly-efficient drug screening approaches by using cells with specific disease 
phenotypes (Chun et al., 2011). Human iPSCs could be used to increase the 
efficiency of novel drug development and to allow more accurate prediction of drug 
toxicity (Chun et al., 2011). Hepatotoxicity and cardiotoxicity are leading causes of 
drug failure during pre-clinical toxicological testing (Chun et al., 2011). Although 
they lose their functional and phenotypic properties during in vitro cell culture, 
primary human hepatocytes remain the “gold standard” for investigating drug 
metabolism (Drews et al., 2012). The development of in vitro models of both healthy 
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and disease-specific hepatocytes could therefore allow the faster introduction of 
more effective and less toxic drugs into clinical practice.   
1.14.4.3 Personalized Cell Replacement Therapy 
Unlike hESCs, hiPSCs do not pose significant ethical and immunological rejection 
concerns. They could therefore be used for the purpose of tissue regeneration and 
organ transplantation (Drews et al., 2012). The field of regenerative medicine is 
reaching the phase of clinical trials and one such trial has recently been launched by 
Advanced Cell Technology (http://www.advancedcell.com/clinical-trials/; accessed 
17
th
 of July 2012). Its principle was to determine the biosafety and efficacy of 
subretinal transplantations of hESC-derived retinal pigment epithelium (RPE) cells in 
patients suffering from two blinding macular disorders: Stargardt's macular 
dystrophy and dry age-related macular degeneration (Schwartz et al., 2012). 
Depending on the success of hESC-based trials and future developments in hiPSC 
technology, the generation of high-quality patient-specific hiPSCs is likely to open a 
promising area for future translational research into untreatable neurodegenerative 
disorders, including mitochondrial genetic disorders.  
Research Aims 
 
 
77 
 
 
Chapter 2 Research Aims 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Aims 
 
 
78 
 
In my PhD project, I set about exploring the disease mechanisms underlying nuclear 
disorders of mtDNA maintenance by focusing on three main genes: OPA1, MFN2, 
and POLG1. To achieve this, I carried out this series of studies with the following 
aims: 
1. To determine whether OPA1 and MFN2 mutations affect mtDNA copy 
number in blood.   
2. To investigate if pathogenic MFN2 mutations result in secondary mtDNA 
instability in skeletal muscle. 
3. To determine whether specific OPA1 genetic variants are associated with 
neuromyelitis optica (NMO). 
4. To study the pathological consequences of OPA1 and POLG1 mutations on 
mtDNA replication. 
5. To quantify the degree of mitochondrial network instability caused by OPA1 
and POLG1 mutations under physiological conditions and following a period 
of induced mtDNA depletion. 
6. To generate human induced pluripotent stem cells (hiPSCs) from patient-
derived OPA1-mutant fibroblasts. 
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3.1 Genomic DNA Isolation 
3.1.1 Genomic DNA Isolation from Cultured Cells 
DNA from cultured cells was extracted using DNeasy® Blood & Tissue Kit (Qiagen, 
Crawley, UK). All centrifugation steps were performed at room temperature and 
10,000 rpm unless stated differently. Following the manufacturer’s protocol, a cell 
pellet (maximum of 5 x 10
6
 cells) was resuspended in 200µl Phosphate Buffered 
Solution (PBS; Oxoid, Basingstoke, UK). In order to lyse cells, 20µl of Proteinase K 
and 200µl of Buffer AL were added, sample was mixed thoroughly by vortexing and 
incubated at 56°C for 10 minutes. Following that, 200µl of 100% ethanol (EtOH) 
was added to precipitate each sample. The mixture was then mixed by vortexing and 
pipetted into the DNeasy® Mini spin-column located in a 2ml collection tube. Each 
sample was centrifuged for 1 minute and then every spin-column was placed into a 
fresh collection tube. The old column and the flow-through were discarded. The 
sample was initially washed with 500µl of Buffer AW1. The column was 
subsequently centrifuged for 1 minute, the flow-through and collection tube was 
discarded, and the spin-column was then placed in a new collection tube. The final 
washing step was carried out by adding 500µl of Buffer AW2 to each sample and 
centrifuging for 3 minutes at 14,000 rpm to dry the DNeasy® membrane. The spin-
column was then placed in a clean 1.5ml tube (Eppendorf, Stevenage, UK) and 100µl 
of elution Buffer AE was pipetted directly onto the DNeasy® membrane. Following 
incubation for 1 minute at room temperature, the spin-column was centrifuged for 1 
minute to elute the DNA. The concentration of the eluted DNA sample was 
determined using a NanoDrop
TM
 ND-1000 (NanoDrop Technologies, Wilmington, 
USA) and the sample was placed at -20°C for long-term storage.   
3.1.2 Genomic DNA Isolation from Muscle Homogenate 
DNA from muscle homogenate was extracted using Nucleon® Genomic DNA 
Extraction Kit Hard Tissue (Tepnel Life Sciences, Manchester, UK) following the 
manufacturer’s protocol. All centrifugation steps were performed at room 
temperature. Initially muscle biopsy was sectioned at 20µm thickness using a 
Microm™ HM560 cryostat (Thermo Fisher, Schwerte, Germany) and twenty of 
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these sections were placed in a 1.5ml tube (Eppendorf). To lyse muscle sections, 
18µl of Proteinase K (Sigma-Aldrich, Dorset, UK) was added. Sample was then 
mixed thoroughly by vortexing and incubated overnight at 55°C. Following the 
incubation, sample was centrifuged at 2,000g for 5 minutes and supernatant was then 
transferred into a fresh 1.5ml tube (Eppendorf). In order to deproteinize the sample, 
100µl of sodium perchlorate was added to the supernatant and mixed manually 
inverting tube several times. It was followed by adding 600µl of chloroform and 
manual mixing as before. Finally, 150µl of Nucleon Resin suspension was added, 
rotary mixed for 5 minutes and centrifuged at 350g for 1 minute. To precipitate 
DNA, the upper phase was transferred to a fresh 1.5ml tube (Eppendorf) without 
disturbing the brown Nucleon Resin layer. It was followed by adding 2 volumes of 
ice cold 100% EtOH and manually inverting several times until the DNA was 
precipitated. In order to wash the DNA, the sample was centrifuged at 8,000g for 5 
minutes to pellet the DNA and the supernatant was then discarded. The washing step 
was repeated with ice cold 70% EtOH, sample re-centrifuged and the supernatant 
discarded again. The DNA pellet was then air-dried for 1 hour at 37°C and once all 
ethanol was evaporated, the sample was resuspended in TE buffer and left to dissolve 
for 2 hours at 37°C. The concentration of DNA was quantified using NanoDrop
TM
 
ND-1000 (NanoDrop Technologies) and the sample was then stored at -20°C.  
 
3.2 RNA Isolation from Cultured Cells 
RNA from cultured cells was isolated using RNeasy® Mini Kit (Qiagen) according 
to the manufacturer’s protocol. All centrifugation steps were performed at room 
temperature at 14,000 rpm. A cell pellet (maximum of 5 x 10
6
 cells) was resuspended 
in 350µl of Buffer RLT and the lysate was then pipetted directly into QIAshredder® 
homogenizer spin-column (Qiagen) placed in a 2ml collection tube. The spin-column 
was centrifuged for 2 minutes at 14,000 rpm and 350µl of 70% EtOH was then 
pipetted and mixed into the homogenized lysate. The resulting mix was transferred 
into an RNeasy® spin-column already placed in a 2ml collection tube. After 
centrifuging for 15 seconds, the flow-through was discarded and 700µl of Buffer 
RW1 was added to the RNeasy® spin-column. This was centrifuged again for 15 
seconds to wash the spin-column membrane. After this, the flow-through was 
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discarded, 500µl of Buffer RPE was added, and the column was centrifuged for 
further 15 seconds. The flow-through was again removed, 500µl of Buffer RPE was 
added, and the spin-column centrifuged for 2 minutes. Following flow-through 
removal, the RNeasy® spin-column was placed in a fresh 1.5ml collection tube 
(Eppendorf) before the addition of 30µl of RNase-free water directly onto the 
membrane. After an incubation period of 1 minute at room temperature, the spin-
column was finally centrifuged for 1 minute to elute the RNA. The RNA 
concentration was measured using NanoDrop
TM
 ND-1000 (NanoDrop Technologies) 
and the sample was then stored at -80°C. 
 
3.3 Polymerase Chain Reaction (PCR)  
Polymerase chain reactions (PCRs) were performed using Veriti® 96-well Thermal 
Cycler (Applied Biosystems, Life Technologies, Paisley, UK) in 96-well plates 
(Greiner, Stonehouse, UK) or 0.2ml PCR tubes (Eppendorf). Each individual DNA 
sample (1.5µl; 30ng) was amplified in a 50µl PCR master mix containing: 10X 
ImmoBuffer (5l/reaction; Bioline GmbH, London, UK), 2mM dNTPs (dATP, 
dTTP, dCTP and dGTP; Bioline GmbH) (5l/reaction; VH Bio, Gateshead, UK), 
50mM MgCl2 (1.5l/reaction; Bioline GmbH), 10M forward and reverse primers 
(both 1.25l/reaction; Sigma-Aldrich), 5U/µl ImmolaseTM DNA Polymerase 
(0.25l/reaction; Bioline GmbH) and dH2O (34.25l/reaction).  
DNA was amplified under the following cycling conditions: an initial denaturation 
step at 95°C for 7 minutes, then 30 cycles of denaturation at 95°C for 1 minute, 
annealing at 58°C for 1 minute, and extension at 72°C for 1 minute. For the last 
cycle, a final extension step of 10 minutes at 72°C was performed before the sample 
was cooled to 4°C. PCR products were stored at -20°C.  
 
3.4 Agarose Gel Electrophoresis 
The specificity (size) of amplified PCR product was determined by electrophoresis 
using 2% (w/v) TAE agarose gel with 0.4g/ml ethidium bromide (EtBr; Sigma-
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Aldrich) as an intercalating dye. To prepare a gel, agarose (Helena Biosciences, 
Gateshead, UK) was first dissolved in 1X TAE buffer (0.04M Tris-acetate, 0.001M 
EDTA, pH = 8.3; Helena Biosciences) by heating in a microwave and allowed to 
cool. This was then supplemented with 0.4g/ml EtBr (Sigma-Aldrich), poured into 
an electrophoresis tray with a gel comb, and allowed to set. A 5µl aliquot of each 
amplified PCR product was mixed with 5μl of 2X Orange G loading buffer, 
consisting of 0.1% (w/v) Orange G (powder; Sigma-Aldrich), 30% (v/v) glycerol 
(Sigma-Aldrich) and 70% (v/v) dH2O. This mixture was loaded into a well and then 
electrophoresed in 1X TAE buffer at a constant voltage of 60-70V. In addition, 5μl 
of Hyperladder IV (Bioline GmbH) was used as a product size marker. The PCR 
product bands were visualised by exposure to UV light using an AlphaImager® 2200 
system (Alpha Innotech, Kasendorf, Germany).  
 
3.5 Agarose Gel Extraction of PCR Amplicons 
DNA amplicons were generated using a standard PCR procedure (Section 3.3) and 
separated on a 1% (w/v) TAE agarose gel (Section 3.4). Following separation, bands 
of the individual DNA samples were scalpel-excised from the agarose gel, placed in 
a 2ml tube (Eppendorf) and weighed, allowing each tube to hold a maximum of 
200mg of gel. To extract DNA, QIAquick® Gel Extraction Kit was used (Qiagen) 
according to the manufacturer’s protocol. All centrifugation steps were carried out at 
room temperature at 13,000 rpm. Initially, 600µl of Buffer QG was added to each 
tube and the sample was then incubated for 10 minutes at 50°C. During incubation, 
samples were mixed by vortexing every 2 minutes to help dissolve the gel. Following 
incubation, 200µl of isopropanol was added to each tube and then mixed to 
precipitate the DNA. The resulting solution mix was applied to a QIAquick® spin-
column placed in a 2ml collection tube and centrifuged for 1 minute. The flow-
through was discarded, 750μl of buffer PE was added to the column, and then 
centrifugation was carried out for 1 minute. After this step, the spin-column was 
placed into a clean 2ml collection tube (Eppendorf) and centrifuged for 1 minute to 
dry the membrane. The spin-column was then placed in a clean 1.5ml tube 
(Eppendorf) and 30μl of elution Buffer EB was added to the centre of the eluting 
membrane. After a 1-minute incubation period at room temperature, the spin-column 
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was centrifuged for 1 minute to elute the extracted DNA. The DNA concentration 
was determined using NanoDrop
TM
 ND-1000 (NanoDrop Technologies) and the 
obtained samples were stored at -20°C.  
 
3.6 Sequencing of Nuclear Genes 
3.6.1 PCR and Agarose Gel Electrophoresis 
PCR products were amplified according to the protocol described in Section 3.3 
using primer pairs containing the universal M13 sequence tag (Table 3-1). The 
amplified PCR products were visualised as described in Section 3.4.   
3.6.2 ExoSAP-IT Protocol 
ExoSAP-IT® (GE Healthcare, Amersham, UK) was added to remove unincorporated 
dNTPs and primers that could interfere with subsequent sequencing reactions. The 
ExoSAP-IT® solution contains two hydrolytic enzymes: exonuclease I and shrimp 
alkaline phosphatase. The clean-up treatment was carried out in 96-well plates 
(Greiner) in a reaction containing 2µl of ExoSAP-IT® buffer and approximately 
20ng of PCR product per well. The mixture was incubated at 37°C for 30 minutes, 
followed by 15 minutes at 80°C to inactivate hydrolytic enzymes.   
3.6.3 BigDyeTM Sequencing 
The BigDye
TM
 Terminator v3.1 Cycle Sequencing Kit® (Applied Biosystems, Life 
Technologies) contains all the reagents required for the sequencing reaction. 
Following ExoSAP-IT® (GE Healthcare) treatment, a mastermix containing 1µl 
BigDye® Cycle Sequencing RR-100, 2µl of BigDye® Terminator v3.1 5X 
Sequencing Buffer, 1µl of 0.5µM forward or reverse M13 primer and 9µl dH2O was 
added to 7µl of PCR product. The BigDye® cycling protocol had an initial step of 1 
minute at 96°C, followed by 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds 
and 60°C for 4 minutes.  
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3.6.4 Ethanol Precipitation 
Ethanol precipitation was performed to remove unincorporated nucleotides and 
removal of excess salt. A mixture of 2µl 125mM EDTA (Ethylenediaminetetraacetic 
acid; Sigma-Aldrich), 2µl 3M sodium acetate (Sigma-Aldrich), and 70µl 100% 
EtOH was added to each sample. After mixing gently and incubating at room 
temperature for 20 minutes, the samples were centrifuged at 2060g for 30 minutes. 
The supernatant was removed, 70µl of 70% EtOH was added, and the plate was 
centrifuged at 1650g for another 15 minutes. The supernatant was removed and the 
precipitated products were air-dried in the dark for 10 minutes at room temperature, 
to allow evaporation of the remaining EtOH before resuspending the pellets. 
3.6.5 Resuspension and Sequence Analysis 
The precipitated products were resuspended in 10µl Hi-Di® (Applied Biosystems, 
Life Technologies) before being denatured at 95°C for 2 minutes and then rapidly 
quenched on ice. BigDye® sequencing was performed on the ABI 3130xl Genetic 
Analyser (Applied Biosystems, Life Technologies) and the raw data was analysed 
using SeqScape® v2.1.1 software (Applied Biosystems, Life Technologies). The 
sequencing results were compared with the corresponding Genbank reference gene 
sequence (http://www.ncbi.nlm.nih.gov/RefSeq/) and all the identified genetic 
variants were confirmed by reverse sequencing to exclude any PCR or sequencing 
errors. 
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Table 3-1 PCR primers used to amplify the 30 coding exons of the OPA1 gene. 
Genbank accession number: NM_015560.2. All primers were incorporated with the 
universal M13 tags to allow sequencing with a single primer.  
Exon Size (bp) Forward Primer Sequence (5’ – 3’) Reverse Primer Sequence (5’ – 3’) 
1 220 CACTTCCTGGGTCATTCCTG CACCTGCACATTTTTGGAGA 
2 487 TTGCTCTTTTAATGTCATTTCCTTT CATCCAATTGTATTCCACTACACAA 
3 424 TGCTTGTTTGCTGAGACCAC TGGGCTACTGGGTATTTCTTTT 
4 341 GGGTTGTCATGAGGATTAAACAA AAAAATGTCCTGTTTTTCATTGG 
4b 249 TCTCAGACATCTTTGTTTGCTCA CTGGGGTTTTAAAATTCAGCAT 
5 247 TGAAATTCAGCTTAGGCTGTTG TGGATGTTTTTGTATTTGCTTCTC 
5b 271 CTTTGTTGCACCCTTGGTTT TCCATGAACAGATTGAGGTGA 
6 231 AAAAATTTAACTTGCTGTACATTCTGT CACCTTCCAAATTTTGCTCTG 
7 389 TTCCTAATGTTTTCGTAGATGCTTT CTCCATCCTCCAAGCACATT 
8 370 CAGTACAATGATTATGGAAAAACAA TTGCTTAAGACATTACTTGGAACA 
9 266 AAAAACTCAGAGCAGCATTACAAA TGAACAGGTCTCACTGAAGCA 
10+11 477 GCAATGCAGTAGCCCTGTCT GCAGCAATCTAAACATCAATACCT 
12+13 504 AGCGTCTTATCTGAATGGATG AAAATGAATACGAAGAGAAGGC 
14 298 GCTATAATGTAGACACAGGGG AATAACAAATCCCTATCACAGC 
15+16 399 TTTTGCTTTCTAAATTGTATATTACGC GTGAAAACAGTTCAATTTAAGCTACTC 
17 333 AAGAGTGGCTGTTAGCAAGC TAAATGAACTACCAAGCAACTG 
18 347 TACTAAGGGGTCATAGGCG AGATAACTGCTCCTAGAGATG 
19 282 AGCCTAGTCAAAAACCTCCC GCCAAGGCAACAATAAATCAC 
20 340 TAATGATACTTCAGTCAAGCTG AAGATAGAGGCTGTGATGGG 
21 333 CACATCTGTTTGGCTTGAGC TTAGTCATATAAAGTCTCCTATG 
22 296 TTTATGCTGGTTTATATACATGG TCACTAAAGTTGGATGACTCC 
23 300 TGCCTTCATATTGATATAGCAC ATATTCCTGAGACTGGTCTAG 
24 382 AATGTATTTATTAAAATTGAGACTG ACGCAATCAAAATGACTAAGC 
25 246 TACAACTTCTCAGTGTGGTTG GCATATTTTGACAACTGTTGC 
26 286 TTAGGACATATCTACTGGTTC TTGGGAAGTATTTTGGCATCC 
27 360 CTATGACTATGAAAAGTATTAGC TCAGCCCAGTTCCTTGTAAC 
28 241 TACCTCCTGATTTGTGATACC TACAGCATAAGTGACAAGCAG 
M13  TGTAAAACGACGGCCAGT CAGGAAACAGCTATGACC 
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3.7 Long-Range PCR of Mitochondrial DNA 
Investigation of multiple mtDNA deletions was performed using TaKaRa LA Taq
TM
 
PCR system (Takara Bio, Otsu, Japan), which contains a mixture of Taq Polymerase 
and a proofreading polymerase, capable of amplifying long DNA templates. For each 
DNA sample, a 16 kb mtDNA fragment encompassing almost the entire 
mitochondrial genome was amplified. Long-range PCRs were performed using a 
Veriti® 96-well Thermal Cycler (Applied Biosystems, Life Technologies) in 96-well 
plates (Greiner). Each DNA sample (approximately 30ng) was amplified in a 50µl 
long-range PCR master mix containing Mg
2+
 free 10X LA PCR Buffer II 
(5µl/reaction; Takara Bio), 2.5mM dNTP Mixture (8µl/reaction; Takara Bio), 10M 
forward and reverse primers (both 1.25l/reaction; Sigma-Aldrich; Table 3-2), 5U/µl 
TaKaRa LA Taq
TM
 DNA polymerase (0.5µl/reaction; Takara Bio) and dH2O (made 
up to 50µl).  
DNA was amplified under the following cycling conditions: an initial denaturation 
step at 94°C for 1 minute, then 35 cycles of denaturation at 94°C for 30 seconds, 
annealing at 62°C for 30 seconds, and extension at 68°C for 16 minutes. For the last 
cycle, a final extension step of 12 minutes at 72°C was performed before cooling the 
sample to 4°C.  
Multiple mtDNA deletions were investigated by separating amplicons on a 0.7% 
(w/v) TAE agarose gel as described in Section 3.4. An aliquot (5µl) of each 
amplified PCR product was mixed with 5μl 2X Orange G loading buffer (Sigma-
Aldrich) and then electrophoresed in 1X TAE buffer at a constant voltage of 30V for 
4 hours. To allow the amplified PCR fragments to be sized, 5μl of GeneRuler™ 1 kb 
Plus DNA Ladder (75-20,000 bp) (Fermentas, St. Leon-Rot, Germany) was placed in 
one lane to provide a DNA ladder marker. The PCR product bands were visualised 
following exposure to the UV light source with an AlphaImager® 2200 system 
(Alpha Innotech).  
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Table 3-2 Properties of primers used to amplify a 16 kb mtDNA fragment using 
long-range PCR system. Genbank accession number: NC_012920.1. 
 Size (bp) Forward Primer Sequence (5’ – 3’) Reverse Primer Sequence (5’ – 3’) 
16 kb assay 15433 TTA AAA CTC AAA GGA CCT GGC AGG GTG ATA GAC CTG TGA TC 
 
3.8 Quantitative Real-Time PCR 
Unlike standard PCR, quantitative real-time PCR (qPCR) provides a reliable method 
of measuring the amount of PCR product being amplified as the reaction progresses. 
The non-specific fluorescent dye, iQ™ SYBR® green (Bio-Rad, Herts, UK), 
intercalates with double-stranded DNA and it was used to detect the amplified PCR 
products. The reaction was run on a MyIQ
TM
 thermocycler (Bio-Rad) and after each 
cycle, the level of fluorescence was measured by an in-built detector. The iQ5™ 
optical system software v.2.0 (Bio-Rad) determined the threshold cycle (Ct) when 
the level of fluorescence exceeded the background level and there was a linear 
increase in the amplification curve, corresponding to the exponential increase in the 
amount of amplified product as the PCR reaction proceeded (Figure 3-1). All the 
qPCR preparation steps were performed in a UV-sterilised Aura PCR workstation 
(Bioair Instruments, Milan, Italy) to avoid any cross-contamination.    
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Figure 3-1 Example of the amplification plot of serial dilutions of the B2M 
template generated by Bio-Rad iQ5™ optical system software v.2.0. 
 
3.8.1 Quantification of MtDNA Copy Number 
Quantification of mtDNA copy number was performed using the MyIQ
TM
 
thermocycler (Bio-Rad) in 96-well optical plates (Bio-Rad) sealed with Microseal 
‘B’ plate sealers (Bio-Rad). Each DNA sample (approximately 10ng) was amplified 
in a 25µl qPCR mastermix containing: 1X iQ™ SYBR® Green supermix 
(12.5µl/reaction; Bio-Rad), 10M forward and reverse primers (both 0.75l/reaction; 
Sigma-Aldrich; Table 3-3) and autoclaved nanopure water (9 l/reaction). For each 
individual DNA sample, a mitochondrial reference gene (MTND1) and a 
housekeeping nuclear gene (B2M or GAPDH) were amplified to allow quantification 
of mtDNA copy number. Additionally, to confirm the efficiency and reliability of the 
qPCR assay, standard curves with serial dilutions of MTND1 and B2M (or GAPDH) 
templates were generated (Figure 3-2). These templates were produced using a 
standard PCR protocol (Table 3-3) and the amplified fragments were extracted from 
the agarose gel as described in Section 3.5. The number of copies per µl for each 
template was calculated using the following equation; where C is the template’s 
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concentration [g/µl], Mw is its molecular weight (product length in bp x 2 x 330), 
and A is Avogadro’s constant (6.02 x 1023 mol-1):  
 
           
 
  
     
 
The qPCR protocol consisted of an initial denaturation phase at 95°C for 3 minutes, 
then 40 cycles of denaturation at 95°C for 10 seconds, with annealing and extension 
at 62.5°C for 1 minute. At the end of the cycling protocol, a final denaturation at 
95°C for 1 minute was performed. A melting curve was generated to identify all 
specific and nonspecific PCR products e.g. primer dimers. The melt-curve analysis 
was performed by detecting the fluorescent signal at each of the 10-second 
incubation steps during which the sample’s temperature rises from 65°C to 95°C in 
0.5°C increments (Figure 3-3).  
Since the qPCR assay assumes a linear relationship between the initial quantity of  
the template and the Ct value obtained during amplification, the quantification results 
were taken into consideration only if the amplification efficiency (E) and the 
coefficient of determination (R^2) were within the optimal ranges: E = 90-105%; 
R^2 > 0.980 (Nolan et al., 2006).      
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Figure 3-2 Example of a standard curve generated by Bio-Rad iQ5™ optical 
system software v.2.0 using serial dilutions of the B2M template. (E – 
amplification efficiency; R^2 – coefficient of determination). 
 
  
 
Figure 3-3 Example of a melt-curve analysis performed on serial dilutions of 
B2M template by Bio-Rad iQ5™ optical system software v.2.0. Fluorescent signal 
was detected at each incubation step during sample’s temperature increase from 65°C 
to 95°C in 0.5°C increments. 
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For each analysed DNA sample, Ct values of MTND1 and B2M (or GAPDH) were 
determined in triplicates and their mean values were used for further calculations. 
The accepted difference between triplicates was up to 0.5 Ct, otherwise the reactions 
were repeated (Nolan et al., 2006). The analysis was performed using iQ5™ optical 
system software v.2.0 (Bio-Rad) with a constant fluorescence threshold level set at 
500 RFU (relative fluorescence units). Relative mtDNA copy number values were 
calculated using a delta Ct (ΔCt) method, where delta Ct (ΔCt) was the difference in 
threshold cycle value (Ct) between MTND1 and a housekeeping nuclear gene (B2M 
or GAPDH). The multiplication factor of 2 is included to account for two copies of 
the housekeeping nuclear gene per cell nucleus. 
 
                     
 
Table 3-3 Properties of primers used to generate B2M, GAPDH and MTND1 
templates, as well as PCR amplification of housekeeping nuclear genes (B2M 
and GAPDH) and a mitochondrial reference gene (MTND1). GenBank accession 
numbers: B2M NM_004048.2; GAPDH NM_001256799.1; MTND1 NC_012920.1 
ND1.  
 Size (bp) Forward Primer Sequence (5’ – 3’) Reverse Primer Sequence (5’ – 3’) 
Template 
B2M 1092 CGC AAT CTC CAG TGA CAG AA GCA GAA TAG GCT GCT GTT CC 
GAPDH 902 CGA GAT CCC TCC AAA ATC AAG AGG GGT CTA CAT GGC AAC TG 
MTND1 1041 AGG AAC TCG GCA AAT CTT ACC GTC ATG TGA GAA GAA GCA GG 
qPCR 
B2M 231 CAC TGA AAA AGA TGA GTA TGC C AAC ATT CCC TGA CAA TCC C 
GAPDH 102 GGA CCT GAC CTG CCG TCT AG GTG TAG CCC AGG ATG CCC TTG 
MTND1 111 ACG CCA TAA AAC TCT TCA CCA AAG GGG TTC ATA GTA GAA GAG CGA TGG 
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3.8.2 Quantification of MtDNA Deletions  
MtDNA deletion levels were assessed using a qPCR assay previously optimized in 
Professor Chinnery’s laboratory. This differential MTND1/MTND4 assay is based on 
the observation that the MTND1 gene is rarely involved in large-scale 
rearrangements, whereas the MTND4 gene is removed in the majority of reported 
mtDNA deletions (He et al., 2002). This real-time qPCR protocol was similar to the 
one described in Section 3.8.1, with the primer pairs designed to amplify MTND1 
and MTND4 fragments (Table 3-4) allowing calculation of the total mutant load 
present. To confirm the efficiency and reliability of this qPCR assay, standard curves 
were created with serial dilutions of MTND1 and MTND4 templates, generated as 
described in Section 3.5.  
For each analysed DNA sample, Ct values of MTND1 and MTND4 were determined 
in triplicates and their mean values were used for further calculations. The accepted 
difference between triplicates was up to 0.5 Ct, otherwise the reactions were repeated 
(Nolan et al., 2006). The analysis was performed using MyIQ™ optical system 
software v.2.0 (Bio-Rad) with a constant fluorescence threshold level of 500 RFU. 
The relative total (wild-type and mutant) mtDNA copy number was determined from 
the MTND1 Ct values, whereas the relative wild-type mtDNA copy number was 
obtained from the MTND4 Ct values. The mtDNA deletion level was calculated 
using the delta Ct method (Section 3.8.1) by subtracting the MTND4 ΔCt value from 
the MTND1 ΔCt value.  
 
 
 
 
 
 
Materials and Methods 
 
 
95 
 
Table 3-4 Properties of primers used to amplify two mitochondrial regions:  
MTND1 and MTND4. GenBank accession numbers: MTND1 NC_012920.1 ND1; 
MTND4 NC_012920.1 ND4.    
 Size (bp) Forward Primer Sequence (5’ – 3’) Reverse Primer Sequence (5’ – 3’) 
Template 
MTND1 1041 AGG AAC TCG GCA AAT CTT ACC GTC ATG TGA GAA GAA GCA GG 
MTND4 1071 GGC ATT TTG TAG ATG TGG TTT G AGG AGG AGA ATG GGG GAT AG 
qPCR 
MTND1 111 ACG CCA TAA AAC TCT TCA CCA AAG GGG TTC ATA GTA GAA GAG CGA TGG 
MTND4 107 ACC TTG GCT ATC ATC ACC CGA T AGT GCG ATG AGT AGG GGA AGG 
 
3.9 Reverse-Transcription PCR 
Reverse-transcription polymerase chain reaction (RT-PCR) was performed to 
determine gene transcription at the messenger RNA (mRNA) level. All RT-PCR 
preparation steps were performed in a UV-sterilised Aura PCR workstation (Bioair 
Instruments) to avoid any cross-contamination. 
3.9.1 First-Strand cDNA Synthesis  
First-strand complementary DNA (cDNA) was synthesized from isolated RNA (refer 
to Section 3.2 for details) using SuperScript™ III First-Strand Synthesis System for 
Reverse-Transcription PCR (RT-PCR) (Invitrogen, Life Technologies, Paisley, UK) 
following the manufacturer’s protocol. In order to denature the RNA sample, up to 
5µg of RNA was combined in a 0.5ml tube with 1µl of 50µM oligo(dT)20, 1µl of 
10mM dNTP mix (dATP, dTTP, dCTP and dGTP) and filled up to 10µl with DEPC-
treated water. The denaturing mix was then incubated at 65°C for 5 minutes and 
immediately placed on ice for at least 1 minute. Once the denaturing mix was on ice, 
the cDNA synthesis mix was prepared. For one reaction, 10µl cDNA synthesis mix 
was prepared containing: 2µl of 10X RT buffer (200mM Tris-HCl pH = 8.4, 500mM 
KCl), 4µl of 25mM MgCl2, 2µl of 0.1M DTT (Dithiothreitol), 1µl of RNaseOUT™ 
(40U/µl) and 1µl of SuperScript™ III RT (200U/µl) combined in the given order. 
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Following preparation, 10µl of cDNA synthesis mix was added to 10µl of each 
RNA/primer mixture, mixed gently and collected by brief centrifugation. Once 
ready, each sample was incubated at 50°C for 50 minutes to synthesise cDNA. This 
reaction was terminated at 85°C for 5 minutes and sample chilled on ice. To remove 
any remaining RNA, 1µl of RNase H was added to each tube and incubated for 20 
minutes at 37°C. Finally, cDNA synthesis reaction was stored at -20°C. 
3.9.2 Quantitative PCR from cDNA Samples 
Quantitative PCR on cDNA samples was performed using a MyIQ
TM
 thermocycler 
(Bio-Rad) in 96-well optical plates (Bio-Rad) sealed with Microseal ‘B’ plate sealers 
(Bio-Rad). Each cDNA sample (approximately 10ng) was amplified in a PCR 
mastermix containing: 1X iQ™ SYBR® green supermix (12.5µl/reaction; Bio-Rad), 
10M forward and reverse primers (both 1.25l/reaction; Sigma-Aldrich) and 
autoclaved nanopure water (9l/reaction).     
The PCR protocol consisted of an initial denaturation phase at 95°C for 3 minutes, 
then 40 cycles of denaturation at 95°C for 10 seconds, with annealing and extension 
at 62.5°C for 1 minute. At the end of the cycling protocol, a final denaturation at 
95°C for 1 minute was performed. Following that, a melting curve was generated to 
identify all specific and nonspecific PCR products. The melting-curve analysis was 
performed by detecting fluorescent signal at each of the 10-second incubation steps 
during the sample’s temperature increase from 65°C to 95°C in 0.5°C increments. 
The quality of each cDNA sample was assessed by performing quantitative PCR 
reactions using primers for three widely-expressed housekeeping genes: GAPDH and 
RPL13A (Table 3-5). The collected qPCR data were assessed with qBASE relative 
quantification software (http://medgen.ugent.be/qbase/; Ghent University, Belgium), 
which uses the Ct values obtained for the reference housekeeping genes as the 
internal controls. This method allowed normalization for variations in the amount 
and quality of each RNA/cDNA sample that was investigated. The normalized 
expression levels of various genes were measured by calculating ratios between the 
quantity of amplified target gene molecules and reference gene molecules. Levels of 
target gene expression were further used to make comparisons between different 
samples.  
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Table 3-5 Properties of primers used to amplify GAPDH and RPL13A 
housekeeping reference genes in RT-PCR. GenBank accession numbers: GAPDH 
NM_001256799.1; RPL13A NM_001270491.1.    
 Size (bp) Forward Primer Sequence (5’ – 3’) Reverse Primer Sequence (5’ – 3’) 
Housekeeping reference genes 
GAPDH 133 CTG ACT TCA ACA GCG ACA CC ATG AGG TCC ACC ACC CTG T 
RPL13A 307 CCT GGA GGA GAA GAG GAA TTG AGG ACC TCT GTG TAT 
 
3.10 Immunofluorescence 
3.10.1 Fixation of Cells 
Cells were fixed in 4% (w/v) paraformaldehyde (Sigma-Aldrich) diluted in PBS 
(Oxoid) by incubating for 20 minutes at room temperature and then washed three 
times in cold PBS (5 minutes per wash). To detect target proteins expressed 
intracellularly, cells were additionally permeabilized by incubating with 0.2% (v/v) 
Triton™ X-100 (Sigma-Aldrich) for 10 minutes at room temperature. Following this 
step, cells were washed two times in PBS (5 minutes per wash) and stored in PBS 
(Oxoid) at 4°C for up to one week prior to immunostaining.  
3.10.2 Blocking and Incubation with Antibodies 
All incubation steps described below were performed at a room temperature in a 
humidified chamber. To block any unspecific binding of antibodies, cells were 
incubated in blocking buffer consisting of 1% (w/v) bovine serum albumin (BSA; 
Sigma-Aldrich) diluted in PBS (Oxoid) for 1 hour. Following the blocking step, the 
solution was removed and cells were incubated for another hour with a suitable 
primary antibody diluted to an appropriate concentration in the blocking buffer. The 
solution was then decanted and cells were washed three times in PBS (5 minutes per 
wash). Following the last wash, PBS (Oxoid) was removed and the cells were 
incubated for an hour in the dark with a diluted fluorochrome-conjugated secondary 
antibody in blocking buffer. After incubation, cells were washed three times in PBS 
(5 minutes per wash; in the dark) and following the last wash, cells were incubated 
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for 3 minutes in the dark with 1µg/ml Hoechst 33342 (Molecular Probes, Life 
Technologies, Paisley, UK) to stain for the nuclei. Cells were then washed in the 
dark for 5 minutes in PBS (Oxoid) and stored in fresh PBS at 4°C (in the dark). The 
fluorescent images were obtained using Axiovert 200M microscope (Carl Zeiss, 
Cambridge, UK) equipped with a digital camera, and analysed with the AxioVision 
Rel. 4.8 software (Carl Zeiss).  
 
3.11 Mitochondrial Histochemistry  
3.11.1 Muscle Biopsy 
Muscle biopsies were snap frozen in melting liquid isopentane (-150ºC) and then 
stored at -80ºC. These were mounted on O.C.T. compound (VWR, Lutterworth, UK) 
and then serially sectioned at 20µm thickness onto PEN-membrane (Leica, 
Newcastle upon Tyne, UK) and glass (Fisher Scientific, Loughborough, UK) slides 
using a Microm™ HM560 cryostat (Fisher Scientific). The serial muscle sections 
were subsequently stained for COX, SDH, dual COX-SDH, and myofibrillar ATPase 
activities. 
3.11.2 COX/SDH Dual Staining 
To stain for cytochrome c oxidase (COX) activity, muscle sections were incubated 
for 35 minutes at 37ºC in medium containing 20% (v/v) 500µM cytochrome c 
(Sigma-Aldrich), 80% (v/v) 3,3’- diaminobenzidine tetrahydrochloride (DAB; 
Sigma-Aldrich) and a small amount of catalase (Sigma-Aldrich). After incubation, 
sections were washed twice in PBS (Oxoid; 1 minute per wash). Staining for 
succinate dehydrogenase (SDH) was performed by incubation for 45 minutes at 37ºC 
in medium containing 80% (v/v) 1.875mM nitroblue tetrazolium (NBT; Sigma-
Aldrich), 10% (v/v) 1.3M sodium succinate (Sigma-Aldrich), 10% (v/v) 2.0mM 
phenazine methosulphate (PMS;  Sigma-Aldrich) and 0.01% (v/v) 100mM sodium 
azide (Sigma-Aldrich). The incubation was followed by washing twice in PBS 
(Oxoid; 1 minute per wash).  
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For dual COX/SDH staining, COX staining was immediately followed by SDH 
incubation steps. After washing in PBS (Oxoid), muscle sections were dehydrated in 
a series of graded EtOH solutions: 70%, 95% and 100%. After removing slides from 
100% EtOH, the slides were immersed in clean 100% EtOH and left there for 10 
minutes. The glass slides were cleared twice in Histo-Clear (VWR) before being 
mounted in D.P.X. synthetic resin (VWR). The membrane slides were not subjected 
to Histo-Clear treatment. 
3.11.3 ATPase Staining 
To stain for ATPase activity, muscle sections were firstly incubated for 30 minutes at 
room temperature in 0.2M acetate buffer (pH = 4.3) containing 0.2M acetic acid 
(Sigma-Aldrich) and 0.2M sodium acetate (Sigma-Aldrich). This incubation step was 
followed by washing 3 times in tap water, and then three times in distilled water. The 
second incubation step was performed for 45 minutes at 37ºC in medium consisting 
of ATP disodium salt (Sigma-Aldrich), 0.1M Tris-HCl (Sigma-Aldrich) and 0.08M 
calcium chloride (Sigma-Aldrich) at an exact pH of 9.5. The slides were then washed 
twice with 1% calcium chloride (Sigma-Aldrich), followed by incubation in 2% 
cobalt nitrate (Sigma-Aldrich) for 3 minutes. Afterwards, the slides were washed in 
three changes of tap water, three changes of distilled water, and developed in 1% 
ammonium sulphide (Sigma-Aldrich) for 2 minutes. The last step required 
dehydration through a graded EtOH concentration series: 70%, 95%, and twice in 
100%, with the final 100% EtOH immersion lasting 10 minutes. The muscle sections 
were finally cleared in Histo-Clear (VWR) and mounted in Canada balsam (Sigma-
Aldrich).  
 
3.12 Fibroblast Culture 
All fibroblast tissue cultures were performed in a class II biohazard hood (Heraeus 
Herasafe HS-12; Fisher Scientific). In order to maintain stable tissue culture 
conditions, all culture media were warmed to 37°C in a water bath (JB Aqua 18 Plus; 
Fisher Scientific) 30 minutes prior to use. All washing steps were performed with 
PBS (Oxoid).  
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3.12.1 Tissue Culture Maintenance  
Human fibroblasts were cultured in Minimal Essential Medium (MEM) with Earle’s 
salts (Gibco, Life Technologies, Paisley, UK) supplemented with 10% (v/v) heat 
inactivated fetal bovine serum (FBS; Gibco, Life Technologies), 50U/ml penicillin 
and 50µg/ml streptomycin (Gibco, Life Technologies), 1X MEM vitamin solution 
(Gibco, Life Technologies), 1mM sodium pyruvate (Gibco, Life Technologies), 1X 
non-essential amino acids (Gibco, Life Technologies), 2mM L-glutamine (Gibco, 
Life Technologies) and 50µg/ml uridine nanopure (Sigma-Aldrich). The cells were 
grown in suitable tissue culture flasks or plates (Greiner) at 37°C in a humidified cell 
culture incubator (Heracell 150i, Fisher Scientific) containing 5% CO2. The cells 
were monitored on a daily basis with the inverted Leica DM IL microscope (Leica). 
Once the cells became 90% confluent, they were passaged into a fresh flask. To sub-
culture fibroblasts, these were washed once with PBS (Oxoid) and then incubated 
with 0.05% Trypsin/EDTA (Gibco, Life Technologies) for 5 minutes in a humidified 
cell culture incubator (37°C, 5% CO2; Heracell 150i; Fisher Scientific) to detach the 
cells. The combined Trypsin/EDTA solution was then neutralized by adding 5 
volumes of culture medium and the cells were pelleted by centrifugation at 1,200 
rpm for five minutes. After removing the supernatant, the cellular pellets obtained 
were resuspended in medium and reseeded onto fresh flasks/plates in ratios required 
for specific experimental conditions.  
3.12.2 Mycoplasma Detection 
Each time a fibroblast cell line was cultured or frozen down, cells were tested for 
mycoplasma infection using a PCR-based Venor®GeM Mycoplasma Detection Kit 
(Cambio, Cambridge, UK) following the manufacturer’s protocol. PCRs were 
performed using Veriti® 96-well Thermal Cycler (Applied Biosystems, Life 
Technologies) in 0.5ml PCR tubes (Eppendorf). All preparation steps were 
performed on ice. To generate templates for PCR analysis, 100µl of supernatant from 
each investigated cell line was transferred to a 1.5ml tube (Eppendorf), incubated at 
95°C for 5 minutes and briefly centrifuged to pellet cellular debris before adding a 
PCR mix. The analysed supernatant (2µl) was amplified in a 25µl PCR master mix 
containing 10X Reaction Buffer (2.5l/reaction), Primer/Nucleotide Mix 
Materials and Methods 
 
 
101 
 
(2.5l/reaction), Internal control (2.5l/reaction), 5U/µl DNA Polymerase 
(0.2l/reaction) and PCR grade water (15.3l/reaction). Templates were amplified 
under the following conditions: an initial denaturation step at 94°C for 10 minutes, 
then 39 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 
seconds, and extension at 72°C for 30 seconds. Samples were finally cooled to 4°C.  
Amplified templates were investigated by separating amplicons on a 1.5% (w/v) 
TAE agarose gel as described in Section 3.4. An aliquot (5µl) of each amplified PCR 
product was mixed with 5μl of bromophenol blue loading buffer (Sigma-Aldrich), 
and then electrophoresed in 1X TAE buffer at a constant voltage of 60V for 1 hour. 
In addition, 5μl of Hyperladder V (Bioline GmbH) was used as a product size 
marker. The PCR product bands were visualised and compared with a Mycoplasma-
positive control (Cambio).   
3.12.3 Cell Counting and Viability Assessment 
Cell counting was carried out using a haemocytometer chamber (AC1000 Improved 
Neubauer; Hawksley, Lancing, UK) with Trypan Blue (Sigma-Aldrich) staining for 
viable cells. This procedure required harvesting fibroblasts as illustrated in Section 
3.12.1, followed by resuspension of the cell pellet in 1ml of PBS (Oxoid) and the 
transfer of 100µl of this mixture into a 1.5ml tube (Eppendorf). The suspension was 
then mixed with 100µl of Trypan Blue (Sigma-Aldrich), which is a blue, vital stain 
absorbed by damaged or dead cells only. After this step, 15µl of the stained cell 
suspension was added to two coverslip-sealed haemocytometer chambers. The 
amount of viable (unstained) and dead (blue in colour) cells were counted in four 
main corner squares of each haemocytometer chamber. The average count per corner 
square was then multiplied first by 2, to account for the dilution with Trypan Blue, 
and then by 10
4
 to obtain the number of cells per ml.         
3.12.4 Storage of Fibroblasts 
3.12.4.1 Cryovial Cryopreservation of Fibroblasts – Freezing     
For long-term storage, cells were harvested as described in Section 3.12.1 and the 
cell pellet was resuspended in 1ml of the freezing medium (filtered through 0.22µm 
PES filter; PALL, Portsmouth, UK), containing 70% (v/v) DMEM (Dulbecco’s 
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Modified Eagle Medium; Gibco, Life Technologies) supplemented with 20% (v/v) 
FBS (Gibco, Life Technologies) and 10% (v/v) dimethylsulphoxide (DMSO; Sigma-
Aldrich). Resuspended cells were drop-wise pipetted into a cryovial (Greiner), which 
then was placed in a Mr. Frosty isopropyl-filled freezing container (Nalgene, 
Matlock, UK) allowing for a gradual 1°C/min cooling rate. The Mr. Frosty container 
was placed in a -80°C freezer for 48 hours and after this time, the cryovials were 
transferred to liquid nitrogen for long-term storage.   
3.12.4.2 Cryovial Cryopreservation of Fibroblasts – Thawing      
The fibroblast cell lines were placed into culture from frozen cryovials stored in 
liquid nitrogen storage. Cells were quickly thawed at 37°C (JB Aqua 18 Plus water 
bath; Fisher Scientific), transferred drop-wise into a 30ml universal container (Fisher 
Scientific) containing pre-warmed fibroblast medium. The mixture was centrifuged 
for 5 minutes at 1,200 rpm. The supernatant was aspirated and the cell pellet was 
resuspended in fresh medium before the cells were seeded in a 25cm
2
 flask (Greiner). 
The medium was changed every 48 hours until the cells reached a confluence of 
approximately 90% and were ready for another passage.  
 
3.13 Microscopy 
Brightfield and fluorescent cell images were captured with an inverted Axiovert 
200M microscope (Carl Zeiss) coupled with an AxioCam HRc (Carl Zeiss) digital 
camera, unless stated otherwise.  
  
3.14 Statistical Analysis 
For the purpose of group comparisons statistical analysis was performed using 
GraphPad™ v.5 statistical software (GraphPad Software, La Jolla, USA). Group 
comparisons were considered to be statistically non-significant (NS) if the calculated 
P value was greater than 0.05, significant (*) with P = 0.01 to 0.05, very significant 
(**) with P = 0.001 to 0.01, and extremely significant (***) when the P value was 
less than 0.001. 
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4.1 Introduction 
OPA1 and MFN2 code for two dynamin-like GTPase proteins intrinsically associated 
with mitochondrial membrane fusion (Section 1.8.2). OPA1 mutations cause 
autosomal dominant optic atrophy (DOA) (Section 1.10.2), and approximately 20% 
of OPA1 carriers will develop a more severe form of the disease, DOA+, where the 
optic atrophy is compounded by additional neurological features, including 
sensorineural deafness, ataxia, myopathy, and peripheral neuropathy (Yu-Wai-Man 
et al., 2010b). OPA1 is a multifunctional mitochondrial inner membrane protein 
(Section 1.10.3), and high levels of cytochrome c oxidase (COX)-negative muscle 
fibres have been identified in muscle biopsies from patients manifesting both pure 
and syndromal DOA phenotypes (Amati-Bonneau et al., 2008; Hudson et al., 2008a). 
These COX-negative muscle fibres harboured high levels of somatically-acquired 
mitochondrial DNA deletions and marked mtDNA proliferation was also observed, 
clearly revealing OPA1 to be a novel disorder of mtDNA maintenance (Yu-Wai-Man 
et al., 2010c).  
MFN2 mutations typically cause a dominantly-inherited neurodegenerative Charcot-
Marie-Tooth type 2A (CMT-2A) disorder (Züchner et al., 2004) (Section 1.11.2). 
Intriguingly, the observed clinical features can overlap with those seen in OPA1-
related DOA+ phenotypes, with some patients harbouring MFN2 mutations 
developing a progressive axonal sensorimotor neuropathy, complicated by optic 
atrophy, deafness, cerebellar ataxia and proximal myopathy (Rouzier et al., 2012). 
The presence of COX-deficient fibres and multiple mtDNA deletions in skeletal 
muscle biopsies suggest that MFN2 mutations result in disturbed mitochondrial DNA 
maintenance, similar to OPA1 mutations (Rouzier et al., 2012).  
To further investigate pathological mechanisms associated with disturbed OPA1 and 
MFN2 function, mtDNA copy number was quantified in blood leukocytes with 
molecularly-confirmed OPA1 and MFN2 mutations.  
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4.2 Materials and Methods 
4.2.1 Patient Cohort 
Genomic DNA samples, isolated from the leukocyte fraction of venous blood, were 
available for the following groups (summarized in Table 4-1): (i) individuals 
harbouring pathogenic OPA1 mutations (Mean age = 41.3 years, standard deviation 
(SD) = 18.1 years, range = 3.0-79.0 years, N = 150) from three different populations: 
British (N = 61), German (N = 40) and Danish (N = 49); (ii) individuals harbouring 
MFN2 mutations (N = 58) from three different populations: British (N = 24), German 
(N = 16) and Czech (N = 18); and (iii) normal healthy controls (Mean age = 55.1 
years, SD = 13.1 years, range = 10.0-92.0 years, N = 131) from two different 
populations: British (N = 87) and German (N = 44). This study had the relevant 
institutional approval and written informed consent was obtained from all of the 
subjects involved.  
For the list of OPA1 and MFN2 mutations identified in our patient cohorts, please 
refer to Table A-1 and Table A-2, respectively (Appendix A). 
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Table 4-1 Summary of investigated patient cohorts. Individuals with confirmed 
pathogenic OPA1 mutations (N = 150) originated from three ethnically diverse 
subgroups: British (N = 61), German (N = 40) and Danish (N = 49). DNA samples of 
MFN2-affected patients were available from three populations: British (N = 24), 
German (N = 16) and Czech (N = 18). Control samples were obtained from British 
(N = 87) and German (N = 44) individuals.     
Patient cohort N = 
OPA1-positive 
(N = 150) 
British cohort 61 
German cohort 40 
Danish cohort 49 
MFN2-positive 
(N = 58) 
British cohort 24 
German cohort 16 
Czech cohort 18 
Controls 
(N = 131) 
British cohort 87 
German cohort 44 
 
4.2.2 MtDNA Copy Number Determination 
Relative mtDNA copy number was determined using iQ™ SYBR® Green (Bio-Rad) 
protocol on MyiQ
TM
 real-time PCR detection system (Bio-Rad) with MTND1 as the 
mtDNA reference gene and GAPDH as the nuclear DNA reference gene (as 
described in Section 3.8.1). MtDNA copy number data for the control cohort were 
kindly provided by Dr Angela Pyle (Institute of Genetic Medicine, Newcastle 
University) and Dr Patrick Yu-Wai-Man (Institute of Genetic Medicine, Newcastle 
University). There was no statistically significant difference in mtDNA content 
between the British and German normal controls (P = 0.1306; Figure 4-1 A).  
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4.2.3 Detection of Multiple MtDNA Deletions  
The presence of multiple mtDNA deletions had previously been investigated in a 
subgroup of 22 British OPA1-positive DNA samples using the long-range PCR 
protocol described in Section 3.7. Multiple mtDNA deletions were not detected in 
DNA samples extracted from peripheral blood leukocytes. These data were kindly 
provided by Dr Patrick Yu-Wai-Man (Institute of Genetic Medicine, Newcastle 
University).  
4.2.4 Visual Acuity Assessment  
Visual acuity (VA) was measured in the British cohort of OPA1-positive patients (N 
= 61) using a standard Snellen vision chart. For the purpose of statistical analysis, 
Snellen visual acuity ratios were converted to LogMAR (Logarithm of the minimum 
angle of resolution) decimal values. A LogMAR value of 0 is equivalent to 20/20 
Snellen vision and a value of 1.0 is equivalent to 20/200 Snellen vision, the largest 
optotype on standard Snellen charts. By convention, patients with visual acuities 
reduced to counting fingers (CF) are assigned a LogMAR value of 2.0, whilst those 
with only hand movement (HM) perception are assigned a LogMAR value of 2.3. 
These data were kindly provided by Dr Patrick Yu-Wai-Man (Institute of Genetic 
Medicine, Newcastle University), who performed the clinical assessment. 
4.2.5 Statistical Analysis 
Statistical analysis was performed using GraphPad
TM
 v.4 statistical software 
(GraphPad Software). Group comparisons were carried out with an unpaired two-
tailed Student’s t-test with confidence interval (CI) set at 95%.  
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4.3 Results  
4.3.1 OPA1 Study Group 
The analysis of total mtDNA content in three different OPA1-positive patient cohorts 
– British, German and Danish, revealed significantly higher mtDNA copy numbers 
in peripheral blood leukocytes compared with normal controls (Figure 4-1 B, Figure 
4-1 C, Figure 4-1 D). On subgroup analysis, there was no statistically significant 
difference in mtDNA content between OPA1-positive patients harbouring different 
mutation subtypes (non-significant with Bonferroni correction at P = 0.0199; Figure 
4-2 A), and when the main functional gene domains were individually compared 
with each other (non-significant with Bonferroni correction at P = 0.0244; Figure 
4-2 B). In the British cohort, there was no significant difference in total mtDNA 
content between patients with pure DOA and DOA+ phenotypes (non-significant 
with Bonferroni correction at P = 0.0471; Figure 4-2 C). No significant correlation 
was found between visual acuity and mtDNA copy number in the British OPA1-
mutant group (P = 0.4081; Figure 4-2 D). 
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Figure 4-1 Subgroup analysis of total mtDNA content in blood leukocytes of 
OPA1-positive patients. (A) British and German controls (British controls: mean = 
56.9, SD = 43.3, N = 87; German controls: mean = 68.7, SD = 39.4, N = 44; NS – 
not significant at P = 0.1306); (B) British OPA1-positive patients (Mean = 111.3, SD 
= 46.1, N = 61) and British controls (Mean = 56.9, SD = 43.3, N = 87); (C) German 
OPA1-positive patients (Mean = 186.8, SD = 254.1, N = 40) and German controls 
(Mean = 68.7, SD = 39.4, N = 44); (D) Danish OPA1-positive patients (Mean = 
314.2, SD = 185.8, N = 49) compared with merged British and German controls 
(Mean = 60.9, SD = 42.3, N = 131); ** - significant at P value = 0.0031; *** - refers 
to P value < 0.0001. 
 
A                                       B 
 
 
 
 
 
 
C                                       D 
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Figure 4-2 Subgroup analysis of total mtDNA content in blood leukocytes of 
OPA1-positive patients. (A) OPA1 mutational subgroup analysis (missense 
mutations: mean = 126.8, SD = 62.6, N = 31; other mutational subtypes: mean = 
216.1, SD = 208.2, N = 119, NS with Bonferroni correction at P value = 0.0199), (B) 
OPA1 functional gene domain analysis (GTPase region: mean = 219.8, SD = 202.6, 
N = 60; other gene domains: mean = 164.0, SD = 94.0, N = 90, NS with Bonferroni 
correction at P value = 0.0244); (C) Phenotype subgroup analysis of the British 
patient cohort (pure DOA subgroup: mean = 101.6, SD = 39.0, N = 36; DOA+ 
subgroup: mean = 125.3, SD = 52.6, N = 25, NS with Bonferroni correction at P 
value = 0.0471); (D) Correlation of LogMAR visual acuity (VA) with total mtDNA 
content in blood leukocytes from British OPA1+ve patients (Spearman rank 
correlation coefficient = 0.083, NS at P value = 0.4081); *** refers to a P value < 
0.0001. NS refers to a non-significant P value, with P < 0.0167 being the level of 
statistical significance after Bonferroni correction for multiple testing. 
A                                       B 
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4.3.2 MFN2 Study Group 
MtDNA copy numbers measured in the blood leukocyte fraction from three 
independent MFN2-positive patient cohorts: British, German and Czech, were 
significantly higher compared with normal controls (Figure 4-3 A, Figure 4-3 B, 
Figure 4-3 C). No significant difference in total mtDNA content was observed 
between MFN2-positive patients harbouring mutations within GTPase domain and 
outside this region (P = 0.5957; Figure 4-3 D). 
Direct comparison of mtDNA content in blood leukocytes from OPA1-positive and 
MFN2-positive cohorts revealed no statistical difference between these two disease 
groups (P = 0.9408; Figure 4-4). 
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Figure 4-3 Subgroup analysis of total mtDNA content in blood leukocytes of 
MFN2-positive patients. (A) British MFN2-positive patients (Mean = 203.7, SD = 
103.1, N = 24) and British controls (Mean = 56.9, SD = 43.3, N = 87); (B) German 
MFN2-positive patients (Mean = 171.9, SD = 88.7, N = 16) and German controls 
(Mean = 68.7, SD = 39.4, N = 44); (C) Czech MFN2-positive patients (Mean = 
211.3, SD = 177.0, N = 18) compared with merged British and German controls 
(Mean = 60.9, SD = 42.3, N = 131); (D) MFN2 functional gene domain analysis 
(GTPase region: mean = 207.9, SD = 150.2, N = 24; other gene domains: mean = 
189.8, SD = 108.2, N = 34, NS at P value = 0.5957; *** - refers to P value < 0.0001. 
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Figure 4-4 Comparison of mtDNA content in blood leukocytes from entire 
OPA1- and MFN2-positive patient cohorts. OPA1-mutated patients: mean = 197.7, 
SD = 190.9, N = 150; MFN2-mutated patients: mean = 195.7, SD = 126.6, N = 58; 
NS – non-significant at P = 0.9408; *** - refers to P value < 0.0001. 
 
4.4 Discussion 
This study has revealed significant mtDNA proliferation in blood leukocytes of 
patients harbouring pathogenic OPA1 and MFN2 mutations. Compared with control 
values, there was a two- to five-fold increase in mtDNA content in three independent 
OPA1-positive patient cohorts (British, German and Danish). Similarly, there was a 
two- to three-fold increase in mtDNA content in three independent MFN2-positive 
patient groups (British, German and Czech). Although it has been previously shown 
that the differential blood cell count can affect blood-derived mtDNA copy number 
(Pyle et al., 2010), the consistent increase in mtDNA content observed in both OPA1 
and MFN2 cohorts across different population groups, strongly suggests that these 
results are unlikely to have been influenced by this possible confounding factor.  
The level of mtDNA proliferation observed in peripheral blood leukocytes of OPA1-
positive individuals was comparable to the two- to four-fold increase in mtDNA 
content observed at the single fibre level in skeletal muscle biopsies from OPA1-
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positive patients (Yu-Wai-Man et al., 2010c). As described previously (Section 
1.10.3.2), the OPA1 protein plays a key role in the assembly and stability of the 
respiratory chain complexes and these pathological findings, in both blood and 
skeletal muscle, are consistent with the detrimental effect of OPA1 mutations on 
mitochondrial OXPHOS. In this situation, the increased mtDNA copy number is 
probably acting as a compensatory bioenergetic mechanism to maintain adequate 
levels of ATP for normal cellular function (Yu-Wai-Man et al., 2010c). The mtDNA 
proliferative response in OPA1-positive blood leukocytes was not statistically 
different between patients with pure optic atrophy and those who developed 
additional neurological complications. Furthermore, irrespective of whether or not 
OPA1 carriers developed DOA+ features, there was no significant correlation 
between total mtDNA copy number and the severity of visual loss. Given the three-
fold increased risk of developing DOA+ with missense mutations and those with 
mutations involving the GTPase catalytic domain, additional subgroup analysis was 
carried out based on these OPA1 mutational subtypes (Yu-Wai-Man et al., 2010b). 
No consistent significant difference in mtDNA copy number was identified, which 
suggests that this parameter of mitochondrial dysfunction is not associated with 
clinical severity per se, at least in blood leukocytes. Unlike the skeletal muscle, 
multiple mtDNA deletions were not identified in blood leukocytes from patients with 
OPA1 mutations. This is likely related to the relatively short half life of these cells in 
the blood circulation, their rapid turnover precluding the formation and subsequent 
clonal expansion of somatic mtDNA abnormalities.  
MFN2 and OPA1 mediate mitochondrial membrane fusion synergistically. It is 
therefore noteworthy that blood leukocytes from patients with MFN2 mutations 
demonstrated the same phenomenon observed in tissue samples from patients with 
OPA1 mutations i.e. significant mtDNA proliferation. As for OPA1-positive patients, 
this proliferative response in MFN2-mutant individuals is probably acting as a 
compensatory mechanism in response to an underlying cellular bioenergetic crisis 
(Rouzier et al., 2012). Similar to the OPA1 patient group, no significant difference in 
mtDNA proliferation was observed in MFN2 carriers harbouring mutations within or 
outside the functional GTPase domain. MFN2-related disease is the newest member 
of an expanding group of nuclear mitochondrial disorders characterised by disturbed 
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mtDNA maintenance, a process which seems to be intrinsically related to the state of 
the mitochondrial network (Chen et al., 2010) (Section 1.11.3). 
 
The data presented in this chapter have been published following peer review: 
1. Sitarz K.S., Almind G.J., Horvath R., Czermin B., Grønskov K., Pyle A., 
Taylor R.W., Larsen M., Chinnery P.F., Yu-Wai-Man P., 2012. OPA1 
mutations induce mtDNA proliferation in leukocytes of patients with 
dominant optic atrophy. Neurology: in press.  
2. Sitarz, K.S., Yu-Wai-Man, P., Pyle, A., Stewart, J.D., Rautenstrauss, B., 
Seeman, P., Reilly, M.M., Horvath, R., Chinnery, P.F., 2012. MFN2 
mutations cause compensatory mitochondrial DNA proliferation. Brain. First 
published online: April 4, 2012.   
 
 
 
  
Investigations of MFN2-Positive Muscle Biopsy 
 
 
117 
 
Chapter 5 Investigations of MFN2-
Positive Muscle Biopsy 
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5.1 Introduction 
MFN2 mutations cause Charcot-Marie-Tooth type 2A (CMT-2A) (Züchner et al., 
2004) and rather intriguingly, the clinical manifestations observed in this disorder 
can be observed in a subgroup of patients with OPA1-related DOA+ phenotypes 
(Rouzier et al., 2012). OPA1 mutations have previously been linked with the 
occurrence of pathological COX-negative muscle fibres, the accumulation of high 
levels of somatically-acquired mtDNA deletions, and significant mtDNA 
proliferation (Amati-Bonneau et al., 2008; Hudson et al., 2008a; Yu-Wai-Man et al., 
2010c). As detailed previously (Chapter 4), blood leukocytes from both OPA1 and 
MFN2 mutant carriers were found to contain significantly higher mtDNA copy 
numbers compared with those from normal controls (Sitarz et al., 2012a; Sitarz et al., 
2012c). It is therefore highly relevant that COX-deficient muscle fibres and multiple 
mitochondrial DNA deletions have recently been identified in skeletal muscle 
biopsies from affected family members segregating a pathogenic c.629A>T 
(p.D210V) MFN2 missense mutation, clearly implicating disturbed mtDNA 
maintenance being an important pathogenic mechanism in this family (Rouzier et al., 
2012). The main objectives of this study were: (i) to determine whether COX-
deficient muscle fibres were present in a skeletal muscle specimen biopsied from one 
patient with a confirmed MFN2 mutation (c.1091G>C; p.R364P) within CC1 region; 
(ii) to investigate whether multiple mtDNA deletions were present in muscle 
homogenate DNA; and (iii) to quantify mtDNA copy number and the level of 
mtDNA deletions present in single COX-positive and COX-negative muscle fibres.  
5.1.1 Dual COX/SDH Staining  
Mitochondrial histochemical staining of skeletal muscle sections is a well-validated, 
reliable method for detecting impaired OXPHOS. Most diagnostic protocols involve 
sequential staining to determine the level of activity of two mitochondrial respiratory 
chain enzymes: succinate dehydrogenase (SDH) for complex II and cytochrome c 
oxidase (COX) for complex IV (Section 1.9.4.1). Complex II is entirely nuclear 
encoded, whereas complex IV consists of subunits encoded by both the nuclear and 
mitochondrial genomes. If mtDNA integrity is compromised e.g. by point mutations 
or large-scale deletions, this will have a deleterious effect on overall COX activity, 
but there will be no detectable loss in SDH activity. Following dual COX/SDH 
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staining, COX-negative fibres are highlighted blue, whereas COX-positive fibres 
remain brown in colour (Figure 5-1). 
 
 
Figure 5-1 Example of dual COX/SDH staining performed on a muscle section. 
COX-negative fibre highlighted in blue.  
 
5.1.2 Myofibrillar ATPase Staining 
Myofibrillar ATPase activity can be used to distinguish between muscle fibre types, 
which can be broadly classified as type I (slow contracting, oxidative) or type II (fast 
contracting, glycolytic/oxidative) subtypes. ATPase staining can reveal pathological 
changes such as muscle fibre atrophy or fibre type grouping, classically seen in 
patients with peripheral neuropathy. In the first step of the ATPase staining protocol, 
fibres were preincubated with an acid solution (pH ~ 4), which inhibits ATPase 
activity in fast (type II) fibres (Section 1.9.4.1). As a result, type I muscle fibres were 
stained dark brown, whereas type II muscle fibres remained light brown (Figure 
5-2).  
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Figure 5-2 Example of ATPase staining performed on a muscle section. Type I 
muscle fibres are dark brown whereas type II muscle fibres stain light brown. 
 
5.2 Materials and Methods 
5.2.1 Tissue Samples 
Muscle biopsies from a patient with a confirmed MFN2 mutation and from a normal 
healthy individual were investigated in this study. The MFN2 carrier was a 65-year-
old female harbouring a c.1091G>C (p.R364P) missense mutation in CC1 domain, 
who developed a progressive sensori-motor neuropathy with respiratory muscle 
involvement. The normal control was a 33-year-old male with no evidence of ocular 
or neuromuscular pathologies. This study had the relevant institutional approval and 
written informed consent was obtained from all of the subjects involved.  
5.2.2 Mitochondrial Histochemistry 
Dual COX/SDH and ATPase histochemical stains were performed on 20µm muscle 
biopsy sections as described in Section 3.11.2 and Section 3.11.3, respectively.  
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5.2.3 Long-Range PCR 
To detect multiple mtDNA deletions, a 16-kb long-range PCR assay was carried out 
with the TaKaRa LA Taq
TM
 PCR system (Takara Bio) on extracted muscle 
homogenate DNA, as described in Section 3.7.   
5.2.4 Single Fibre Analysis 
Individual muscle fibres were cut using a LMD 6000™ laser dissecting microscope 
(Leica) and their cross-sectional areas (µm²) were recorded at the same time. The 
laser-microdissected muscle fibres were lysed in a Mastercycler
TM
 Gradient System 
(Eppendorf) for 16 hours at 55ºC, in a 30µl reaction mix containing: 50% (v/v) 1% 
Tween-20 (Sigma-Aldrich), 10% (v/v) Tris-HCl (Sigma-Aldrich), 1% (v/v) 
proteinase K (Sigma-Aldrich) and 39% (v/v) dH2O. This was followed by heat 
inactivation at 95ºC for 10 minutes. The single-fibre lysates were used for qPCR 
analysis. 
5.2.4.1 Quantification of MtDNA Content and Deletion Level 
The mtDNA content of individual muscle fibres was determined using a real-time 
qPCR (MTND1/B2M) assay as described in Section 3.8.1. The different sizes of 
muscle fibres could potentially introduce variations in mtDNA content. To account 
for this, the total mtDNA copy number for each muscle fibre was divided by that 
fibre’s surface area, and the data were presented as the number of mtDNA copies per 
µm². The level of mtDNA deletions was calculated with a real-time qPCR 
(MTND1/MTND4) assay as detailed in Section 3.8.2. The mtDNA content data for 
four control muscles was kindly provided by Dr Patrick Yu-Wai-Man (Institute of 
Genetic Medicine, Newcastle University). This normative data set was combined 
with the results obtained from an additional control muscle biopsy. 
5.2.5 Statistical Analysis 
Statistical analyses were performed using GraphPad
TM
 v.4 statistical software 
(GraphPad Software). Group comparisons were carried out with an unpaired two-
tailed Student’s t-test with confidence interval (CI) set at 95%.  
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5.3 Results 
5.3.1 Mitochondrial Histochemistry 
Sequential COX/SDH staining of muscle sections from the MFN2-positive patient’s 
biopsy revealed a relatively low level of COX-deficient muscle fibres, estimated at 
9/1285 (0.7%) muscle fibres (Figure 5-3, Figure 5-5 A). Myofibrillar ATPase 
staining showed clear evidence of muscle fibre atrophy and fibre-type grouping 
(Figure 5-4, Figure 5-5 B). No pathological morphological or histochemical 
changes were noted in control muscle sections, following dual COX/SDH (Figure 
5-6) and ATPase (Figure 5-7) staining.    
 
 
Figure 5-3 Dual COX/SDH staining in a muscle section from the MFN2-positive 
patient. COX-deficient fibres highlighted in blue. 
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Figure 5-4 Staining for ATPase activity in a muscle section from the MFN2-
positive patient. Type I fibres are dark brown, whereas type II fibres are light brown 
in colour. Fibre-type grouping can be observed in this section with loss of the normal 
checkerboard appearance.   
 
  
Figure 5-5 Higher magnification views of stained MFN2-positive muscle sections 
revealing: (A) a COX-negative (blue) muscle fibre following dual COX/SDH 
histochemistry; (B) atrophic muscle fibres and fibre-type grouping following 
myofibrillar ATPase staining.  
A                                           B 
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Figure 5-6 Dual COX/SDH staining in a muscle section from a normal control 
individual. No COX-deficient fibres were detected. 
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Figure 5-7 Staining for ATPase activity in a muscle section from a normal 
control individual. Fibre-type grouping and atrophy were not observed. 
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5.3.2 Detection of Multiple MtDNA Deletions 
Multiple mtDNA deletions were not detected in muscle homogenate DNA from the 
MFN2-positive patient (Figure 5-8).  
 
                                               L            1            2           3            4 
 
Figure 5-8 Agarose gel revealing no multiple mtDNA deletions detected in total 
DNA isolated from muscle homogenate of a MFN2-positve individual. Legend: L 
= GeneRuler™ 1 kb Plus DNA Ladder (75-20,000 bp; Fermentas); 1 = MFN2-
mutated patient; 2 and 3 = positive multiple mtDNA deletion controls; 4 = normal 
healthy control.  
 
5.3.3 Single Muscle Fibre Analysis 
In the MFN2-positive muscle biopsy, there was evidence of significant mtDNA 
proliferation in COX-negative fibres compared with both type I and type II COX-
positive fibres (Figure 5-9 A). There was no significant difference in mtDNA copy 
number between different type I and type II COX-positive muscle fibres (P = 0.1827; 
Figure 5-9 A). Four out of eight (50%) COX-negative muscle fibres had mtDNA 
deletion levels > 70% (Figure 5-9 B). Compared with normal control muscle, total 
mtDNA content was significantly increased in the MFN2-positive muscle for both 
COX-positive type I (P = 0.0328; Figure 5-10 A) and COX-positive type II (P < 
0.0001; Figure 5-10 B) muscle fibres.    
20kb 
10kb 
5kb 
1.5kb 
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Figure 5-9 Single fibre analysis of a MFN2-positive muscle specimen. (A) 
Comparison of mtDNA content for COX-positive (type I and type II) and COX-
negative (COX-ve) fibres (type I: mean = 7.3, SD = 1.9, N = 17; type II: mean = 6.4, 
SD = 1.8, N = 19; COX-ve: mean = 14.7, SD = 5.1, N = 8); NS - not significant at P 
= 0.1827; *** - refers to P value < 0.0001. (B) MtDNA deletion levels in different 
muscle fibre types (type I: mean = 3.2, SD = 15.3, N = 17; type II: mean = -3.7, SD = 
11.6, N = 19; COX-ve: mean = 40.1, SD = 46.7, N = 8); NS - non-significant at P = 
0.1339; ** - significant at P = 0.0065; *** - refers to P value < 0.0001. 
 
  
Figure 5-10 Comparison of mtDNA content in type I and type II COX-positive 
fibres for MFN2-positive and control muscle specimens. (A) MFN2 type I: mean 
= 7.3, SD = 1.9, N = 17; control type I: mean = 5.4, SD = 3.5, N = 81; * - significant 
at P = 0.0328. (B) MFN2 type II: mean = 6.4, SD = 1.8, N = 19; control type II: 
mean = 2.6, SD = 1.2, N = 90; *** - refers to P value < 0.0001. 
A                           
A 
B                           
 B                           
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5.4 Discussion 
The histochemical investigation of a muscle biopsy specimen from a patient 
harbouring a pathogenic c.1091G>C (p.R364P) mutation has revealed the presence 
of atrophic muscle fibres and characteristic fibre-type grouping in keeping with an 
ongoing pathological denervation-reinnervation process. A relatively low level of 
COX-negative muscle fibres was detected (0.7%), and this could simply reflect the 
age of the patient, who was 65-years-old when the biopsy was carried out. Up to 1% 
COX-deficient muscle fibres have been identified in muscle biopsies obtained from 
healthy, physically-active elderly individuals over the age of 60 years, due to the 
clonal expansion of somatic mtDNA deletions (Brierley et al., 1998; Bodyak et al., 
2001). Single-fibre analysis of the MFN2-positive muscle specimen revealed a 
statistically significant increase in mtDNA copy number in COX-negative muscle 
fibres compared with both type I and type II COX-positive fibres. Interestingly, 
significant mtDNA proliferation was also observed in type I and type II COX-
positive muscle fibres when compared with muscle fibres from normal control 
muscle biopsies. This increase in mtDNA copy number could be a compensatory 
mechanism that helps to maintain adequate levels of ATP production, analogous to 
the marked mtDNA proliferation observed in muscle biopsies from patients with 
OPA1 mutations (Yu-Wai-Man et al., 2010c). More importantly, the observed 
mtDNA proliferation in the MFN2-positive muscle biopsy supports the similar 
phenomenon detected in blood leukocytes of MFN2-mutant carriers (Sitarz et al., 
2012c). 
Only 50% of COX-negative muscle fibres had deletion levels > 70% i.e. above the 
generally accepted mutational threshold required to induce a biochemical defect 
(Shoubridge et al., 1990; Bua et al., 2002; Durham et al., 2007). It is possible that the 
remaining COX-negative fibres (4/8; 50.0%) harboured small mtDNA deletions, 
which spared both MTND1 and MTND4, and therefore remained undetectable with 
the qPCR assay (Bua et al., 2006). Another possibility is that COX-deficiency in 
these fibres is due to accumulation of high levels of somatic mtDNA point mutations, 
and not deletions (Del Bo et al., 2003; Wanrooij et al., 2004; Chinnery and Zeviani, 
2008; Reeve et al., 2008). 
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Rouzier and colleagues have recently described a Tunisian family with a progressive 
multisystem neurological disorder secondary to a novel heterozygous missense 
mutation in MFN2 (c.629A>T; p.D210V) (Rouzier et al., 2012). MFN2 mutations 
typically cause autosomal-dominant axonal Charcot-Marie-Tooth disease type 2A 
(CMT2A) (Züchner et al., 2004). Interestingly, the clinical features among 
mutational carriers in this Tunisian family were more variable, ranging from 
asymptomatic subclinical disease to an axonal sensorimotor neuropathy complicated 
by optic atrophy, deafness, cerebellar ataxia, and proximal myopathy (Rouzier et al., 
2012). COX-deficient fibres and multiple mtDNA deletions were detected in skeletal 
muscle biopsies from affected family members, clearly suggesting that the MFN2 
mutation segregating in this family is having a deleterious impact on mtDNA 
maintenance, ultimately triggering an overt mitochondrial respiratory chain defect 
and the onset of clinical symptoms. Further studies on a larger number of MFN2-
positive muscle biopsies are needed to confirm the important findings reported by 
Rouzier and colleagues and the additional observations made in this study.  
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Chapter 6 Neuromyelitis Optica and 
Genetic Variations within OPA1 
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6.1 Introduction 
Neuromyelitis optica (NMO), also known as Devic’s disease is an idiopathic, 
autoimmune, demyelinating condition of the central nervous system (CNS) that 
preferentially affects the optic nerve and spinal cord (Wingerchuk et al., 2007). NMO 
is a relatively rare cause of CNS demyelination with the prevalence estimated at 0.5 
to 1.0 per 100,000 among the white population (Jacob et al., 2009). The discovery of 
a specific NMO-IgG autoantibody marker against the aquaporin-4 (AQP4) water 
channel and the consistent presence of longitudinally extensive myelitis on magnetic 
resonance imaging have further refined the diagnostic criteria for this disorder 
(Lennon et al., 2004; Wingerchuk, 2006).  
Interestingly, NMO shares overlapping clinical features with the more complicated 
DOA+ variants caused by some pathogenic OPA1 mutations (Section 1.10.2). These 
observations therefore suggest that some patients diagnosed as having NMO could in 
fact be harbouring pathogenic OPA1 mutations, or that the expression of NMO could 
be influenced by specific OPA1 single nucleotide polymorphisms (SNPs). The aim 
of this study was to investigate the role of OPA1 genetic variants in a cohort of 
patients with a clinical diagnosis of NMO, supported by consistent magnetic 
resonance imaging findings and/or positivity for anti-AQP4 antibodies (Wingerchuk, 
2006).  
 
6.2 Materials and Methods  
6.2.1 Patient Cohort 
Genomic DNA samples, extracted from whole blood, were available for the 
following groups of white British individuals: (i) patients with NMO (N = 32), 
diagnosed as a part of a British Neurological Surveillance Unit (BNSU) national case 
ascertainment study. All these patients fulfilled the revised diagnostic criteria for 
NMO, with clinically and radiologically-confirmed episodes of optic neuritis and 
transverse myelitis (Wingerchuk, 2006). The clinical characteristics of these patients 
have been described previously (Hudson et al., 2008b). NMO anti-AQP4 antibodies 
were detected in 12 of these patients; (ii) patients with primary open angle glaucoma 
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(POAG; N = 137; mean (SD) age = 71.6 (8.0) years), diagnosed with either the high 
tension (HTG; N = 67) or normal tension (NTG; N = 70) form of the disease (Yu-
Wai-Man et al., 2010d); and (iii) healthy controls (N = 75; mean (SD) age = 79.3 
(4.4) years) with no evidence of ophthalmological or neuromuscular disorders. This 
study had the relevant institutional approval and written informed consent was 
obtained from all of the subjects involved. 
6.2.2 OPA1 Sequencing  
All 30 coding exons and adjacent intronic regions of OPA1 were amplified by PCR 
using a set of 27 M13-tagged primer pairs (Table 3-1). Sanger sequencing was 
carried out as described previously (Section 3.6). The sequencing results were 
compared with GenBank OPA1 reference sequence (accession number 
NG_011605.1, mRNA transcript variant 1, NM_015560.2), and all identified genetic 
variants were confirmed by reverse sequencing to exclude PCR and sequencing 
errors. The significance of the OPA1 variants found in the NMO cohort was 
determined by searching online OPA1 databases: eOPA1 (http://lbbma.univ-
angers.fr/) and NCBI, as well as recent DOA case series reporting novel pathogenic 
mutations (Yu-Wai-Man et al., 2010a). Bioinformatic analysis and the functional 
consequence of intronic OPA1 nucleotide changes were determined using the 
Fruitfly BDGP predictor software (http://www.fruitfly.org/seq_tools/ splice.html and 
http://www.fruitfly.org/seq_tools/promoter.html) (Yu-Wai-Man et al., 2010a). The 
control and glaucoma OPA1 SNP data used for comparative purposes in this study 
have been previously published (Yu-Wai-Man et al., 2010d).  
6.2.3 Statistical Analysis 
The Hardy-Weinberg equilibrium for OPA1 genotypes was assessed for patient and 
control groups using the on-line calculator: http://ihg.gsf.de/cgi-bin/hw/hwa1.pl. 
Allele and genotype SNP frequencies were compared with 2 analysis using 
GraphPad
TM
 v.4 statistical software (GraphPad Software).  
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6.3 Results 
6.3.1 OPA1 Genotyping 
No pathogenic OPA1 mutations were identified in the NMO cohort. A total of 13 
OPA1 variants were identified. Nine of these had previously been reported as SNPs, 
whereas the remaining four OPA1 variants were novel heterozygous changes found 
in four different patients with NMO (Table 6-1). The novel exon 11 (c.1071A>G, 
p.A357A) and exon 22 (c.2256G>T, p.L752L) variants were synonymous. The two 
novel intronic variants were not predicted to affect the neighbouring splice donor 
sites.  
6.3.2 OPA1 SNP Associations 
The OPA1 SNP frequency in the NMO cohort was compared with the following 
groups: (i) healthy controls, (ii) patients with POAG, and (iii) high tension (HTG) 
and normal tension (NTG) glaucoma subgroups. No significant allele or genotype 
associations were detected with the following three OPA1 SNPs: IVS8+4C>T, 
IVS8+32T>C and c.473A>G (Table 6-2, Table 6-3, and Table 6-4). Analysis of 
both the IVS8+4C>T and IVS8+32T>C OPA1 SNPs did not reveal a significantly 
increased risk of developing NMO with specific compound genotypes (Table 6-5). 
There was no significant allele or genotype associations for the remaining nine SNPs 
identified in patients with NMO compared with healthy controls.  
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Table 6-1 OPA1 variants identified in the neuromyelitis optica (NMO) cohort. A 
total of 13 OPA1 variants were detected. These changes were confirmed by reverse 
sequencing and then checked against publicly-available databases to determine 
whether they had previously been reported: (i) the eOPA1 Database; (ii) the NCBI 
dbSNP Database; and (iii) the Human Genome Mutation Database.  
cDNA Location AA change N = Homozygous Heterozygous 
c.473A>G Exon 4 p. N158S 25/32 15/25 (60%) 10/25 (40%) 
c.557-19T>C Intron 4 - 17/32 7/17 (41%) 10/17 (59%) 
IVS8+4C>T Intron 8 - 9/32 2/9 (22%) 7/9 (78%) 
IVS8+32T>C Intron 8 - 17/32 7/17 (41%) 10/17 (59%) 
c.1071A>G* Exon 11 p. A357A 1/32 0/1 (0%) 1/1 (100%) 
c.1312+32A>G Intron 13 - 1/32 0/1 (0%) 1/1 (100%) 
c.1589+22T>G* Intron 16 - 1/32 0/1 (0%) 1/1 (100%) 
c.1770+16T>G Intron 18 - 6/32 0/6 (0%) 6/6 (100%) 
c.1770+47T>A* Intron 18 - 1/32 0/1 (0%) 1/1 (100%) 
c.1770+51T>G Intron 18 - 17/32 7/17 (41%) 10/17 (59%) 
c.2109C>T Exon 21 p.A703A 25/32 15/25 (60%) 10/25 (40%) 
c.2256G>T* Exon 22 p. L752L 1/32 0/1 (0%) 1/1 (100%) 
c.2707+25T>A Intron 26 - 17/32 7/17 (41%) 10/17 (59%) 
* = novel OPA1 variant, AA = amino acid; cDNA = complementary DNA; N = 
number of NMO patients harbouring the OPA1 variant. 
 
 
 
 
   
 
1
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Table 6-2 Allele and genotype frequencies for the IVS8+4C>T OPA1 SNP. Both patient and control groups were in Hardy-Weinberg 
equilibrium at IVS8+4C>T.  
 
NMO 
(N = 32) 
Healthy Controls 
(N = 75) 
POAG 
(N = 137) 
HTG Subgroup 
(N = 67) 
NTG Subgroup 
(N = 70) 
Allele   P value  P value  P value  P value 
C 53 (83.0%) 131 (87.3%)  222 (81.0%)  114 (85.1%)  108 (77.1%)  
T 11 (17.0%) 19 (12.7%) 0.395 52 (19.0%) 0.859 20 (14.9%) 0.681 32 (22.9%) 0.460 
Genotype   P value
*
  P value
*
  P value
*
  P value
*
 
CC 23 (72.0%) 59 (78.7%)  90 (65.7%)  49 (73.1%)  41 (58.6%)  
CT 7 (22.0%) 13 (17.3%)  42 (30.7%)  16 (23.9%)  26 (37.1%)  
TT 2 (6.0%) 3 (4.0%) 0.626 5 (3.6%) 0.532 2 (3.0%) 0.614 3 (4.3%) 0.305 
* = 2 analysis of all three possible genotypes at IVS8+4C>T; HTG = high tension glaucoma; NMO = neuromyelitis optica; NTG = normal 
tension glaucoma; POAG = primary open angle glaucoma. 
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Table 6-3 Allele and genotype frequencies for the IVS8+32T>C OPA1 SNP. Both patient and control groups were in Hardy-Weinberg 
equilibrium at IVS8+32T>C.  
 
NMO 
(N = 32) 
Healthy Controls 
(N = 75) 
POAG 
(N = 137) 
HTG Subgroup 
(N = 67) 
NTG Subgroup 
(N = 70) 
Allele   P value  P value  P value  P value 
T 40 (62.5%) 79 (52.7%)  155 (56.6%)  74 (55.2%)  81 (57.9%)  
C 24 (37.5%) 71 (47.3%) 0.229 119 (43.4%) 0.403 60 (44.8%) 0.359 59 (42.1%) 0.544 
Genotype   P value
*
  P value
*
  P value
*
  P value
*
 
TT 15 (46.9%) 21 (28.0%)  41 (29.9%)  19 (28.4%)  22 (31.4%)  
CT 10 (31.2%) 37 (49.3%)  73 (53.3%)  36 (53.7%)  37 (52.9%)  
CC 7 (21.9%) 17 (22.7%) 0.132 23 (16.8%) 0.075 12 (17.9%) 0.096 11 (15.7%) 0.126 
* = 2 analysis of all three possible genotypes at IVS8+32T>C; HTG = high tension glaucoma; NMO = neuromyelitis optica; NTG = normal 
tension glaucoma; POAG = primary open angle glaucoma. 
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Table 6-4 Allele and genotype frequencies for the c.473A>G OPA1 SNP. Both patient and control groups were in Hardy-Weinberg 
equilibrium at c.473A>G.  
 
NMO 
(N = 32) 
Healthy Controls 
(N = 75) 
POAG 
(N = 137) 
HTG Subgroup 
(N = 67) 
NTG Subgroup 
(N = 70) 
Allele   P value  P value  P value  P value 
A 24 (37.5%) 75 (50.0%)  128 (46.7%)  65 (48.5%)  63 (45.0%)  
G 40 (62.5%) 75 (50.0%) 0.102 146 (53.3%) 0.380 69 (51.5%) 0.313 77 (55.0%) 0.617 
Genotype   P value
*
  P value
*
  P value
*
  P value
*
 
AA 7 (21.9%) 19 (25.3%)  26 (19.0%)  13 (19.4%)  13 (18.6%)  
AG 10 (31.2%) 37 (49.4%)  76 (55.5%)  39 (58.2%)  37 (52.9%)  
GG 15 (46.9%) 19 (25.3%) 0.080 35 (25.5%) 0.614 15 (22.4%) 0.471 20 (28.5%) 0.840 
* = 2 analysis of all three possible genotypes at c.473A>G; HTG = high tension glaucoma; NMO = neuromyelitis optica; NTG = normal tension 
glaucoma; POAG = primary open angle glaucoma.  
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Table 6-5 Compound genotype frequencies for the IVS8+4C>T and 
IVS8+32T>C OPA1 SNPs.  
IVS8+4 IVS8+32 NMO 
Healthy 
Controls P value* Odds ratio 95% CI 
TT TT 2 (6.3%) 3 (4.0%) 0.634 1.600 0.254 - 10.067 
CT TT 5 (15.6%) 2 (2.7%) 0.024* 6.759 1.237 - 36.935 
CC TT 8 (25.0%) 16 (21.3%) 0.801 1.229 0.465 - 3.250 
TT TC 0 (0.0%) 0 (0.0%) N/A N/A N/A 
CT TC 2 (6.3%) 11 (14.7%) 0.336 0.388 0.081 - 1.860 
CC TC 8 (25%) 26 (34.7%) 0.372 0.628 0.248 - 1.594 
TT CC 0 (0.0%) 0 (0.0%) N/A N/A N/A 
CT CC 0 (0.0%) 0 (0.0%) N/A N/A N/A 
CC CC 7 (21.9%) 17 (22.7%) 1.000 0.955 0.352 - 2.590 
* = non-significant with Bonferroni correction: P < 0.008; N/A = not applicable; CI – 
confidence interval. 
 
6.4 Discussion 
No pathogenic OPA1 mutations were identified in this well-characterised group of 
patients with NMO. Although the possibility of large-scale OPA1 genomic 
rearrangements cannot be excluded, these are rare in DOA, accounting for less than 
1% of singleton cases with suspected inherited optic atrophy (Yu-Wai-Man et al., 
2011b). Importantly, OPA1 mutations have only been reported within the first ten 
intronic nucleotide positions, making it highly unlikely that the PCR-based 
sequencing strategy used in this study has missed functional intronic variants 
influencing mRNA splicing or transcriptional activity (Yu-Wai-Man et al., 2011b). 
Only one non-synonymous OPA1 SNP (c.473A>G, p.N158S) was present in patients 
with NMO, but it is an evolutionarily poorly-conserved amino acid residue. No 
significant allele and genotype associations were found for c.473A>G and the 
remaining SNPs identified in the NMO cohort when compared with both healthy 
controls and patients with POAG. These findings contrast with the recent 
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observations in POAG, where specific OPA1 variants at IVS8+4C>T and 
IVS8+32T>C, have been linked with an increased risk of developing NTG, 
suggesting a role for OPA1 in glaucomatous optic nerve degeneration (Aung et al., 
2002; Yu-Wai-Man et al., 2010d). NMO is a relatively rare disorder with an 
estimated prevalence of 0.5 to 1.0 per 100,000 among the white population (Jacob et 
al., 2009). Although it is possible that a study of 32 patients with NMO might not 
have been sufficiently powered to detect a small effect, the results of this study 
suggest that OPA1 is not a major susceptibility gene in the pathophysiology of this 
demyelinating CNS disease.  
 
The data presented in this chapter has been published following peer review: 
Sitarz K.S., Yu-Wai-Man P., Hudson G., Jacob A., Boggild M., Horvath R., 
Chinnery P.F., 2011. Genetic variations within the OPA1 gene are not associated 
with neuromyelitis optica. Multiple Sclerosis. 18(2): 240-243. 
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7.1 Introduction 
OPA1 plays an important role in mtDNA maintenance, with some pathogenic OPA1 
mutations leading to the accumulation of multiple mtDNA deletions (Amati-Bonneau 
et al., 2008; Hudson et al., 2008a). As shown recently by Elachouri and colleagues, 
the OPA1-exon 4b isoform generates a specific 10-kDa N-terminus OPA1 peptide, 
which contains a domain corresponding to exon 4b (NT-OPA1-exon 4b) (Elachouri 
et al., 2011). This specific peptide fragment is thought to directly interact with 
nucleoids, which are located within the mitochondrial matrix compartment, by 
binding these nucleoids to the IMM, thereby enabling their proper distribution within 
the mitochondrial network and promoting mtDNA replication (Elachouri et al., 
2011). C-terminally truncated OPA1 alleles result in haploinsufficiency, with a 50% 
reduction in the protein level, whereas missense mutations affecting the GTPase 
region are more likely to produce a dysfunctional protein with a dominant-negative 
effect (Marchbank et al., 2002; Olichon et al., 2007; Amati-Bonneau et al., 2008; 
Hudson et al., 2008a). In both situations, a disturbance in cristae morphology could 
disrupt the anchoring of mtDNA molecules to the IMM, with an adverse effect on 
mitochondrial genome replication (Landes et al., 2010). OPA1 mutations involving 
the GTPase domain could also affect the dGTP nucleotide pool, disturbing the 
delicate balance of nucleotides within the matrix compartment and thus having a 
detrimental effect on the faithful replication of the mitochondrial genome (Amati-
Bonneau et al., 2008). Furthermore, by impairing mitochondrial fusion and the 
exchange of mitochondrial contents some OPA1 mutations could prevent defective 
nucleoids from being repaired or complemented, further contributing to mtDNA 
instability (Landes et al., 2010).   
Both dominant and recessive POLG1 mutations have been shown to decrease POLG 
activity resulting in impaired mtDNA replication (Graziewicz et al., 2006). The 
consequences of pathogenic POLG1 mutations on mitochondrial genome integrity 
can be both quantitative (mtDNA depletion) as well as qualitative (mtDNA point 
mutations and deletions) (Chan and Copeland, 2009). In a recent study by Stewart 
and colleagues a significant decrease in mtDNA repopulation rates was observed in 
POLG1-mutant fibroblasts following ethidium bromide (EtBr)-induced mtDNA 
depletion (Stewart et al., 2011).        
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The aims for this study were: (i) to determine the efficiency of mtDNA replication 
using the same repopulation assay described by Stewart and colleagues (Stewart et 
al., 2011), and (ii) to document the changes in mitochondrial network morphology 
following EtBr-induced mtDNA depletion  and the subsequent mtDNA repopulation 
phase in fibroblast cell lines harbouring pathogenic OPA1 or POLG1 mutations. EtBr 
is a drug that inhibits mitochondrial transcription and replication in proliferating 
cells, but it has no effect on nuclear DNA (Leibowitz, 1971; Seidel-Rogol and 
Shadel, 2002). EtBr prevents [
3
H]-thymidine incorporation into mtDNA, but not 
nDNA, and it ultimately leads to the physical breakdown of circular mtDNA 
molecules (Nass, 1970; Desjardins et al., 1985). Crucially, the effect of EtBr is 
reversible, so when the drug is removed from the culture medium, cells are able to 
repopulate their mtDNA population (King and Attardi, 1989). The principle 
underpinning this assay has previously been used to investigate the mechanisms 
controlling mtDNA copy number in human osteosarcoma 143B and HeLa cells 
(Moraes et al., 1999; Seidel-Rogol and Shadel, 2002). A similar experimental 
protocol has also been used to demonstrate the faster repopulation of smaller deleted 
mtDNA genomes compared with wild-type mtDNA molecules (Diaz et al., 2002).   
A comprehensive quantitative analysis of the mitochondrial network was performed 
on all investigated cell lines prior to EtBr treatment, at the end of induced mtDNA 
depletion period, and at the end of subsequent mtDNA repopulation phase. The 
extent of mitochondrial network fragmentation can vary widely depending on the 
functional effect of the specific pathogenic OPA1 mutation (Olichon et al., 2007). A 
highly fragmented mitochondrial network morphology has previously been observed 
in fibroblasts from patients harbouring mutations affecting the functional GTPase 
domain, but not in those harbouring truncated OPA1 alleles that lead to 
haploinsufficiency (Olichon et al., 2007; Chevrollier et al., 2012). This pathological 
mitochondrial network fragmentation has also been documented in OPA1-mutant 
human fibroblasts in response to glycolysis shortage (following culture in glucose-
free media) or exogenous oxidative stress (Agier et al., 2012). The aim of this study 
was therefore to investigate further the pathological consequences of mtDNA 
depletion on the mitochondrial network in patient-derived fibroblasts harbouring 
OPA1 or POLG1 mutations. The kinetics of mtDNA recovery following EtBr- 
induced depletion will also provide additional insight into the complexity between 
MtDNA Repopulation Assay and Mitochondrial Network Analysis 
 
 
146 
 
mitochondrial structure-function relationship and how this becomes disrupted by 
mutations involving OPA1 and POLG proteins, which are intricately involved in 
mtDNA maintenance.   
 
7.2 Materials and Methods  
7.2.1 Cell Lines 
Fibroblasts from 17 individuals were selected for this study: (i) eight DOA patients 
harbouring confirmed OPA1 mutations (OPA1a – OPA1h; Table 7-1); (ii) five 
patients with confirmed POLG1 mutations (POLG1a – POLG1e; Table 7-2); and 
(iii) four normal healthy controls with no evidence or family history of 
neuromuscular disorders (C1 – C4) (Table 7-2). The clinical characteristics of the 
patients included in this study have been detailed further in Table 7-1 and Table 7-2.  
Three OPA1 fibroblast cell lines were derived from affected family members 
carrying the same OPA1 nonsense mutation (c.889C>T; p.Q297X) in exon 9. Despite 
the fact that they harboured the same pathogenic mutation, the mother (OPA1a), the 
son (OPA1b) and the daughter (OPA1c) had marked differences in disease severity 
(Table 7-1). The OPA1d and OPA1g cell lines were derived from an affected mother 
(OPA1g) and her affected son (OPA1d), both of them harbouring the same 
c.1294A>G (p.I432V) missense OPA1 mutation in exon 13. The OPA1g female 
patient, who is in her seventies, is clinically asymptomatic, but she had subtle 
evidence of optic atrophy on optical coherence tomography retinal imaging. The 
OPA1d male individual suffered from a severe DOA+ phenotype. The two male 
OPA1 carriers (OPA1e and OPA1f) were from the same extended pedigree 
segregating the c.876-878del(TGT) deletion in exon 9, which causes a frameshift at 
codon 294 and leads to premature protein termination at codon 960 (p.V294fsX667). 
The OPA1h fibroblasts were derived from a male patient with a c.1516+1G>T splice 
site mutation. 
Three POLG1-mutantcell lines (POLG1a, POLG1b and POLG1e) were derived from 
unrelated patients with Alpers-Huttenlocher syndrome (AHS) secondary to 
compound heterozygous POLG1 mutations: (i) POLG1a: c.2243G>C (p.W748S) and 
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deletion c.3600delT; (ii) POLG1b: c.1399G>A (p.A467T) and c.3311C>T 
(p.S1104F); (iii) POLG1e: c.2209 G>C (p.G737R) and c.2300 C>A (p.A767N). 
Alpers-Huttenlocher syndrome is an early-onset, progressive neurodegenerative 
disorder characterised by intractable epilepsy, developmental delay, and with a 
subgroup of patients developing limb spasticity, dementia, and liver failure. The 
remaining two POLG1-mutant fibroblast cell lines came from unrelated individuals 
with mitochondrial recessive ataxia syndrome (MIRAS) secondary to (i) compound 
heterozygous c.1399 G>A (p.A467T) and c.2243G>C (p.W748S) POLG1 mutations 
(POLG1c), and (ii) homozygous c.2243G>C (p.W748S) POLG1 mutation 
(POLG1d).    
This study had the relevant institutional approval and written informed consent was 
obtained from all of the subjects involved.       
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Table 7-1 Clinical phenotype and mutational spectrum of investigated OPA1 cell lines.  
Patient 
Age 
(yrs) 
Sex cDNA Consequence 
Protein 
Domain 
Affected 
Detailed Clinical Phenotype 
OA Deafness Ataxia Myopathy Neuropathy PEO Others 
OPA1a 50 F c.889C>T p.Q297X - + - - - + - HSP 
OPA1b 23 M c.889C>T p.Q297X - + - - - - - HSP 
OPA1c 28 F c.889C>T p.Q297X - + - - - - - - 
OPA1d 44 M c.1294A>G p.I432V GTPase + - + + + + - 
OPA1e 62 M 
c.876–
878del(TGT) 
p.V294fsX667 - + - - - + - HSP 
OPA1f 43 M 
c.876–
878del(TGT) 
p.V294fsX667 - + - - - - - - 
OPA1g 72 F c.1294A>G p.I432V GTPase + - - - - - - 
OPA1h 39 M c.1516+1G>T 
Splicing 
defect 
- + - - - - - - 
F – female; HSP – hereditary spastic paraplegia; M – male; OA – optic atrophy; PEO – progressive external ophthalmoplegia.  
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Table 7-2 Properties of investigated cell lines derived from POLG1-positive patients and healthy control individuals.  
Patient 
Age 
(yrs) 
Sex cDNA Consequence 
Protein 
Domain 
Affected 
Detailed Clinical Phenotype 
OA Epilepsy Ataxia Myopathy Neuropathy PEO Others 
POLG1a
 3 F 
c.2243G>C;      
c.3600delT 
p.W748S;            
c.3600delT 
LR; PD - + - + N/A - AHS 
POLG1b 5 M 
c.1399G>A;      
c.3311C>T 
p.A467T;                
p.S1104F 
LR; PD - + + + N/A - AHS 
POLG1c 39 M 
c.1399 G>A;      
c.2243G>C 
p.A467T;                
p. W748S  
LR - - + - + + MIRAS 
POLG1d 36 M 
c.2243G>C;      
c.2243G>C 
p. W748S;    
p. W748S 
LR - - + - + + MIRAS 
POLG1e 1 M 
c.2209 G>C;            
c.2300 C>A 
p.G737R;                      
p.A767N 
LR - + - + N/A - AHS 
C1 57 F - - - - - - - - - - 
C2 0 M - - - - - - - - - - 
C3 30 F - - - - - - - - - - 
C4 49 M - - - - - - - - - - 
AHS – Alpers-Huttenlocher syndrome; F – female; LR – Linker region; M – male; MIRAS - Mitochondrial recessive ataxia syndrome; PD – Polymerase domain; PEO – 
progressive external ophthalmoplegia; OA – optic atrophy; N/A – data not available. 
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7.2.2 Tissue Culture 
Fibroblast cell lines were cultured according to the protocol described in Section 
3.12.1. Cells were maintained at 50-90% confluency with the excess fresh media 
allowing exponential growth. Culture media were supplemented with uridine to 
account for the active dihydroorotate hydrogenase loss occurring in the mitochondria 
lacking mtDNA (Morais et al., 1980; Gregoire et al., 1984). Sodium pyruvate was 
added as an additional carbon source for energy production. All investigated cell 
lines were found to be negative for mycoplasma infections when checked using a 
PCR-based Venor®GeM Mycoplasma Detection Kit (Cambio) (Section 3.12.2).       
7.2.2.1 Ethidium Bromide Treatment 
Ethidium bromide (Sigma-Aldrich) at a concentration of 50ng/ml was added to the 
fibroblast media to induce mtDNA depletion (Diaz et al., 2002). Cells were grown in 
EtBr supplemented media for 15 days. Following this period, cells were cultured in 
normal media for 33 days (Figure 7-1). Rates of mtDNA depletion and repopulation 
were determined by harvesting cells and estimating their mtDNA copy number at 
days: 0, 6, 12, 18, 24, 30, 36, 42 and 48.   
 
 
 
 
 
 
 
 
Figure 7-1 Repopulation assay - experimental outline. 
 
 
 
 Days since start of experiment 
0               6              12             18             24             30             36            40             48 
Day 15 - EtBr removed from media 
EtBr treatment MtDNA repopulation phase 
MtDNA Repopulation Assay and Mitochondrial Network Analysis 
 
 
151 
 
For each cell line, EtBr-treated cells were cultured in parallel with untreated controls, 
in order to correct for normal mtDNA copy number fluctuations. The treated and 
untreated arms were grown in 6-well plates (Greiner) - 3 wells containing normal 
media, and 3 wells with EtBr supplemented media (Figure 7-2). At each harvesting 
point, cells were pelleted separately from each well, to allow for independent 
replicate measurements. For each investigated cell line, mtDNA copy number was 
determined for two pellets from the EtBr-treated cells, and two pellets from the 
untreated cells. 
  
 
 
 
 
 
 
 
 
 
Figure 7-2 Experimental 6-well plate with untreated (Normal) and ethidium 
bromide treated (EtBr) wells for each fibroblast line. 
 
7.2.3 DNA Extraction from Cell Pellets 
For DNA isolation, cells instead of being reseeded, were pipetted into 2ml tubes 
(Eppendorf) and centrifuged at 12,000 rpm for 3 minutes. Following this, the 
supernatant was discarded and the obtained pellets were resuspended in PBS 
(Oxoid), before being centrifuged again at 12,000 rpm for 3 minutes. Finally, PBS 
(Oxoid) was removed and the pellets stored at -20°C for the future use. DNA from 
cultured cells was extracted using DNeasy® Blood & Tissue Kit (Qiagen), as 
described in Section 3.1.1.  
Normal (1)                     Normal (2)                     Normal (3) 
 
 
 
  EtBr (1)                           EtBr (2)                         EtBr (3) 
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7.2.4 Quantification of MtDNA Copy Number 
The mtDNA copy number was quantified using qPCR-based (MTND1/B2M) assay, 
as described in Section 3.8.1. The principle of this method is based on the 
comparison between the relative levels of the mitochondrial ND1 gene and the 
nuclear housekeeping B2M gene, thereby allowing the cellular mtDNA content to be 
determined. 
7.2.5 MtDNA Repopulation Level Calculation 
Repopulation level (RL) at each analysis point was calculated as the ratio between 
mtDNA copy number for treated (CNtreated) and untreated (CNuntreated) cells:  
 
    
          
           
 
 
Relative mtDNA copy numbers were determined for two independent pellets from 
the treated group, and two independent pellets from the untreated group. The final 
repopulation level (RLTOT) was therefore calculated as the average of four different 
RL values. To allow for an accurate comparison among various cell lines, the change 
in mtDNA copy number was determined in relation to the initial mtDNA copy 
number at day 0.  
7.2.6 Mitochondrial Network Analysis 
In order to investigate and quantify the mitochondrial network morphology, 
fibroblasts were seeded at a density of 20,000 cells/well in 12-well plates (Greiner) 
containing sterilized round 16 mm coverslips (VWR). The cells were allowed to 
attach during an incubation period of 24-48 hours at 37°C and 5% CO2 in standard 
culture medium (as described in Section 3.12.1). The medium was then aspirated, 
after which the cells were washed twice with PBS (Oxoid) before the addition of a 
staining mix (1ml/well) containing (i) Hank’s Balanced Salt Solution (HBSS) 
buffered with Ca
2+ 
and Mg
2+
 (Gibco, Life Technologies), (ii) 100nM MitoTracker® 
Green (Molecular Probes, Life Technologies), and (iii) 1µg/ml Hoechst 33342 
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(Molecular Probes, Life Technologies). The cells were incubated in this staining 
mixture for 30 minutes at 37°C and 5% CO2 to allow incorporation of the dyes. 
Following this step, the cells were washed three times in PBS (Oxoid) and then 
placed in standard culture medium (refer to Section 3.12.1) before being visualized 
with a microscope. 
Prior to imaging, each coverslip with the cells attached was removed from a well 
using sterile tweezers and inverted onto a drop (5µl) of PBS (Oxoid), previously 
pipetted on a glass slide (Thermo Scientific). Excess PBS was removed, then images 
of the mitochondrial network and nucleus were captured with an upright 
epifluorescent widefield Axio Imager.Z1 microscope (Carl Zeiss) equipped with an 
oil-immersion objective (x63 / N.A.=1.4; Plan APOCHROMAT, Carl Zeiss) and 
AxioCam HRm digital camera (Carl Zeiss), using AxioVision 4.6 software (Carl 
Zeiss). The mitochondrial network staining (MitoTracker® Green; Molecular Probes, 
Life Technologies) was visualized using the green (GFP) channel. The nuclear 
staining (Hoechst 33342; Molecular Probes, Life Technologies) was detected with 
the blue (DAPI) channel (Figure 7-3). For each individual cell, images were 
captured as a series of Z-stacks with 20 slices, each 0.2μm apart. 
Following acquisition, images were deconvolved with Volocity Software
TM
 
(PerkinElmer, Seer Green, UK) (Figure 7-4) using a theoretically calculated point 
spread function (PSF) for each of the dyes. All selected images were iteratively 
deconvolved until the level of confidence reached 99% or the number of iterations 
scored 50. The deconvolved images were used for quantitative mitochondrial 
network analysis using Huygens Essential Software
TM
 (Scientific Volume Imaging, 
Hilversum, The Netherlands) (Figure 7-5) with the following standardised set of 
parameters: threshold = 10%; seed = 0% and garbage = 30. The quantitative data 
were further analysed in Excel (Microsoft, Reading, UK) and GraphPad
TM
 v.5 
statistical software (GraphPad Software).   
Imaging and subsequent mitochondrial network analyses were performed for each 
individual fibroblast cell line at three time points: (i) at baseline before EtBr addition 
(day 0); (ii) at the end of the induced period of mtDNA depletion (day 15); and (iii) 
following a phase of culture in EtBr-free normal medium (day 45). At each sampling 
point, a minimum of 12 images per cell line were acquired. Following image 
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deconvolution, mitochondrial network length was quantified for 10 randomly-
selected individual cells per each studied fibroblast cell line. The data obtained were 
used to calculate: (i) the total length of the mitochondrial network per cell 
(abbreviated as the total length); (ii) the average mitochondrial fragment length 
(abbreviated as the average length); and (iii) the total number of individual 
mitochondrial fragments per cell (abbreviated as the number of fragments). The 
nuclear stain was used as a marker, to only select non-dividing cells for analysis.    
 
 
Figure 7-3 Mitochondrial network morphology in control fibroblasts prior to 
image deconvolution. Staining was performed using MitoTracker™ Green 
(Molecular Probes, Life Technologies) to delineate the mitochondrial network. The 
Hoechst 33342 (Molecular Probes, Life Technologies) stain was used to visualise the 
nucleus. 
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Figure 7-4 Mitochondrial network morphology in control fibroblasts following 
image deconvolution with Volocity Software
TM
 (PerkinElmer). Staining was 
performed using MitoTracker™ Green (Molecular Probes, Life Technologies) to 
define the mitochondrial network. The Hoechst 33342 (Molecular Probes, Life 
Technologies) stain was used to visualise the nucleus. 
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Figure 7-5 Mitochondrial network morphology in control fibroblasts analysed 
with Huygens Essential Software
TM
 (Scientific Volume Imaging). 
     
7.2.7 Statistical Analysis 
Group comparisons were carried out with an unpaired two-tailed Student’s t-test 
using GraphPad
TM
 v.5 statistical software (GraphPad Software). 
 
7.3 Results: Repopulation Assay 
Significant EtBr-induced mtDNA depletion was observed within the fibroblasts. 
However, no visible cell loss was detected during the EtBr-induced mtDNA 
depletion phase (day 0 to day 15), which implies that the concentration of EtBr was 
not terminally toxic to the cells. To account for the normal biological fluctuations in 
mtDNA copy number, each cell line was also cultured in normal media, in the 
absence of EtBr treatment. For the variation in mtDNA copy number observed in 
untreated cell lines at each analysis time point from day 0 to day 48, please refer to 
Appendix B.1. 
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7.3.1 MtDNA Depletion and Repopulation – Control Cell 
Lines 
The mtDNA depletion and repopulation curves for four control cell lines and their 
mean (abbreviated as the mean control) are presented in Figure 7-6. The depletion 
and subsequent repopulation curve for each individual control line was plotted from 
the repopulation levels (RLTOT) calculated at each time point from four different RL 
values (N = 4). The curve for the mean control was constituted from the entire cohort 
of RL values obtained for all four control cell lines, except days 24 and 36, when 
data were available only for the three control lines.  
Under EtBr culture conditions, significant mtDNA depletion was observed by day 12 
in all control cell lines (C1: mean = 0.129, SEM = 0.004; C2: mean = 0.017, SEM = 
0.001; C3: mean = 0.012, SEM = 0.0002; C4: mean = 0.037, SEM = 0.011). MtDNA 
repopulation was observed in three control lines (C1, C3 and C4) as from day 18, and 
in the C2 control line as from day 24. The mtDNA repopulation rate of the C3 line 
was significantly lower compared with the other controls until day 42 (mean = 0.535, 
SEM = 0.025). However, by day 48, all control fibroblast lines repopulated their 
mtDNA content to the levels observed in untreated cells (C1: mean = 0.949, SEM = 
0.079; C2: mean = 1.177, SEM = 0.156; C3: mean = 1.149, SEM = 0.060; C4: mean 
= 0.944, SEM = 0.045). For subsequent comparisons in this chapter, the mean 
control will refer to the combined data set for these four control cell lines.  
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Figure 7-6 MtDNA depletion and repopulation curves of the four individual control lines and the mean control. Each data point represents 
the average mtDNA copy number ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). 
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7.3.2 MtDNA Depletion and Repopulation – POLG1 Lines 
The mtDNA depletion and repopulation curves for the five POLG1-positive cell lines 
(Figure 7-7) and their mean (abbreviated as the mean POLG1; Figure 7-8) are 
described below. The curve for the mean POLG1 was constituted from the entire 
cohort of RL values obtained for all five POLG1-positive cell lines, except days 30 
and 36 when data were available for four POLG1 lines only, and days 42 and 48 
when results were available for only three POLG1 cell lines. This was due to the 
premature post-EtBr treatment death of the POLG1b and POLG1c fibroblast cell 
lines, despite maintaining optimal cell culture conditions in the repopulation phase 
and the confirmed absence of mycoplasma infection.  
During the mtDNA depletion phase, a significant reduction in mtDNA content was 
observed in all POLG1 cell lines by day 12 (Figure 7-7). During the repopulation 
phase, the POLG1 fibroblast lines repopulated their mtDNA populations to no more 
than 0.046 (SEM = 0.002) i.e. 4.6% of the baseline values. There were significant 
differences between the mean POLG1 and the mean control during the whole course 
of the experimental study (Figure 7-8). For subsequent comparisons in this chapter, 
the mean POLG1 will refer to the combined data set for the five POLG1 cell lines.  
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Mean 
Control 
vs. 
POLG1a 0.3909 0.4872 0.0111 0.0226 0.0028 0.0015 < 0.0001 < 0.0001 
POLG1b  0.6445 0.8603 0.0065 0.0220 N/A N/A N/A N/A 
POLG1c  0.0333 0.0801 0.0051 0.0229 0.0026 0.0014 N/A N/A 
POLG1d  0.0260 0.0831 0.0033 0.0207 0.0025 0.0014 < 0.0001 < 0.0001 
POLG1e  0.1417 0.1417 0.0586 0.0242 0.0033 0.0019 < 0.0001 < 0.0001 
Figure 7-7 MtDNA depletion and repopulation curves of the five individual POLG1 lines. Each data point represents the average mtDNA 
copy number ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). Table presents the P 
values of statistical comparisons made between different POLG1-mutant fibroblast lines and the mean control data set. Each column corresponds 
to the time point on the graph above. The intensity of the red shading correlates with the degree of statistical significance. N/A – data not 
available due to the death of EtBr-treated cells despite optimal cell culture conditions in the repopulation phase and the confirmed absence of 
mycoplasma infection.        
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Mean Control vs. Mean POLG1 0.0033 0.0140 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Figure 7-8 MtDNA depletion and repopulation curve of the mean POLG1 compared with the mean control. Each data point represents the 
average mtDNA copy number ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). 
Table presents the P values of statistical comparisons made between the mean POLG1 and the mean control data sets. Each column corresponds 
to the time point on the graph above. The intensity of the red shading correlates with the degree of statistical significance.  
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7.3.3 MtDNA Depletion and Repopulation – OPA1 Lines 
The mtDNA depletion and repopulation curves for eight individual OPA1 cell lines 
(Figure 7-9 to Figure 7-16) and their mean (abbreviated as the mean OPA1; Figure 
7-17) are presented below. The curves for the mean control and the mean POLG1 
have been plotted for comparison.  
During mtDNA depletion, a significant reduction in mtDNA content was observed 
for all OPA1 cell lines, with a drop in the relative copy number to approximately 
0.050 at day 12. There was no significant difference between the OPA1 patient lines 
and the mean control. The mtDNA depletion curves for all OPA1 fibroblasts were 
however statistically different from the mean POLG1, except for the OPA1b (Figure 
7-10) and OPA1h (Figure 7-16) cell lines at day 6 (P = 0.0551 and P = 0.9434, 
respectively).   
Variability among the individual OPA1 cell lines was noted during the mtDNA 
repopulation phase. The OPA1a cell line (Figure 7-9) demonstrated only a low level 
of mtDNA repopulation, with a maximal relative mtDNA copy number of 0.084 
(SEM = 0.007) at day 48. The repopulation of this cell line was statistically different 
from the mean control, during the entire repopulation phase, and from the mean 
POLG1 from day 24 onwards.  
The OPA1b patient line (Figure 7-10) reached a maximal mtDNA repopulation level 
of 0.278 (SEM = 0.047) at day 24. Subsequently, a decrease in the relative mtDNA 
copy number was observed until day 36 (mean = 0.152, SEM = 0.019), followed by a 
plateau and a final repopulation level of 0.179 (SEM = 0.001) at day 48. The 
repopulation of the OPA1b cell line was statistically different from the mean control 
(except at day 24; P = 0.2003) and the mean POLG1.  
The OPA1c cell line (Figure 7-11) showed only a low level of mtDNA repopulation, 
with a maximal relative copy number of 0.059 (SEM = 0.011) at day 24. Following 
this, the OPA1c cell line plateaued with a relative repopulation level of 
approximately 0.040. The repopulation of this cell line was significantly different 
from both the mean control and the mean POLG1 (except at day 18; P = 0.0631). 
During the repopulation phase, the OPA1d cell line (Figure 7-12) demonstrated an 
initial gradual increase in its relative mtDNA content to a maximal value of 0.359 
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(SEM = 0.018) at day 30. This was followed by a decrease until day 42 (mean = 
0.251, SEM = 0.021) and a final increase to a repopulation level of 0.426 (SEM = 
0.043) at day 48. The repopulation of the OPA1d line was significantly different 
from the mean control (except at day 24; P = 0.1480) and the mean POLG1.  
The OPA1e cell line (Figure 7-13) reached the mtDNA repopulation level exceeding 
60% by day 30 (mean = 0.627, SEM = 0.020). A decrease in repopulation levels was 
then observed, which led to a final relative mtDNA copy number of 0.441 (SEM = 
0.025) at day 48. The repopulation of the OPA1e cell line was not significantly 
different from the mean control up to day 30. The OPA1e cell line was however 
significantly different from the mean POLG1 during the entire study.  
The OPA1f cell line (Figure 7-14) showed a gradual increase in relative mtDNA 
copy number until day 30 (mean = 0.353, SEM = 0.054), followed by a decrease to a 
repopulation level of 0.274 (SEM = 0.004) at day 36, and a subsequent increase to 
0.335 (SEM = 0.012) at day 48. The repopulation curve of the OPA1f line was not 
significantly different from the mean control up to day 24, but it was significantly 
different from the mean POLG1 during the entire experiment.  
The OPA1g cell line (Figure 7-15) repopulated its mtDNA content to a maximal 
level of 0.247 (SEM = 0.002) at day 36, this being followed by a decrease to a final 
mtDNA copy number of 0.214 (SEM = 0.037) at day 48. The repopulation patterns 
of the OPA1g line and the mean control were not statistically different until day 24. 
The OPA1g cell line was however significantly different from the mean POLG1 for 
all experimental time points during the repopulation phase.  
The OPA1h cell line (Figure 7-16) demonstrated a relatively low level of 
repopulation, reaching a maximum of 0.080 (SEM = 0.021) at day 24. This was 
followed by a decrease in mtDNA repopulation and a final value of 0.053 (SEM = 
0.001) was reached at day 48. This cell line was significantly different from the mean 
control throughout the entire repopulation phase. The OPA1h cell line was 
significantly different from the mean POLG1, except at days 18 and 36 (P = 0.1040 
and P = 0.0611, respectively).  
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OPA1a 
vs. 
Mean Control 0.9581 0.6622 0.0188 0.0348 0.0034 0.0020 < 0.0001 < 0.0001 
Mean POLG 0.0059 0.0454 0.2416 < 0.0001 0.0103 0.0003 < 0.0001 < 0.0001 
 
Figure 7-9 MtDNA depletion and repopulation curve of the OPA1a cell line. Each data point represents the average mtDNA copy number 
ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). The table shows the P values for 
the following statistical comparisons: OPA1a vs. mean control, and OPA1a vs. mean POLG1. Each column corresponds to the time point on the 
graph above. The intensity of the red shading correlates with the degree of statistical significance. 
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OPA1b 
vs. 
Mean Control 0.5192 0.7793 0.0328 0.2003 0.0163 0.0038 < 0.0001 0.0002 
Mean POLG 0.0551 0.0198 0.0337 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 
Figure 7-10 MtDNA depletion and repopulation curve of the OPA1b cell line. Each data point represents the average mtDNA copy number 
ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). The table shows the P values for 
the following statistical comparisons: OPA1b vs. mean control, and OPA1b vs. mean POLG1. Each column corresponds to the time point on the 
graph above. The intensity of the red shading correlates with the degree of statistical significance.  
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OPA1c 
vs. 
Mean Control 0.8394 0.2461 0.0280 0.0344 0.0035 0.0018 < 0.0001 < 0.0001 
Mean POLG 0.0050 < 0.0001 0.0631 < 0.0001 0.0040 0.0271 0.0494 0.0068 
 
Figure 7-11 MtDNA depletion and repopulation curve of the OPA1c cell line. Each data point represents the average mtDNA copy number 
ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). The table shows the P values for 
the following statistical comparisons: OPA1c vs. mean control, and OPA1c vs. mean POLG1. Each column corresponds to the time point on the 
graph above. The intensity of the red shading correlates with the degree of statistical significance. 
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OPA1d 
vs. 
Mean Control 0.1922 0.9187 0.0314 0.1480 0.0457 0.0077 0.0002 0.0023 
Mean POLG < 0.0001 0.0073 0.0397 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 
Figure 7-12 MtDNA depletion and repopulation curve of the OPA1d cell line. Each data point represents the average mtDNA copy number 
ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). The table shows the P values for 
the following statistical comparisons: OPA1d vs. mean control, and OPA1d vs. mean POLG1. Each column corresponds to the time point on the 
graph above. The intensity of the red shading correlates with the degree of statistical significance. 
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OPA1e 
vs. 
Mean Control 0.0824 0.5870 0.4494 0.1400 0.2743 0.0220 0.0363 0.0026 
Mean POLG < 0.0001 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 
Figure 7-13 MtDNA depletion and repopulation curve of the OPA1e cell line. Each data point represents the average mtDNA copy number 
ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). The table shows the P values for 
the following statistical comparisons: OPA1e vs. mean control, and OPA1e vs. mean POLG1. Each column corresponds to the time point on the 
graph above. The intensity of the red shading correlates with the degree of statistical significance.  
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OPA1f 
vs. 
Mean Control 0.0672 0.9020 0.0622 0.2247 0.0444 0.0083 0.0008 0.0010 
Mean POLG < 0.0001 0.0023 0.0040 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 
Figure 7-14 MtDNA depletion and repopulation curve of the OPA1f cell line. Each data point represents the average mtDNA copy number 
ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). The table shows the P values for 
the following statistical comparisons: OPA1f vs. mean control, and OPA1f vs. mean POLG1. Each column corresponds to the time point on the 
graph above. The intensity of the red shading correlates with the degree of statistical significance. 
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OPA1g 
vs. 
Mean Control 0.0712 0.3754 0.0804 0.0751 0.0122 0.0070 < 0.0001 0.0003 
Mean POLG < 0.0001 < 0.0001 0.0009 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 
Figure 7-15 MtDNA depletion and repopulation curve of the OPA1g cell line. Each data point represents the average mtDNA copy number 
ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). The table shows the P values for 
the following statistical comparisons: OPA1g vs. mean control, and OPA1g vs. mean POLG1. Each column corresponds to the time point on the 
graph above. The intensity of the red shading correlates with the degree of statistical significance. 
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OPA1h 
vs. 
Mean Control 0.1403 0.7091 0.0256 0.0413 0.0047 0.0018 < 0.0001 < 0.0001 
Mean POLG 0.9434 0.0310 0.1040 < 0.0001 < 0.0001 0.0611 0.0459 0.0001 
 
Figure 7-16 MtDNA depletion and repopulation curve of the OPA1h cell line. Each data point represents the average mtDNA copy number 
ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). The table shows the P values for 
the following statistical comparisons: OPA1h vs. mean control, and OPA1h vs. mean POLG1. Each column corresponds to the time point on the 
graph above. The intensity of the red shading correlates with the degree of statistical significance. 
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Mean OPA1 
vs. 
Mean Control 0.2435 0.6068 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Mean POLG < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 
Figure 7-17 MtDNA depletion and repopulation curve of the mean OPA1 compared with the mean control and the mean POLG1. Each 
data point represents the average mtDNA copy number ratio of EtBr-treated to untreated cells. The error bars are presented as the standard errors 
of the mean (SEM). The table shows the P values for the following statistical comparisons: mean OPA1 vs. mean control, and mean OPA1 vs. 
mean POLG1. Each column corresponds to the time point on the graph above. The intensity of the red shading correlates with the degree of 
statistical significance.  
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7.3.3.1 Subgroup Analysis of OPA1 Patient Lines 
To investigate for possible differences in mtDNA repopulation levels between 
individual OPA1 patient lines, the following subgroup analyses were performed 
based upon: (i) the affected OPA1 functional domain (GTPase vs. non-GTPase; 
Figure 7-18), (ii) the clinical phenotype (pure DOA vs. DOA+; Figure 7-19), and 
(iii) specific familial OPA1 mutations (Figure 7-20).  
There were no marked differences in the kinetics of mtDNA depletion and 
repopulation between the two cell lines harbouring OPA1 missense mutations 
involving the GTPase domain compared with the six other OPA1-mutant cell lines 
not involving this functional gene domain exclusively (Figure 7-18). At day 48, the 
GTPase group repopulated to a relative level of 0.320 (SEM = 0.098) comparing 
with 0.188 (SEM = 0.065) for the non-GTPase cohort, and this difference was of 
borderline significance (P = 0.0450). The repopulation curves of both the GTPase 
and non-GTPase groups were statistically different from the mean control and the 
mean POLG1.  
Using this repopulation assay, no significant differences were noted between the 
OPA1 subgroups based on their clinical phenotypes (i.e. pure DOA vs. DOA+; 
Figure 7-19). The repopulation curves of both the pure DOA and DOA+ groups 
were significantly different from the mean control and the mean POLG1 during the 
whole repopulation phase.  
The four familial OPA1 mutations were compared both with the mean control and 
the mean POLG1 groups (Figure 7-20). During mtDNA depletion phase, the 
p.Q297X and the splice defect OPA1 mutation groups behaved in a similar fashion to 
the mean control. The p.I432V and the p.V294fsX667 OPA1 mutation groups 
demonstrated a less profound mtDNA depletion by day 6, which was statistically 
different from the mean control (P = 0.0303 and P = 0.0133, respectively). All OPA1 
mutation groups were significantly different from the mean POLG1 during the entire 
depletion phase, except for the OPA1h cell line (splice defect) at day 6 (P = 0.9434). 
During the mtDNA repopulation phase, all familial OPA1 mutation groups were 
significantly different from the mean control as from day 18, except for 
p.V294fsX66 mutation group, which became significantly different from the mean 
control only from day 30 onwards. The levels of mtDNA repopulation calculated for 
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all OPA1 mutational groups were significantly different from the mean POLG1 
during the entre repopulation phase, except for the OPA1h cell line (splice defect) at 
day 18 (P = 0.1040) and at day 36 (P = 0.0611).  
For the statistical comparisons of the different familial OPA1 mutation groups with 
each other, please refer to Figure B-6 in Appendix B.2.  
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Mean OPA1 GTPase      
vs. 
Mean control 0.0303 0.5796 0.0071 0.0263 0.0021 0.0003 < 0.0001 < 0.0001 
Mean POLG1 < 0.0001 < 0.0001 0.0004 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Mean OPA1 non-GTPase 
vs. 
Mean control 0.6788 0.7662 < 0.0001 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Mean POLG1 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0005 0.0004 0.0033 0.0007 
Mean GTPase vs. Mean non-GTPase 0.0110 0.3460 0.9639 0.5294 0.5668 0.1043 0.9885 0.0450 
Figure 7-18 MtDNA depletion and repopulation curves for OPA1 cell lines involving the GTPase region (N = 2) compared with those 
carrying mutations outside this functional gene domain (N = 6). Each data point represents the average mtDNA copy number ratio of EtBr-
treated to untreated cells. The error bars are presented as the standard errors of the mean (SEM). The table shows the P values for the following 
statistical comparisons: each OPA1 subgroup vs. mean control, each OPA1 subgroup vs. mean POLG1, and OPA1 subgroups vs. each other. 
Each column corresponds to the time point on the graph above. The intensity of the red shading correlates with the degree of statistical 
significance.   
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Mean OPA1 Pure DOA      
vs. 
Mean control 0.5261 0.8554 0.0002 0.0028 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Mean POLG1 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0001 < 0.0001 
Mean OPA1 DOA+        
vs. 
Mean control 0.1975 0.5672 0.0006 0.0008 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Mean POLG1 < 0.0001 < 0.0001 0.0004 < 0.0001 0.0006 0.0002 0.0031 0.0006 
Mean pure DOA vs. Mean DOA+ 0.5239 0.4136 0.5625 0.1422 0.4463 0.7061 0.4111 0.3742 
Figure 7-19 MtDNA depletion and repopulation curves for OPA1 lines from patients with pure DOA (N = 4) compared with those with 
DOA+ (N = 4) phenotypes. Each data point represents the average mtDNA copy number ratio of EtBr-treated to untreated cells. The error bars 
are presented as the standard errors of the mean (SEM). The table shows the P values for the following statistical comparisons: each OPA1 
subgroup vs. mean control, each OPA1 subgroup vs. mean POLG1, and OPA1 subgroups vs. each other. Each column corresponds to the time 
point on the graph above. The intensity of the red shading correlates with the degree of statistical significance.  
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DAY OF STUDY 6 12 18 24 30 36 42 48 
Mean         
Control              
vs. 
OPA1 p.Q297X 0.6071 0.7959 0.0002 0.0028 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
OPA1 p.I432V 0.0303 0.5796 0.0071 0.0263 0.0021 0.0003 < 0.0001 < 0.0001 
OPA1 p.V294fsX667 0.0133 0.6372 0.0700 0.0615 0.0316 0.0008 0.0004 < 0.0001 
OPA1 Splice 0.1403 0.7091 0.0256 0.0413 0.0047 0.0018 < 0.0001 < 0.0001 
Mean 
POLG1      
vs. 
OPA1 p.Q297X 0.0001 < 0.0001 0.0043 < 0.0001 0.0015 0.0001 0.0008 0.0002 
OPA1 p.I432V < 0.0001 < 0.0001 0.0004 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
OPA1 p.V294fsX667 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
OPA1 Splice 0.9434 0.0310 0.1040 < 0.0001 < 0.0001 0.0611 0.0459 0.0001 
Figure 7-20 MtDNA depletion and repopulation curves for OPA1 cell lines 
grouped into familial mutational subgroups: OPA1 p.Q297X (N = 3), OPA1 
p.I432V (N = 2), OPA1 p.V294fsX667 (N = 2) and OPA1 splice (N = 1). Each data 
point represents the average mtDNA copy number ratio of EtBr-treated to untreated 
cells. The error bars are presented as the standard errors of the mean (SEM). The 
table shows the P values for the following statistical comparisons: each OPA1 
subgroup vs. mean control and each OPA1 subgroup vs. mean POLG1. The intensity 
of the red shading correlates with the degree of statistical significance. 
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7.4 Results: Mitochondrial Network Analysis 
In parallel with the mtDNA repopulation assay, the mitochondrial network was also 
analysed at three experimental time points: (i) prior to EtBr supplementation (day 0), 
(ii) at the end of EtBr-induced mtDNA depletion (day 15), and (iii) at the end of the 
mtDNA repopulation phase (day 45). At each time point, mitochondrial network 
parameters were quantified for 10 fibroblasts per cell line. The collected data were 
used to calculate: (i) the total length of the mitochondrial network per cell 
(abbreviated as the total length; data in µm scale), (ii) the average length of a 
mitochondrial fragment in a cell (abbreviated as the average length; data in µm 
scale), and (iii) the total number of mitochondrial fragments per cell (abbreviated as 
the number of fragments).   
7.4.1 Mitochondrial Network in Control Fibroblasts 
The total length, the average length and the number of fragments for each of the four 
independent control cell lines were estimated as the mean values for 10 individual 
fibroblasts (N = 10). These mitochondrial network parameters for the mean control 
were calculated from the entire cohort of control cells (N = 40). The analyses for the 
total length (Figure 7-21), the average length (Figure 7-22), and the number of 
fragments (Figure 7-23) for the four control fibroblast lines and the mean control, 
are described further below. 
7.4.1.1 Total Mitochondrial Network Length in Control Fibroblasts  
There was variability in the total mitochondrial network length calculated for the 
control cell lines at day 0 (Figure 7-21 A). The greatest total length was seen in the 
C1 line (mean = 369.44, SEM = 34.87), whereas the C2 line (mean = 135.01, SEM = 
10.13) showed the smallest value for this parameter. The difference between the C1 
and C2 was statistically significant (P < 0.0001). By the end of the mtDNA depletion 
phase (day 15), all the control cell lines had significantly increased the total length of 
their mitochondrial networks (Figure 7-21 B). By day 45, the total length for three 
control cell lines had decreased to their baseline values (Figure 7-21 C). The only 
exception was the C3 cell line, for which the total length at day 45 was significantly 
higher compared with day 0 (P = 0.0341). The total length for the mean control 
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(Figure 7-21 D) confirmed a significant increase between day 0 (mean = 236.11, 
SEM = 17.19) and day 15 (mean = 390.17, SEM = 29.84) (P < 0.0001), followed by 
a significant reduction by day 45 (P = 0.0020). The total length (mean = 267.68, 
SEM = 23.72) at day 45 was not significantly different from the value measured at 
day 0 (P = 0.2724).  
7.4.1.2 Average Length of Mitochondrial Fragment in Control Fibroblasts 
All control cell lines had similar values for the average length of a mitochondrial 
fragment at day 0, with only the C2 and the C3 lines being significantly different 
from each other (P = 0.0407) (Figure 7-22 A). At the end of the mtDNA depletion 
phase (day 15), all control cell lines, except for C1, showed a significant reduction in 
the average length of a single mitochondrial fragment (Figure 7-22 B). By day 45, 
all control lines had restored their average lengths to levels that were not 
significantly different from those at day 0 (Figure 7-22 C). In the mean control 
(Figure 7-22 D) there was a significant drop in the average length between day 0 
(mean = 3.15, SEM = 0.06) and day 15 (mean = 2.63, SEM = 0.10) (P = 0.0001), 
followed by a significant increase in the average fragment length by day 45 (P = 
0.0016). At day 45, the average length (mean = 3.17, SEM = 0.09) was not 
significantly different from the value observed at day 0 (P = 0.8848). 
7.4.1.3 Total Number of Mitochondrial Fragments in Control Fibroblasts  
Variability was also observed in the total number of mitochondrial fragments per cell 
(Figure 7-23 A). The maximum number of fragments at day 0 was detected in the 
C1 cell line (mean = 115.60, SEM = 11.22), whereas the minimum value was 
observed in the C2 cell line (mean = 46.60, SEM = 4.51). The difference between the 
C1 and C2 was statistically significant (P < 0.0001). By the end of EtBr-induced 
mtDNA depletion (day 15), there was a significant increase in the total number of 
mitochondrial fragments per cell for all four control cell lines (Figure 7-23 B). By 
the end of mtDNA repopulation (day 45), the total number of fragments per cell 
decreased to the pre-EtBr level for three control lines (Figure 7-23 C). The C3 cell 
line behaved differently, with the number of fragments at day 45 being still 
significantly higher compared with the baseline i.e. day 0 (P = 0.0173). There was a 
significant increase in the total number of fragments in the mean control (Figure 
7-23 D) between day 0 (mean = 75.40, SEM = 5.39) and day 15 (mean = 150.04, 
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SEM = 11.49) (P < 0.0001), followed by a significant reduction by day 45 (P = 
0.0005). The total number of fragments at day 45 (mean = 91.03, SEM = 10.99) was 
not significantly different from the value observed at day 0 (P = 0.1727). 
For subsequent comparisons in this chapter, the mean control will refer to the 
combined data set for the four control cell lines.  
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Figure 7-21 Total length of the mitochondrial network per cell in the control fibroblast cell lines: (A) prior to EtBr-treatment (Day 0), 
(B) at the end of EtBr-induced mtDNA depletion (Day 15), (C) at the end of mtDNA repopulation (Day 45), and (D) at all experimental 
points in the mean control. Each data point represents the mean total length. The error bars are presented as the standard errors of the mean 
(SEM). NS – non-significant at P = 0.2724; ** - refers to P value = 0.0020; *** - refers to P value < 0.0001.  
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Figure 7-22 Average mitochondrial fragment length in the control fibroblast cell lines: (A) prior to EtBr-treatment (Day 0), (B) at the 
end of EtBr-induced mtDNA depletion (Day 15), (C) at the end of mtDNA repopulation (Day 45), and (D) at all experimental points in 
the mean control. Each data point represents the mean average length. The error bars are presented as the standard errors of the mean (SEM). 
NS – non-significant at P = 0.8848; ** - refers to P value = 0.0016; *** - refers to P value = 0.0001. 
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Figure 7-23 Total number of mitochondrial fragments per cell in the control fibroblast cell lines: (A) prior to EtBr-treatment (Day 0), 
(B) at the end of EtBr-induced mtDNA depletion (Day 15), (C) at the end of mtDNA repopulation (Day 45), and (D) at all experimental 
points in the mean control. Each data point represents the mean number of fragments. The error bars are presented as the standard errors of the 
mean (SEM). NS – non-significant at P = 0.1727; *** - refers to P < 0.0001 (day 0 vs. day 15) and P value = 0.0005 (day 15 vs. day 45). 
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7.4.2 Mitochondrial Network in POLG1 Fibroblasts  
The total length, the average length and the number of fragments for each of the five 
independent POLG1 lines were estimated as the mean values for 10 individual 
fibroblasts (N = 10). These mitochondrial network parameters for the mean POLG1 
were calculated from the entire cohort of POLG1-mutant cells (N = 50). The only 
exception was at day 45, when data for only three POLG1 lines were available. That 
was caused by the premature death of EtBr-treated POLG1b and POLG1c 
fibroblasts, despite optimal culture conditions. The analyses of the total length 
(Figure 7-24), the average length (Figure 7-25), and the number of fragments 
(Figure 7-26) for individual POLG1-mutant fibroblast lines and the mean POLG1, 
are demonstrated below.  
7.4.2.1 Total Mitochondrial Network Length in POLG1 Fibroblasts 
There was variability in the total mitochondrial length calculated for the POLG1 
patient lines at day 0 (Figure 7-24 A). The greatest total length was seen in the 
POLG1b line (mean = 417.79, SEM = 29.38), whereas the smallest values were 
demonstrated in the POLG1c (mean = 243.18, SEM = 20.97) and the POLG1d (mean 
= 245.37, SEM = 22.08) lines. By the end of mtDNA depletion (day 15), only the 
POLG1c and POLG1d lines had significantly increased their total mitochondrial 
length (Figure 7-24 B). By day 45, only the POLG1d line had decreased its total 
length to the baseline value (Figure 7-24 C). The total length for the mean POLG1 
(Figure 7-24 D) confirmed a significant increase between day 0 (mean = 314.47, 
SEM = 15.52) and day 15 (mean = 394.13, SEM = 29.07) (P = 0.0180). No 
significant reduction was then observed by day 45 (P = 0.0991), when the total 
length (mean = 325.17, SEM = 21.62) was not significantly different from the value 
measured at day 0 (P = 0.6833). 
7.4.2.2 Average Length of Mitochondrial Fragment in POLG1 Fibroblasts 
The average length of mitochondrial fragment at day 0 was similar in four out of the 
five POLG1 cell lines, with only the POLG1e line (mean = 2.58, SEM = 0.10) being 
significantly shorter (Figure 7-25 A). By the end of the mtDNA depletion phase (day 
15), all POLG1 fibroblast lines showed a decrease in their average length (Figure 
7-25 B). By day 45, none of the three POLG1 patient lines had significantly restored 
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the average mitochondrial length (Figure 7-25 C). The mean POLG1 showed a 
significant drop in the average length (Figure 7-25 D) between day 0 (mean = 3.25, 
SEM = 0.10) and day 15 (mean = 2.29, SEM = 0.07) (P < 0.0001). No significant 
increase in the average mitochondrial fragment length was then observed by day 45 
(P = 0.2575). At day 45, the average length (mean = 2.43, SEM = 0.11) was 
significantly different from the value observed at day 0 (P < 0.0001). 
7.4.2.3 Total Number of Mitochondrial Fragments in POLG1 Fibroblasts 
The maximum number of mitochondrial fragments per cell at day 0 was presented in 
the POLG1e line (mean = 126.20, SEM = 16.83), whereas the minimum value was 
observed in the POLG1c line (mean = 69.40, SEM = 18.40) (Figure 7-26 A). By the 
end of mtDNA depletion phase (day 15), only the POLG1c and POLG1d lines 
showed significant increase in their number of fragments (Figure 7-26 B). By day 
45, none of the three POLG1 lines showed a significant reduction in this parameter 
(Figure 7-26 C). There was a significant increase in number of fragments in the 
mean POLG1 (Figure 7-26 D) between day 0 (mean = 101.46, SEM = 5.97) and day 
15 (mean = 168.52, SEM = 13.33) (P < 0.0001). No significant reduction was then 
observed by day 45 (P = 0.0735). The total length at day 45 (mean = 138.40, SEM = 
10.12) was statistically different from the value observed at day 0 (P = 0.0012). 
For the comparison of mitochondrial network parameters between individual POLG1 
lines and the mean control, please refer to Appendix C.1. 
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Figure 7-24 Total length of the mitochondrial network per cell in the POLG1 fibroblast cell lines: (A) prior to EtBr-treatment (Day 0), 
(B) at the end of EtBr-induced mtDNA depletion (Day 15), (C) at the end of mtDNA repopulation (Day 45), and (D) at all experimental 
points in the mean POLG1. Each data point represents the mean total length. The error bars are presented as the standard errors of the mean 
(SEM). NS – non-significant at P = 0.0991 (day 15 vs. day 45) and P value = 0.6833 (day 0 vs. day 45); * - refers to P value = 0.0180. Data 
points for the POLG1b and POLG1c cell lines were unavailable at day 45 due to the premature death of the POLG1b and the POLG1c EtBr-
treated fibroblasts before that sampling point.  
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Figure 7-25 Average mitochondrial fragment length in the POLG1 fibroblast cell lines: (A) prior to EtBr-treatment (Day 0), (B) at the 
end of EtBr-induced mtDNA depletion (Day 15), (C) at the end of mtDNA repopulation (Day 45), and (D) at all experimental points in 
the mean POLG1. Each data point represents the mean average length. The error bars are presented as the standard errors of the mean (SEM). 
NS – non-significant at P = 0.2575; *** - refers to P value < 0.0001. Data points for the POLG1b and POLG1c cell lines were unavailable at day 
45 due to the premature death of the POLG1b and the POLG1c EtBr-treated fibroblasts before that sampling point.   
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Figure 7-26 Total number of mitochondrial fragments per cell in the POLG1 fibroblast cell lines: (A) prior to EtBr-treatment (Day 0), 
(B) at the end of EtBr-induced mtDNA depletion (Day 15), (C) at the end of mtDNA repopulation (Day 45), and (D) at all experimental 
points in the mean POLG1. Each data point represents the mean number of fragments. The error bars are presented as the standard errors of the 
mean (SEM). NS – non-significant at P = 0.0735; ** - refers to P value = 0.0012; *** - refers to P < 0.0001. Data points for the POLG1b and 
POLG1c at day 45 were unavailable due to the premature death of the POLG1b and the POLG1c EtBr-treated fibroblasts before that sampling 
point.  
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7.4.3 Mitochondrial Network in OPA1 Fibroblasts 
The total length, the average length and the number of fragments for each of the 
eight independent OPA1 cell lines were estimated as the mean values for 10 
individual fibroblasts (N = 10). These mitochondrial network parameters for the 
mean OPA1 were calculated from the entire cohort of OPA1 cells (N = 80). The 
analyses of the total length (Figure 7-27), the average length (Figure 7-28), and the 
number of fragments (Figure 7-29) for the eight OPA1 fibroblast lines and the mean 
OPA1, are demonstrated below. 
7.4.3.1 Total Mitochondrial Network Length in OPA1 Fibroblasts 
There was variability in the total mitochondrial length calculated for various OPA1 
patient lines at day 0 (Figure 7-27 A). The greatest total length was observed in the 
OPA1f line (mean = 505.32, SEM = 53.26), whereas the OPA1h line (mean = 
228.44, SEM = 29.15) showed the lowest value of this parameter. By the end of 
mtDNA depletion phase (day 15) all OPA1 lines apart from the OPA1f demonstrated 
increase in their total lengths (Figure 7-27 B). By the end of mtDNA repopulation 
(day 45), all OPA1 lines except the OPA1b, decreased their total length (Figure 7-27 
C). The mean OPA1 (Figure 7-27 D) demonstrated a significant increase in the total 
length between day 0 (mean = 369.31, SEM = 15.59) and day 15 (mean = 452.52, 
SEM = 22.47) (P = 0.0027), with a subsequent decrease by day 45 (mean = 352.80, 
SEM = 16.36) (P = 0.0006). The total length at day 45 was not significantly different 
from the value measured at day 0 (P = 0.4719). 
7.4.3.2 Average Length of Mitochondrial Fragment in OPA1 Fibroblasts 
There was variability in the average mitochondrial fragment length calculated for 
OPA1 patient lines at day 0 (Figure 7-28 A). The maximum average length was 
demonstrated in the OPA1d line (mean = 3.49, SEM = 0.22), whereas the minimal 
value was present in the OPA1b line (mean = 2.37, SEM = 0.14). By the end of the 
mtDNA depletion phase (day 15), a significant reduction in the average length was 
observed only in the OPA1c and OPA1h lines (P = 0.0002 and P = 0.0202, 
respectively) (Figure 7-28 B). By day 45, the significant increase in the average 
length was demonstrated for the OPA1c (P < 0.0001), OPA1f (P = 0.0022) and 
OPA1g (P = 0.0084) lines (Figure 7-28 C). The OPA1h was the only cell line which 
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showed a significant reduction in the average length between days 15 (mean = 2.42, 
SEM = 0.10) and 45 (mean = 2.07, SEM = 0.11) (P = 0.0301). There was a 
significant decrease in the average length for the mean OPA1 (Figure 7-28 D) 
between day 0 (mean = 2.91, SEM = 0.08) and day 15 (mean = 2.65, SEM = 0.08) (P 
= 0.0273). That was followed by a significant increase in the average length by day 
45 (mean = 2.98, SEM = 0.09; P = 0.0084). The average length at day 45 was 
statistically not different from the value measured at day 0 (P = 0.5476). 
7.4.3.3 Total Number of Mitochondrial Fragments in OPA1 Fibroblasts 
The variability was observed in the number of fragments calculated for the OPA1 
lines at day 0 (Figure 7-29 A). The maximum number of networks was demonstrated 
in the OPA1f line (mean = 194.80, SEM = 25.10), whereas the minimal value was 
observed in the OPA1h line (mean = 83.89, SEM = 12.99). By day 15, all OPA1 
lines apart from the OPA1f, showed an increase in their number of fragments 
(Figure 7-29 B), whereas by day 45, all OPA1 patient lines, apart from the OPA1b, 
had decreased their number of fragments values (Figure 7-29 C). The number of 
fragments in the mean OPA1 (Figure 7-29 D) showed a significant increase between 
day 0 (mean = 136.04, SEM = 7.05) and day 15 (mean = 177.91, SEM = 8.60) (P = 
0.0002). Following that, the number of fragments had significantly decreased by day 
45 (mean = 124.12, SEM = 6.46; P < 0.0001). The number of fragments at day 45 
was not significantly different from the value measured at day 0 (P = 0.2209). 
For the comparison of mitochondrial network parameters between individual OPA1 
lines and the mean control, please refer to Appendix C.2.  
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Figure 7-27 Total length of the mitochondrial network per cell in the OPA1 fibroblast patient lines: (A) prior to EtBr-treatment (Day 0), 
(B) at the end of EtBr-induced mtDNA depletion (Day 15), (C) at the end of mtDNA repopulation (Day 45), and (D) at all experimental 
points in the mean OPA1. Each data point represents the mean total length. The error bars are presented as the standard errors of the mean 
(SEM). NS – non-significant at P = 0.4719; ** - refers to P = 0.0027; *** - refers to P = 0.0006.   
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Figure 7-28 Average mitochondrial fragment length in the OPA1 fibroblast patient lines: (A) prior to EtBr-treatment (Day 0), (B) at the 
end of EtBr-induced mtDNA depletion (Day 15), (C) at the end of mtDNA repopulation (Day 45), and (D) at all experimental points in 
the mean OPA1. Each data point represents the mean average length. The error bars are presented as the standard errors of the mean (SEM). NS 
– non-significant at P = 0.5476; * - refers to P = 0.0273; ** - refers to P = 0.0084.  
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Figure 7-29 Total number of mitochondrial fragments per cell in the OPA1 fibroblast patient lines : (A) prior to EtBr-treatment (Day 0), 
(B) at the end of EtBr-induced mtDNA depletion (Day 15), (C) at the end of mtDNA repopulation (Day 45), and (D) at all experimental 
points in the mean OPA1. Each data point represents the mean number of fragments. The error bars are presented as the standard errors of the 
mean (SEM). NS – non-significant at P = 0.2209; *** - refers to P = 0.0002 (day 0 vs. day 15) and P < 0.0001 (day 15 vs. day 45).   
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7.4.4 Mitochondrial Network – Group Comparisons 
To investigate the consequence of pathogenic POLG1 and OPA1 mutations on 
mitochondrial network morphology, both patient groups were compared to the mean 
control in normal culture conditions at the baseline (day 0), after EtBr-induced 
mtDNA depletion (day 15), and following the 30-day mtDNA repopulation phase 
(day 45). The comparisons of the total mitochondrial length per cell (Figure 7-30), 
the average mitochondrial fragment length (Figure 7-31) and the total number of 
mitochondrial fragments per cell (Figure 7-32) are presented below.  
7.4.4.1 Total Mitochondrial Network Length 
As demonstrated in Figure 7-30 A, the mean POLG1 showed a significant increase 
in the total mitochondrial length between day 0 (mean = 314.47, SEM = 15.52) and 
day 15 (mean = 394.13, SEM = 29.07) (P = 0.0180). At day 45, the total length was 
not significantly different from the value calculated at day 0 (P = 0.6833) and day 15 
(P = 0.0991). Compared with the mean control (Figure 7-30 C), the total length in 
the mean POLG1 was significantly greater at day 0 (Mean POLG1: mean = 314.47, 
SEM = 15.52; Mean control: mean = 236.11, SEM = 17.19; P = 0.0011). Both at day 
15 and at day 45, the difference between these two groups was not statistically 
significant. Similarly to the mean POLG1, the mean OPA1 also demonstrated a 
significant increase in the total length between day 0 (mean = 369.31, SEM = 15.59) 
and day 15 (mean = 452.52, SEM = 22.47) (P = 0.0027; Figure 7-30 B), and a 
significant decrease by day 45 (mean = 352.80, SEM = 16.36) (P = 0.0006). The total 
length for the mean OPA1 at day 45 was not significantly different from the value 
obtained at day 0 (P = 0.4719). When the mean OPA1 was compared with the mean 
control (Figure 7-30 D), the total mitochondrial length was significantly greater in 
the mean OPA1, both at day 0 (the mean OPA1: mean = 369.31, SEM = 15.59; the 
mean control: mean = 236.11, SEM = 17.19; P < 0.0001) and at day 45 (the mean 
OPA1: mean = 352.80, SEM = 16.40; the mean control: mean = 267.68, SEM = 
23.72; P = 0.0064). No significant difference between these two groups was observed 
at day 15. 
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7.4.4.2 Average Length of Mitochondrial Fragment   
The average mitochondrial length in the mean POLG1 (Figure 7-31 A), showed a 
significant drop between day 0 (mean = 3.25, SEM = 0.10) and day 15 (mean = 2.29, 
SEM = 0.07) (P < 0.0001). No significant increase in average fragment length was 
observed during the repopulation phase from day 15 at day 45 (P = 0.2575). The 
average length (mean = 2.43, SEM = 0.11) at day 45 was significantly different from 
the value observed at day 0 (P < 0.0001). The comparison of the average length 
between the mean POLG1 and the mean control (Figure 7-31 C) revealed no 
statistically significant differences between these two groups at day 0. At the end of 
mtDNA depletion (day 15), the mean POLG1 had significantly smaller average 
length compared with the mean control (the mean POLG1: mean = 2.29, SEM = 
0.07; the mean control: mean = 2.63, SEM = 0.10; P = 0.0149). By the end of the 
mtDNA repopulation phase (day 45), the mean POLG1 remained significantly 
shorter compared with mean control (the mean POLG1: mean = 2.43, SEM = 0.11; 
the mean control: mean = 3.17, SEM = 0.09; P < 0.0001). Similarly to the POLG1-
mutant fibroblasts, the mean OPA1 showed a significant decrease in the average 
length between day 0 (mean = 2.91, SEM = 0.08) and the end of EtBr-induced 
mtDNA depletion (day 15) (mean = 2.65, SEM = 0.08) (P = 0.0273; Figure 7-31 B). 
That was followed by a significant increase in the average length observed in the 
mean OPA1 by day 45 (mean = 2.98, SEM = 0.09; P = 0.0084). The average length 
for the mean OPA1 at day 45 was not significantly different to the value obtained at 
day 0 (P = 0.5476). The average length in the mean OPA1 was different of borderline 
significance from the mean control at day 0 (the mean OPA1: mean = 2.91, SEM = 
0.08; the mean control: mean = 3.15, SEM = 0.06) (P = 0.0457, Figure 7-31 D).  
7.4.4.3 Total Number of Mitochondrial Fragments 
The total number of mitochondrial fragments per cell in the mean POLG1 (Figure 
7-32 A) increased significantly between day 0 (mean = 101.46, SEM = 5.97) and day 
15 (mean = 168.52, SEM = 13.33) (P < 0.0001). This increase was maintained until 
day 45 and there was no significant reduction compared with day 15 (P = 0.0735). 
When compared with the mean control (Figure 7-32 C), the total number of 
mitochondrial fragments per cell in the mean POLG1 was significantly greater both 
at day 0 (the mean POLG1: mean = 101.46, SEM = 5.97; the mean control: mean = 
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75.40, SEM = 5.39; P = 0.0021) and at day 45 (the mean POLG1: mean = 138.40, 
SEM = 10.12; the mean control: mean = 91.03, SEM = 10.99; P = 0.0024). The 
difference between these two groups was not significant at day 15. Similar to 
POLG1, there was a significant increase in the number of mitochondrial fragments 
per cell in the mean OPA1 at the end of mtDNA depletion (day 15) (mean = 177.91, 
SEM = 8.60) compared with day 0 (P = 0.0002) (Figure 7-32 B). At day 45, the total 
number of fragments decreased significantly (mean = 124.12, SEM = 6.46; P < 
0.0001), reaching a value that was not significantly different from the baseline at day 
0 (P = 0.2209). The total number of fragments was significantly higher in the mean 
OPA1 compared with the mean control (Figure 7-32 D), both prior to EtBr treatment 
at day 0 (P < 0.0001) and at the end of mtDNA repopulation (day 45) (P = 0.0024). 
There was no significant difference between the mean OPA1 and the mean control 
groups at day 15. 
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Figure 7-30 Total length of the mitochondrial network per cell: (A) in the mean 
POLG1, (B) in the mean OPA1, (C) comparison between the mean POLG1 and 
the mean control, and (D) comparison between the mean OPA1 and the mean 
control. Each data point represents the mean total length. The error bars are 
presented as the standard errors of the mean (SEM). The level of statistical 
significance is indicated for the comparison between: (A) different experimental time 
points in the mean POLG1, (B) different experimental points in the mean OPA1, (C) 
the mean POLG1 and the mean control groups at each time point, (D) the mean 
OPA1 and the mean control groups at each time point. 
(A):  NS – non-significant at P = 0.0991 (day 15 vs. day 45) and P value = 0.6833 
(day 0 vs. day 45); * - refers to P value = 0.0180; 
(B):  NS – non-significant at P = 0.4719; ** - refers to P = 0.0027; *** - refers to P 
= 0.0006; 
(C):  NS – non-significant at P = 0.9310 (day 15) and P = 0.0784 (day 45), ** - 
refers to P = 0.0011; 
(D): NS – non-significant at P = 0.1447, ** - refers to P = 0.0064, *** - refers to P 
< 0.0001.           
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Figure 7-31 Average mitochondrial fragment length: (A) in the mean POLG1, 
(B) in the mean OPA1, (C) comparison between the mean POLG1 and the mean 
control, and (D) comparison between the mean OPA1 and the mean control. 
Each data point represents the mean average length. The error bars are presented as 
the standard errors of the mean (SEM). The level of statistical significance is 
indicated for the comparison between: (A) different experimental time points in the 
mean POLG1, (B) different experimental points in the mean OPA1, (C) the mean 
POLG1 and the mean control groups at each time point, (D) the mean OPA1 and the 
mean control groups at each time point. 
(A):  NS – non-significant at P = 0.2575; *** - refers to P value < 0.0001; 
(B):  NS – non-significant at P = 0.5476; * - refers to P = 0.0273; ** - refers to P = 
0.0084; 
(C):  NS – non-significant at P = 0.4435, * - refers to P = 0.0149, *** - refers to P 
< 0.0001; 
(D): NS – non-significant at P = 0.9068 (day 15) and P = 0.2375 (day 45), * - 
refers to P = 0.0457.         
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Figure 7-32 Total number of mitochondrial fragments per cell: (A) in the mean 
POLG1, (B) in the mean OPA1, (C) comparison between the mean POLG1 and 
the mean control, and (D) comparison between the mean OPA1 and the mean 
control. Each data point represents the mean number of fragments. The error bars are 
presented as the standard errors of the mean (SEM). The level of statistical 
significance is indicated for the comparison between: (A) different experimental time 
points in the mean POLG1, (B) different experimental points in the mean OPA1, (C) 
the mean POLG1 and the mean control groups at each time point, (D) the mean 
OPA1 and the mean control groups at each time point. 
(A):  NS – non-significant at P = 0.0735; ** - refers to P value = 0.0012; *** - 
refers to P < 0.0001; 
(B):  NS – non-significant at P = 0.2209; *** - refers to P = 0.0002 (day 0 vs. day 
15) and P < 0.0001 (day 15 vs. day 45); 
(C):  NS – non-significant at P = 0.2967, ** - refers to P = 0.0021 (day 0) and P = 
.0024 (day 45); 
(D): NS – non-significant at P = 0.0894, ** - refers to P = 0.0099, *** - refers to P 
< 0.0001.            
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7.5 Discussion: Repopulation Assay 
The aim of this experimental assay was to investigate the kinetics of mtDNA 
repopulation in POLG1, OPA1 and control fibroblast cell lines following a period of 
sustained mtDNA depletion secondary to EtBr treatment.   
7.5.1 MtDNA Depletion Kinetics 
Profound EtBr-induced mtDNA depletion was evident for all the investigated patient 
and control fibroblast cell lines. No apparent cell loss was observed during the period 
of EtBr treatment, suggesting that the drug concentration was sufficient to cause loss 
of mtDNA molecules, without being terminally toxic to the cells. Interestingly, the 
rate of mtDNA depletion was significantly faster in POLG1-mutant fibroblasts lines 
compared with both the mean control and the mean OPA1 groups (Figure 7-17). 
Mutations in POLG1 have previously been associated with a reduction in POLG 
catalytic activity, the latter having a major impact on mtDNA replication 
(Graziewicz et al., 2006; Copeland, 2008). It is therefore likely that the pathological 
consequences of the POLG1 mutations present in these mutant cell lines were further 
magnified by the addition of EtBr. 
7.5.2 MtDNA Repopulation Kinetics  
EtBr is a powerful inhibitor of mitochondrial DNA replication and transcription 
(Nass, 1970; Desjardins et al., 1985). The effect of EtBr is reversible, so when the 
drug is removed from the culture medium, cells should, in principle, be able to 
repopulate their mtDNA population (King and Attardi, 1989). However, our 
repopulation data revealed a clear distinction between POLG1, OPA1 and control 
cell lines. As expected, control fibroblasts showed a complete recovery in their 
mtDNA population when compared to the baseline. On the other hand, the rate of 
mtDNA repopulation following the removal of EtBr was significantly affected in 
both POLG1 and OPA1 cell lines.  
MtDNA copy number in POLG1-mutant cell lines remained markedly depressed 
following removal of EtBr, clearly indicating that the presence of the pathogenic 
POLG1 mutations was having a detrimental effect on mtDNA replication, preventing 
any significant recovery from taking place (Graziewicz et al., 2006; Copeland, 2008). 
MtDNA Repopulation Assay and Mitochondrial Network Analysis 
  
 
201 
 
These findings are consistent with the results previously obtained using the same 
repopulation assay for a cohort of five POLG1-mutant fibroblast cell lines (Stewart 
et al., 2011). It is noteworthy that despite optimal culture conditions, two of the EtBr-
treated POLG1 fibroblast lines (POLG1b, POLG1c) died prematurely during the 
repopulation phase. It is likely that the severe EtBr-induced mtDNA depletion, 
coupled with already dysfunctional mtDNA replication machinery, ultimately led to 
a gradual decline in mtDNA content after each successive cell division. The 
progressive reduction in respiratory efficiency would then have ultimately triggered 
cellular apoptosis, leading to growth failure of these two specific POLG1 cell lines.  
This repopulation experiment has also provided additional data linking OPA1 
mutations with impaired mtDNA maintenance. All eight OPA1 cell lines included in 
this study showed a reduction in rate of mtDNA repopulation following removal of 
EtBr when compared with the control fibroblasts. Despite this incomplete recovery, 
the level of mtDNA repopulation was significantly greater than for the POLG1-
mutant cell lines. This contrasting observation could be related to the different roles 
played by the POLG and OPA1 proteins in the complex process that regulates 
mtDNA replication (Hudson and Chinnery, 2006; Elachouri et al., 2011). POLG1 
mutations directly affect polymerase gamma activity, which is essential for mtDNA 
replication (Graziewicz et al., 2006; Copeland, 2008). OPA1 mutations can result in 
significant disturbance in cristae morphology, which could disrupt the anchoring of 
mtDNA molecules to the IMM and hence exert a detrimental effect on the faithful 
and efficient replication of the mitochondrial genome (Landes et al., 2010; Elachouri 
et al., 2011). No significant difference in the kinetics of mtDNA repopulation was 
observed between OPA1 cell lines from patients manifesting both pure DOA and 
DOA+ clinical phenotypes. The impaired mtDNA repopulation seen in this 
experimental assay does not therefore correlate with the heterogeneous clinical 
phenotype observed in human OPA1 carriers. Similarly, no difference in mtDNA 
repopulation was observed between missense OPA1 mutations affecting the GTPase 
domain compared with those that result in haploinsufficiency. However, this 
comparison is somewhat limited by the unequal number of cell lines in these two 
groups (GTPase: N = 2; non-GTPase: N = 6). Rather strikingly, there were obvious 
differences noted between the different familial OPA1 mutations. It is tempting to 
speculate that different OPA1 mutations have variable deleterious consequences on 
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the process of mtDNA replication. However, a larger cohort of OPA1 cell lines is 
needed to address this hypothesis further.   
 
7.6 Discussion: Mitochondrial Network Analysis 
At the baseline (day 0), a significant increase in the total mitochondrial network size 
was observed in both POLG1 and OPA1 mutant fibroblasts compared with the mean 
control. This remarkable observation could represent a compensatory mechanism to 
the underlying OXPHOS defect triggered by POLG1 and OPA1 mutations in these 
mutant cell lines. The physical increase in the surface area available for 
mitochondrial OXPHOS could theoretically balance the reduction in mitochondrial 
respiratory chain efficiency seen with POLG1 and OPA1 mutations. Interestingly, a 
significant mitochondrial elongation has recently been described by Agiers and 
colleagues in four OPA1-mutant fibroblasts, suggesting a compensatory mechanism 
observed across a broad range of pathogenic OPA1 mutations (Agier et al., 2012). 
The marked elevation in the total mitochondrial network size in all fibroblast lines 
subsequently to EtBr treatment is in keeping with the previous results demonstrating 
greatly enlarged mitochondrial profiles with few or none cristae, observed in cultured 
mouse fibroblasts and hamster kidney cells after exposure to EtBr (Nass, 1970). It is 
therefore tempting to speculate, that the universal compensatory mechanism allows 
cells to cope with the EtBr-induced stress resulting in mtDNA degradation and 
subsequent deficit in OXPHOS. 
In basal culture conditions (day 0), both POLG1 and OPA1 cell lines had a 
significantly larger number of individual mitochondrial network fragments compared 
with the mean control. However, this increase needs to be taken in the context of the 
overall increase in the mitochondrial length. Of note, the average length of a single 
mitochondrion network fragment in the mean OPA1 (Figure 7-31) was slightly 
shorter compared with the mean control value. However, this difference was of a 
borderline significance (P = 0.0457). The lack of a dramatic reduction in the average 
mitochondrial length is not too surprising given that these cells were grown in 
standard high glucose media, where a deficient mitochondrial OXPHOS mechanism 
can be bypassed to a certain extent by glycolysis (Robinson et al., 1992; D'Aurelio et 
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al., 2001). Zanna and colleagues have clearly shown that significant mitochondrial 
network fragmentation in OPA1-mutant fibroblasts was only observed in glucose-
free media, when cells were forced to rely exclusively on OXPHOS, which was 
markedly impaired in these fibroblasts (Zanna et al., 2008). At day 15 and day 45 
(Figure 7-31), the average mitochondrial fragment length for the mean POLG1 was 
significantly lower compared with the mean control. These results point towards 
mitochondrial network fragmentation in these POLG1-mutant cell lines. Unlike 
OPA1, POLG is not directly involved in mitochondrial membrane dynamics. It is 
more likely that the marked impairment in mtDNA repopulation observed in these 
POLG1-mutant cell lines is resulting in a bioenergetic crisis, the latter triggering 
mitochondrial network fragmentation as a part of the apoptotic cascade that 
eventually leads to the cell death.   
 
7.7 Concluding Remarks 
This series of mtDNA depletion-repopulation experiments has provided convincing 
data that both POLG1 and OPA1 mutations can have a detrimental effect on the 
capacity of cell to replenish its store of mtDNA molecules following the application 
of an exogenous stress, in this case EtBr. The striking difference in the kinetics of 
mtDNA repopulation between these two mutational groups is clearly highlighting 
diverging pathophysiological mechanisms. This is the first study to objectively 
measure mitochondrial network morphology in POLG1-mutant fibroblasts and future 
studies are needed to further elucidate how POLG1 mutations ultimately cause 
mitochondrial network fragmentation. Mitochondrial elongation is likely to be a 
common powerful compensatory mechanism and it will be interesting to determine if 
a similar feature is present in the other mitochondrial maintenance disorders e.g. 
those linked with PEO1 and RRM2B mutations (Cohen and Naviaux, 2010). Finally, 
there is a convincing link between mitochondrial network morphology and mtDNA 
content, with the mitochondrial network fragmentation being a feature of cells that 
are severely depleted of their mtDNA molecules. 
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8.1 Introduction 
OPA1 mutations are identified in approximately 60% of patients with a clinical 
diagnosis of DOA (Alexander et al., 2000; Delettre et al., 2000). This inherited optic 
neuropathy is characterised by progressive bilateral visual loss starting in early 
childhood secondary to the preferential loss of RGCs and subsequent degeneration of 
the optic nerve (Votruba, 1998; Alavi et al., 2009). A greater understanding of the 
factors underlying this greater vulnerability of RGCs is fundamental to our 
understanding of OPA1-related DOA. 
Unlike skin or skeletal muscle, RGCs cannot be biopsied directly without causing 
irreversible structural damage. There is also a lack of post-mortem disease samples 
from patients with confirmed OPA1 mutations. Over the past few years, a number of 
OPA1 mouse models have been created to bypass this lack of human tissue samples 
(Lenaers et al., 2009). Two vertebrate DOA mouse models have been developed, one 
harbouring a heterozygous nonsense c.1051C>T (p.Q283X) Opa1 mutation in exon 
8, and the other one demonstrating a splicing c.1065+5G>A Opa1 mutation, leading 
to exon 10 skipping and in-frame deletion of 27 amino acid residues in the GTPase 
domain (Alavi et al., 2007; Davies et al., 2007). In both models, the homozygous 
(Opa1-/-) mutant mice were embryonic lethal, whereas heterozygous (Opa1+/-) mice 
revealed a slowly progressive optic neuropathy, replicating the clinical phenotype 
found in non-syndromic patients with DOA (Davies et al., 2007; Yu-Wai-Man et al., 
2011b). The analysis of RGC axons harvested from these heterozygous Opa1+/- 
mice revealed abnormal mitochondria with disorganised cristae structure and an 
elevated number of autophagosomes (Alavi et al., 2007; White et al., 2009). A third 
Opa1 mouse model, harbouring a heterozygous c.2708-2711delTTAG mutation in 
exon 27, is currently under investigation by Dr Guy Lenaers and colleagues 
(personal communications).  
Pluripotent stem cells are able to propagate indefinitely, maintaining the capability to 
spontaneously differentiate into any cell type from all three embryonic germ layers – 
ectoderm, mesoderm and endoderm (Pera et al., 2000; Hyslop et al., 2005). The first 
induced pluripotent stem cells (iPSCs) were generated from somatic cells following 
transductions with a set of specific transcription factors that are crucial for the 
maintenance of the pluripotent state (Takahashi and Yamanaka, 2006; Takahashi et 
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al., 2007; Yu et al., 2007). This seminal discovery has opened up a new frontier in 
scientific research, with the exciting prospect of creating a range of patient- and 
disease-specific human cell lines. The application of human iPSC (hiPSC) 
technology to generate RGCs of patients with OPA1-related DOA is an obvious 
technical innovation that would bypass the current lack of access to diseased human 
tissues. The aim for this study was therefore to generate hiPSCs from three OPA1-
mutant human fibroblast lines. 
 
8.2 Materials and Methods 
The research in this chapter was carried out in collaboration with Professor Majlinda 
Lako’s Stem Cell Group (Institute of Genetic Medicine, Newcastle University). The 
techniques used for the derivation of hiPSC lines and subsequent characterisation of 
their pluripotencial nature have previously been optimised in Professor Lako’s group 
(Armstrong et al., 2010; Jiang et al., 2012).    
8.2.1 Fibroblast Patient Lines 
Three OPA1 mutant fibroblast lines (labelled as: P1, P2 and P3) and a single control 
(labelled as: Control) fibroblast line, were selected for this study (Table 8-1). All 
these cell lines had previously been investigated in Chapter 7. The P1, P2, P3 and 
Control labels used in this study correspond to the OPA1b, OPA1c, OPA1h and C3, 
respectively in Chapter 7.     
 
 
 
  
 
2
0
8
 
Table 8-1 Properties of patient fibroblast cell lines selected for the hiPSCs generation.  
F – female; HSP – hereditary spastic paraplegia; M – male; OA – optic atrophy; PEO – progressive external ophthalmoplegia. 
 
 
 
Cell 
Line 
Age 
(yrs) 
Sex cDNA Consequence 
Initial 
Passage 
Number   
Detailed Clinical Phenotype 
OA Deafness Ataxia Myopathy Neuropathy PEO Others 
P1 23 M c.889C>T p.Q297X 4 + - - - - - - 
P2 28 F c.889C>T p.Q297X 4 + - - - - - HSP 
P3 39 M c.1516+1G>T 
Splicing 
defect 
5 + - - - - - - 
Control 30 F - - 4 - - - - - - - 
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8.2.2 Derivation of hiPSCs from Human Fibroblasts  
The generation and culture of hiPSCs was performed in a class II vertical laminar 
flow hood (IVF Workstation N24; K-Systems, Birkerød, Denmark) equipped with a 
fitted dissection microscope (Carl Zeiss). In order to avoid contamination and 
maintain stable tissue culture conditions, all culture media were initially filtered 
(filter bottles with PES membrane; Nalgene) and warmed to 37°C (JB Aqua 18 Plus 
water bath; Fisher Scientific) at least 30 minutes prior to use.   
To generate hiPSC lines, mycoplasma-free (details in Section 3.12.2) human 
fibroblasts of low passage numbers from three OPA1 lines and the control (Table 
8-1), were seeded in 12-well plates (TPP, Basel, Switzerland) at a density of 20,000 
cells/well, 2 wells per a cell line. After 24 hours of incubation, fibroblasts were 
transduced with a lentiviral 4-in-1 human OSKM polycistronic expression vector 
containing two loxP sites flanking the OSKM expression cassette (Figure 8-1) 
(Allele Biotechnology, San Diego, USA). In this transduction system, all four 
reprogramming factors (OCT4, SOX2, KLF4 and c-MYC) were expressed from an 
individual polycistronic transcript into separate polypeptides through the property of 
2A “self-cleaving” peptide. To transduce fibroblasts, the transduction medium 
containing 1ml of fibroblast medium (Section 3.12.1), 1µl of reprogramming 
lentiviruses (multiplicity of infection, MOI = 2) and 1µl polybrene (final 
concentration of 6µg/ml), was added per well of a 12-well plate and evenly 
distributed. After 48 hours, transduction medium was replaced by fresh fibroblast 
medium and this procedure was repeated every 48 hours until day 6. On the sixth day 
post-transduction, fibroblasts were disaggregated to single cells by trypsynization 
with 0.05% Trypsin/EDTA (Gibco, Life Technologies), centrifuged for 5 minutes at 
200g and each pellet resuspended in 500µl of fibroblast medium. Following that, 
cells were counted (as in Section 3.12.3 but without Trypan Blue staining) and 
seeded into 6-well MEF feeder plates at a density of 15,000 cells per well. The 
preparation of these MEF feeder plates has been described in Section 8.2.2.1. 
Twenty four hours after re-seeding, fibroblast medium was changed to hESC/hiPSC 
culture medium containing: 80% Knockout™ DMEM (KO-DMEM; Gibco, Life 
Technologies), 20% Knockout™ Serum Replacement (Gibco, Life Technologies), 
1X non-essential amino acids (Gibco, Life Technologies), 2mM L-glutamine (Gibco, 
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Life Technologies), 50U/ml penicillin and 50µg/ml streptomycin (Gibco, Life 
Technologies), and 10ng/ml human basic recombinant fibroblast growth factor 
(bFGF; Gibco, Life Technologies). The hESC/hiPSC medium was changed every 
second day until day 14
th
 post-transduction. From thereon, cells were cultured in 
MEF conditioned medium (as described in Section 8.2.2.1), which was changed 
every 48 hours until the first hiPSC colonies appeared. Newly-generated, 
morphologically-correct hiPSC colonies were mechanically dissected into pieces and 
transferred into fresh MEF feeder plates for further expansion before 
characterisation. 
 
 
Figure 8-1 Map of a lentiviral 4-in-1 human OSKM polycistronic expression 
vector with loxP sites. Reprogramming factors (OCT4, SOX2, KLF4 and c-MYC) 
are expressed from an individual polycistronic transcript into separate polypeptides 
through the function of 2A “self-cleaving” peptide sites. The cDNAs are flanked by 
loxP sites which allow viral cassette removal using Cre recombinase system. 
(Adapted from http://www.allelebiotech.com/4-in-1-lentiviral-particles-for-ipscs-
generation-human-oskm/). 
 
8.2.2.1 MEF Feeder Plates and MEF Conditioned Medium Preparation 
Mitotically-inactivated mouse embryonic fibroblasts (MEFs) were used as feeder 
cells to support growth and maintain the undifferentiated state of hiPSCs. To prepare 
MEF feeder plates, 6-well or 4-well plates (TPP) were initially gelatine-coated by 
adding 0.1% gelatine (Sigma-Aldrich) to each well and then incubated at 37°C for 2 
hours. Following this, MEFs mitotically-inactivated with mitomycin-C (MEF CF-1 
MITC; Global Stem, Rockville, USA) were thawed, resuspended in pre-warmed 
fibroblast medium and centrifuged at 200g for 5 minutes. After the supernatant had 
been aspirated, MEF cells were resuspended in fibroblast medium (Section 3.12.1) 
and counted as in Section 3.12.3 (no Trypan Blue staining). MEFs were seeded at a 
density of 130,000 cells/well of a 6-well plate or 37,500 cells/well of a 4-well plate 
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and incubated overnight. Before placing hiPSCs in MEF feeder plates, the culture 
medium was changed to hESC/hiPSC medium. 
MEF conditioned medium was prepared by seeding MEFs at a density of 5.6 x 10
4
 
cells per cm
2
 of a gelatine-coated flask (TPP) as described above for 4-well and 6-
well plates. After overnight incubation, fibroblast medium was replaced by 
hESC/hiPSC medium (0.33ml per cm
2 
of a flask). MEF conditioned medium was 
collected daily for a maximum period of 10 days. Prior to being added to hiPSCs, the 
conditioned medium was supplemented with 4ng/ml bFGF (Gibco, Life 
Technologies), 1X insulin-transferrin-selenium-A (Gibco, Life Technologies) and 
filtered through a PES membrane into a fresh bottle (Nalgene).   
8.2.3 Maintenance and Passaging of hiPSCs 
The hiPSC colonies were cultured in an undifferentiated state on MEF feeder layers 
in hESC/hiPSC medium that was changed every second day. Before each medium 
change, hiPSC colonies were cleaned with a 21G x 2 inch needle (BD Microlance™ 
3; Camlab, Cambridge, UK) or 200µl pipette tip, and any differentiated cells were 
removed with the aspirated medium. The sub-culture of hiPSC colonies was usually 
required every 5-7 days, but if for some reasons colonies were not ready to be split, 
MEF conditioned medium was introduced to prevent hiPSCs differentiation due to 
insufficient medium supplementation by the old MEF feeders. For sub-culturing, 
undifferentiated hiPSC colonies were manually cut into smaller pieces, detached and 
then transferred in 1:3 ratios onto fresh MEF feeders with hESC/hiPSC medium. An 
alternative method was also used, which involved detaching hiPSC colonies 
enzymatically by 15-minute incubation at 37°C with 1mg/ml (w/v) collagenase IV in 
KO-DMEM (both Gibco, Life Technologies). After incubation, the collagenase IV 
solution was carefully removed and replaced by hESC/hiPSC medium. Colonies 
were then detached and broken into smaller pieces by pipetting, before being 
transferred into a 15ml tube (Greiner) containing hESC/hiPSC medium. After 
centrifugation at 600g for 5 minutes, the supernatant was aspirated and the resulting 
hiPSC pellet was resuspended in fresh hESC/hiPSC medium prior to transfer onto 
fresh MEF feeder plates.  
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8.2.4 Storage of hiPSCs 
8.2.4.1 Cryovial Cryopreservation of hiPSCs – Freezing 
For long-term storage, whole hiPSC colonies were harvested (manually or 
enzymatically, as described in Section 8.2.3) and centrifuged at 600g for 5 minutes. 
The cell pellet was resuspended in 0.5ml of the filtered hiPSC freezing medium 
containing 60% (v/v) hESC/hiPSC medium (Section 8.2.2), 20% (v/v) FBS (Gibco, 
Life Technologies), 20% (v/v) dimethylsulphoxide (DMSO; Sigma-Aldrich) and 
0.01% (v/v) Rho-associated coiled-coil forming protein serine/threonine kinase 
(ROCK) inhibitor (Sigma-Aldrich), the latter protecting cells from apoptosis. Human 
iPSC colonies were carefully resuspended in freezing medium and then pipetted 
drop-wise to a cryovial (Greiner), which then was placed in a Mr. Frosty isopropyl-
filled freezing container (Nalgene). The freezing container was then placed in a -
80ºC freezer for 24 hours and afterwards, the cryovials were transferred to liquid 
nitrogen for long-term storage.  
8.2.4.2 Cryovial Cryopreservation of hiPSCs – Thawing  
The hiPSC lines were placed into culture from the frozen cryovials stored in liquid 
nitrogen. Cells were quickly thawed at 37°C (JB Aqua 18 Plus water bath; Fisher 
Scientific), transferred drop-wise into a 30ml universal container (Fisher Scientific) 
with pre-warmed hESC/hiPSC medium (Section 8.2.2) and centrifuged for 5 minutes 
at 200g. The supernatant was aspirated and the hiPSC pellet gently resuspended in 
fresh hESC/hiPSC medium supplemented with 0.01% (v/v) ROCK inhibitor (Sigma-
Aldrich), before the hiPSCs were seeded in a MEF feeder plate with 0.01% (v/v) 
ROCK inhibitor-supplemented hESC/hiPSC medium. The colonies were cleaned and 
the medium was changed with fresh hESC/hiPSC medium every 48 hours until the 
colonies were ready for passage. 
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8.2.5 In Vitro Characterisation of hiPSCs 
8.2.5.1 Quantification of Pluripotency Gene Expression Using RT-PCR 
All quantitative RT-PCRs were carried out on the first-strand cDNA samples 
(synthesised as described in Section 3.9.1) according to the protocol described in 
Section 3.9.2, with the primer sets listed in Table 8-2. The levels of pluripotency 
marker expression (endogenous and exogenous c-MYC) were first quantified in 
original hiPSC lines still containing viral cassettes to select clones, with the least 
amount of the viral load, for subsequent Cre-mediated excision (described in Section 
8.2.6). Following Cre-loxP recombination, hiPSC lines were RT-PCR analysed 
again, to assess final OCT4 expression levels (refer to Section 8.2.6.3). Results of the 
quantitative RT-PCRs were normalized to GAPDH and RPL13A expression and 
compared with the data obtained for the pluripotent H9 hESC line.   
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Table 8-2 Properties of primers used to amplify endogenous OCT4, total OCT4, 
endogenous c-MYC, exogenous c-MYC, Cre-recombinase gene and GAPDH. 
GenBank accession numbers: GAPDH NM_001256799.1; RPL13A 
NM_001270491.1. 
Primer Name Type of Primer Primer Sequence (5’ – 3’) 
OCT4 Endogenous (168 bp) 
OCT4 Endogenous F Forward AAG CCC TCA TTT CAC CAG G 
OCT4 Endogenous R Reverse CTT GGA AGC TTA GCC AGG TC 
OCT4 Total (100 bp) 
OCT4 Total F Forward GAG GAG TCC CAG GAC ATC AA 
OCT4 Total R Reverse CAT CGG CCT GTG TAT ATC CC 
c-MYC Endogenous (259bp) 
c-MYC Endogenous F Forward AGC AGA GGA GCA AAA GCT CAT T 
c-MYC Endogenous R Reverse CCA AAG TCC AAT TTG AGG CAG T 
c-MYC Exogenous (182bp) 
c-MYC Exogenous F Forward AGC AGA GGA GCA AAA GCT CAT T 
c-MYC Exogenous R Reverse AAC CTA CAG GTG GGG TCT TTC A 
Cre-recombinase gene (113 bp) 
Cre F Forward TGT CCG TTT GCC GGT CGT GG 
Cre R Reverse CAG ACC GCG CGC CTG AAG AT 
GAPDH (133 bp) 
GAPDH F Forward CTG ACT TCA ACA GCG ACA CC 
GAPDH R Reverse ATG AGG TCC ACC ACC CTG T 
RPL13A (307 bp) 
RPL13A F Forward CCT GGA GGA GAA GAG GAA 
RPL13A R Reverse TTG AGG ACC TCT GTG TAT 
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8.2.5.2 DNA Sequencing  
In order to confirm that OPA1 mutations present in the original fibroblast lines were 
retained through the lentiviral-mediated reprogramming procedure, total genomic 
DNA was extracted from all OPA1-affected hiPSC lines, as described in Section 
3.1.1. The specific OPA1 mutation was then sequenced, as described in Section 3.6.   
8.2.5.3 DNA Fingerprinting 
To confirm that the generated hiPSC lines were genetically identical to the original 
fibroblast lines, DNA fingerprinting was performed. Total genomic DNA was 
extracted from hiPSC lines and the corresponding original fibroblast cell lines as 
described in Section 3.1.1. The extracted DNA samples were amplified with 16 
microsatellite markers (Penta E, D18S51, D21S11, TH01, D3S1358, FGA, TPOX, 
D8S1179, vWA, Amelogenin, Penta D, CSF1PO, D16S539, D7S820, D13S317 and 
D5S818) using the PowerPlex® 16 HS System (Promega, Southampton, UK) and the 
fragments were then analysed on the ABI 3130xl sequence analyser (Applied 
Biosystems, Life Technologies). DNA fingerprinting analysis was performed by 
Northgene Ltd Company (http://www.paternitytesting.co.uk/) on the DNA samples 
provided.  
8.2.5.4 Karyotype Analysis 
To determine whether the viral-mediated reprogramming of human fibroblasts 
caused any chromosomal abnormalities in the derived hiPSCs, karyotype analysis 
was performed on all hiPSC lines and the original fibroblast cell lines, using a 
standard G-banding procedure on 20 metaphase cells. Karyotyping was carried out 
by the Cytogenetics Laboratory (Northern Genetics Service, Newcastle upon 
Tyne Hospitals NHS Foundation Trust) on the provided samples.  
8.2.5.5 Immunodetection of Pluripotency Markers 
For the immunodetection of pluripotency markers, hiPSC lines were cultured in 4-
well MEF feeder plates for 4 days to allow sufficient colony expansion. On the 
fourth day, hiPSCs were fixed to detect cell surface markers (SSEA-4 and TRA-1-
81), or fixed and permeabilized to detect intracellular markers (OCT4 and SOX2) of 
pluripotency, as described in Section 3.10.1. Immunostaining was carried out as 
described in Section 3.10.2, using monoclonal fluorochrome-conjugated primary 
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antibodies listed in Table 8-3. The incubation steps were performed in the dark and 
secondary antibodies were not required.  
The fluorescent images were obtained with the inverted Axiovert 200M microscope 
(Carl Zeiss) equipped with x20 air objective (N.A. = 0.4; Plan APOCHROMAT, 
Carl Zeiss) and AxioCam HRc digital camera (Carl Zeiss), using AxioVision Rel. 4.8 
software (Carl Zeiss). The images were further processed using the public domain 
ImageJ software (http://rsbweb.nih.gov/ij/).  
 
Table 8-3 Properties of monoclonal fluorochrome-conjugated primary 
antibodies used for detection of hiPSC pluripotency markers.   
Antibody Fluorochrome Manufacturer Species Dilution 
anti OCT4 Fluorescein R&D Systems, UK (IC1759F) Rat anti-human IgG2B 1:100 
anti SOX2 Alexa Fluor® 488 BD Biosciences, UK (560301) Mouse anti-human IgG2A 1:100 
anti SSEA-4 FITC BD Biosciences, UK (560126) Mouse anti-human IgG3 1:100 
anti TRA-1-81 Alexa Fluor® 647 BD Biosciences, UK (560124) Mouse anti-human IgM 1:100 
 
8.2.6 Cre-loxP Recombination System  
To remove loxP-flanked OSKM polycistronic viral vector from reprogrammed 
hiPSCs, Cre-loxP mediated excision was performed. The Cre-recombinase gene was 
introduced in a Cre expression plasmid containing puromycin-resistance gene 
(Plasmid 17408: Puro.Cre empty vector; Addgene) (Figure 8-2). Prior to hiPSCs 
nucleofection with PvuII-linearized plasmid (10µg of plasmid/10
6
 hiPSCs; for 
linearization procedure refer to Section 8.2.6.1), hiPSC colonies were harvested 
(manually or enzymatically, as described in Section 8.2.3) and centrifuged at 600g 
for 5 minutes. The cell pellet was washed once in PBS (Oxoid) and resuspended in 
90µl of Nucleofector™ Solution (Amaxa; Lonza, Basel, Switzerland) before being 
nucleofected with PvuII-linearized plasmid (diluted in 10µl of Nucleofector™ 
Solution) using programme A23 of an Amaxa® Nucleofector device (Lonza). 
Following nucleofection, hiPSCs were immediately mixed with pre-warmed 
hESC/hiPSC medium supplemented with 0.01% (v/v) ROCK inhibitor (Sigma-
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Aldrich), before being transferred at high density into a MEF feeder plate. The 
medium was changed at 48 hours post-nucleofection, and 24 fours later, 0.5 – 1µg/ml 
puromycin was supplemented to select for hiPSCs that had been successfully 
nucleofected. Puromycin selection was maintained for 5 days and puromycin-
resistant hiPSC colonies were allowed to re-emerge for approximately 7 more days. 
Selected hiPSC colonies were then transferred to fresh MEF feeder plates and 
expanded clonally. 
To validate successful Cre-mediated excision of loxP sites and the generation of viral 
cassette-free hiPSCs, genomic DNA and RNA were extracted from: (i) puromycin-
resistant hiPSC clones, (ii) original (non-nucleofected) hiPSC lines, and (iii) H9 
hESC line. DNA and RNA isolations (Section 3.1.1 and Section 3.2, respectively) 
were performed on manually-harvested cells (as described in Section 8.2.3), which 
were centrifuged at 600g for 5 minutes. The obtained cell pellets were then washed 
once in PBS (Oxoid). To assess the efficiency of nucleofection, PCR reactions 
primed to detect the viral cassettes (Section 8.2.6.2), and RT-PCRs to determine 
viral gene expression levels (Section 8.2.6.3), were performed.    
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Figure 8-2 Map of the puro – Cre plasmid. (Reproduced from: 
http://www.addgene.org/browse/sequence/8585/).  
  
8.2.6.1 Puro-Cre Plasmid Linearization 
In order to generate stable hiPSC clones post-nucleofection, the puro-Cre plasmids 
were initially linearized in a PvuII-mediated reaction. Briefly, the plasmids 
(0.824µg/µl) were incubated overnight at 37°C with PvuII-HF restriction enzyme 
(4U per 1µg of plasmid; New England Biolabs, Hitchin, UK), 1X Buffer 4 (New 
England Biolabs) and dH2O. The next day, the PvuII-HF enzyme was inactivated by 
incubating for 20 minutes at 80°C. The validation of linearization was assessed by 
running a 0.7% (w/v) TAE agarose gel and comparing the obtained bands with the 
band of undigested puro-Cre plasmids (protocol described in Section 3.4). Following 
successful linearization, the digested plasmids were cleaned from the remaining 
enzymatic reactions using QIAquick™ Gel Extraction Kit (Qiagen) according to the 
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manufacturer’s protocol. In brief, the plasmids in the digestion mixture were initially 
added to 3 volumes of QG Buffer (Qiagen) and 1 volume of isopropanol, before 
being applied to QIAquick® spin-columns (up to 10µg of plasmid per column). 
Further steps were carried out as described in Section 3.5. 
8.2.6.2 PCR-mediated Viral Cassette Detection 
PCRs were performed using the same equipment as described in Section 3.3. Each 
individual DNA sample (30ng) was amplified in a PCR master mix containing: 
colourless 5X GoTaq® Reaction Buffer (10l/reaction; Promega), 2mM dNTP Mix 
(5l/reaction; VH Bio), 10 M forward and reverse primers (both 2l/reaction; 
Sigma-Aldrich) (Table 8-4), 5U/µl GoTaq® DNA Polymerase (0.25l/reaction; 
Promega) and dH2O (filled up to 50 l/reaction). Each DNA sample was amplified 
using primers which allowed the detection of: (i) two viral cassette products of 
different sizes (~250 bp and ~600 bp); (ii) the Cre-recombinase transgene; and (iii) 
GAPDH housekeeping gene as a loading control. 
DNA was amplified under the following conditions: an initial denaturation step at 
95°C for 2 minutes, then 35 cycles of denaturation at 95°C for 1 minute, annealing at 
56°C for 1 minute, and extension at 72°C for 1 minute. For the last cycle, a final 
extension step of 5 minutes at 72°C was performed before cooling the sample to 4°C. 
Amplified DNA samples were further validated on the agarose gel as described in 
Section 3.4. 
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Table 8-4 Properties of primers used to amplify short and long OSKM 
polycistronic viral vector cassette products, Cre-recombinase gene and GAPDH.  
GenBank accession number: GAPDH NM_001256799.1; 
1)
 product size estimated 
only approximately as the actual sequence information is considered proprietary by 
Allele Biotechnology, USA.     
Primer Name Type of Primer Primer Sequence (5’ – 3’) 
Viral cassette short product (~250 bp1)) 
EF1α Forward TCA AGC CTC AGA CAG TGG TTC 
OCT4 Endogenous Reverse CTT GGA AGC TTA GCC AGG TC 
Viral cassette long product (~ 600bp1)) 
EF1α Forward TCA AGC CTC AGA CAG TGG TTC 
OCT4 Total Reverse CAT CGG CCT GTG TAT ATC CC 
Cre-recombinase gene (113 bp) 
Cre F Forward TGT CCG TTT GCC GGT CGT GG 
Cre R Reverse CAG ACC GCG CGC CTG AAG AT 
GAPDH (133 bp) 
GAPDH F Forward CTG ACT TCA ACA GCG ACA CC 
GAPDH R Reverse ATG AGG TCC ACC ACC CTG T 
 
8.2.6.3 Cre-mediated Recombinase Assessment Using RT-PCR 
Following first-strand cDNA synthesis (as described in Section 3.9.1), RT-PCRs 
were performed according to the protocol illustrated in Section 3.9.2 and normalized 
to GAPDH and RPL13A expression (all primer sets listed in Table 8-2). Quantitative 
PCRs primed to detect Cre-recombinase transgene were performed to allow a precise 
assessment of the nucleofection efficiency. The remaining viral contribution to OCT4 
expression was calculated by subtracting the endogenous OCT4 expression from the 
total OCT4 expression. 
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8.3 Results 
8.3.1 Derivation of hiPSCs from Human Fibroblasts 
The efficiency of retroviral transduction and the number of morphologically-correct 
hiPSC colonies generated have been summarized in Table 8-4. The hiPSC colonies 
obtained had morphological characteristics typical of hESCs, with a high cellular 
density and an elevated nuclear-to-cytoplasmic ratio. The subsequent stages of hiPSC 
colony formation have been illustrated in Figure 8-3.     
 
Table 8-5 The final outcome of the viral-mediated derivation of hiPSCs from all 
studied fibroblast cell lines. 
Cell Line Efficiency of Transduction Number of Clones Established 
P1 0.00467% 3 
P2 0.00600% 2 
P3 0.00133% 1 
Control 0.14800% 6 
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Figure 8-3 Subsequent stages of hiPSCs derivation for the P1 fibroblasts. (A) 
The morphology of the original fibroblasts. (B) The morphology of primary hiPSC 
clone at day 21 and (C) at day 42 post-transduction. Brightfield phase contrast 
images were taken with the Axiovert 200M microscope (Carl Zeiss) equipped with 
the Plan-Neofluar 5x/0.15 air objective (Carl Zeiss).      
 
 
 
 
A 
 
 
 
 
 
B 
 
 
 
 
 
C 
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8.3.2 In Vitro Characterisation of hiPSCs 
To allow for a descriptive characterisation, our aim was to clonally expand two 
independent hiPSC clones from each individual parent fibroblast line. The only 
exception was the P3 patient line, for which only a single hiPSC line was available. 
For the P1 line and the control fibroblasts, for which more than two hiPSC clones 
were available, two were randomly selected for the subsequent analysis. The 
expanded hiPSC lines were named as follows: (i) P1-1 and P1-2 from the P1 
fibroblast line; (ii) P2-1 and P2-2 from the P2 fibroblasts; (iii) P3-1 from the P3 
fibroblast line; and (iv) C-1 and C-2 from the control fibroblast line. 
8.3.2.1 Quantification of c-MYC Expression Using RT-PCR 
The RT-PCR analysis was performed on all expanded hiPSC clones to measure the 
endogenous and exogenous expressions of one of the pluripotency markers used:     
c-MYC. The rationale was to select the hiPSC clone (per patient line) that showed the 
lower level of exogenous c-MYC expression, since the lesser the initial viral load 
was, the more successful Cre-mediated viral removal could have been. The RT-PCR 
detection of endogenous and exogenous c-MYC transcript expression levels is 
presented in Figure 8-4, with the hESC H9 line used as a control. 
The RT-PCR analysis confirmed both the endogenous and the viral/exogenous 
expression of c-MYC transcript in all investigated hiPSC clones (Figure 8-4). As 
expected, the hESC H9 line, which lacked the polycistronic viral cassette, showed 
only the endogenous c-MYC expression. There was variability in the levels of 
exogenous c-MYC transcripts between the two hiPSC lines originating from the same 
parent fibroblast line (Figure 8-4). For the subsequent experimental stage of 
characterisation, the hiPSC clone with the lowest viral c-MYC expression was 
selected per original fibroblast line: P1-2, P2-2, P3-1 and C-1 line.       
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Figure 8-4 Endogenous and exogenous expression patterns of c-MYC transcript 
in hiPSC lines and H9 hESC line. Per each original fibroblast line, the hiPSC clone 
with the lowest exogenous c-MYC expression (indicated with the green arrow) was 
selected. Expression levels of c-MYC transcript are normalized to GAPDH and 
RPL13A housekeeping genes and relative to expression in ESC H9 line. The error 
bars indicate the standard errors of the mean (SEM). 
8.3.2.2 OPA1 Sequencing  
Sanger sequencing confirmed that the specific OPA1 mutations present in the 
original fibroblast lines were retained in the corresponding generated hiPSC lines:  
c.889C>T (p.Q297X) in the P1 and P1-2 lines (Table 8-6); c.889C>T (p.Q297X) in 
the P2 and P2-2 lines (Table 8-7); c.1516+1G>T (splice defect) in the P3 and P3-1 
lines (Table 8-8).      
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Table 8-6 Sequence chromatograms showing the c.889C>T (p.Q297X) 
heterozygous OPA1 mutation in the original P1 fibroblasts and the P1-2 hiPSCs. 
Chromatograms were generated with SeqScape® v2.1.1 software (Applied 
Biosystems, Life Technologies).    
P1 (original fibroblast line) P1-2 (hiPSC line) 
 
 
c.889C>T 
 
 
c.889C>T 
Y – refers to C or T in IUPAC nucleotide code. 
 
Table 8-7 Sequence chromatograms showing the c.889C>T (p.Q297X) 
heterozygous OPA1 mutation in the original P2 fibroblasts and the P2-2 hiPSCs. 
Chromatograms were generated with SeqScape® v2.1.1 software (Applied 
Biosystems, Life Technologies).    
P2 (original fibroblast line) P2-2 (hiPSC line) 
 
 
c.889C>T 
 
 
c.889C>T 
Y – refers to C or T in IUPAC nucleotide code. 
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Table 8-8 Sequence chromatograms showing the c.1516+1G>T (splice defect) 
heterozygous OPA1 mutation in the original P3 fibroblasts and the P3-1 hiPSCs. 
Chromatograms were generated with SeqScape® v2.1.1 software (Applied 
Biosystems, Life Technologies).   
P3 (original fibroblast line) P3-1 (hiPSC line) 
 
 
c.1516+1G>T 
 
 
c.1516+1G>T 
K – refers to G or T in IUPAC nucleotide code. 
 
8.3.2.3 DNA Fingerprinting 
DNA fingerprinting confirmed that all generated hiPSC lines were genetically 
identical to the original fibroblast lines from which they were derived. Similar allele 
callings for all 16 different microsatellite markers were obtained for each original 
fibroblast-hiPSC pair (Table 8-9). 
 
  
2
2
7
 
 
Table 8-9 DNA fingerprinting results for each pair of original fibroblast and corresponding hiPSC lines. Specific allele numbers for 16 
different microsatellite markers are presented for both chromosomes. Matching results for the original fibroblasts and generated from them 
hiPSCs indicate their common genotypic background. 
Sample 
Microsatellite Marker 
D3S1358 TH01 D21S11 D18S51 Penta E D5S818 D13S317 D7S820 D16S539 CSF1PO Penta D Amelogenin vWA D8S1179 TPOX FGA 
 
Control 15  16 9.3  9.3 29  30 16  20 15  19 10  13 8  11 10  11 12  12 10  11 10  10 X  X 16  17 10  14 11  11 20   24 
C-1 15  16 9.3  9.3 29  30 16  20 15  19 10  13 8  11 10  11 12  12 10  11 10  10 X  X 16  17 10  14 11  11 20   24 
 
P1 16  16 9  9 30  30 16  18 14  18 12  13 8  11 9  10 11  12 10  13 9  12 X  Y 17  18 8  10 8  11 20  23 
P1-2 16  16 9  9 30  30 16  18 14  18 12  13 8  11 9  10 11  12 10  13 9  12 X  Y 17  18 8  10 8  11 20  23 
 
P2 14  16 9  9 30  32.2 16  16 10  15 12  13 9  13 9  10 11  12 11  13 8  11 X  X 17  18 10  13 11  11 21  23 
P2-2 14  16 9  9 30  32.2 16  16 10  15 12  13 9  13 9  10 11  12 11  13 8  11 X  X 17  18 10  13 11  11 21  23 
 
P3 15  17 6  9 30  30.2 14  18 14  18 12  13 8  11 8  12 11  13 12  13 12  13 X  Y 18  18 14  16 8  11 21  23 
P3-1 15  17 6  9 30  30.2 14  18 14  18 12  13 8  11 8  12 11  13 12  13 12  13 X  Y 18  18 14  16 8  11 21  23 
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8.3.2.4 Karyotype Analysis 
The G-banding procedure was performed on all original primary fibroblasts and the 
derived hiPSC lines. Karyotype analysis of the control fibroblast line revealed the 
(15;21)(q10;q10) chromosomal translocation in 2/20 metaphase cells, whereas only 
normal (46, XX) karyotypes were obtained for all 20 metaphase cells from the C-1 
hiPSC line (Figure 8-5). The P1 fibroblast line showed chromosome 8 trisomy 
mosaicism (2/20 metaphase cells), whereas the P1-2 hiPSC line revealed just normal 
(46, XY) karyotypes for all 20 metaphase cells (Figure 8-6). Both the P2 fibroblast 
and P2-2 hiPSC lines had entirely normal (46, XX) karyotypes (Figure 8-7). 
Similarly, the P3 fibroblast and P3-1 hiPSC lines revealed only normal (46, XY) 
karyotypes for all investigated metaphase cells (Figure 8-8).    
 
 
  
2
2
9
 
Figure 8-5 Karyograms of the control fibroblast line and the C-1 hiPSC line. The entire numbered chromosome complement is demonstrated 
individually for both cell lines. In the control fibroblasts, translocation (15;21)(q10;q10) mosaicism (indicated with red arrows) was observed  
(2/20 metaphase cells, otherwise normal 46, XX karyotype). The C-1 hiPSC line showed normal 46, XX karyotype in all 20 metaphase cells.             
Control (fibroblast line) C-1 (hiPSC line) 
  
18/20 metaphase cells: 46, XX 
2/20 metaphase cells: 46, XX, der(15;21)(q10;q10) 20/20 metaphase cells: 46, XX 
  1  2  3             4                  5       1     2  3             4                   5 
  6          7              8     9               10             11   12             
  6         7             8         9               10              11   12             
  13            14                  15                 16     17                   18               13            14                  15                  16      17                   18             
  19            20                21                  22                     X              Y               19            20                21                  22                    X               Y             
  
2
3
0
 
Figure 8-6 Karyograms of the P1 fibroblast line and the P1-2 hiPSC line. The entire numbered chromosome complement is demonstrated 
individually for both cell lines. In the P1 fibroblasts, chromosome 8 trisomy mosaicism (indicated with red arrows) was observed (2/20 
metaphase cells, otherwise normal 46, XY karyotype). The P1-2 hiPSC line showed normal 46, XY karyotype in all 20 metaphase cells. 
P1 (fibroblast line) P1-2 (hiPSC line) 
  
18/20 metaphase cells: 46, XY 
2/20 metaphase cells: 46, XY,+8 20/20 metaphase cells: 46, XY 
    1             2             3                     4           5            1             2          3                    4                       5 
  6       7              8         9              10            11            12               6           7              8         9              10              11   12             
  13            14                  15                 16     17                   18               13            14                  15                  16      17                   18             
  19            20                  21                  22                  X              Y                19             20      21                  22                   X               Y             
  
2
3
1
 
Figure 8-7 Karyograms of the P2 fibroblast line and the P2-2 hiPSC line. The entire numbered chromosome complement is demonstrated 
individually for both cell lines. The P2 fibroblast and the P2-2 hiPSC lines showed normal 46, XX karyotypes in all metaphase cells.  
P2 (fibroblast line) P2-2 (hiPSC line) 
 
 
20/20 metaphase cells: 46, XX 20/20 metaphase cells: 46, XX 
 
  1       2       3                 4            5       1   2   3              4            5 
  6          7              8     9               10             11   12               6         7             8         9               10              11   12             
  13            14                  15                 16     17                   18               13            14                  15                  16      17                   18             
  19            20                21                  22                     X              Y               19             20      21                 22                   X               Y             
  
2
3
2
 
Figure 8-8 Karyograms of the P3 fibroblast line and the P3-1 hiPSC line. The entire numbered chromosome complement is demonstrated 
individually for both cell lines. The P3 fibroblast and the P3-1 hiPSC lines showed normal 46, XY karyotypes in all metaphase cells. 
P3 (fibroblast line) P3-1 (hiPSC line) 
  
20/20 metaphase cells: 46, XY 20/20 metaphase cells: 46, XY 
 
 1   2              3            4                        5 
   6          7             8               9               10               11             12               6         7            8       9                 10               11   12             
   13             14                 15                 16     17                 18               13             14      15                  16       17                  18             
   19             20                 21                 22                  X             Y               19             20      21                 22                   X                Y             
  1   2              3            4                        5 
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8.3.2.5 Immunodetection of Pluripotency Markers 
Immunocytochemical analysis revealed the expected patterns of nuclear expression 
of OCT4 (Figure 8-9) and SOX2 (Figure 8-10), as well as the expression of cell 
surface pluripotency markers SSEA-4 (Figure 8-11) and TRA-1-81 (Figure 8-12), in 
all characterised hiPSC lines.  
 
Figure 8-9 Immunocytochemical analysis of hiPSC lines for the expression of 
OCT4. Nuclei were labelled with Hoechst 33342, whereas OCT4 was detected with 
fluorescein-conjugated primary antibody. All images were captured with a 20x air 
objective. Scale bar: 100µm.   
 Nuclei (Hoechst 33342) OCT4 (Fluorescein) Overlay 
C-1 
   
P1-2 
   
P2-2 
   
P3-1 
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Figure 8-10 Immunocytochemical analysis of hiPSC lines for the expression of 
SOX2. Nuclei were labelled with Hoechst 33342, whereas SOX2 was detected with 
Alexa Fluor® 488-conjugated primary antibody. All images were captured with a 
20x air objective. Scale bar: 100µm. 
 Nuclei (Hoechst 33342) SOX2 (Alexa Fluor® 488) Overlay 
C-1 
   
P1-2 
   
P2-2 
   
P3-1 
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Figure 8-11 Immunocytochemical analysis of hiPSC lines for the expression of 
SSEA-4. Nuclei were labelled with Hoechst 33342, whereas SSEA-4 was detected 
with FITC-conjugated primary antibody. All images were captured with a 20x air 
objective. Scale bar: 100µm. 
 Nuclei (Hoechst 33342) SSEA-4 (FITC) Overlay 
C-1 
   
P1-2 
   
P2-2 
   
P3-1 
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Figure 8-12 Immunocytochemical analysis of hiPSC lines for the expression of 
TRA-1-81. Nuclei were labelled with Hoechst 33342, whereas TRA-1-81 was 
detected with Alexa Fluor® 647-conjugated primary antibody. All images were 
captured with a 20x air objective. Scale bar: 100µm. 
 Nuclei (Hoechst 33342) TRA-1-81 (Alexa Fluor® 647) Overlay 
C-1 
   
P1-2 
   
P2-2 
   
P3-1 
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8.3.3 Cre-loxP Recombination  
To remove loxP-flanked OSKM polycistronic viral vector from the selected hiPSC 
lines (please refer to Section 8.3.2.1), Cre-loxP mediated excision was performed by 
nucleofecting hiPSCs with the PvuII-linearized Cre expression plasmid containing 
puromycin-resistance transgene. After 5 days of selection with puromycin (0.5µg/ml 
for the first two days; 1µg/ml for the next three days) and a subsequent 7-day period 
to allow hiPSC colonies to re-emerge, three puromycin-resistant hiPSC clones were 
established from the P2-2 line, and nine from the C-1 line. Puromycin-resistant 
hiPSC clones failed to be established for the P1-2 and P3-1 hiPSC lines. The final 
outcome of the puromycin selection process is summarized in Table 8-10.  
 
Table 8-10 The final outcome of the puromycin selection in hiPSC lines 
nucleofected with the PvuII-linearized Cre expression plasmid containing 
puromycin-resistance transgene.  
Original hiPSC Line 
Number of Puromycin-
Resistant Clones 
Established 
Numbering of 
Puromycin-Resistant 
Clones 
P1-2 0 - 
P2-2 3 P2-2a; P2-2b; P2-2c 
P3-1 0 - 
C-1 9 
C-1a; C-1b; C-1c;  
C-1d; C-1e; C-1f; 
C-1g; C-1h; C-1i;  
 
To determine the efficiency of Cre-loxP recombination in each puromycin-resistant 
hiPSC clone, the presence of the lentiviral OSKM polycistronic cassette was 
assessed using PCR. Primers designed to amplify the short (~250 kb; Figure 8-14 A) 
and the long (~600 kb; Figure 8-14 B) viral cassette products were used (Figure 
8-13). The viral cassette was also amplified in hiPSC lines before Cre recombination 
(positive control) and the H9 ESC line (negative control). Consistent results were 
obtained for the short and long PCR products for all the analysed samples. Both short 
and long viral cassette amplicons were detected at significant levels in all samples, 
except the C-1f hiPSC line (abbreviated as 9 in Figure 8-14). Of note, the band for 
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this hiPSC line was however noticeably fainter for the GAPDH housekeeping gene 
(Figure 8-14 D). As expected, the viral cassette products were not amplified in the 
H9 hESC line. PCRs designed to amplify Cre recombinase transgene were performed 
in all investigated samples and no product bands were detected (Figure 8-14 D). 
The efficiency of Cre-mediated loxP sites excision was further verified with the RT-
PCR assay described in Section 8.2.6.3. The expression of both the total and 
endogenous OCT4 transcripts was determined for the P2-2 hiPSC line (before 
plasmid nucleofection) and the three puromycin-selected P2-derived hiPSC clones 
(P2-2a to P2-2c) (Figure 8-15 A). Similar measurements were obtained for the C-1 
hiPSC line and the nine puromycin-selected C-1-derived hiPSC clones (C-1a to C-1i) 
(Figure 8-15 B). All OCT4 gene expression levels were calculated relatively to the 
control H9 hESC line. The viral (exogenous) OCT4 expression was derived from the 
difference between the total and the endogenous levels of expression. These 
differences were not statistically significant for the P2-2b and P2-2c puromycin-
resistant hiPSC clones, suggesting successful removal of the viral cassette. To 
investigate this observation further, expression of Cre recombinase transgene was 
measured for all puromycin-resistant hiPSC lines (Figure 8-16). Significant 
expression of the Cre transgene was evident only for the P2-2a and P2-2b hiPSC 
clones. Cre transgene expression was undetectable for the other samples tested.   
The P2-2c line was therefore the only one showing significant Cre recombinase 
transgene expression coupled with the lack of exogenous viral OCT4 expression. 
 
 
 
Figure 8-13 Map of a lentiviral 4-in-1 human OSKM polycistronic vector with 
location of primers used to amplify short and long viral cassette products. 
Approximate primer positions are indicated with the red arrows. The short viral 
cassette product was amplified with EF1α (forward) and OCT4 Endo (reverse) 
primer set. The long product was amplified with EF1α (forward) and OCT4 Total 
(reverse) primers. (Adapted from http://www.allelebiotech.com/4-in-1-lentiviral-
particles-for-ipscs-generation-human-oskm/). 
 
        EF1α     
OCT4   OCT4             
Endo     Total                 
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             L     H9    P     1     2     3     C     4      5      6      7      8      9     10    11    12     N 
A 
 
              L    H9    P     1      2     3     C     4      5      6     7     8      9    10    11   12     N 
B 
 
           L       H9    P     1     2     3     C     4      5      6      7      8      9     10    11    12     N 
C 
 
             L     H9    P     1     2     3     C     4      5      6      7      8      9     10    11    12     N 
D 
 
 
Figure 8-14 PCR-mediated detection of: (A) the short viral cassette product 
(~250 bp); (B) the long viral cassette product (~600 bp); (C) Cre-recombinase 
transgene (113 bp); and (D) GAPDH housekeeping gene as the loading control 
(133 bp). Legend: L = Hyperladder IV; H9 = ESC H9 line; P = P2-2 hiPSC line; 1 = 
P2-2a; 2 = P2-2b; 3 = P2-2c; C = C-1 hiPSC line; 4 = C-1a; 5 = C-1b; 6 = C-1c; 7 = 
C-1d; 8 = C-1e; 9 = C-1f; 10 = C-1g; 11 = C-1h; 12 = C-1i; N = water.    
300 bp 
200 bp 
 
 
 
 
 
700 bp 
600 bp 
 
 
 
 
 
 
 
 
 
 
 
200 bp 
100 bp 
 
 
 
 
 
 
 
200 bp 
100 bp 
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                                                       before Cre                        after Cre 
 
 
                         before Cre                                              after Cre 
 
Figure 8-15 Expression levels of total and exogenous OCT4 transcripts in hiPSC 
lines and H9 hESC line. (A) The P1 hiPSC lines before and after Cre-mediated 
loxP sites excision; (B) Control hiPSC lines before and after Cre-mediated loxP 
sites excision. Expression levels of OCT4 transcripts are normalized to GAPDH and 
RPL13A housekeeping genes, and calculated relatively to expression in H9 hESC 
line. The exogenous (viral) OCT4 expression is estimated from the difference 
between total and endogenous OCT4 expression levels. The error bars indicate the 
standard errors of the mean (SEM).  
 
A 
 
 
 
 
 
 
 
 
B 
 
Generation of hiPSCs from OPA1-Mutant Human Fibroblasts 
 
 
241 
 
 
Figure 8-16 Cre recombinase transgene expression in puromycin-resistant 
hiPSC lines and H9 ESC line. Expression levels of Cre recombinase transgene are 
normalized to GAPDH and RPL13A housekeeping genes, and relative to the highest 
expression demonstrated by the P2-2a hiPSC line. Significant Cre expression levels 
were observed in the P2-2a and P2-2b hiPSC lines. The expression levels for the 
remaining samples were calculated from the Ct values > 35 and therefore can be 
considered within the qPCR assay noise. The error bars indicate the standard errors 
of the mean (SEM).   
 
8.4 Discussion 
We have demonstrated the feasibility of generating and characterising OPA1-mutant 
hiPSC lines using a lentiviral transduction protocol based on the four pluripotency 
factors (OCT4, SOX2, KLF4 and c-MYC). The efficiency of viral-mediated 
reprogramming in this study was similar to those previously reported in other recent 
studies (Armstrong et al., 2010; Jiang et al., 2012). Although relatively low, the 
transduction efficiency was sufficient to obtain multiple hiPSC clones from all 
parental fibroblast lines, with the exception of the P3 line, where only one hiPSC 
clone was generated (Table 8-5). Importantly, all the generated hiPSC clones had the 
typical morphological features of hESCs. The in vitro characterisation of the selected 
hiPSC lines confirmed that the specific OPA1 mutations present in the original 
fibroblast lines were retained through the reprogramming procedure. Based on the 
fingerprinting analysis, the hiPSC lines had similar DNA profiles to their original 
fibroblast lines. Karyotype analysis revealed chromosomal abnormalities in 10% of 
the metaphase cells from the control ((15;21)(q10;q10) translocation) and the P1 
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(chromosome 8 trisomy) fibroblast lines. However, these chromosomal aberrations 
were importantly not observed in the hiPSC lines derived from these two fibroblast 
lines, indicating that they must have originated from the chromosomally-normal 
parental fibroblasts. These observations agree with the theory suggesting that 
reprogramming per se can exert a selective pressure on the genetically or 
epigenetically impaired cells of the donor population, resulting in karyotypically-
normal hiPSC lines (Kawamura et al., 2009).   
All derived hiPSC lines showed characteristic expression of both the nuclear (OCT4, 
SOX2) and the cell surface (SSEA-4, TRA-1-81) pluripotency markers, similar to 
previously-published patterns for different fibroblast-derived hiPSCs (Armstrong et 
al., 2010; Jiang et al., 2012). The significant endogenous and exogenous expression 
of both OCT4 and c-MYC transcripts confirmed successful viral transduction of these 
pluripotency genes. Following hiPSC generation, the virally-mediated expression of 
the pluripotent genes (OCT4, SOX2, KLF4 and c-MYC) used in this reprogramming 
protocol has to be suppressed as this can affect the future differentiation properties of 
the generated hiPSC lines (Soldner et al., 2009; Hu et al., 2010). For example, it has 
previously been shown that the residual expression of c-MYC and OCT4 transgenes 
can inhibit the differentiation efficiency of hiPSC lines (Yu et al., 2007; Armstrong 
et al., 2010). To allow the removal of these viral transgenes, modified lentiviral 
polycistronic vectors carrying loxP sites were used in this study. The elimination of 
integrated transgenes by the Cre-loxP-mediated recombination system should allow 
the creation of vector-free hiPSCs (Soldner et al., 2009). Following puromycin 
selection, twelve hiPSC clones were obtained for two original hiPSC lines: C-1 and 
P-2. Interestingly, although all these hiPSC lines expressed the puromycin resistance 
transgene, only two of these showed detectable (albeit low) expression of the Cre 
transgene (P2-2a and P2-2b; Figure 8-16). The puromycin resistance and Cre 
transgenes were under the control of two separate promoters: hUbC (human ubiquitin 
C) and mPGK (murine phosphoglycerate kinase), respectively (Figure 8-2). As 
studied previously, activities of these two promoters may however be restricted to 
specific hESC/hiPSC lineages (Norrman et al., 2010). It is therefore conceivable that 
although the hUbC promoter was active in all puromycin-resistant hiPSC lines, the 
mPGK promoter could have become methylated in some of them, leading to the lack 
of Cre transgene expression. The RT-PCR analyses revealed persistent significant 
expression of the exogenous OCT4 transcript in all puromycin-selected hiPSCs lines, 
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with the exception of P2-2b and P2-2c (Figure 8-15). Only the P2-2b hiPSC line 
showed significant Cre transgene expression in conjunction with a reduction in 
exogenous OCT4 expression. However, the PCR-based detection used (Figure 8-14) 
still indicated the presence of the viral OCT4 amplicons in the P2-2b line. The 
discrepancy between these two assays could be explained by the integration of the 
lentiviral polycistronic vectors into genomic regions, which after successful 
reprogramming became tightly-packed heterochromatin. The standard PCR would 
still detect the viral signature, but being in non-expressed genomic regions, no 
mRNA transcripts are produced, explaining the lack of detection with the qPCR 
assay used in this study.   
The incomplete excision of the loxP flanked transgenes in the selected puromycin-
resistant hiPSC lines was also probably due to the high volume of lentiviral 
integrations, making the complete removal of all these viral cassettes impossible 
when only relatively low levels of Cre transgene expression were achieved (Soldner 
et al., 2009). To address this issue, a second round of hiPSCs nucleofection with the 
puro-Cre plasmids is planned. To enhance the efficiency of this process, the 
concentration of plasmids will be increased from 10µg to 20µg/10
6
 hiPSCs. 
Following successful removal of the viral vectors, the differentiation capability and 
developmental potential of the generated hiPSCs will be tested in vitro, by generating 
embryoid bodies (EBs) of all three embryonic germ layers, and in vivo, by injecting 
hiPSCs into mouse kidney capsules and allowing them to form teratomas containing 
cell types representative of all three primordial germ layers (Yu et al., 2007; 
Armstrong et al., 2010; Boulting et al., 2011).       
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Mitochondria only have limited genetic autonomy and they rely heavily on a 
complex array of nuclear-encoded mitochondrial proteins for their normal function 
(Zeviani et al., 2003). The complexity of this synergistic nuclear-mitochondrial 
interaction is magnified by the multifunctional nature of these nuclear-encoded 
mitochondrial proteins. The heterogeneous clinical presentation of nuclear 
mitochondrial disorders remains as yet unexplained, and even more intriguingly,  
mitochondrial dysfunction seems to have a marked predilection for the optic nerve, 
causing degeneration of the RGC layer and ultimately progressive blindness (Yu-
Wai-Man et al., 2011b). It has become apparent over the past decade that disturbed 
mitochondrial dynamics represents an important group of human disease, in which 
optic atrophy again features strongly. The classical example is DOA, a nuclear 
mitochondrial disorder that disrupts the normal function of OPA1 – a critical inner 
mitochondrial membrane protein with pro-fusion properties. In this PhD thesis, I 
have further investigated the disease mechanisms underlying nuclear disorders of 
mtDNA maintenance by focusing on three main nuclear genes: OPA1, MFN2, and 
POLG1.  
OPA1 and MFN2 encode dynamin-like GTPase proteins intrinsically associated with 
the fusion of the IMM and OMM, respectively (Chen et al., 2003; Meeusen et al., 
2004; Meeusen et al., 2006). About 20% of OPA1 mutation carriers will develop a 
more severe multi-systemic neurological phenotype (DOA+) comprising 
sensorineural deafness, ataxia, myopathy, and peripheral neuropathy, in addition to 
progressive visual failure (Yu-Wai-Man et al., 2010b). Besides its critical pro-
fusional properties, OPA1 is a multifunctional protein that regulates a number of 
crucial interrelated cellular processes. These include an integral role in maintaining 
the assembly and stability of the mitochondrial respiratory chain complexes (Zanna 
et al., 2008), the regulation of programmed cell death by controlling the release of 
pro-apoptotic cytochrome c molecules (Lee et al., 2004; Olichon et al., 2007), and 
mtDNA maintenance through a direct physical contact with mtDNA molecules 
(Wang and Bogenhagen, 2006; Elachouri et al., 2011). MFN2 mutations typically 
cause a dominantly-inherited neurodegenerative disorder – CMT-2A (Züchner et al., 
2004). Interestingly, the observed clinical features can overlap with those seen in 
OPA1-related DOA+ phenotypes, some affected MFN2 carriers developing a 
progressive axonal sensorimotor neuropathy complicated by optic atrophy and other 
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neurological features such as deafness, cerebellar ataxia and proximal myopathy 
(Rouzier et al., 2012). POLG1 encodes the catalytic subunit of DNA polymerase 
gamma (POLG) and it is the most frequently-identified causative nuclear gene 
among patients with mtDNA maintenance disorders, accounting for ~25% of all 
cases (Chinnery and Zeviani, 2008). The disease phenotypes associated with POLG1 
mutations are highly varied, ranging from early-onset AHS to ataxia and late-onset 
isolated CPEO. A characteristic molecular signature shared by mutations in OPA1, 
MFN2 and POLG1 is the disturbed mtDNA maintenance, with clinically affected 
patients showing both quantitative (depletion) and qualitative (point mutations and 
deletions) secondary mtDNA abnormalities in a range of tissue samples. 
Significant mtDNA proliferation was observed in peripheral blood leukocytes of 
patients harbouring confirmed pathogenic OPA1 and MFN2 mutations (Chapter 4). 
A similar observation was made when measuring mtDNA copy number in single 
muscle fibres laser-microdissected from a MFN2-positive muscle biopsy specimen 
(Chapter 5), with a significant mitochondrial proliferative response being present in 
both COX-positive and COX-negative muscle fibres. Previous work in our group has 
shown increased mtDNA copy number in single muscle fibres from biopsy 
specimens that had been obtained from patients with a range of pathogenic OPA1 
mutations (Yu-Wai-Man et al., 2010c). These consistent experimental observations 
in two different tissue types and for both OPA1 and MFN2 mutations strongly 
support the current hypothesis that mtDNA proliferation is a normal compensatory 
cellular response to the underlying fusion and OXPHOS imbalance. 
OPA1 mutations result in the accumulation of high levels of COX-deficient muscle 
fibres in muscle biopsies from patients manifesting both pure optic atrophy and 
multisystemic DOA+ phenotypes (Amati-Bonneau et al., 2008; Hudson et al., 
2008a). The biochemical defect in these COX-deficient muscle fibres is secondary to 
high levels of somatically-acquired mtDNA deletions (Yu-Wai-Man et al., 2010b; 
Yu-Wai-Man et al., 2010c). The presence of COX-deficient fibres and multiple 
mtDNA deletions in skeletal muscle samples from patients with MFN2 mutations 
suggests the possibility of shared disease mechanisms precipitating mtDNA 
instability in both OPA1 and MFN2 disease carriers (Rouzier et al., 2012).  
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A fundamental question remains – is the accumulation of secondary mtDNA 
deletions in tissues harbouring OPA1 and MFN2 mutations due to a high rate of de 
novo mutagenesis or is it due to an increased clonal expansion rate? Following the 
formation of a mtDNA deletion, a biochemical defect is only expressed once the 
level of the mutated mtDNA species clonally expands to exceed a critical threshold 
(Chinnery and Samuels, 1999). Crucially, OPA1 and MFN2 mutations precipitate 
mitochondrial network fragmentation and this impairs the effective functional 
complementation of deleted mtDNA molecules by wild-type genomes, through the 
normal process of mitochondrial content mixing (Nakada et al., 2009; Chen et al., 
2010). Another attractive hypothesis that needs to be tested is whether mitochondrial 
network fragmentation leads to an increased rate of clonal expansion by reducing the 
effective number of mtDNA molecules in individual compartments, thereby allowing 
more rapid segregation of the deleted mtDNA species by random genetic drift 
(Chinnery and Samuels, 1999; Elson et al., 2001). 
Only 50% of COX-negative muscle fibres from the MFN2-positive muscle specimen 
had mtDNA deletion levels above the generally accepted mutational threshold 
required to induce a biochemical defect (Shoubridge et al., 1990; Bua et al., 2002; 
Durham et al., 2007) (Chapter 5). It is possible that the biochemical defect in these 
muscle fibres was secondary to the accumulation of high levels of somatic mtDNA 
point mutations, and not deletions, as it has been described previously for POLG1-
mutant patient tissues (Del Bo et al., 2003; Wanrooij et al., 2004; Chinnery and 
Zeviani, 2008; Reeve et al., 2008). The future use of high-throughput next-generation 
sequencing should allow for a precise characterisation of the range of mtDNA 
abnormalities (both mutations and deletions) present in tissue samples collected from 
patients with OPA1 and MFN2 mutations, as these could have been missed by the 
technical limitations inherent to standard methods such as Sanger sequencing and 
quantitative real-time PCR (Zaragoza et al., 2010).    
The effect of OPA1 and POLG1 mutations on mtDNA replication efficiency was 
assessed in patient fibroblast cell lines using a previously-validated EtBr-based 
mtDNA repopulation assay (Chapter 7). Our repopulation data revealed a clear 
distinction between POLG1 and OPA1 mutant cell lines. Following EtBr-induced 
depletion, the mtDNA content of POLG1 cell lines remained markedly depressed, a 
finding which reinforces the central importance of POLG in promoting efficient 
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mtDNA replication (Graziewicz et al., 2006; Stewart et al., 2011). OPA1 cell lines 
also exhibited impaired mtDNA repopulation following EtBr removal. However, 
OPA1 cell lines repopulated to ~20% of their baseline values, which was 
significantly higher compared with POLG1 cell lines. Interestingly, there were some 
apparent differences between the various familial OPA1 mutations, which were not 
clearly linked to the severity of the clinical phenotype. The basis for the varied 
clinical presentations of OPA1 mutations cannot therefore be explained on the basis 
of the efficiency of mtDNA repopulation following withdrawal of EtBr. The striking 
difference in the kinetics of mtDNA repopulation between the OPA1 and POLG1 
mutational groups, highlights the distinct roles played by their respectively encoded 
proteins in the complex process that regulates mtDNA replication (Hudson and 
Chinnery, 2006; Elachouri et al., 2011).  
To examine the link between mitochondrial network morphology and mtDNA 
content, a comprehensive quantitative analysis of the mitochondrial network was 
performed on OPA1- and POLG1-mutant cell lines (Chapter 7). A number of 
pathogenic OPA1 mutations have previously been associated with increased 
fragmentation of the mitochondrial network (Olichon et al., 2007; Zanna et al., 2008; 
Agier et al., 2012; Chevrollier et al., 2012). A recently published study has also 
documented increased mitochondrial network fragmentation in OPA1-mutant human 
fibroblasts as a response to glucose deprivation in the culture media or the 
application of exogenous oxidative stress (Agier et al., 2012). OPA1-mutant cell 
lines investigated in our study did not demonstrate marked fragmentation 
phenotypes. This finding was probably related to the fact that these cells were 
cultured in media containing a high glucose content, which allowed for a deficient 
mitochondrial OXPHOS system to be bypassed, at least to a certain extent, by 
glycolysis (Robinson et al., 1992; D'Aurelio et al., 2001). In support of this 
argument, significant mitochondrial network fragmentation in OPA1 fibroblasts was 
only observed when cells were forced to rely exclusively on OXPHOS for ATP 
production e.g. when cultured in glucose-free (galactose) media (Zanna et al., 2008). 
Our study is the first to objectively quantify mitochondrial network morphology in 
POLG1-mutant fibroblasts. The results revealed marked mitochondrial network 
fragmentation in POLG1-mutant cell lines following EtBr-induced mtDNA 
depletion. Although speculative, it is likely that this disruption in mitochondrial 
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network morphology was triggered by a bioenergetic crisis, which was perpetuated 
by the subsequent failure of mtDNA repopulation on withdrawal of EtBr from the 
culture media. Interestingly, a significant increase in the total length of the 
mitochondrial network was observed in both POLG1 and OPA1 mutant fibroblasts. 
This overall elongation of the mitochondrial network could have been triggered by 
the underlying mitochondrial respiratory chain defect in these mutant cell lines. This 
physical increase in the surface area available for OXPHOS could, to a certain 
extent, compensate for the deleterious biochemical consequences of POLG1 and 
OPA1 mutations. It should be noted that both cell size and shape can be crucial 
factors influencing the overall morphology of the mitochondrial network, and these 
were not controlled for in our study (Chevrollier et al., 2012). In a series of elegant 
experiments, Chevrollier and colleagues have recently showed that skin fibroblasts 
can be successfully cultured in micropatterned coverslips, with this technique 
allowing cell morphology to be standardised. The specific micropattern that was used 
allowed the cells to spread over a defined surface area, so that they finally adopted 
equilateral triangular shapes (Chevrollier et al., 2012). It would be interesting to 
repeat future mtDNA repopulation experiments with additional POLG1 and OPA1 
mutant cell lines using these micropatterned coverslips, and to see whether the main 
findings from our current study on the effect of mtDNA depletion on mitochondrial 
network morphology are replicated.   
Neuromyelitis optica (NMO) is an idiopathic, autoimmune, demyelinating condition 
of the CNS that, rather strikingly, preferentially affects the optic nerve and spinal 
cord (Wingerchuk et al., 2007). Given that NMO shares overlapping clinical features 
with OPA1-related DOA+ phenotype, our a priori hypothesis was that OPA1 genetic 
variants could influence the development of NMO. However, we did not find any 
pathogenic OPA1 mutations or any specific SNP associations in relation to the risk of 
developing NMO (Chapter 6). It is possible that the relatively small sample size of 
our study did not have enough statistical power to identify a minor genetic influence. 
However, NMO is a relatively rare CNS disorder and the major genetic influence of 
OPA1 on the development of this demyelinating disease can be excluded.  
The lack of access to diseased optic nerve and the technical difficulties in isolating 
RGCs have been major obstacles in uncovering the disease mechanisms which lead 
to a progressive visual loss among patients with mitochondrial optic neuropathies. As 
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an alternative to mouse models, our aim was to generate hiPSC lines harbouring 
pathogenic OPA1 mutations, which would then allow the generation of RGCs for the 
future mechanistic studies. In this thesis, we present data confirming the generation 
of hiPSC lines from three patient-derived fibroblast lines harbouring two different 
pathogenic OPA1 mutations (Chapter 8). However, the complete removal of the 
viral vectors used to induce pluripotency has proven technically challenging. The 
differentiation of RGCs from these hiPSCs should ideally take place in a viral-free 
cellular environment, as the residual viral remnants could result in sustained 
pluripotent gene expression, with possible aberrant consequences for differentiation 
properties of hiPSCs (Soldner et al., 2009; Hu et al., 2010). If future repeat attempts 
at clearing the remaining viral transgenes prove unsuccessful, an alternative strategy 
would involve reprogramming the original OPA1 fibroblast cell lines using 
alternative transduction vectors. Since the original Takahashi and Yamanaka’s 
protocol (Takahashi and Yamanaka, 2006; Takahashi et al., 2007) was published, 
several techniques have been developed to allow for the generation of transgene-free 
hiPSCs, including non-integrating adenoviruses (Zhou and Freed, 2009), nonviral 
minicircle DNAs (Jia et al., 2010) and proteins (Kim et al., 2009; Zhou et al., 2009). 
However, the major disadvantages of these methods are the low transduction 
efficiency and the requirement for repeated inductions of reprogramming vectors 
(Ban et al., 2011). An attractive alternative strategy to generate hiPSCs involves the 
use of Sendai virus (SeV) vectors (Fusaki et al., 2009). These RNA-based viral 
vectors only replicate within the cytoplasm of infected cells and importantly, they do 
not integrate into the host genome (Li et al., 2000). SeV vectors have been 
successfully applied to efficiently generate hiPSCs from human fibroblasts (Fusaki et 
al., 2009; Macarthur et al., 2012; Nakamura et al., 2012). After successful 
reprogramming has taken place, the SeV vectors are gradually diluted during the 
rapid cell division of hiPSCs, and this process is normally completed within eight to 
twelve passages (Fusaki et al., 2009; Kudva et al., 2012). The generation of RGCs 
harbouring a range of pathogenic OPA1 mutations will be a major step in dissecting 
the fundamental disease mechanisms that precipitate the range of clinical phenotypes 
seen in patients with DOA. This disease is the most common inherited optic 
neuropathy in the general population and it causes progressive irreversible blindness 
from early childhood (Yu-Wai-Man et al., 2011b). The in vitro characterisation of 
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RGCs in both pure DOA and DOA+ disease models will hopefully provide a 
powerful tool to screen for neuroprotective agents that could prove beneficial to 
patients affected with this debilitating disorder.    
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Appendix A 
 
 
Table A-1 OPA1 mutations identified in our patient cohort. 
Mutation (AA change) Type Functional Domain N = 
c.32+1G>A* Splice - 4 
p.R38_S43del In-frame Deletion Basic 2 
p.F119X Nonsense Basic 2 
p.A192GfsX36 Frameshift Basic 1 
p.S210X Nonsense Basic 3 
p.K212RfsX4 Frameshift Basic 2 
p.K214fsX2 Frameshift Basic 1 
p.R231NfsX21 Frameshift Basic 2 
p.E242X Nonsense Basic 2 
p.S256R Missense Basic 4 
p.K262_R290del In-frame Deletion Basic 4 
p.I265TfsX42 Frameshift Basic 1 
p.V291_K328del In-frame Deletion GTPase 20 
p.V294fsX667 Frameshift GTPase 6 
p.Q297X Nonsense GTPase 3 
p.T302P Missense GTPase 2 
p.L331LfsX3 Frameshift GTPase 2 
c.1065+1G>A* Splice - 1 
p.L384fsX397 Frameshift GTPase 2 
p.R366X Nonsense GTPase 2 
p.P400L Missense GTPase 1 
c.1212+3A>T* Splice - 1 
p.I432V Missense GTPase 3 
p.D438V Missense GTPase 4 
p.D442N Missense GTPase 1 
p.A443T Missense GTPase 2 
p.G459E Missense GTPase 1 
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Mutation (AA change) Type Functional Domain N = 
p.K468E Missense GTPase 2 
c.1516+1G>T* Splice - 3 
p.I515KfsX4 Frameshift Middle 1 
p.S545R Missense Middle 3 
p.Q563X Nonsense Middle 1 
p.M555NfsX7 Frameshift Middle 1 
c.1770+2T>G* Splice - 1 
p.W660X Nonsense Middle 1 
p.D662VfsX9 Frameshift Middle 1 
p.E671EfsX675 Frameshift Middle 1 
c.2013+1G>C* Splice - 1 
p.R711X Nonsense Middle 1 
c.2167-12T>A* Splice - 1 
p.R733X Nonsense Middle 1 
p.F747LfsX53 Frameshift Middle 2 
p.E749X Nonsense Middle 1 
c.2496+1G>T* Splice - 1 
c.2496+4_2496+5delinsGT
AAC* 
Splice - 3 
p. L832F Missense Middle 1 
p.Y841X Nonsense Middle 1 
p.L872_Q884del In-frame Deletion Middle 1 
c.2613+1G>A* Splice - 5 
c.2613+1G>C* Splice - 2 
p.A888GfsX15 Frameshift Middle 1 
c.2707+1G>C* Splice - 3 
p. V903GfsX3 Frameshift Coiled-Coil 2 (CC2) 20 
p.R905X Nonsense Coiled-Coil 2 (CC2) 7 
c.2818+5G>A* Splice - 3 
p.E947EfsX2 Frameshift Coiled-Coil 2 (CC2) 1 
*The consequences of these splice site OPA1 mutations on the resulting mRNA transcripts have not 
yet been determined and deposited on the eOPA1 database 
(http://lbbma.univangers.fr/lbbma.php?id=9). 
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Table A-2 MFN2 mutations identified in our patient cohort.  
Mutation (AA change) Type Functional Domain N = 
p.E65X Nonsense - 3 
p.R94W Missense - 8 
p.R94Q Missense - 2 
p.A100G Missense GTPase 1 
p.R104L Missense GTPase 3 
p.R104W Missense GTPase 1 
p.T105A Missense GTPase 1 
p.H165Y Missense GTPase 6 
p.G202A Missense GTPase 4 
p.T206I Missense GTPase 2 
p.T232N Missense GTPase 1 
p.R250Q Missense GTPase 1 
p.R259C Missense GTPase 1 
p.R280H Missense GTPase 1 
p.G298R Missense GTPase 1 
p.E308X* Nonsense GTPase 1 
p.R364W Missense Coiled-Coil 1 (CC1) 1 
p.R364P Missense Coiled-Coil 1 (CC1) 1 
p.R364Q Missense Coiled-Coil 1 (CC1) 1 
p.M376V Missense Coiled-Coil 1 (CC1) 1 
p.M376I Missense Coiled-Coil 1 (CC1) 1 
p.A383V Missense Coiled-Coil 1 (CC1) 1 
p.R468H Missense - 2 
p.D496G Missense - 2 
p.R519P* Missense - 1 
p.L673P Missense - 3 
p.V705I Missense Coiled-Coil 2 (CC2) 2 
p.R707W Missense Coiled-Coil 2 (CC2) 1 
p.R707P Missense Coiled-Coil 2 (CC2) 1 
p.A716T Missense Coiled-Coil 2 (CC2) 1 
p.H750P Missense - 1 
p.Q751X Nonsense - 1 
p.Y752X Nonsense - 1 
* One patient harboured two heterozygous MFN2 mutations. 
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Appendix B.1 
The variation in mtDNA copy number observed in untreated fibroblast cell lines at 
each analysis time point from day 0 to day 48: (i) control cell lines (Figure B-1), (ii) 
OPA1 fibroblasts (Figure B-2 and Figure B-3) and (iii) POLG1 cell lines       
(Figure B-4 and Figure B-5). The results for each experimental time point were 
calculated as the average mtDNA copy number obtained from two replicates, relative 
to the mtDNA copy number at day 0. An average mtDNA copy number value of 1.0 
at a specific experimental time point implies a similar mtDNA content to the one 
measured at the baseline.  
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Figure B-1 MtDNA copy number variation in untreated control cell lines: (A) C1, (B) C2, (C) C3, and (D) C4. Each data point represents 
the average mtDNA copy number relative to the mtDNA copy number at day 0 for two replicates. The error bars are presented as standard 
deviations (SDs).  
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Figure B-2 MtDNA copy number variation in untreated OPA1 cell lines: (A) OPA1a, (B) OPA1b, (C) OPA1c, and (D) OPA1d. Each data 
point represents the average mtDNA copy number relative to the mtDNA copy number at day 0 for two replicates. The error bars are presented as 
standard deviations (SDs).    
A 
 
 
 
 
 
C                             
B 
 
 
 
 
 
D                             
  
2
6
0
 
  
  
Figure B-3 MtDNA copy number variation in untreated OPA1 cell lines: (A) OPA1e, (B) OPA1f, (C) OPA1g, and (D) OPA1h. Each data 
point represents the average mtDNA copy number relative to the mtDNA copy number at day 0 for two replicates. The error bars are presented as 
standard deviations (SDs).    
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Figure B-4 MtDNA copy number variation in untreated POLG1 cell lines: (A) 
POLG1a, (B) POLG1b and (C) POLG1c. Each data point represents the average 
mtDNA copy number relative to the mtDNA copy number at day 0 for two 
replicates. The error bars are presented as standard deviations (SDs).    
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Figure B-5 MtDNA copy number variation in untreated POLG1 cell lines: (A) 
POLG1d, and (B) POLG1e. Each data point represents the average mtDNA copy 
number relative to the mtDNA copy number at day 0 for two replicates. The error 
bars are presented as standard deviations (SDs).   
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Appendix B.2 
 
DAY OF STUDY 6 12 18 24 30 36 42 48 
OPA1 
p.Q297X    
vs. 
OPA1 p.I432V < 0.0001 0.6030 0.0006 0.0123 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
OPA1 p.V294fsX667 < 0.0001 0.5132 0.0120 0.1963 0.0013 < 0.0001 0.0034 0.0001 
OPA1 Splice 0.0037 0.2419 0.9279 0.4152 0.5946 0.1178 0.1084 0.1687 
OPA1 
p.I432V     
vs. 
OPA1 p.V294fsX667 0.2547 0.8451 0.0487 0.0375 0.0086 0.0114 0.0004 0.2355 
OPA1 Splice < 0.0001 0.0680 0.1592 0.0049 0.0033 < 0.0001 0.0019 0.0037 
OPA1 
Splice vs. 
OPA1 p.V294fsX667 < 0.0001 0.0323 0.0432 0.0004 0.0008 < 0.0001 < 0.0001 < 0.0001 
Figure B-6 MtDNA depletion and repopulation curves for OPA1 cell lines 
grouped into familial mutational subgroups: OPA1 p.Q297X (N = 3), OPA1 
p.I432V (N = 2), OPA1 p.V294fsX667 (N = 2) and OPA1 splice (N =1). Each data 
point represents the average mtDNA copy number ratio of EtBr-treated to untreated 
cells. The error bars are presented as the standard errors of the mean (SEM). The 
table presents the P values of the statistical comparisons between all mutational 
subgroups. The intensity of the red shading correlates with the degree of statistical 
significance. 
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Appendix C.1 
Mitochondrial network parameters (the total length of the mitochondrial network per 
cell, the average length of a mitochondrial fragment, and the number of 
mitochondrial fragments per cell) at each experimental point, in individual POLG1 
lines compared with the mean control. Please refer to Section 7.4.2 for details.   
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A                      Total Length B                   Average Length C               Number of Fragments 
   
Figure C-1 Comparison of the mitochondrial network parameters between the POLG1a line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the POLG1a line and the 
mean control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    NS – non-significant at P = 0.5022, * - refers to P = 0.0162, ** - refers to P = 0.0068;  
Average length:   NS – non-significant at P = 0.9484 (day 0) and P = 0.1640 (day 15), ** - refers to P = 0.0057;  
Number of fragments:  NS – non-significant at P = 0.5624, * - refers to P = 0.0473, ** - refers to P = 0.0041.   
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A                      Total Length B                   Average Length C               Number of Fragments 
   
Figure C-2 Comparison of the mitochondrial network parameters between the POLG1b line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the POLG1b line and the 
mean control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM). Data points for 
the POLG1b cell line were unavailable at day 45 due to the premature death of the POLG1b EtBr-treated fibroblasts before that sampling point.  
Total length:    NS – non-significant at P = 0.5655, *** - refers to P < 0.0001; 
Average length:   NS – non-significant at P = 0.8427, * - refers to P = 0.0142;   
Number of fragments:  NS – non-significant at P = 0.2401, *** - refers to P = 0.0004. 
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A                      Total Length B                   Average Length C               Number of Fragments 
   
Figure C-3 Comparison of the mitochondrial network parameters between the POLG1c line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the POLG1c line and the 
mean control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM Data points for 
the POLG1c cell line were unavailable at day 45 due to the premature death of the POLG1c EtBr-treated fibroblasts before that sampling point.  
Total length:    NS – non-significant at P = 0.8454 (day 0) and P = 0.8946 (day 15); 
Average length:   NS – non-significant at P = 0.1307, ** - refers to P = 0.0035;  
Number of fragments:  NS – non-significant at P = 0.6098 (day 0) and P = 4314 (day 15). 
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A                      Total Length B                   Average Length C               Number of Fragments 
   
Figure C-4 Comparison of the mitochondrial network parameters between the POLG1d line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the POLG1d line and the 
mean control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    NS – non-significant at P = 0.7993 (day 0), P = 0.6402 (day 15) and P = 0.9607 (day 45); 
Average length:   NS – non-significant at P = 0.4646 (day 0) and P = 0.5535 (day 15), *** - refers to P < 0.0001;   
Number of fragments:  NS – non-significant at P = 0.9443 (day 0), P = 0.6079 (day 15) and P = 0.1917 (day 45).   
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A                      Total Length B                   Average Length C               Number of Fragments 
   
Figure C-5 Comparison of the mitochondrial network parameters between the POLG1e line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the POLG1e line and the 
mean control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    NS – non-significant at P = 0.7495, * - refers to P = 0.0300 (day 0) and P = 0.0168 (day 45);  
Average length:   NS – non-significant at P = 0.0854, ** - refers to P = 0.0047, *** - refers to P = 0.0002;  
Number of fragments:  NS – non-significant at P = 0.7522, ** - refers to P = 0.0029, *** - refers to P = 0.0002. 
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Appendix C.2 
Mitochondrial network parameters (the total length of the mitochondrial network per cell, 
the average length of a mitochondrial fragment, and the number of mitochondrial 
fragments per cell) at each experimental point, in individual OPA1 lines compared with 
the mean control. Please refer to Section 7.4.3 for details. 
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Figure C-6 Comparison of the mitochondrial network parameters between the OPA1a line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the OPA1a line and the mean 
control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    NS – non-significant at P = 0.2573 (day 15) and P = 0.2186 (day 45), * - refers to P = 0.0244; 
Average length:   NS – non-significant at P = 0.0503 (day 0) and P = 0.9847 (day 15), *** - refers to P = 0.0002;  
Number of fragments:  NS – non-significant at P = 0.1967, * - refers to P = 0.0350, *** - refers to P = 0.0002.  
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Figure C-7 Comparison of the mitochondrial network parameters between the OPA1b line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the OPA1b line and the mean 
control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    * - refers to P = 0.0350, *** - refers to P = 0.0003 (day 0) and P < 0.0001 (day 45);  
Average length:   NS – non-significant at P = 0.7992 (day 15) and P = 0.1692 (day 45), *** - refers to P < 0.0001;  
Number of fragments:  * - refers to P = 0.0320, *** - refers to P < 0.0001 (day 0) and P = 0.0002 (day 45). 
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Figure C-8 Comparison of the mitochondrial network parameters between the OPA1c line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the OPA1c line and the mean 
control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    NS – non-significant at P = 0.4598, * - refers to P = 0.0321, *** - refers to P < 0.0001; 
Average length:   NS – non-significant at P = 0.2336, ** - refers to P = 0.0012, *** - refers to P = 0.0007;  
Number of fragments:  NS – non-significant at P = 0.0727, ** - refers to P = 0.0038, *** - refers to P < 0.0001.  
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Figure C-9 Comparison of the mitochondrial network parameters between the OPA1d line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the OPA1d line and the mean 
control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    NS – non-significant at P = 0.2229 (day 0), P = 0.4379 (day 15) and P = 0.1135 (day 45); 
Average length:   NS – non-significant at P = 0.4405, * - refers to P = 0.0443 (day 0) and P = 0.0174 (day 45);  
Number of fragments:  NS – non-significant at P = 0.3445 (day 0), P = 0.6366 (day 15) and P = 0.0915 (day 45). 
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Figure C-10 Comparison of the mitochondrial network parameters between the OPA1e line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the OPA1e line and the mean 
control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    ** - refers to P = 0.0044, *** - refers to P < 0.0001 (day 0) and P = 0.0007 (day 15); 
Average length:   NS – non-significant at P = 0.1990 (day 0), P = 0.1393 (day 15) and P = 0.9311 (day 45);  
Number of fragments:  * - refers to P = 0.0130 (day 15) and P = 0.0427 (day 45), *** - refers to P < 0.0001. 
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Figure C-11 Comparison of the mitochondrial network parameters between the OPA1f line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the OPA1f line and the mean 
control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    NS – non-significant at P = 0.4006 (day 15) and P = 0.6519 (day 45), *** - refers to P < 0.0001; 
Average length:   NS – non-significant at P = 0.6595, * - refers to P = 0.0294, *** - refers to P = 0.0009;  
Number of fragments:  NS – non-significant at P = 0.4063 (day 15) and P = 0.6545 (day 45), *** - refers to P < 0.0001. 
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Figure C-12 Comparison of the mitochondrial network parameters between the OPA1g line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the OPA1g line and the mean 
control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    NS – non-significant at P = 0.7556 (day 15) and P = 0.0760 (day 45), ** - refers to P = 0.0052; 
Average length:   NS – non-significant at P = 0.1020 (day 0) and P = 0.2351 (day 15), ** - refers to P = 0.0027;  
Number of fragments:  NS – non-significant at P = 0.8324 (day 15) and P = 0.8702 (day 45), * - refers to P = 0.0231. 
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Figure C-13 Comparison of the mitochondrial network parameters between the OPA1h line and the mean control: (A) average total 
length of the mitochondrial network per cell, (B) average length of a mitochondrial fragment, and (C) average number of mitochondrial 
fragments per cell. The level of statistical significance at each time point is indicated for the comparison between the OPA1h line and the mean 
control. Each data point represents the mean value with the error bars representing the standard errors of the mean (SEM).  
Total length:    NS – non-significant at P = 0.8384 (day 0), P = 0.9297 (day 15) and P = 0.2499 (day 45); 
Average length:   NS – non-significant at P = 0.0547 (day 0) and P = 0.3436 (day 15), *** - refers to P < 0.0001;  
Number of fragments:  NS – non-significant at P = 0.5022 (day 0), P = 0.6070 (day 15) and P = 0.4047 (day 45).  
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OPA1 MUTATIONS INDUCE mtDNA
PROLIFERATION IN LEUKOCYTES OF
PATIENTS WITH DOMINANT OPTIC ATROPHY
OPA1mutations cause autosomal dominant optic atro-
phy (DOA), a debilitating mitochondrial optic neurop-
athy characterized by irreversible loss of retinal ganglion
cells (RGCs) and progressive visual failure starting in
early childhood.1 Interestingly,20% ofOPA1 carriers
will develop a more severe form of the disease, DOA,
where the optic atrophy is compounded by additional
neurologic features.1 OPA1 is a multifunctional
mitochondrial inner membrane protein, and rather
unexpectedly, high levels of cytochrome c oxidase (COX)-
negative muscle fibers were recently identified in biopsy
specimens from patients manifesting both the pure and
syndromal phenotypes.2,3 These COX-negative muscle
fibers harbored high levels of somatically acquiredmito-
chondrial DNA (mtDNA) deletions and marked
mtDNA proliferation was also observed, clearly reveal-
ing OPA1 to be a novel disorder of mtDNA mainte-
nance.4 To further investigate this key pathologic
mechanism, mtDNA copy number was quantified in
blood leukocytes from 3 independent patient cohorts
with molecularly confirmedOPA1mutations.
Methods. Using different extraction protocols (Method
e-1 on theNeurology®Web site at www.neurology.org),
total genomic DNA was isolated from the leukocyte
fraction of venous blood from 3 groups of patients har-
boring pathogenic OPA1 mutations: 1) British cohort
(n  61), 2) German cohort (n  40), and 3) Danish
cohort (n  49). Relative mtDNA copy number was
determined using the MyiQTM real-time PCR detec-
tion system (BioRad, Hercules, CA).5 The presence of
multiple mtDNA deletions was investigated in a sub-
group of 22 BritishOPA1-positive DNA samples using
long-range PCR.1 Visual acuity was measured using a
standard Snellen vision chart (Method e-2).
Standard protocol approvals, registrations, and patient
consents. This study had the relevant institutional eth-
ical approval and complied with the Declaration of
Helsinki.
Results. Blood leukocytes from British OPA1-
positive patients had significantly higher mtDNA
copy numbers compared with controls (figure 1A).
In the British cohort, there was no significant differ-
ence in total mtDNA content between patients with
pure DOA and DOA phenotypes (figure 1B).
There was no significant correlation between pa-
tients’ visual acuity and mtDNA copy number in
blood leukocytes (figure 1C). There was evidence of
significant mtDNA proliferation in blood leukocytes
from German OPA1-positive patients (figure 1D)
and Danish OPA1-positive patients (figure e-1). On
subgroup analysis, there was no significant difference
in total mtDNA content between patients with dif-
ferent OPA1 mutation subtypes (figure e-2). Multi-
ple mtDNA deletions were not detected in blood
leukocytes.
Discussion. This study has revealed significant
mtDNA proliferation in blood leukocytes harboring
pathogenic OPA1 mutations in 3 independent pa-
tient cohorts. The degree of mtDNA proliferation in
blood was comparable to the 2- to 4-fold increase
in mtDNA content observed at the single fiber level
in skeletal muscle biopsies from OPA1-positive pa-
tients.4 The OPA1 protein plays a key role in the
assembly and stability of the respiratory chain com-
plexes and these pathologic findings, in both blood
and skeletal muscle, are consistent with the detri-
mental effect of OPA1 mutations on mitochondrial
oxidative phosphorylation, the increased mtDNA
copy number probably acting as a compensatory bio-
energetic mechanism.4 OPA1 mediates mitochon-
drial membrane fusion in tandem with mitofusin 2
(MFN2), which is dysfunctional in the most com-
mon, autosomal dominant, axonal form of Charcot-
Marie-Tooth disease (CMT2A).6 It is therefore
noteworthy that MFN2 mutations also triggered a
significant mtDNA proliferative response in blood,
supporting our observation for OPA1 mutations.6
Unlike skeletal muscle, multiple mtDNA deletions
were not identified in blood leukocytes from patients
with OPA1 mutations. This is likely related to the
relatively short half-life of those cells in the circula-
tion, their rapid turnover precluding the formation
and subsequent clonal expansion of somatic mtDNA
abnormalities.
The mtDNA proliferative response in OPA1-
positive blood leukocytes was not statistically differ-
ent between patients with pure optic atrophy and
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those who developed additional neurologic compli-
cations. Furthermore, irrespective of whether or not
OPA1 mutation carriers developed DOA features,
there was no correlation between absolute mtDNA
copy number and the severity of visual loss. Given
the 3-fold increased risk of developing DOA with
missense mutations and those mutations involving
the GTPase catalytic domain, additional subgroup
analysis was carried out based on these OPA1 muta-
tional subtypes.1 No consistent significant difference
in mtDNA copy number was identified, which sug-
gests that this parameter of mitochondrial dysfunc-
tion is not associated with clinical severity per se, at
least in blood leukocytes. Paradoxically, a previous
study found relative mtDNA depletion in blood sam-
ples collected from patients with DOA. However, only
8 OPA1-positive cases were included and the observed
reduction inmtDNA copy number was relatively small,
Figure 1 MtDNA copy number analysis
(A) Comparison of total mtDNA content in blood leukocytes from the British cohort (OPA1-positive patients: mean111.3,
SD46.1, n61; controls: mean56.9, SD43.3, n87). (B) Phenotype subgroup analysis of the British patient cohort
(pure dominant optic atrophy subgroup: mean101.6, SD39.0, n36; DOA subgroup: mean125.3, SD52.6, n
25, NS with Bonferroni correction at p value  0.0471). (C) Correlation of logMAR visual acuity (VA) with total mtDNA
content in blood leukocytes from British OPA1-positive patients (Spearman rank correlation coefficient  0.08, NS at p
value  0.4081). (D) Comparison of total mtDNA content in blood leukocytes from the German cohort (OPA1-positive
patients: mean 149.8, SD 95.0, n 40; controls: mean 68.7, SD 39.4, n 44). Statistical analysis was performed
using GraphPadTM v.4 statistical software (San Diego, CA). Group comparisons were made with the unpaired t test. The
relationship between logMAR VA and total mtDNA content level was assessed with Spearman rank correlation coefficient.
***p  0.0001. NS refers to a nonsignificant p value, with p  0.0167 being the threshold level for statistical significance
after Bonferroni correction for multiple testing.
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25% of the mean control value.7 Further work is
needed to clarify the still poorly understood pathways
linking OPA1 mutations with mtDNA instability and
ultimately RGC loss in DOA.
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REVISITING THE ISSUE OF MITOCHONDRIAL DNA
CONTENTINOPTICMITOCHONDRIOPATHIES
Involvement of the visual system in mitochondrial
diseases, in particular of retinal ganglion cells
(RGCs) and the optic nerve, is very common and has
been defined “optic mitochondriopathies.”1 The
prototype is Leber hereditary optic neuropathy
(LHON, OMIM 535000), the first disease to be as-
sociated with a mitochondrial DNA (mtDNA) point
mutation and now considered the most frequent mi-
tochondrial disease.2 LHON has been joined by
dominant optic atrophy (DOA, OMIM 165500)
Kjer type, which in a large set of cases is associated
with heterozygous mutations in the nuclear gene
OPA1 encoding for a mitochondrial fusion protein.2
Both disorders have features in common: clinically
the preferential involvement of the papillomacular
bundle and central vision, biochemically a defective
respiratory chain and an increased propensity toward
apoptosis.2
Furthermore, the shared selectivity for RGCs and
the associated optic nerve has been related to the pe-
culiar arrangement of this axonal system, which is
nonmyelinated and very energy dependent in the ret-
ina, and only posterior to the anatomic constrain of
the lamina cribrosa becomes myelinated and less en-
ergy dependent.2 It has been hypothesized that this
anatomic peculiarity imposes a fine tuning of the un-
even mitochondrial distribution within the system,
particularly abundant in the nonmyelinated section.
Thus, either through an energy failure or an impaired
fusion of mitochondria, this distribution may be-
come abnormal and lead to loss of RGCs viability.2 It
has been reported that the mtDNA content of blood
cells was significantly lower in OPA1 mutant cases of
DOA compared to controls, providing an indirect
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Sir, We read with great interest the report of a Tunisian family by
Rouzier et al. (2011) describing the neurological disorder linked to
a novel heterozygous missense mutation in MFN2 (1p36.2)
(Rouzier et al., 2011). MFN2 mutations typically cause autosomal
dominant axonal Charcot–Marie–Tooth disease (CMT2A, OMIM
609260), with peripheral nerve degeneration occasionally asso-
ciated with visual failure and optic atrophy (Zuchner et al.,
2004, 2006). Interestingly, the clinical manifestations among
mutational carriers in this Tunisian family were even more variable,
ranging from asymptomatic subclinical disease to an axonal
sensorimotor neuropathy complicated by optic atrophy, deafness,
cerebellar ataxia and proximal myopathy. Furthermore, the
intriguing finding of cytochrome c oxidase (COX)-deficient fibres
and multiple mitochondrial DNA deletions in skeletal muscle
biopsies suggest that MFN2 mutations can result in disturbed
mitochondrial DNA maintenance and an overt respiratory chain
defect, in addition to marked fragmentation of the mitochondrial
network. These deleterious consequences are strikingly reminiscent
of the pathological features recently highlighted in Brain for
autosomal dominant optic atrophy due to OPA1 mutations
(Amati-Bonneau et al., 2008; Hudson et al., 2008; Yu-Wai-Man
et al., 2010a). Here, we provide additional evidence that
MFN2-associated neuropathy is a novel disorder of mitochondrial
DNA maintenance in a study of 58 probands with CMT2A and
confirmed MFN2 mutations (Table 1), compared with 131
age-matched normal controls.
Total genomic DNA was extracted from the leucocyte fraction of
venous blood samples. The average cellular mitochondrial DNA con-
tent was quantified with a SYBR GreenTM quantitative polymerase
chain reaction assay on a MyiQTM real-time polymerase chain reac-
tion detection system (Biorad), with MTND1 as the mitochondrial
template and GAPDH as the nuclear-encoded housekeeping tem-
plate (Yu-Wai-Man et al., 2010a). Relative mitochondrial DNA
copy number was derived from the difference in threshold cycle
(Ct) values obtained for MTND1 and GAPDH using the 2ð2t CÞ
equation to account for two copies of GAPDH per cell nucleus.
Mitochondrial DNA levels in the MFN2 group [mean mitochon-
drial DNA copy number = 195.7, standard deviation (SD) = 126.6,
n = 58] were significantly higher compared with controls (mean
mitochondrial DNA copy number = 60.9, SD = 42.3, n = 131,
doi:10.1093/brain/aws049 Brain 2012: 135; 1–3 | e219
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P5 0.0001) (Fig. 1A). Given the suggestion by Rouzier et al.
(2011) that MFN2 mutations involving the functional GTPase
domain were more likely to precipitate the severe multi-system
phenotype documented in their family, we performed a subgroup
analysis based on whether or not patients in our cohort harboured
mutations within the highly conserved GTPase gene region.
No significant difference was found between these two distinct
mutational subgroups (P = 0.5957) (Fig. 1B).
Although we have previously shown that variation in the differ-
ential blood cell count can affect blood-derived mitochondrial
DNA copy number (Pyle et al., 2010), the 3-fold increase in
mitochondrial DNA content detected in our MFN2 cohort was
substantially greater than the error attributable to this possible
confounding factor. Mitochondrial proliferation is a well-
recognized important diagnostic feature in skeletal muscle of
patients with a range of mitochondrial cytopathies (Taylor et al.,
2004; Aure et al., 2006). This compensatory mechanism is
thought to occur in response to an underlying cellular bioenergetic
crisis (the ‘sick mitochondrion hypothesis’), which leads to the
classical ‘ragged-red fibre’ appearance on Gomori Trichrome or
succinate dehydrogenase staining (Chinnery and Samuels, 1999;
Capps et al., 2003; Durham et al., 2007). In this study, we have
demonstrated the same phenomenon in blood leucocytes derived
from patients with MFN2 mutations. Although Rouzier et al.
(2011) determined mitochondrial DNA copy number in four
skeletal muscle biopsies, they only report on the absence of
mitochondrial DNA depletion in homogenate muscle extracts
(Table 1). Pathologically increased mitochondrial DNA levels
have been detected in laser-microdissected single skeletal muscle
fibres from patients with OPA1 mutations, this effect being
particularly marked in COX-deficient muscle fibres (Yu-
Wai-Man et al., 2010b). Given the overlapping clinical, histolo-
gical and molecular characteristics observed in these two
primary disorders of mitochondrial dynamics, it would be of
great interest to know whether mitochondrial DNA proliferation
was also present in muscle fibres from patients with MFN2 muta-
tions, especially in the two biopsies noted to have ragged-red
fibres.
MFN2 is the newest member of an expanding group of nuclear
mitochondrial disorders characterized by disturbed mitochondrial
DNA maintenance, a process which, increasingly, seems to be
intrinsically related to the state of the mitochondrial network
(Chen et al., 2010; Elachouri et al., 2011). Our observation that
MFN2 mutations cause mitochondrial proliferation in blood adds
weight to the novel disease mechanism reported by Rouzier et al.
(2011). Future work is needed to disentangle the complex
interplay between disturbed mitochondrial fusion and fission,
mitochondrial DNA instability and the eventual development of
both neurological and visual deficits in patients with CMT2A and
MFN2 mutations.
Figure 1 Comparison of mitochondrial DNA (MtDNA) blood copy number: (A) MFN2 mutational carriers compared with age-matched
normal controls; (B) patients harbouring MFN2 mutations within the GTPase domain (mean mitochondrial DNA copy number = 207.9,
SD = 150.2, n = 0 24) compared with those located outside this region (mean mitochondrial DNA copy number = 189.8, SD = 108.2,
n = 34); ***P50.0001; ns = not significant at P = 0.5957.
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Table 1 MFN2 mutations identified in our patient cohort
Mutation Type Functional domain Number of
patients
p.Glu65Stop Nonsense – 3
p.Arg94Trp Missense – 8
p.Arg94Gln Missense – 2
p.Ala100Gly Missense GTPase 1
p.Arg104Leu Missense GTPase 3
p.Arg104Trp Missense GTPase 1
p.Thr105Ala Missense GTPase 1
p.His165Tyr Missense GTPase 6
p.Gly202Ala Missense GTPase 4
p.Thr206Ile Missense GTPase 2
p.Thr232Asn Missense GTPase 1
p.Arg250Gln Missense GTPase 1
p.Arg259Cys Missense GTPase 1
p.Arg280His Missense GTPase 1
p.Gly298Arg Missense GTPase 1
p.Glu308Stopa Nonsense GTPase 1
p.Arg364Trp Missense Coiled-Coil 1 (CC1) 1
p.Arg364Pro Missense Coiled-Coil 1 (CC1) 1
p.Arg364Gln Missense Coiled-Coil 1 (CC1) 1
p.Met376Val Missense Coiled-Coil 1 (CC1) 1
p.Met376Ile Missense Coiled-Coil 1 (CC1) 1
p.Ala383Val Missense Coiled-Coil 1 (CC1) 1
p.Arg468His Missense – 2
p.Asp496Gly Missense – 2
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p.Ala716Thr Missense Coiled-Coil 2 (CC2) 1
p.His750Pro Missense – 1
p.Gln751Stop Nonsense – 1
p.Tyr752Stop Nonsense – 1
aOne patient harboured two heterozygous MFN2 mutations.
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Short Report
Genetic variations within the
OPA1 gene are not associated
with neuromyelitis optica
Kamil S Sitarz1, Patrick Yu-Wai-Man1,2, Gavin Hudson1,
Anu Jacob3, Mike Boggild3, Rita Horvath1 and
Patrick F Chinnery1
Abstract
Neuromyelitis optica (NMO) is an idiopathic demyelinating disease which predominantly affects the optic nerve and
spinal cord. Multiplex NMO pedigrees have been reported but the genetic risk factors conferring this increased familial
susceptibility have not yet been determined. OPA1 mutations have recently been identified in families with progressive
visual failure and spastic paraparesis, raising the possibility that OPA1 genetic variants could contribute to the aetiology of
NMO. We therefore screened for OPA1 in 32 patients with NMO. No pathogenic mutations were found, and none of the
13 single-nucleotide polymorphisms identified were associated with an increased risk of developing NMO.
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Introduction
Neuromyelitis optica (NMO), also known as Devic’s
disease, is an idiopathic inflammatory demyelinating
disease of the central nervous system (CNS) that
preferentially targets the optic nerve and spinal cord.1
The discovery of a specific NMO-IgG autoantibody
marker against the aquaporin-4 (AQP4) water channel
and the consistent presence of longitudinally extensive
myelitis on magnetic resonance imaging have further
refined the diagnostic criteria for this disorder.2
Recent clinicopathological studies have also revealed
striking differences between NMO and prototypic
multiple sclerosis (MS), establishing them as two dis-
tinct disease entities.3 Compared with MS, NMO is a
relatively rare cause of CNS demyelination and the
prevalence has been estimated at 0.5 to 1.0 per
100,000 among the white population.4
The localized pathology observed within the optic
nerve and spinal cord in NMO is intriguing and it is
reminiscent of the more complicated phenotypes we
have recently described in a subgroup of patients
harbouring pathogenic OPA1 mutations: the major
causative gene for autosomal dominant optic atrophy
(DOA; OMIM 165500).5 The cardinal feature of DOA
is progressive visual failure secondary to the focal loss
of retinal ganglion cell (RGC) axons and optic nerve
demyelination. However, up to 20% of OPA1 muta-
tional carriers will develop multi-system organ involve-
ment in later life, with a predilection for the neuraxis.6
In two of these families with DOAþ, the OPA1 muta-
tion segregated with both optic atrophy and a severe
progressive form of spastic paraplegia.6 Transcranial
magnetic stimulation has also revealed subclinical
demyelination of the corticospinal tract in patients
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with pure DOA, further highlighting the increased sus-
ceptibility of long neuronal pathways, including RGC
axons, in OPA1 disease.7 In one British and one French
OPA1-positive family, the probands developed an
MS-like illness, strikingly similar to the association
between the primary mitochondrial DNA mutations
causing Leber hereditary optic neuropathy and demye-
lination (Harding’s disease).6 OPA1 is an inner mito-
chondrial membrane protein, reinforcing the emerging
links between mitochondrial dysfunction, oligodendro-
cyte survival, and neurodegeneration.5 Interestingly,
multi-generational NMO pedigrees have been reported
with clinical features indistinguishable from the more
common sporadic variant.8 Candidate gene analysis has
excluded pathogenic AQP4 mutations and the major
genetic risk determinants in these familial cases
remain to the determined.8,9 Our clinical observations
relating to DOAþ therefore imply that some patients
diagnosed with NMO could be harbouring pathogenic
OPA1 mutations, or that the expression of NMO could
be influenced by specific OPA1 single-nucleotide poly-
morphisms (SNPs). To investigate these hypotheses, we
screened a large case series of patients with NMO for
possible disease-modifying OPA1 genetic variants.
Patients and methods
Study groups
Genomic DNA samples, extracted from whole blood,
were available from the following groups of white
British subjects: (i) patients with NMO (N¼ 32), iden-
tified as part of a British Neurological Surveillance Unit
(BNSU) national case ascertainment study. All these
patients fulfilled the revised diagnostic criteria,2 with
clinically and radiologically confirmed episodes of
optic neuritis and transverse myelitis.4,9 NMO anti-
AQP4 antibodies were detected in 12 of these patients;
(ii) patients with primary open angle glaucoma (POAG;
N¼ 137), diagnosed with either the high tension (HTG;
N¼ 67) or normal tension (NTG; N¼ 70) form of the
disease;10 and (iii) healthy controls (N¼ 75) with no
evidence of ophthalmological or neuromuscular disor-
ders. This study had the relevant institutional approval
and written informed consent was obtained from all of
the subjects involved.
OPA1 genotyping
The entire coding region of the OPA1 gene, including
flanking exon–intron boundaries, was amplified by the
polymerase chain reaction (PCR), using a set of 27
M13-tagged primer pairs, which is available on request.
PCR products were sequenced using BigDyeTM ter-
minator cycle chemistries on an ABI3100 Genetic
Analyser (Applied Biosystems, UK). The sequence
electropherograms obtained were compared with the
Genbank OPA1 reference sequence (accession number
NG_011605.1, mRNA transcript variant 1, NM_
015560.2), using SeqScapeTM software v2.6 (Applied
Biosystems, UK).
Statistical analysis
The Hardy–Weinberg equilibrium for OPA1 genotypes
was assessed for patient and control groups (http://
ihg.gsf.de/cgi-bin/hw/hwa1.pl). Allele and genotype
SNP frequencies were compared with w2 analysis
using GraphPadTM v.4 statistical software (San
Diego, CA).
Results
OPA1 variants identified
No pathogenic OPA1 mutations were identified in the
NMO cohort. A total of 13 OPA1 variants were iden-
tified, and of these, nine were previously reported SNPs
(Table 1). The remaining four variants were novel het-
erozygous changes found in four different patients with
NMO. The exon 11 (c.1071A>G, p.A357A) and exon
22 (c.2256G>T, p.L752L) variants were synonymous,
and the two novel intronic variants were not predicted
to affect the neighbouring splice donor sites.
SNP associations
The SNP frequency in the NMO cohort was compared
with healthy controls and the POAG group. No signif-
icant allele or genotype associations were detected with
the following three OPA1 SNPs: c.473A>G,
IVS8þ 4c> t, and IVS8þ 32t> c (Online e-Tables 1,
2, and 3). Analysis of both the IVS8þ 4c> t and
IVS8þ 32t> c SNPs showed no significantly increased
risk of developing NMO with specific compound geno-
types (Online e-Table 4). There was no significant allele
or genotype associations for the remaining SNPs iden-
tified in patients with NMO compared with healthy
controls (data not shown). Further subgroup analysis
did not reveal any significant OPA1 SNP association
between: (i) anti-AQP4 antibody-seropositive NMO
patients and controls; (ii) anti-AQP4 antibody-serone-
gative NMO patients and controls; and (iii) anti-AQP4
antibody-seropositive and antibody-seronegative NMO
patients (data not shown).
Discussion
No pathogenic OPA1 mutations were identified in
this well-characterized group of patients with NMO.
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Although we cannot exclude the possibility of large-
scale OPA1 genomic rearrangements, the latter are
rare in DOA, accounting for less than 1% of singleton
cases with suspected inherited optic atrophy.5 OPA1
mutations have only been reported within the first
10 intronic nucleotide positions, making it also unlikely
that our PCR-based sequencing strategy has missed
functional intronic variants influencing mRNA splic-
ing or transcriptional activity.5 Only one non-synon-
ymous OPA1 SNP (c.473A>G, p.N158S) was
present in patients with NMO, but it is an evolution-
arily poorly conserved amino acid residue. No signif-
icant allele and genotype associations were found
for c.473A>G and the remaining SNPs identified in
this NMO cohort when compared with both healthy
controls and patients with POAG. Our findings contrast
with recent observations in POAG, where specific
OPA1 variants at IVS8þ 4c> t and IVS8þ 32t> c
have been linked with an increased risk of developing
NTG, suggesting a role forOPA1 in glaucomatous optic
nerve degeneration.10 Theoretically, these two intronic
SNPs could still exert a minor influence on the expres-
sion of the NMO disease phenotype. However, NMO is
a relatively rare form of CNS demyelination, and the
sample size required to demonstrate these more subtle
genetic modulatory effects will prove challenging.
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Disorders of the Optic Nerve in Mitochondrial Cytopathies:
New Ideas on Pathogenesis and Therapeutic Targets
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Abstract Mitochondrial cytopathies are a heterogeneous
group of human disorders triggered by disturbed mitochon-
drial function. This can be due to primary mitochondrial
DNA mutations or nuclear defects affecting key components
of the mitochondrial machinery. Optic neuropathy is a fre-
quent disease manifestation and the degree of visual failure
can be profound, with a severe impact on the patient’s
quality of life. This review focuses on the major mitochon-
drial disorders exhibiting optic nerve involvement, either as
the defining clinical feature or as an additional component
of a more extensive phenotype. Over the past decade, sig-
nificant progress has been achieved in our basic understand-
ing of Leber hereditary optic neuropathy and autosomal-
dominant optic atrophy—the two classical paradigms for
these mitochondrial optic neuropathies. There are currently
limited treatments for these blinding ocular disorders and,
ultimately, the aim is to translate these major advances into
tangible benefits for patients and their families.
Keywords Dominant optic atrophy . Haplogroup .
Hereditary spastic paraplegia, Heteroplasmy . Idebenone .
Leber hereditary optic neuropathy .Mitochondrial DNA .
Mitofusin .Multiple sclerosis . Neuroprotection . Retinal
ganglion cell . Optic nerve .Mitochondrial cytopathies
Introduction
Mitochondria are found in all nucleated cells and reflecting
this ubiquitous presence, patients with mitochondrial cyto-
pathies often manifest a diverse combination of tissue and
organ involvement [1]. However, for reasons that still re-
main unclear, mitochondrial dysfunction has a marked pre-
dilection for the optic nerve, the latter being affected in
about half of all patients with confirmed mitochondrial
disease (Fig. 1). Irrespective of the molecular pathways
involved, remarkably, these mitochondrial optic neuropa-
thies all share the same pathological features—selective
degeneration of the retinal ganglion cell (RGC) layer, lead-
ing to progressive axonal loss and the onset of visual failure
[2]. In this review, recent advances in our understanding of
this important group of disorders are discussed, in addition
to promising therapeutic strategies.
Leber Hereditary Optic Neuropathy
Epidemiology
Leber hereditary optic neuropathy (LHON, OMIM 535000)
is named after Theodore Leber (1840–1917), a German
ophthalmologist who was the first to describe the key fea-
tures of this disorder [3]. LHON is the most common of the
primary mitochondrial DNA (mtDNA) disorders and the
minimum prevalence has been estimated at 1 in 31,000 in
the North of England (Fig. 1) [4]. Epidemiological studies
from the Netherlands and Finland have reported comparable
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figures of 1 in 39,000 and 1 in 50,000, respectively. In one
Australian study, 2% of individuals on the National Blind
Registry had optic atrophy secondary to LHON, highlighting
the significant socioeconomic burden of this inherited optic
nerve disorder. Three mtDNA point mutations—m.3460 G>
A, m.11778 G>A, and m.14484 T>C—account for the vast
majority (~ 90%) of LHON cases and, for this reason, they are
often referred to as “primary” (Table 1) [3, 5].
Clinical Manifestations
Typically, disease conversion in LHON is characterized by
acute or subacute central visual loss in one eye, followed 2
to 4 months later by the fellow eye [3, 5]. Unilateral optic
nerve involvement in LHON is exceptionally rare and an-
other underlying pathological process should be actively
excluded in these atypical cases. Bilateral simultaneous
onset probably occurs in about 25% of patients, although
it can be difficult for some individuals to accurately report
whether visual loss had been ongoing in one eye prior to the
fellow eye being affected. The peak age of onset is in the
second and third decades of life and it is unusual for symp-
toms to develop beyond 50 years of age.
The initial visual loss in LHON is severe and it usually
plateaus over the next 6 months, with most patients achiev-
ing visual acuities of 20/200 or worse [3, 5]. There is an
associated dense central or centrocecal scotoma and color
vision is significantly impaired. The pupillary light reflexes
are relatively preserved and this rather surprising feature has
recently been ascribed to a special class of melanopsin-
containing RGCs that are more resistant to the mtDNA
LHON mutations [6••]. In the acute phase, classically, there
is optic disc hyperemia, peripapillary telangiectatic vessels,
vascular tortuosity, and retinal nerve fiber layer (RNFL)
edema secondary to axonal stasis. In a proportion (20% to
40%) of LHON carriers undergoing disease conversion, the
optic discs can look entirely normal, followed 6 weeks later
by the development of neuroretinal rim pallor [5]. Patholog-
ical cupping of the optic disc is also a recognized feature of
longstanding LHON cases, reflecting the ongoing loss of
RGC axons in the chronic phase of the disease. The overall
prognosis in LHON is poor, even among patients harboring
the m.14484 T>C mutation, which carries the best chance
for partial visual recovery [5]. If it occurs, a slow improve-
ment in visual parameters can be expected within the first
year, although more delayed visual recovery has been
reported.
Syndromal LHON Phenotypes
LHON is typically a monosymptomatic disease but addi-
tional features such as cardiac conduction defects, peripheral
neuropathy, dystonia, and myopathy have been reported as
occurring more frequently among LHON carriers. In partic-
ular, there is a well-reported association between the three
primary mtDNA LHON mutations and a multiple sclerosis–
like illness, especially among female carriers. Rarer patho-
genic mtDNA variants have been linked with more atypical
“LHON +” syndromes, where the optic neuropathy segre-
gated with prominent neurological features including spastic
dystonia, ataxia, juvenile-onset encephalopathy, and psychi-
atric disturbances [2].
Figure 1 Mitochondrial
disease in the North of England.
(Adapted from Yu-Wai-Man et
al. [2] and Schaefer et al. [50])
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Disease Modifiers
LHON is characterized by incomplete penetrance and a
marked sex bias, with only about 50% of male carriers and
about 10% of female carriers losing vision during their life-
time. The pathological consequences of the mtDNA LHON
mutations are clearly being influenced by other disease modi-
fiers, and these can be classified into four main groups: 1) the
mitochondrial genetic background, 2) nuclear susceptibility
genes, 3) hormonal differences, and 4) environmental triggers.
As mitochondria have a high copy number genome,
LHON carriers can be homoplasmic (100% mutant) for the
mtDNA mutation, or heteroplasmic with a combination of
both the wild-type and mutant mtDNA species. Although
the risk of visual loss is minimal at heteroplasmy levels
below 60%, this observation cannot account for the bulk
of unaffected LHON carriers, most of whom are homoplas-
mic mutant and therefore beyond this biochemical threshold
[7]. MtDNA is highly polymorphic and during human evo-
lution, ancient mtDNA variants have clustered together in
specific combinations known as haplogroups. As mtDNA
haplogroups influence mitochondrial oxidative phosphory-
lation, these more subtle variations could magnify or lessen
the impact of the LHON mutation on RGC survival. In a
large study involving 159 Caucasian LHON pedigrees, hap-
logroup J was associated with a significantly increased risk
of visual loss among m.11778 G>A and m.14484 T>C
carriers, whereas m.3460 G>A carriers were more likely
to become affected on a haplogroup K background [8].
Haplogroup H had a protective effect but only among indi-
viduals harboring the m.11778 G>A mutation. Haplogroup
associations have been reported in other ethnic groups,
supporting a contributory role for the mtDNA background
in influencing LHON penetrance [9].
The predilection for males to lose vision in LHON cannot
be explained by mitochondrial genetics and a visual loss
susceptibility gene on the X chromosome has long been
suspected, the so-called two-locus disease model [10]. Al-
though such an X-linked disease modifier gene has yet to be
formally identified, three independent linkage studies have
revealed overlapping candidate regions, providing strong ev-
idence for its existence [11–13]. Another obvious factor to
account for the observed male bias in LHON is a protective
influence conferred by female sex hormones. This hypothesis
was recently investigated using LHON cybrid cell lines, and
interestingly, treatment with 17β-estradiol resulted in reduced
reactive oxygen species (ROS) levels, increased activity of the
antioxidant enzyme superoxide dismutase, and more efficient
mitochondrial biogenesis [14•].
Various environmental factors have been implicated in
precipitating visual loss among LHON carriers including
head trauma, industrial toxins, and drugs with mitochondrial
toxic effects [15]. The evidence for these environmental
triggers is largely anecdotal, but a recent multicenter study
of 125 LHON pedigrees has provided convincing evidence
for an increased risk of visual failure among smokers, and to
a lesser extent, heavy drinkers [16•].
Mitochondrial Encephalomyopathies
The mitochondrial encephalomyopathies encompass sev-
eral distinct phenotypes such as mitochondrial encepha-
lomyopathy, lactic acidosis, and stroke-like episodes
(MELAS), myoclonic epilepsy and ragged-red fibers
(MERRF), maternally inherited Leigh syndrome (MILS),
mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE), and the Kearns-Sayre syndrome (KSS) [1,
Table 1 mtDNA variants associated with LHON
Mitochondrial
gene
Nucleotide change
Common variants
(~ 90%)
MTND1 m.3460 G>Aa
MTND4 m.11778 G>Aa
MTND6 m.14484 T>Ca
Rare variants
(~ 10%)
MTND1 m.3376 G>A, m.3635 G>Aa,
m.3697 G>A, m.3700 G>A,
m.3733 G>Aa, m.4025 C>T,
m.4160 T>C, m.4171 C>Aa
MTND2 m.4640 C>A, m.5244 G>A
MTND3 m.10237 T>C
MTND4 m.11696 G>A, m.11253 T>C
MTND4L m.10663 T>Ca
MTND5 m.12811 T>C, m.12848 C>T,
m.13637 A>G, m.13730 G>A
MTND6 m.14325 T>C, m.14568 C>T,
m.14459 G>Aa, m.14729 G>A,
m.14482 C>Aa, m.14482 C>
Ga,
m.14495 A>Ga, m.14498 C>T,
m.14568 C>Ta, m.14596 A>T
MTATP6 m.9101 T>C
MTCO3 m.9804 G>A
MTCYB m.14831 G>A
Over 70% of LHON carriers harbor the m.11778 G>A mutation, but as
a result of a founder event, the m.14484 T>C mutation has been
identified in nearly 90% of all affected patients of French Canadian
descent [3, 5]. In most laboratories worldwide, the diagnostic protocol
involves screening for the three “primary” LHON mutations in the first
instance. As full mitochondrial genome sequencing remains time con-
suming and expensive, this is only indicated if the initial LHON screen
is negative and there is a strong clinical suspicion
a These mtDNAvariants are definitely pathogenic. They have been iden-
tified in two or more independent LHON pedigrees, showing segregation
with affected disease status. The remaining putative LHON mutations
have been found in singleton cases or in a single family, and additional
evidence is required before pathogenicity can be irrefutably ascribed
LHON Leber hereditary optic neuropathy; mtDNA mitochondrial DNA
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17]. Although variable and not a disease-defining fea-
ture, the occurrence of optic atrophy is well described
in this group of patients, exacerbating the already con-
siderable disease burden [18]. Additional studies are
required to determine the true prevalence of both clini-
cal and subclinical optic neuropathy in these mitochon-
drial encephalomyopathies, and whether specific mtDNA
mutations or phenotypes are linked with an increased
risk of optic nerve involvement.
Nuclear Mitochondrial Disorders
Autosomal-Dominant Optic Atrophy
Epidemiology
Frederick Batten (1865–1918), a pediatric neurologist, is
credited with the first report of autosomal-dominant optic
atrophy (DOA) in one British family. The characteristic
features were described in greater detail by Poul Kjer in a
large cohort of Danish families, establishing DOA as a
distinct clinical entity from LHON [3]. The prevalence of
DOA was estimated at 1 in 35,000 in the North of England
(Fig. 1), but additional families have since been identified
and the true figure is likely to be much higher (Yu-Wai-Man,
Unpublished data).
Disease Genes and Candidate Loci
Between 50% and 60% of families with DOA harbor path-
ogenic mutations in OPA1, which codes for a mitochondrial
inner membrane protein (Table 2) [3, 5]. OPA1 is highly
polymorphic and over 200 pathogenic variants have been
identified, clustering in the GTPase region and the dynamic
central domain. To minimize cost, OPA1 is routinely se-
quenced using polymerase chain reaction–based methods,
which will not detect exonic deletions or duplications. These
large-scale rearrangements have been identified in 10% to
20% of OPA1-negative families, and these additional mo-
lecular studies, although not yet widely available, are rec-
ommended for probands with a clear-cut DOA phenotype
and a strong family history [2].
Mutations in OPA3 were first described in Iraqi-Jewish
families with autosomal-recessive type III 3-methylglutaconic
aciduria (Costeff syndrome), a progressive neurodegenerative
disorder with early-onset optic atrophy, hypotonia, ataxia,
extrapyramidal dysfunction, and cognitive decline [19]. Het-
erozygous OPA3mutations were subsequently reported in two
French families with a dominantly inherited form of optic
atrophy associated with premature cataract formation
(ADOAC) [20]. Similar to OPA1, OPA3 has a mitochondrial-
targeting domain and it was initially considered to be a mito-
chondrial inner membrane protein. However, a recent study
has suggested instead thatOPA3 localizes to the mitochondrial
outer membrane, with its C-terminus facing the cytosol [21].
The causative genetic defects in the remaining families with
DOA have not yet been identified, although a number of
candidate loci have been reported (Table 2).
Visual Function and Disease Progression
Visual loss in DOA is bilateral and symmetrical with the
majority patients reporting subnormal vision from early child-
hood. There is a wide intra- and inter-familial variability in
disease severity, with visual acuities ranging from 20/20 to the
detection of hand movement [2, 3]. Individuals with visual
acuities of 20/30 or better are frequently asymptomatic and
they are only identified as having features of a bilateral optic
neuropathy at the time of contact tracing. On long-term
follow-up, visual function was observed to deteriorate in
50% to 75% of patients with DOA but the rate of progression
was highly variable, making genetic counseling difficult [2,
3]. Although a milder optic nerve disease compared with
LHON, DOA still results in significant visual impairment with
nearly half of all patients eventually registered blind.
As in LHON, the primary site of pathology in DOA is the
papillomacular bundle and central, centrocecal, and
Table 2 Nuclear mitochondrial disorders with prominent optic nerve involvement
Inheritance Locus Gene OMIM Phenotypes
Dominant 1p36.2 MFN2 601152 Hereditary motor and sensory neuropathy type 6 (HMSN-6, CMT2A)
3q28–q29 OPA1 165500 Isolated optic atrophy and syndromal dominant optic atrophy (DOA+)
19q13.2–q13.3 OPA3 165300 Autosomal-dominant optic atrophy and early-onset cataracts (ADOAC)
Recessive 9q13–q21.1 FXN 229300 Friedreich’s ataxia (FRDA)
11q14.1–q21 TMEM126A 612989 Optic atrophy ± auditory neuropathy
16q24.3 SPG7 607259 Hereditary spastic paraplegia type 7 (HSP-7)
19q13.2–q13.3 OPA3 258501 Type III 3-methylglutaconic aciduria (Costeff syndrome)
(Adapted from Yu-Wai-Man et al. [2, 5])
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paracentral scotomas are the most common visual field
defects. The degree of dyschromatopsia is commensurate
with the level of vision and pure tritanopia, once considered
a pathognomonic feature of DOA, is only rarely seen. Histo-
pathological studies of a postmortem eye retrieved from one
patient showed relative preservation of melanopsin-
containing RGCs, accounting for the lack of an afferent pu-
pillary defect in DOA—another peculiarity shared with
LHON [6••]. The optic nerve head in DOA can look diffusely
pale or it can have a characteristic temporal wedge, especially
in patients with early disease where RGC loss remains mostly
localized to the papillomacular bundle [2, 3].
The Expanding Phenotypic Spectrum
Up to 20% of patients harboringOPA1mutations will develop
a syndromal form of the disease (DOA+) marked by signifi-
cant neurological complications [22•]. The most common
extraocular feature observed in this group is sensorineural
hearing loss, which usually manifests itself in the second
and third decades of life after visual failure has become
apparent. A proportion of OPA1 carriers will progress to a
more debilitated state with variable combinations of ataxia,
peripheral neuropathy, myopathy, and progressive external
ophthalmoplegia in later life. From a mechanistic perspective,
it is also revealing that some patients with DOA+ can present
with clinical features indistinguishable from other neurode-
generative disorders such as multiple sclerosis, hereditary
spastic paraplegia (HSP), and the inherited spinocerebellar
degenerations. The phenotypic spectrum of OPA1 disease is
likely to expand even further with greater clinical awareness
and easier access to molecular genetic testing.
Other Nuclear Mitochondrial Optic Neuropathies
The nuclear defects underlying several common neuromus-
cular disorders have been clarified. A remarkable element
has been the increasing realization that mitochondrial dys-
function plays a central role in the pathophysiology of
disease groups as diverse as Charcot-Marie-Tooth (CMT)
disease, HSP, and the inherited spinocerebellar ataxias—
reflecting to a certain extent the broader phenotypic spec-
trum recently described for OPA1 disease [2]. Mutations in
MFN2, which codes for a critical mitochondrial outer mem-
brane protein, have been identified in patients with heredi-
tary motor and sensory neuropathy type 6 (HMSN-6), an
autosomal-dominant axonal CMT subtype (Table 2) [23].
Affected individuals develop an early-onset peripheral neu-
ropathy with a progressive bilateral optic atrophy in later
childhood. Optic neuropathy also features prominently in
Friedreich ataxia and HSP type 7 (HSP-7), caused by nu-
clear mutations in FXN and SPG7, respectively [2]. Frataxin
is essential for the assembly of the iron-sulfur clusters
embedded within the mitochondrial respiratory chain com-
plexes, whereas paraplegin is a key mitochondrial protease
involved in the proteolytic processing of OPA1 [24, 25]. All
these disease pathways are likely interrelated, and distur-
bance in one element will set into motion a vicious cycle,
which eventually disturbs mitochondrial homeostasis trig-
gering neuronal cell loss. As the molecular basis of other
inherited human diseases is uncovered, it will be interesting
to note whether optic atrophy is present in those cases where
the genetic defect is ultimately revealed to affect mitochon-
drial function. A recent example is the identification of
TMEM126A mutations among patients with autosomal-
recessive optic atrophy, with or without an associated audi-
tory neuropathy [26]. Although its exact functions still re-
main to be determined, fascinatingly, TMEM126A is a
mitochondrial transmembrane protein present at high levels
within the RGC layer and the optic nerve head [26].
Mechanisms Contributing to RGC Loss
The final pathological outcome in mitochondrial optic neu-
ropathies is apoptotic RGC loss and several disease path-
ways can contribute to this irreversible process. Although a
greater emphasis has been placed on the experimental data
obtained for LHON and DOA, similar mechanisms have
also been shown to operate in other mitochondrial
cytopathies.
Bioenergetic Failure
Mitochondria are the cell’s powerhouses providing most of its
adenosine triphosphate (ATP) requirements through the tight
control of mitochondrial respiratory chain activity. All three
primary LHON mutations—m.3460 G>A, m.11778 G>A,
andm.14484 T>C—disrupt key polypeptide subunits of com-
plex I. Similarly, OPA1 mutations have a detrimental impact
on mitochondrial oxidative output by impairing the assembly
and stability of the respiratory chain complexes [27]. Most
studies, based on in vitro or in vivo assays, indicate a signif-
icant impairment in complex I activity, leading to a reduction
in mitochondrial membrane potential and overall ATP synthe-
sis (reviewed in [5] and [15]). Although this bioenergetic
deficit is bound to impact negatively on RGCs, by itself, this
cannot account for their selective vulnerability. Photorecep-
tors, for example, have a much higher energetic demand and
outer retinal function is usually preserved in both LHON and
DOA.
ROS and Excitotoxicity
The disrupted flow of high-energy electrons along the res-
piratory chain leads to free radical production and increased
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ROS levels have been consistently observed in transmito-
chondrial LHON cybrids (reviewed in [5] and [15]). The
efficient reuptake of glutamate is also disrupted in these
cellular models due to the downregulation of excitatory
amino acid transporter (EAAT1) activity. A drosophila
Opa1 (dOpa1) model has recently been established and
homozygous mutant flies developed a rough and glossy
eye phenotype due to the loss of hexagonal lattice cells,
with decreased lens and pigment deposition. This genetical-
ly engineered dOpa1 mutation led to a dramatic increase in
ROS levels, which could be partially rescued with dietary
antioxidant supplementation or overexpression of SOD1
[28]. Heterozygous adult flies were phenotypically normal
but similar to the homozygotes, ROS levels were elevated
with clear evidence of cellular oxidative stress. Increased
ROS levels and glutamate excitotoxicity clearly represent a
toxic combination, sufficiently potent to initiate the apopto-
tic cascade.
Disturbed Calcium Handling
Besides its localization to the mitochondrial outer mem-
brane, MFN2 is also associated with the endoplasmic retic-
ulum (ER), resulting in a close communication between the
mitochondrial and ER membranes [29••, 30]. When the
MFN2 protein is disrupted or absent, as in CMT-2A this
tethering effect is lost with dramatic consequences on cel-
lular calcium homeostasis. The ER and mitochondrial net-
work are important calcium stores and the dynamic flux
between these two compartments buffers against cytosolic
calcium spikes, which can sensitize the cell to various pro-
apoptotic signals such as glutamate [29••, 30]. Mirroring the
pathomechanism of MFN2 mutations, mtDNA point muta-
tions involving complex I and complex IV subunits have
also been directly linked with disturbed calcium handling in
neuronal populations [31]. Although speculative, it is likely
that a similar process is operating in LHON and DOA,
contributing to RGC dysfunction and ultimately disease
conversion among at-risk mutational carriers [32]. The
emerging links between calcium homeostasis and mitochon-
drial dysfunction are an exciting new development, high-
lighting potential disease pathways amenable to therapeutic
intervention.
Mitochondrial Network Dynamics
Cytochrome c is a powerful pro-apoptotic mediator and as a
protective mechanism, high concentrations of these mole-
cules are carefully sequestered within the mitochondrial
cristae. Irrespective of the mtDNA mutation involved, the
dissipation of the mitochondrial membrane potential
accelerates the cytosolic release of these cytochrome c mol-
ecules, precipitating an irreversible commitment toward
programmed cell death [33]. The identification of OPA1
and MFN2 mutations in DOA and CMT-2A has provided
further insights into this key disease mechanism. OPA1
ensures the integrity of the mitochondrial cristae’s tight
junctions, preventing cytochrome c from leaching out into
the cytosolic space. In addition, OPA1 and MFN2 both
belong to the dynamin superfamily of mechanoenzymes,
sharing considerable structural similarities, including a high-
ly conserved catalytic GTPase domain [24]. These two
proteins have important pro-fusional properties and by
working closely together, they maintain a highly-
interconnected mitochondrial network throughout the cell’s
structure [24, 33]. Unsurprisingly, the pathological hallmark
of OPA1- and MFN2-mutant fibroblasts is mitochondrial
network fragmentation, which not only impairs mitochon-
drial oxidative phosphorylation, but also leads to the uncon-
trolled release of calcium and cytochrome c into an already
compromised cellular environment [27, 34, 35••].
Somatic mtDNA Defects
Pathological levels of cytochrome c oxidase–negative fibers
have been identified in skeletal muscle biopsies from
patients with DOA+ [35••, 36••]. The underlying biochem-
ical defect in these muscle fibers is secondary to the accu-
mulation of high levels of somatic mtDNA deletions, which
have clonally expanded during the patient’s lifetime, partly
accounting for the delayed onset of these extraocular fea-
tures [37••]. Intriguingly, the risk of developing DOA+ is
three times higher with missense mutations targeting the
functional GTPase domain, consistent with a dominant-
negative mutational effect [22•]. OPA1 is clearly involved
in preserving the integrity of the mitochondrial genome and
recent studies have provided some tantalizing insights into
the mechanisms that contribute to mtDNA instability [38],
[39••, 40••]. OPA1 is thought to anchor the mtDNA repli-
cative machinery, known as nucleoids, to the mitochondrial
inner membrane and a dominant-negative mutation could
plausibly upset this delicate balance, leading to mtDNA
deletion formation [40••]. Why is this relevant to our under-
standing of RGC loss? Patients with DOA+ have worse
visual acuities and significantly thinner RNFL thickness
compared with those who only develop isolated optic atro-
phy [41]. The accumulation of these somatic mtDNA dele-
tions is therefore clearly having an incremental effect on the
other deleterious consequences linked to OPA1 mutations.
Why Are RGCs Selectively Vulnerable?
One factor that could explain this tissue-specific vulnerabil-
ity is the rather unusual anatomical peculiarity encountered
at the lamina cribrosa, where RGC axons first acquire their
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myelin sheaths. This transition is marked by a sharp differ-
ential gradient, with a much higher density of mitochondria
and voltage-gated sodium channels in the pre-laminar un-
myelinated segment of the optic nerve [42, 43]. These
physiological adaptations facilitate the efficient propagation
of action potentials in the absence of an insulating myelin
covering. The pre-laminar region therefore represents a
weak link, significantly more exposed to the disadvanta-
geous consequences of, even subtle, mitochondrial bio-
chemical defects.
Histopathological studies of optic nerves retrieved from
two patients with LHON, one harboring the m.3460 G>A
mutation and the other the m.11778 G>A mutation, have
revealed some interesting observations on the susceptibility
of specific RGC populations (reviewed in [2] and [15]). A
prominent loss of smaller-caliber axons was observed,
corresponding to the parvocellular RGC population, where-
as the larger-caliber magnocellular RGCs were relatively
preserved. These ultrastructural findings were subsequently
confirmed with higher-resolution transmission electron mi-
croscopy. Parvocellular RGCs are a major component of the
papillomacular bundle and this greater vulnerability to im-
paired mitochondrial oxidative phosphorylation could be
related to their relatively smaller cross-sectional areas, the
latter further exacerbating axonal stasis in conditions of
sustained metabolic stress.
The maintenance of a higher mitochondrial concentration
in the pre-laminar region also highlights the central role
played by the cytoskeleton, especially the microtubule net-
work, in channeling mitochondria to their appropriate cel-
lular locations. Axonal transport in highly specialized
neuronal populations such as RGCs is critically dependent
on these mitochondrial-cytoskeletal interactions (reviewed
in [2] and [15]). These can be adversely affected either by an
underlying mitochondrial respiratory chain defect, or by a
primary disturbance in microtubule assembly—the patho-
logical hallmark of the HSP group of disorders [2]. Optic
atrophy is well described in HSP-7 and it is likely that optic
nerve involvement remains an under-reported feature in
other HSP genetic subtypes.
Therapeutic Interventions
Visual Rehabilitation
The majority of patients with mitochondrial optic neuropa-
thies are severely visually impaired and the sudden onset of
visual loss in otherwise healthy individuals carries a signif-
icant psychological and socioeconomic burden. Therefore,
clinicians have an important role to play in facilitating
access to rehabilitative services such as low visual aids
and occupational therapy.
Clinical Surveillance
It is essential to screen for associated systemic complica-
tions, such as diabetes and cardiomyopathy, among patients
with mitochondrial cytopathies. The development of diabet-
ic peripheral neuropathy and cardiac-related exertional dys-
pnea can further compound the physical difficulties faced by
patients with poor vision, and they should be aggressively
managed as part of a multidisciplinary team. As a general
health measure, patients with mitochondrial disease should
be advised not to smoke and to moderate their alcohol
intake. Furthermore, in LHON, smoking, and to a lesser
extent excessive binge drinking, have been linked with an
increased risk of visual loss [16•].
Pharmacological Agents
Various pharmacological agents with putative neuroprotec-
tive properties have been used to mitigate the deleterious
consequences of mitochondrial dysfunction and to prevent
further RGC loss (reviewed in [44••]). The most promising
agent to date is idebenone (2,3-dimethoxy-5-methyl-6-[10-
hydroxydecyl]-1,4-benzoquinone), a short-chain synthetic
benzoquinone analogue, which promotes mitochondrial
ATP synthesis in addition to having antioxidant properties.
Coenzyme Q10 (CoQ10) is a longer-chain quinone analogue
and based on limited evidence, CoQ10 supplementation is
often used to treat patients with mitochondrial cytopathies.
Idebenone is thought to have some advantageous properties
over CoQ10, both in terms of its bioavailability and its mode
of action. Unlike CoQ10, idebenone is able to bypass com-
plex I inhibition by shuttling electrons directly from the
cytosol to complex III, thereby restoring ATP production
and decreasing lactate levels [45].
The results of a multicenter randomized placebo-
controlled trial (RHODOS [Rescue of Hereditary Optic
Disease Outpatient Study]) of idebenone in LHON have
recently been released. Idebenone was well tolerated at a
dose of 900 mg per day and no adverse drug-related events
were reported. The visual outcome data indicate that
patients with discordant visual acuities (LogMAR>0.2),
and thus at highest risk of further deterioration in the least
affected eye, were more likely to benefit from treatment
with idebenone [44••]. The findings from the RHODOS trial
are promising and for the first time, they offer the hope of
preserving vision for affected LHON carriers who are still at
an early stage of the disease process.
Looking into the Future: Gene Therapy
Gene therapy for primary mitochondrial cytopathies poses
several discrete challenges; the mitochondrial inner mem-
brane is a relatively impermeable membrane that needs to be
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bypassed, and a highly efficient vector is needed to
transfect a sufficient number of mitochondria per cell
to achieve the desired effect. A possible solution is to
bypass the mitochondrial genome using an allotopic
approach. Instead, the gene of interest is transfected into
the nuclear genome and the protein product is engi-
neered with a specific targeting sequence that facilitates
its uptake into the mitochondrial compartment, thereby
compensating for the mtDNA mutation. Proof of prin-
ciple has been demonstrated in experimental LHON
models where adeno-associated virus vectors have been
used to successfully transfect cells with a replacement
wild-type mtDNA allele or neuroprotective genes such
as SOD2 [46–48]. These results are encouraging and
allotopic rescue could be easily applied to the RGC
layer which is easily accessible. However, key issues
of safety and efficacy need to be further addressed
before their application to human clinical trials can be
advocated [2].
Preventing Disease Transmission
Several strategies are currently being explored to prevent the
transmission of pathogenic mitochondrial and nuclear muta-
tions among women of child-bearing age. The difficult
technical and ethical issues raised by preimplantation genet-
ic testing and new in vitro fertilization techniques such as
pronuclear transfer are outside the scope of this review, and
these have been detailed elsewhere [2, 49].
Conclusions
A number of recurring disease mechanisms have been iden-
tified that contribute to RGC loss in mitochondrial optic
neuropathies. These provide a unique opportunity for tar-
geted therapeutic interventions aimed not only at improving
visual function, but also the neurological deficits seen in the
more severe mitochondrial cytopathies. However, despite
these major advances, the risk factors underpinning the
selective vulnerability of RGCs have yet to be clarified.
Research in this area has been severely limited by the lack
of diseased human optic nerves but hopefully, with the
development of faithful animal models and more advanced
biotechnological tools, we will soon be in a position to
disentangle these fundamental research questions both at
the structural and molecular levels.
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Pathogenic OPA1 mutations cause autosomal dominant optic atrophy (DOA), a condition characterized by
the preferential loss of retinal ganglion cells and progressive optic nerve degeneration. Approximately
20% of affected patients will also develop more severe neuromuscular complications, an important disease
subgroup known as DOA1. Cytochrome c oxidase (COX)-negative fibres and multiple mitochondrial DNA
(mtDNA) deletions have been identified in skeletal muscle biopsies from patients manifesting both the
pure and syndromal variants, raising the possibility that the accumulation of somatic mtDNA defects contrib-
ute to the disease process. In this study, we investigated the mtDNA changes induced by OPA1 mutations
in skeletal muscle biopsies from 15 patients with both pure DOA and DOA1 phenotypes. We observed a
2- to 4-fold increase in mtDNA copy number at the single-fibre level, and patients with DOA1 features had
significantly greater mtDNA proliferation in their COX-negative skeletal muscle fibres compared with patients
with isolated optic neuropathy. Low levels of wild-type mtDNA molecules were present in COX-deficient
muscle fibres from both pure DOA and DOA1 patients, implicating haplo-insufficiency as the mechanism
responsible for the biochemical defect. Our findings are consistent with the ‘maintenance of wild-type’
hypothesis, the secondary mtDNA deletions induced by OPA1 mutations triggering a compensatory mito-
chondrial proliferative response in order to maintain an optimal level of wild-type mtDNA genomes.
However, when deletion levels reach a critical level, further mitochondrial proliferation leads to replication
of the mutant species at the expense of wild-type mtDNA, resulting in the loss of respiratory chain COX
activity.
INTRODUCTION
Pathogenic mutations in the OPA1 gene (OMIM 605290)
account for 60% of all cases of autosomal dominant optic
atrophy (DOA), and the carrier rate in the general population
is estimated to be at least 1 in 50 000 (1). The majority of
patients are mono-symptomatic, with the onset of progressive
central visual loss in early childhood invariably resulting in sig-
nificant visual morbidity (2–4). Although optic nerve dysfunc-
tion is the pathognomonic feature of DOA, we have recently
established that up to 20% of OPA1 carriers will experience a
more complicated disease course (5). These syndromal DOA+
variants show a remarkable degree of phenotypic variability,
but sensorineural deafness is a frequent neurological deficit,
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which develops from late childhood to early adulthood, fol-
lowed by a combination of ataxia, myopathy, peripheral neuro-
pathy and progressive external ophthalmoplegia (PEO) from the
third decade of life onwards (5–9). These clinical observations
are of major pathophysiological importance, as they highlight
the deleterious consequences of OPA1 mutations not only for
retinal ganglion cells, whose axons constitute the optic nerve,
but also for other central neuronal populations, peripheral
nerves and skeletal muscle.
The marked inter- and intra-familial variability in disease
severity seen in DOA is likely to be a reflection of the mul-
tiple, distinct roles played by the Opa1 protein in normal cel-
lular function (10,11). Following proteolytic cleavage by
various proteases (12), Opa1 assembles as polymeric struc-
tures within the inner mitochondrial membrane. As a result
of its pro-fusion dynamin-like GTPase properties, Opa1
actively maintains a highly interconnected mitochondrial
network and sequesters pro-apoptotic cytochrome c molecules
within the mitochondrial cristae spaces (13,14). Opa1 is also
thought to regulate oxidative phosphorylation by stabilizing
the mitochondrial respiratory chain complexes and by facilitat-
ing the effective coupling of electron transport with ATP syn-
thesis (15,16). In addition to these essential biological
functions, there is now growing evidence supporting a novel
role for Opa1 in mitochondrial DNA (mtDNA) maintenance.
Central to this argument is the characteristic histochemical
finding of cytochrome c oxidase (COX)-negative fibres in
skeletal muscle biopsies from OPA1-positive patients, together
with the presence of multiple mtDNA deletions on long-range
PCR analysis of homogenate skeletal muscle DNA (5–8).
Different mechanisms have been postulated to account for
the formation of these deleted mtDNA species, including an
imbalance of the intra-mitochondrial nucleotide pool, and
the impaired interaction of the N-terminal domain of Opa1
with mtDNA nucleoids, which are anchored in close physical
proximity to the inner mitochondrial membrane (6,7,17).
Interestingly, the level of COX-deficient muscle fibres was
found to be over four times higher in the DOA+ group com-
pared with the pure optic atrophy group (5). Importantly,
COX-deficient fibres were also significantly more frequent
among patients with pure DOA compared with age-matched
healthy controls (5). These observations strongly implicate a
contributory role for these secondary mtDNA defects in trig-
gering multi-system cellular dysfunction among affected
OPA1 carriers. However, the mechanisms involved have not
been defined and the nature of the mtDNA deletions induced
by OPA1 mutations still remains to be clarified. To explore
these fundamental research questions and how they relate to
disease severity, we performed a quantitative and qualitative
study of the mtDNA changes present in single skeletal
muscle fibres from patients harbouring OPA1 mutations.
RESULTS
MtDNA copy number density varies in normal control
skeletal muscle fibres
The normal control muscles studied were collected from a
1-year-old female (C-1F), a 22-year-old female (C-22F), a
31-year-old female (C-31F), a 35-year-old male (C-35M)
and a 52-year-old female (C-52F). The mtDNA copy
number density was measured as the total number of
mtDNA molecules in a muscle fibre section, divided by the
fibre’s cross-sectional area. There was a statistically significant
variation in mtDNA copy number density among Type I skel-
etal muscle fibres from the five controls, except for C-1F
versus C-22F (C-1F: mean ¼ 3.20, SD ¼ 1.67, n ¼ 18;
C-22F: mean ¼ 2.50, SD ¼ 0.87, n ¼24; C-31F: mean ¼
5.62, SD ¼ 1.97, n ¼19; C-35M: mean ¼ 10.63, SD ¼ 3.22,
n ¼17; C-52F: mean ¼ 4.36, SD ¼ 0.92, n ¼21) (Fig. 1A,
Supplementary Material, Table S1A). Similarly, mtDNA
copy number density varied significantly among Type II skel-
etal muscle fibres, except for C-1F versus C-31F, and C-1F
versus C-52F (C-1F: mean ¼ 2.62, SD ¼ 0.98, n ¼13;
C-22F: mean ¼ 1.57, SD ¼ 0.60, n ¼24; C-31F: mean ¼
2.96, SD ¼ 0.85, n ¼17; C-35M: mean ¼ 4.13, SD ¼ 1.54,
n ¼14; C-52F: mean ¼ 2.45, SD ¼ 0.50, n ¼22) (Fig. 1B,
Supplementary Material, Table S1B).
Figure 1. Total mtDNA content of single skeletal muscle fibres from normal
controls: (A) Type I fibres, (B) Type II fibres.
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OPA1 mutations lead to the accumulation of high levels of
somatic mtDNA deletions in skeletal muscle fibres
The mean frequency of COX-negative fibres present in cryo-
stat muscle sections from 15 OPA1-positive patients was
4.49% (SD ¼ 7.00%, range ¼ 0–21.20%, n ¼15), with two
patients, H and J, not harbouring any COX-negative fibres
(Table 1). The presence and level of mtDNA deletion were
determined for a total of 333 single skeletal muscle fibres
from 15 patients: (i) Type I COX positive, n ¼ 94; (ii) Type
II COX positive, n ¼ 94; and (iii) COX-negative, n ¼ 145
(Table 2). The majority of COX-positive fibres harboured
low deletion levels ,30% (179/188, 95.2%), and there was
no significant difference in mean deletion levels between
Type I and II fibres (Type I: mean ¼ 11.60%, SD ¼ 7.99%;
Type II: mean ¼ 14.58%, SD ¼ 11.51%, P ¼ 0.0723).
Among COX-negative fibres, 113 of 145 (77.9%) had deletion
levels ≥70%, and the mean deletion level was significantly
Table 1. Clinical phenotype and OPA1 mutational spectrum of our study cohort
Patient Age
(years)
Sex Onseta
(years)
OPA1 mutation Clinical phenotype
cDNA AA change Optic atrophy Deafness Ataxia Myopathy Neuropathy PEO Others
A 31 M 11 c.876-878del p.V294fsX667 +
B 59 M 5 c.876-878del p.V294fsX667 + + HSP
C 44 M 2 c.1198C.T p.P400S + + +
D 54 M 5 c.1212+3a.t Splice defect + +
E 43 M 5 c.1334G.A p.R445H + + + +
F 43 F 5 c.1334G.A p.R445H + + + +
G 54 M – c.1516+1g.t Splice defect +
H 39 M 15 c.1516+1g.t Splice defect +
I 58 F – c.2613+1g.a Splice defect + + MS-like illness
J 50 M 8 c.2613+1g.a Splice defect +
K 43 M 5 c.2708_2711del p.V903fsX3 +
L 60 F 16 c.2713C.T p.R905X +
M 40 F 15 c.2713C.T p.R905X +
Nb 60 M – c.768C.G p.S256R + + + + Spasticity
c.854A.G p.Q285R
Ob 64 F – c.768C.G p.S256R + + + + Spasticity
c.854A.G p.Q285R
AA, amino acid; F, female; HSP, hereditary spastic paraparesis; M, male; MS, multiple sclerosis; PEO, progressive external ophthalmoplegia.
aAge of onset of visual failure.
bNorwegian siblings compound heterozygous for two novel OPA1 mutations (5).
Table 2. Histochemical and mtDNA defects identified in skeletal muscle biopsies from our OPA1-positive patients
Patient Skeletal muscle biopsy analysis Real-time PCR analysis COX 2ve single-fibre analysisa
Fibres (n)b COX 2ve (%) RRF (%) Long PCRc Type I (n)d Type II (n)d COX 2ve (n) Deletion ,70% Deletion ≥70%
(n) (%) (n) (%)
A 2826 0.1 0.0 + 15 14 2 1 50.0 1 50.0
B 482 2.1 0.6 ++ 14 14 8 3 37.5 5 62.5
C 1980 1.6 0.6 ++ 14 22 12 3 25.0 9 75.0
D 786 0.3 0.0 + 24 23 2 1 50.0 1 50.0
E 1272 3.1 0.7 ++ 19 12 20 3 15.0 17 85.0
F 1186 13.9 1.3 ++ 13 21 13 2 15.4 11 84.6
G 674 1.8 0.9 ++ 19 17 16 7 43.8 9 56.3
H 762 0.0 0.0 + 19 23 0 N/A N/A N/A N/A
I 1304 1.4 0.3 ++ 21 21 15 1 6.7 14 93.3
J 848 0.0 0.0 – 14 19 0 N/A N/A N/A N/A
K 832 0.6 0.1 + 14 13 6 2 33.3 4 66.7
L 1100 3.0 0.8 ++ 10 10 14 3 21.4 11 78.6
M 1126 0.5 0.1 + 14 15 6 0 0.0 6 100.0
N 1058 17.7 3.3 ++ 22 17 16 4 25.0 12 75.0
O 968 21.2 5.8 ++ 15 28 15 2 13.3 13 86.7
COX, cytochrome c oxidase; MtDNA, mitochondrial DNA; N/A, not applicable; PCR, polymerase chain reaction; RRF, ragged-red fibres.
aLevel of mtDNA deletion detected in single COX-negative muscle fibres using our quantitative real-time PCR assay.
bTotal number of muscle fibres present in the stained cryostat sections.
cLong PCR analysis of homogenate skeletal muscle DNA: (i) no deletion bands (2), (ii) smaller deletion bands in addition to the wild-type PCR fragment (+), and
(iii) multiple deletion bands with no wild-type PCR fragment (++).
dNumber of Type I and II COX-positive muscle fibres laser microdissected from 20 mm thick membrane sections.
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higher compared with both Type I and II COX-positive fibres
(mean ¼ 74.16%, SD ¼ 33.04%, P , 0.0001) (Fig. 2).
COX-negative but not COX-positive muscle fibres are
associated with significant mtDNA proliferation
There was no significant difference in mtDNA copy number
density between COX-positive fibres from OPA1-positive
patients and the combined control data set for both Type I
fibres (OPA1: mean ¼ 4.37, SD¼ 2.23; controls: mean¼ 4.91,
SD¼ 3.17, P ¼ 0.0743), and Type II fibres (OPA1: mean ¼
2.39, SD¼ 1.03; controls: mean ¼ 2.60, SD¼ 1.20, P ¼
0.1095) (Fig. 3). However, there was evidence of significant
mtDNA proliferation in COX-negative fibres when compared
with adjacent COX-positive fibres from the same patient
(Table 3, Supplementary Material, Fig. S1A–O), and COX-
positive fibres from the combined control data set (Fig. 4).
There was no significant difference in mean mtDNA copy
number density between COX-negative fibres with mtDNA del-
etion levels ≥70% (mean ¼ 11.55, SD¼ 8.83, n ¼113) and
,70% (mean ¼ 9.10, SD ¼ 5.32, n ¼32, P ¼ 0.1385). Of the
145 COX-negative fibres analysed, 44 were from patients with
pure DOA (mean mtDNA proliferation ratio ¼ 2.02, SD¼
1.31, 95% confidence interval (CI)¼ 1.63–2.42) and 141 were
from patients with DOA+ phenotypes (mean mtDNA prolifer-
ation ratio ¼ 2.66, SD¼ 1.52, 95% CI¼ 2.36–2.96), the differ-
ence being statistically significant (P ¼ 0.0172) (Fig. 5).
MtDNA proliferation in COX-negative muscle fibres fails
to maintain normal levels of wild-type mtDNA molecules
The mean wild-type mtDNA ratio was significantly lower for
the COX-negative group (mean ¼ 0.20, SD ¼ 0.19, 95% CI ¼
0.17–0.24, n ¼112) compared with the COX-positive group
(mean ¼ 1.00, SD ¼ 0.32, 95% CI ¼ 0.95–1.05, n ¼188,
P, 0.0001) (Fig. 6A). The relationship between the wild-type
mtDNA ratio and the deletion level for COX-negative muscle
fibres was in agreement with our previously established
in silico model of mtDNA replication (R2 ¼ 0.68), and gave
a predicted maximum mitochondrial proliferation factor (a)
of 3.40 (95% CI ¼ 2.60–4.80) (Fig. 6B).
COX-negative muscle fibres from OPA1 patients harbour
clonally expanded deleted mtDNA species
Deleted mtDNA species were detected in 31 COX-negative
muscle fibres using our two-step long-range PCR protocol,
and in none of them was the full-length 10 843 base pairs
PCR product obtained. MtDNA deletions levels ,30% were
measured in 6 of 31 (19.4%) of these COX-negative fibres
with our differential MTND1–MTND4 real-time PCR assay.
The deletion sizes ranged from 1.0 to 8.0 kb (mean ¼ 5.2 kb,
SD ¼ 2.0 kb, n ¼33), and two different deletions were ampli-
fied from the lysate of 2 of 31 (6.5%) COX-negative fibres. All
these deletions were located within the major arc of the mito-
chondrial genome and they were predicted to result in the loss
of critical segments containing both transfer RNA and
protein-encoding genes.
DISCUSSION
Our study has revealed marked mtDNA proliferation in skel-
etal muscle from patients harbouring a range of pathogenic
OPA1 mutations. This observation is entirely compatible
with the reported detrimental effect of OPA1 mutations on
mitochondrial oxidative phosphorylation (15,16,18), with the
increased mtDNA copy number acting as a compensatory
mechanism to maintain an adequate level of ATP for normal
cellular function. COX-negative fibres were present in
muscle biopsies from 13 OPA1-positive patients, and there
was a consistent finding of mtDNA proliferation in these
fibres, irrespective of disease severity. However, patients
with DOA+ phenotypes had significantly higher proliferation
ratios in COX-negative muscle fibres when compared with
those with isolated optic nerve involvement, indicating a poss-
ible important disease mechanism. Although we did not make
any direct measurements of apoptotic markers in this study,
mtDNA proliferation is linked with an increased susceptibility
to undergo apoptosis in mitochondrial myopathies (19,20), and
it is biologically plausible to postulate that such an effect
would not be limited to muscle fibres, but would also extend
to other post-mitotic tissues commonly affected in mitochon-
drial disorders. The relevance to OPA1 disease becomes
even more apparent in view of the fact that the level of
COX deficiency in skeletal muscle is over four times higher
in patients with DOA+ compared with pure DOA (5). Even
though the frequency of COX-negative fibres is lower
among DOA patients with clinical features limited to the
Figure 2. Level of mtDNA deletion in COX-positive and COX-negative
single muscle fibres from OPA1-positive patients. NS at P-value ¼ 0.0723;
∗∗∗P-value ,0.0001. Type I and Type II refer to COX positive fibres.
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optic nerve, this group still has significantly higher levels of
COX-deficiency compared with age-matched healthy controls
(5). The secondary mtDNA abnormalities, which precipitate
this biochemical COX defect are therefore clearly linked to
the underlying OPA1 disease process. Although additional
confirmatory studies are required, it is tempting to speculate
that some OPA1 mutations lead to multi-systemic manifes-
tations and more severe visual failure as a result of their
more pronounced effects on mtDNA deletion formation, and
thus proliferation, with the consequent increase in apoptotic
cell loss. The degree of mitochondrial network instability
induced by different OPA1 mutations also deserves further
investigation, as the extent of fragmentation could have a
crucial influence on the rate at which these somatic deletions
become fixed at supra-threshold levels (21–23).
Our in silico model of mtDNA replication suggests that
mitochondrial proliferation serves a useful biological
purpose by maintaining wild-type mtDNA copy number at
an optimal level (21,22). However, this compensatory mech-
anism only operates effectively up to a certain mutational
load, beyond which it fails to prevent the loss of wild-type
mtDNA genomes, and eventually becomes detrimental to
cellular survival. The relationship observed in COX-negative
OPA1 muscle fibres between the level of wild-type and
deleted mtDNA species is in agreement with our in silico pre-
diction, and provides additional experimental evidence that the
maintenance of wild-type mtDNA genomes is crucial for
normal mitochondrial oxidative function. We previously
showed that this was also the case in skeletal muscle fibres
from a patient with PEO and mild proximal myopathy due
to a 4.9 kb single deletion (23).
MtDNA copy number was determined at the single-fibre
level for five normal control skeletal muscle samples, and a
wide variation was observed for both Type I and II fibres. A
likely confounding variable is the level of physical activity,
which was not documented for the individuals from whom
the biopsies were taken. Skeletal muscle is a highly adaptable
tissue and it is capable of pronounced metabolic and morpho-
logical changes in response to endurance training or disuse
(24,25). It is well established that physical exercise enhances
mitochondrial oxidative capacity in vivo (26–28), and this
beneficial adaptation has been linked to an increase in
mtDNA density (29,30). The regulatory pathways involved
are complex but an important element is the up-regulation in
the level of TFAM expression (31,32), which encodes for a
Figure 3. Comparison of total mtDNA copy number in single muscle fibres from OPA1-positive patients with normal controls. (A) Type I COX-positive fibres
(NS at P-value ¼ 0.0743), (B) Type II COX-positive fibres (NS at P-value ¼ 0.1095). The control values represent the combined data set for C-1F, C-22F,
C-31F, C-35M, and C-52F.
Table 3. Relative level of mtDNA proliferation seen in COX-negative muscle
fibres
Patient COX 2ve fibres (n)a MtDNA proliferation ratiob
Mean 95% confidence interval
A 2 2.68 0.00 16.28
B 8 2.32 1.45 3.18
C 12 1.92 1.28 2.56
D 2 2.49 0.00 16.14
E 20 3.72 2.94 4.49
F 13 2.21 1.36 3.06
G 16 1.90 1.31 2.50
H 0 N/A N/A N/A
I 15 2.76 2.07 3.44
J 0 N/A N/A N/A
K 6 3.11 1.23 4.98
L 14 1.75 1.07 2.44
M 6 1.68 0.34 3.02
N 16 3.24 2.25 4.22
O 15 1.73 1.26 2.21
aTotal number of COX-negative muscle fibres studied for each patient.
bThe proliferation ratio for each COX-negative fibre was determined in relation
to the mean mtDNA copy number (/mm2) for COX-positive fibres from the
same patient, with a value .1 indicating relative mtDNA proliferation
(Supplementary Material, Fig. S1A–O).
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key activator of mtDNA transcription and replication (33,34).
Our finding therefore highlights the need for caution when
comparisons are made between individual patient muscle
biopsies and controls, as erroneous conclusions could easily
be reached, especially if only limited numbers are analysed.
For this reason, we combined Type I and II fibres from our
control data set, and used this normative range to interpret
the results obtained from OPA1-positive muscle biopsies
included in this study.
The majority of COX-positive muscle fibres from OPA1-
positive patients had sub-threshold deletion levels ,30%
(179/188, 95.2%), i.e. within the detection limit of our quan-
titative real-time PCR assay (23,35,36). The mtDNA deletion
level required to precipitate an overt biochemical defect at
the cellular level is typically ≥70% in skeletal muscle
(23,35,36), and using this threshold value, the histochemical
status for over three-quarters of COX-negative muscle fibres
could be accounted for (113/145, 77.9%). By applying a
two-step long-range PCR strategy, clonal expansion of a
single deleted mtDNA species was demonstrated for 29 of
31 (93.5%) COX-negative fibres, with the remaining fibres
each harbouring two different deleted mtDNA species.
Although long-range PCR is not quantitative, these results
suggest that more than one deleted mtDNA species can pro-
pagate and reach high levels within a cell independently of
each other. We recently reported the same observation in
single substantia nigra neurones from three different
groups: controls, patients with sporadic Parkinson’s disease,
and a patient with a heterozygous POLG1 mutation leading
to parkinsonism in association with PEO and multiple
mtDNA deletions (37). It is also noteworthy that 6 of 31
(19.4%) COX-negative muscle fibres had mtDNA deletions
levels ,30% with our real-time PCR assay, which was
designed primarily to detect deletions encompassing
MTND4 but not MTND1 (23,38). It is therefore likely that
Figure 4. Comparison of total mtDNA copy number in COX-negative muscle fibres from OPA1-positive patients with COX-positive muscle fibres from the
combined control data set. MtDNA deletion levels in COX-negative muscle fibres: low (,70%) and high (≥70%); NS at P-value ¼ 0.1385; ∗∗∗P-value
,0.0001.
Figure 5. MtDNA proliferation ratio for COX-negative fibres from patients
with pure DOA and DOA+ phenotypes. The proliferation ratio for each COX-
negative fibre was determined in relation to the mean mtDNA copy number
(/mm2) for COX-positive fibres from the same patient, with a value .1 indi-
cating relative mtDNA proliferation. ∗P-value ¼ 0.0172.
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most of the COX-negative fibres with low deletion levels
(32/145, 22.1%) in our study actually harboured smaller del-
etions, which spared both MTND1 and MTND4, and there-
fore remained undetected. In support of this argument, Bua
et al. (39) sequenced the breakpoints for 48 mtDNA del-
etions identified in aged normal skeletal muscle, and of
these, 8 of 48 (16.7%) did not include MTND1 and
MTND4. We have not excluded the possibility that OPA1
mutations could trigger COX deficiency via the accumulation
of high levels of somatic mtDNA point mutations, but the
evidence for this is weak, especially in post-mitotic tissues
(40,41). Furthermore, previous studies of other mitochondrial
maintenance disorders due to POLG1 and PEO1 mutations
have only identified an increased burden of somatic
mtDNA point mutations in the non-coding D-loop region
(42–44). The significance of these mtDNA variants
remains unclear but they would not be predicted to directly
cause COX deficiency.
In summary, our study has provided some important
insights into the consequences of OPA1 mutations at the cel-
lular level and has revealed possible important disease mech-
anisms. The accumulation of somatic, clonally expanded
mtDNA deletions is a key pathological player, and the result-
ing mtDNA proliferation is likely to be an important mediator
of apoptotic cell loss and disease severity. However, several
intriguing features of OPA1 disease remain to be clarified –
its wide phenotypic spectrum, the marked variability seen
within families segregating the same pathological variant,
and the greater susceptibility of retinal ganglion cells. Dissect-
ing the complex pathophysiological pathways involved will
represent a major challenge, and future experimental para-
digms will require the development of more sophisticated
functional systems, such as animal models replicating the fea-
tures seen in patients with DOA+ phenotypes.
MATERIALS AND METHODS
Patients and controls
Quadriceps or tibialis anterior muscle biopsies from 15 OPA1-
positive patients (mean age ¼ 49.5 years, SD ¼ 9.8 years,
range ¼ 31.0–64.0 years) (Table 1), and five normal controls
with no evidence of ocular or neuromuscular pathologies
(mean age ¼ 28.2 years, SD ¼ 18.7 years, range ¼ 1.0–52.0
years) (Fig. 1) were included in this study. Among the DOA
group, seven patients had isolated optic nerve involvement
whereas eight patients manifested additional neuromuscular
features. The clinical descriptions of these patients have
been detailed previously (5), and muscle biopsies were
obtained at the time of their initial diagnostic investigations.
This study had the relevant institutional approval and com-
plied with the Declaration of Helsinki.
Mitochondrial histochemistry
Skeletal muscle samples were snap frozen in melting liquid
isopentane (21508C) within 6 h of the biopsy being taken
and then stored at 2808C. The specimens were mounted on
OCT (VWR BDH Prolabo, UK) before being sectioned at
20 mm thickness onto glass and membrane slides using a
MicromTM HM560 cryostat (Thermo Fisher, Germany). The
serial muscle sections were then stained for COX, succinate
dehydrogenase (SDH), and sequential COX-SDH activities,
using standard histochemical protocols (45).
Single-muscle fibre analysis
Individual skeletal muscle fibres were cut using an LMD
6000TM laser dissecting microscope (Leica Microsystems,
Germany) and collected into a 0.5 ml microcentrifuge cap
Figure 6. (A) Wild-type mtDNA ratio in single muscle fibres from OPA1-positive patients analysed according to COX status (P , 0.0001), (B) Variation in
wild-type mtDNA ratio for COX-negative muscle fibres according to mtDNA deletion level. The simulated curve describes the relationship predicted by our
in silico model, which is based upon the maintenance of wild-type mtDNA genomes (R2 ¼ 0.68). Circles indicate COX-positive fibres and triangles
COX-negative fibres.
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(Eppendorf, UK). Cross-sectional fibre area (mm2) was
recorded from the LMD 6000TM operating software (Leica
Microsystems) prior to laser microdissection. The fibres
were incubated overnight in a 30 ml lysis solution containing
proteinase K at 558C for 16 h, followed by heat inactivation
at 958C for 10 min (23). The molecular investigations
described below were then performed on the single-fibre
lysate on the following day.
Quantitative real-time PCR
Our quantitative real-time PCR assay for single muscle fibres
was originally designed based upon the fact that the MTND1
gene is only rarely involved in large-scale rearrangements,
whereas the MTND4 gene is removed in the majority of
reported mtDNA deletions (38,46). Absolute quantification
of mtDNA content was performed on the MyiQTM real-time
PCR detection system (Biorad, USA), with iQ SYBR Green
and primers pairs designed to amplify short fragments span-
ning MTND1 and MTND4 (23). The primer sequences for
the various real-time PCR templates used have been provided
in the online Supplementary Material (Table S2). The total
number of mtDNA molecules (total copy number) present in
muscle fibre sections was determined from the MTND1 Ct
values, and the number of wild-type mtDNA molecules (wild-
type copy number) from the MTND4 Ct values, using the
linear regression equations generated by serial dilutions of
the relevant standards. Both assays were optimized and con-
firmed to be linear over an appropriate concentration range
by the standard curve method, and all single-fibre lysates
were measured in triplicates. The mtDNA deletion level was
calculated with the 22DCt method from the obtained
MTND1–MTND4 DCt value.
Long-range PCR
Multiple mtDNA deletions in homogenate skeletal muscle
DNA was investigated with either southern blot and/or long-
range PCR (6,7). The detection of deleted mtDNA species in
single skeletal muscle fibres was achieved using a previously
optimized two-step long-range PCR strategy (37). Two
rounds of PCR were required to achieve adequate amplifica-
tion from the single-fibre lysate, and the primer pairs were
specifically designed to allow the identification of large-scale
rearrangements in the mutational hotspots along the major arc
of the mitochondrial genome (Supplementary Material,
Table S3). The Expand Long Template PCR SystemTM
(Roche, UK) was used with the following cycling procedures
for both the first and second rounds of PCR: 3 min at 938C;
10 cycles of 938C for 30 s, 588C for 30 s, 688C for 12 min;
20 cycles of 938C for 30 s, 588C for 30 s, 688C for
12 min + 5 s per additional cycle; and a final extension step
of 11 min at 688C. The PCR products were electrophoresed
in a 0.7% agarose gel containing ethidium bromide at 40 V
for 3 h, before being visualized under ultra-violet light.
Wild-type mtDNA ratio
For each patient, the mean wild-type mtDNA copy number
density for COX-positive muscle fibres was determined by
averaging the values obtained for all Type I and II fibres sep-
arately. To remove the variation among individuals, the wild-
type mtDNA ratios for COX-positive and COX-negative fibres
were normalized to each patient’s mean wild-type mtDNA
copy number density. The wild-type mtDNA ratio for each
fibre was calculated by dividing the copy number density for
that fibre with the patient’s mean value for COX-positive
fibres, either Type I or II.
In silico modelling
Our mathematical simulation of mtDNA replication is based
upon recessive loss-of-function mutations, with the total
amount of wild-type mtDNA being the primary determinant
of mitochondrial function (21,22). Our modelling equation
predicts that the wild-type mtDNA copy number (w) is a func-
tion of the mutation level (m) within a cell, and the mtDNA
proliferation parameter (a):
w = 1− m
1− (a− 1/a)m
The proliferation parameter (a) was determined from the wild-
type and mutant copy number data by a non-linear least
squares fitting routine using the Levenberg–Marquardt algor-
ithm in Origin 7TM (Northampton, MA). The proliferation par-
ameter (a) represents the maximum proliferation that should
be observed when the mutation level approaches 100%. The
actual proliferation level observed will be smaller than the pre-
dicted a value.
Statistical analysis
Groups were compared using an independent sample t-test
with GraphPadTM v.4 statistical software (San Diego, CA).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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Mitochondria contain multiple copies of mitochondrial DNA
(mtDNA), which codes for 13 essential components of the mitochon-
drial respiratory chain which are essential for aerobic metabolism in
all nucleated mammalian cells. The efficient synthesis of adenosine
triphosphate (ATP) is critically dependent on the amount and quality
of mtDNA within single cells. Pathogenic mutations of mtDNA can
affect the structure of respiratory chain subunits, or affect the intra-
mitochondrial protein synthetic machinery. Likewise, a drastic
reduction in mtDNA levels also leads to a decrease in intra-
mitochondrial protein synthesis, compromising cellular function
through a relative deficiency of available ATP. Unlike nuclear DNA,
mitochondrial DNA (mtDNA) is continually copied and degraded,
independent of the cell cycle (so called “relaxed replication”) [1]. This
means that any disruption of the mtDNA replication machinery can
have almost immediate effects on cellular function.
Nuclear gene mutations causing secondary defects of mitochon-
drial DNA (mtDNA) are amajor cause of human genetic disease [2]. An
overlapping spectrum of dominantly-inherited neuromuscular phe-
notypes have been described in families transmitting mutations in
POLG and POLG2 [3,4], PEO1 [5], ANT1 [6], and OPA1 [7]. These genescode for proteins that are intimately involved in mtDNA synthesis
(reviewed comprehensively in [8]). POLG codes for polγ, the only DNA
polymerase within mitochondria. POLG2 codes for the accessory (or
p55) subunit of polγ, which binds to the linker region of the catalytic
subunit and promotes processivity during mtDNA synthesis. PEO1
codes for themtDNAhelicase Twinkle, and ANT1 codes for the adenine
nucleotide translocase, which maintains intra-mitochondrial nucleo-
side levels. OPA1 codes for the mitochondrial fusion–fission protein
Opa1, which also plays a role in apoptosis. Mutations in the genes
encoding these proteins lead to secondary mtDNA mutations which
accumulate in post-mitotic tissues and cause progressive multisystem
neurological disease. The mtDNA mutations affect the synthesis or
structure of respiratory chain proteins, leading to a biochemical defect
of oxidative phosphorylation and a deficiency of ATP synthesis [9,10].
On the other hand, recessive mutations in POLG and PEO1 also cause a
loss of mtDNA (depletion) and a more severe childhood disorder with
encephalopathy and liver failure, including the Alpers-Huttenlocher
syndrome (AHS) [11,12]. Several other recessive mtDNA depletion
syndromes have been described [2], many due to mutations affecting
proteins that regulate intra-mitochondrial nucleoside levels, such as
TK2 encoding thymidine kinase 2 [13]. The loss of mtDNA also leads to
a decrease in intra-mitochondrial protein synthesis, which compro-
mises oxidative phosphorylation and leads to a decrease in ATP
synthesis [14].
POLG remains the major identified cause of autosomal mitochon-
drial disease, with an exponential growth in the number of new POLG
substitutions identified in patients with secondary mtDNA defects.
322 J.D. Stewart et al. / Biochimica et Biophysica Acta 1812 (2011) 321–325Despite its importance, POLG is highly polymorphic in the general
population, and there have been several cases where putative
pathogenic alleles were later described in control subjects. Proving
the pathogenic nature of novel POLG mutations is a major challenge
facing the field. Several groups have established an in vitro method of
studying the biochemical consequences of different alleles by
isolating recombinant proteins over-expressed in baculovirus-
infected cells [2]. Although this has shown that several potentially
pathogenic alleles compromise catalytic activity, proof-reading and
processivity of the enzyme [2], technical limitations restrict this
approach to specific regions of the protein, excluding some known
and putative pathogenic alleles from analysis. In addition, the in vitro
approaches to measuremtDNA replication are not all applicable when
studying the potential effects of additional proteins that affect intra-
mitochondrial nucleotide pools, or proteins thought to interact with
the mtDNA replisome [15]. An alternative approach involves the
measurement of polγ activity in cell extracts [16]. Although this
enables the evaluation of the intact enzyme, even with the optimal
enrichment through mitochondrial fractionation, there is inevitable
contamination with nuclear DNA polymerase and RNase activity,
limiting the sensitivity of the assay for mildly deleterious POLG
mutations. To address these issues we developed a simple kinetic
assay for mtDNA replication in intact primary human cells by
depleting cell lines of mtDNA by treatment with ethidium bromide
(EtBr) and comparing the rate of repopulation in patient cell lines to
controls. Ethidium bromide is a known inhibitor of mitochondrial
transcription and replication processes but with no effect on nuclear
DNA [17,18]. This double stranded DNA intercalating drug has
effectively been used to reduce the copy number of mtDNA in
proliferating cells [19]. The effect of the drug is reversible; so that once
EtBr is removed from the culture media, cells are able to repopulate
their mtDNA [20]. This approach has been used to investigate the
mechanisms regulating mtDNA copy number within cells [18,21]. It
has also been used to show that deleted smaller mtDNA molecules
repopulate cells faster thanwild-typemolecules [22]. Here we applied
a similar approach to cell lines with a genetically determined mtDNA
replication defect for the first time.
2. Methods
Primary human fibroblasts were cultured from seven patients
available to us in our laboratories (P1–P7) and seven healthy control
subjects (C1–C7). Patients 1, 4, and 5 (P1, P4, and P5) had AHS caused
by compound heterozygous mutations in POLG P1:p.W748S and p.
G848S; P4: p.W748S and c.3600delT; and P5: p.G737R and p.A767N
[23,24] with mtDNA depletion in liver and/or muscle. Patients 2 and 3
(P2, P3) had AHS caused by homozygous mutations in POLG P2:p.
R1096C; and P3:homozygous p.T251I, p587L. Patient 6 (P6) had a
recessive mitochondrial DNA depletion myopathy due to a homozy-
gous deletion of exons 1 and 2 of TK2:−270+2561del-ins; 7287–
7335inv, with mtDNA depletion in the skeletal muscle. Patient 7 (P7)
had autosomal dominant chronic progressive external ophthalmo-
plegia due to a heterozygous POLG2 substitution (c.1352GNA/p.
G451E) with multiple mtDNA deletions in the skeletal muscle [4].
Clinical descriptions of patients 1, 4, 5 and 7 have been published
previously [3,15,16], but the clinical features of patients 2, 3, and 6
have not been described before.
Patient 2 was a one-year-old boy of Arabic ethnic origin, having
first grade cousins as parents. He suffered from multifocal therapy-
refractory epilepsy. At the age of one year and three months MRI
showed a global supratentorial reduction of brain volume with a
discrete signal-increased hippocampus in the FLAIR sequence, which
was interpreted as a probable right-sided hippocampal sclerosis.
Skeletal muscle biopsy was taken at the age of one year. In the biopsy
COX-negative fibers, reduced mtDNA copy number (863+/−101) in
contrast to controls (16045+/−8817), and multiple deletions weredetected. Genetic characterization showed the homozygous R1096C
mutation in POLG1.
Patient 3 was a 26-year-old woman, whose symptoms first
appeared at age 16 as mainly nocturnal nausea followed by loss of
consciousness without motor relinquishing (no tongue bite). In ten
years eight attacks were reported since the first seizure. These were
triggered by stress, but she could prevent the loss of consciousness by
learned strategies in two cases. Furthermore obsessive–compulsive
disorder was diagnosed at the age of 24 and she was treated in the
psychiatry. The electroencephalogram (EEG) at this time showed
fronto-temporal-parietal accented deceleration. Clear spike-wave and
sharp-wave could not be ascertained. EEG a year before showed
repeated high-tension potentials in theta band bifrontally. Genetic
characterization showed a pathogenic homozygous T251I/P587L
mutation combination in POLG1.
Patient 6 was a 2-month-old boy. His Turkish parents are second
grade consanguineous, without any known familiar disorders. The
baby was prematurely delivered at the 36+2 week of pregnancy.
Fetal hypokinesia with dysmorphic signs at a normal fetal karyotype
(46XY) were noted. Further features included: lissencephaly/pachy-
gyria, microecephaly, bilateral optic atrophy, severe peripartal
asphyxia, respiratory insufficiency, arterial hypotonia, low T3/T4
syndrome, anemia, electrolytic dysfunction, thrombosis, capillary-
leak syndrome, bilateral chylothorax, and occipital skin necrosis. EEG
at the second day of life was extremely low-strained, no epileptic
activity was detected. Skeletal muscle biopsy by the age of one month
revealed fiber atrophy, fiber destruction and almost complete COX-
deficiency. MtDNA copy number in skeletal muscle was reduced to
92 +/−6 (controls: 16045+/−8817). Genetic characterization
showed a homozygous mutation in TK2 (−270+2561del-ins;
7287–7335inv). At the age of 56 days the baby died from multi-
organ dysfunction.
Cells were grown in MEM Earles media (GIBCO) supplemented
with 10% fetal bovine serum, 0.1 mg/ml sodium pyruvate, 2 mM L-
glutamine and 0.05 mg/ml uridine. All cells were grown in a
humidified atmosphere with 5% CO2 at 37 °C. MtDNA depletion was
induced by the addition of 50 ng/ml ethidium bromide (EtBr) to the
culture medium for either 7 days (experiment 1) or 16 days
(experiment 2) before a return to normal media. Untreated cell
lines were studied in parallel, and all cells were kept between 50 and
80% confluence with excess fresh medium to ensure exponential
growth. We did not observe differences in the cell doubling times
between the patient and control cell lines during ethidium bromide
treatment, nor during the repopulation phase of the experiment. All
cell culture studies were done in three independent experiments.
The amount of mtDNA in the patient P4, P5, P7 and control C3–C7
fibroblasts was measured in duplicate by real-time PCR using iQ™
Sybr Green on the BioRad ICycler (BioRad, CA) to a target template
spanning from nt3459 to nt3569 of the MTND1 gene as described
[25,26], normalized using a nuclear-encoded template for the beta
microglobulin (B2M) gene spanning from nucleotide 4146 to
nucleotide 4376 (NCBI, AC025270). Relative copy number was
calculated from the threshold cycle value, ΔCt value, where the
mean amount of mtDNA/cell=2(2–ΔCt), to account for the two copies
of B2M. The percentage difference in the mtDNA copy number for the
untreated and treated arms of the study were compared on each
analysis day.
MtDNA copy numbers in patient P1–P3, P6 and control C1-C2
fibroblasts were determined using the primers MT16520F and MT35R
used together with probe MT16557TM to detect mitochondrial DNA
[24]. Nuclear DNA content was estimated by amplifying a fragment
from the single-copy gene Kir4.1 with primers KIR835F and KIR903R
in the presence of probe KIR857TM. The quantitative PCR was
performed on the MyiQ Real-Time PCR System (Bio-Rad, Munich,
Germany). The exact cycle number values were calculated as ln(c)/b,
which corresponds to the inflection point of non-linear fitted
Fig. 1.MtDNA depletion and repopulation in control human fibroblasts and fibroblasts
from three POLG patients and a TK2 patient after 7 days of treatment with 50 ng/ml
ethidium bromide. (A) Controls C1 & C2 (B) Patient P1:p.W748S and p.G848S in POLG;
P2:p.R1096C/p.R1096C in POLG; P3:p.T251I, p587L/p.T251I, p587L in POLG. (C) Patient
6 (P6): homozygous deletion of exons 1 and 2 of TK2 −270+2561del-ins; 7287–
7335inv. Data points show the mean of three independent experiments +/−SD values.
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following equation: y=y0+a (1−e–bx)c (y0, background fluores-
cence intensity; y, measured fluorescence intensity; x, cycle number;
and a, b, c, curve parameters to be fitted). Calculations were
performed using the SigmaPlot 2001 statistical analysis software.
For each value three independent experiments were carried out with
different concentrations of template DNA, each experiment in
triplicates, and primer efficiencies were calculated.
For patients P4, P5, P7 and control C3–C7 fibroblasts multiple
mtDNA deletions were investigated using a long range polymerase
chain reaction (PCR) assay which amplifies a ~10 kb fragment across
the major arc of mtDNA genome using a pair of primers (L6249
(nucleotides 6249–6265) and H16215 (nucleotides 16225–16196)).
The potential presence of large mitochondrial DNA deletions was
investigated for patient P1–P3, P6 and control C1-C2 fibroblasts by
amplifying overlapping PCR products of 9.5–12.7 kb size using a
JumpStart AccuTaq DNA polymerase (Sigma-Aldrich, Steinheim,
Germany) and the following primer pairs: MT2623F with
MT14695R, MT3922F with MT45R, MT16520F with MT10673R,
MT5462F with MT16084R, and MT7027F with MT45R. The mtDNA
deletion was quantified by a modified version of the single-molecule
PCR method [27]. Primers MT3922F and MT45R were used in 42
cycles of the previously described long PCR program to amplify a 12.7-
kb-long part of the mitochondrial genome. DNA samples were diluted
to a degree such that after amplification, in addition to the long wild-
type product, only 1 or 2 deletion specific (i.e. shorter) or no products
were detectable in each lane. We assume that under these
circumstances, each deletion-specific band is derived from a single
deleted mtDNA molecule. Deletion-specific bands were then counted
in all lanes, and this number was compared with total mtDNA copy
numbers determined in a similar manner but using a higher dilution
of the DNA sample (i.e. on average, less than 1 copy of mtDNA per
reaction). In the latter reaction, a primer pair (primers MT16520F and
MT1144R) was used that spanned the D-loop region and part of the
small arc that are very rarely deleted. This gave an amplification
product from all types of mtDNA molecules irrespective of whether
they were deleted.
3. Results
The absolute amount of mtDNA in the untreated fibroblasts from
four of the POLG patients was significantly less than in the controls
(P1, P=1.75×10−9; P2, P=2.27×10−8; P3, P=5.83×10−6; and P5,
P=0.028), but no different to controls for one POLG patient (P4), and
no different to controls for the POLG2 and TK2 patients. There was no
significant change in the level of mtDNA in untreated fibroblasts from
patients and controls (C1–C7 and P1–P7) when these were cultured
through multiple passages in parallel with the treated cells (Supple-
mentary Table 1). Treatment with EtBr caused significant depletion of
mtDNA in control and patient cell lines. Both control and patient
fibroblasts developed mtDNA depletion at the same rate, falling to
b15% of the untreated steady state within 10 days exposure. After
removal of the EtBr on day 7, the mtDNA copy number increased to
pre-treatment levels, reaching normal levels within 10 days in control
cell lines and in the cell line of the TK2 patient (Fig.1A, B and C and
Supplementary Table 2a). ThemtDNA content for the POLG fibroblasts
was significantly less than the controls at all time points in patients P2
and P3, but patient P1 returned to normal levels 12 days after
withdrawal of EtBr (Fig. 1B). By contrast, the fibroblasts from the
patient with a homozygous deletion of two TK2 exons (P6) showed
repopulation profiles faster than that observed in the controls
(Fig. 1C). We therefore carried out further experiments with a longer
period of exposure to EtBr in order to demonstrate more dramatic
effects in fibroblasts with POLG mutations.
The remaining patient (P4, P5, and P7) and control cell lines (C3–
C7) were treated with EtBr for 16 days (Fig. 2). As before, both patientand control cell lines developed the mtDNA depletion at the same rate
(Fig. 2A, B and C and Supplementary Table 2b). The control cell lines
exposed to EtBr for 16 days showed a similar rate of repopulation to
control cell lines exposed to EtBr for 7 days (Figs. 1A and 2A). By
contrast, the three patient fibroblast cell lines showed different rates
of repopulation with mtDNA. MtDNA levels in fibroblasts from the
two POLG patients (P4 and P5) never reached pre-treatment levels
29 days after removal of EtBr (P4=28.1%±19.4, P=0.034 compared
to the controls, P5=7.87%±7.13, P=0.003 compared to the controls;
Fig. 2B). By contrast, fibroblasts from the patient with a heterozygous
POLG2 substitution (P7) showed repopulation profiles similar to that
observed in the controls at all time points (Fig. 2C). To confirm our
findings, we repeated the entire experiment for one cell line (P4) and
obtained identical results (Fig. 2D).
No rearrangements of mtDNA were detected in the treated or
untreated cell fibroblasts from the controls and from P2-P7. In the
Fig. 2. MtDNA depletion and repopulation in control human fibroblasts and patients with a mtDNA maintenance disorder after 16 days of treatment with 50 ng/ml ethidium
bromide. (A) Controls C3–C7. (B) Patients P5: p.G737R and p.A767N in POLG; P4: p.w748S and c.3600delT in POLG. (C) P7: c.1352 GNA/p.G451E in POLG2. (D) Reproducibility data
for Patient P4: p.W748S and c.3600delT in POLG. Data points show the mean of three independent experiments +/−SD values.
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an inverted insertion 7395–9299 was detected, both in the untreated
and the EtBr treated cells. The proportion of deleted mtDNA did not
change during or after treatment with EtBr (Fig. 3). The percentage
level of mutatedmtDNA before EtBr treatmentwas 0.37%±0.03%. The
percentage level of mutated mtDNA immediately after EtBr treatment
was 1.44±0.09%. The percentage level of mutated mtDNA after
repopulation was 0.20±0.02%.
4. Discussion
Here we show that specific POLG mutations can delay the rate of
repopulation of mtDNA in human fibroblasts exposed to EtBr. Given
that we did not observe any difference between control and patient
cell doubling times before or after EtBr treatment, these findings are
consistent with the notion that pathogenic POLG mutations can
directly influence mtDNAmaintenance within intact human cells, and
are in keeping with in vitro data showing reduced catalytic activity
and processivity for several pathogenic POLG alleles [2].
Intriguingly, the steady-state level of mtDNA in untreated
fibroblasts from one POLG patient (P4) was no different to controls.Fig. 3. Percentage level of deleted mtDNA before, during and after EtBr treatment in
patient 1. Long range PCR products were separated on an agarose gel. Uppermost bands
represent non-deleted mitochondrial genomes (WT); lower bands show the presence
of shorter DNA molecules with deletions (DEL). Lanes: 1—marker; 2, 3—after
repopulation; 4, 5—before EtBr treatment; 6, 7—after EtBr treatment; and 8—undeleted
control.This has been observed before [28], and suggests that the capacity for
adequatemtDNA turnover in quiescentfibroblasts is not compromised
by some pathogenic POLG alleles. However, in contrast to the previous
study, where depletion was only observed in cells harbouring two
mutations affecting either the polymerase or exonuclease catalytic
domain [28], we also observed depletion in one patient (P5) with two
linker-regionmutations (p.G737R and p.A767N). This provides further
evidence of the crucial role played by the linker region in mtDNA
replication, probably through the direct interaction with the p55
accessory subunit which promotes processive polymerase activity [4].
Notably, EtBr caused the loss of mtDNA at remarkably similar rates
in patient and control fibroblast cell lines. This suggests that 50 ng/ml
EtBr effectively terminates mtDNA synthesis, and the loss of mtDNA
during EtBr exposure is likely to be due to the natural destruction of
mtDNA as part of the mtDNA turnover during relaxed replication. By
inference, in the steady state, this must be matched by equivalent
rates of mtDNA synthesis to maintain the constant amount of mtDNA
we observed in the untreated cells. Thus, if mtDNA replication is
suddenly abolished by EtBr treatment, then the loss of mtDNA will
occur through the same endogenous destruction mechanism that
occurs in the steady state. In this context, the rate of mtDNA depletion
during EtBr exposure will provide one estimate of the steady-state
turnover of mtDNA by relaxed replication. The time course we
observed is in keeping with previous measurements of mtDNA
turnover using a different approach [29,30].
Since the steady state mtDNA content of a cell is determined by the
balance between replication and degradation, it would be reasonable
to expect a cell to compensate for the mtDNA replication defect by
slowing down mtDNA degradation. However, the same rates of
ethidium-bromide induced mtDNA depletion that we observed in
patient and control cell lines suggest that the presence of POLG, POLG2,
and TK2mutations does not lead to a slower degradation of mtDNA in
an attempt to compensate for the mtDNA maintenance defect. The
cellular mtDNA content therefore is likely to be regulated solely
through the mechanism controlling mtDNA replication.
325J.D. Stewart et al. / Biochimica et Biophysica Acta 1812 (2011) 321–325By contrast, after withdrawal of the EtBr, the rates of repopulation of
the individual cell lines were less consistent. This may reflect differences
in the dynamics of cell proliferation between different sub-clones, cell–
cell mosaicism in mtDNA levels previously observed in POLG fibroblasts
[28], or it may reflect differences in mtDNA replication rates at different
stages of the cell cycle [31]. Despite this variation, we observed clear
differences between mutated POLG fibroblasts, and fibroblasts with the
heterozygous POLG2 and homozygous TK2mutations, although thismust
be interpretedwith caution because we only studied one cell line in each
case. Given that the same POLG2 mutation (c.1352GNA/p.G451E)
compromised polymerase activity through impaired subunit interaction
in the recombinant in vitro system [4], it seems unlikely that the absence
of a repopulation defect in fibroblasts reflects the non-pathogenic nature
of this allele. It is possible, that the defect caused by a heterozygous POLG2
mutation is more subtle compared to the compound heterozygous POLG
cell lines. Alternatively, the normal rates of repopulation could either
reflect the relative insensitivity of the assay we present here, or be due to
compensatorymechanismswithin the intact organelle that arenot at play
in the in vitro assay, which is based on short strands of mtDNA synthesis
using limited components of the replisome under idealized experimental
conditions [4]. The absence of an effect of the TK2 mutations on mtDNA
repopulation rates infibroblasts is inkeepingwith thewell-knowntissue-
specificity of this particular mtDNA depletion disorder, where the major
phenotype is limited to skeletal muscle. Tissue-specific compensatory
mechanisms infibroblasts probably stabilise themitochondrial dTTPpool,
as recently reported in fibroblasts from two patients with different
deleterious TK2mutations [32]. These mechanisms could account for the
rapid repopulation and supra-normal mtDNA levels seen N5 days after
the withdrawal of EtBr (Fig. 1C). Further work will clarify the extent and
magnitude of these effects for the rangeof differentmutations in different
genes known to be involved in mtDNA maintenance, and the sensitivity
and specificity of the repopulation assay.
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